Hydrolase
Hits from PDB Structure Title EC number
5FMD STRUCTURE OF D80A-FRUCTOFURANOSIDASE FROM XANTHOPHYLLOMYCES DENDRORHOUS COMPLEXED WITH NYSTOSE 3.2.1.26
5FOQ ACETYLCHOLINESTERASE IN COMPLEX WITH C7653 3.1.1.7
5FOS HUMANISED MONOMERIC RADA IN COMPLEX WITH OLIGOMERISATION PEPTIDE 3.6.4
5FP0 LIGAND COMPLEX STRUCTURE OF SOLUBLE EPOXIDE HYDROLASE 3.3.2.10
3.1.3.76
5FPH THE GTPASE DOMAINS OF THE IMMUNITY-RELATED IRGA6 DIMERIZE IN A PARALLEL HEAD-TO-HEAD FASHION 3.6.5
5FPS STRUCTURE OF HEPATITIS C VIRUS (HCV) FULL-LENGTH NS3 COMPLEX WITH SMALL-MOLECULE LIGAND 3-AMINOBENZENE-1,2-DICARBOXYLIC ACID (AT1246) IN AN ALTERNATE BINDING SITE. 3.4.21
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5FPT STRUCTURE OF HEPATITIS C VIRUS (HCV) FULL-LENGTH NS3 COMPLEX WITH SMALL-MOLECULE LIGAND 2-(1-METHYL-1H-INDOL-3-YL)ACETIC ACID (AT3437) IN AN ALTERNATE BINDING SITE. 3.4.21
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5FPW PROCATHEPSIN B S9 FROM TRYPANOSOMA CONGOLENSE 3.4.22.1
5FPY STRUCTURE OF HEPATITIS C VIRUS (HCV) FULL-LENGTH NS3 COMPLEX WITH SMALL-MOLECULE LIGAND 5-BROMO-1-METHYL-1H-INDOLE-2-CARBOXYLIC ACID (AT21457) IN AN ALTERNATE BINDING SITE. 3.4.21
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5FQI W229D AND F290W MUTANT OF THE LAST COMMON ANCESTOR OF GRAM-NEGATIVE BACTERIA (GNCA4) BETA-LACTAMASE CLASS A 3.5.2.6
5FQJ W229D MUTANT OF THE LAST COMMON ANCESTOR OF GRAM-NEGATIVE BACTERIA (GNCA) BETA-LACTAMASE BOUND TO 5(6)-NITROBENZOTRIAZOLE (TS-ANALOG) 3.5.2.6
5FQK W229D AND F290W MUTANT OF THE LAST COMMON ANCESTOR OF GRAM-NEGATIVE BACTERIA (GNCA4) BETA-LACTAMASE CLASS A BOUND TO 5(6)-NITROBENZOTRIAZOLE (TS-ANALOG) 3.5.2.6
5FQL INSIGHTS INTO HUNTER SYNDROME FROM THE STRUCTURE OF IDURONATE-2- SULFATASE 3.1.6.13
5FQQ LAST COMMON ANCESTOR OF GRAM-NEGATIVE BACTERIA (GNCA4) BETA-LACTAMASE CLASS A 3.5.2.6
5FR1 DOUBLE ACETYLATED RHOGDI-ALPHA IN COMPLEX WITH RHOA-GDP 3.6.5.2
5FR2 FARNESYLATED RHOA-GDP IN COMPLEX WITH RHOGDI-ALPHA, LYSINE ACETYLATED AT K178 3.6.5.2
5FRM CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) INTASOME IN COMPLEX WITH MAGNESIUM AND THE INSTI XZ384 (COMPOUND 4A) 2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
2.7.7
3.1
5FRN CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) INTASOME IN COMPLEX WITH MAGNESIUM AND THE INSTI XZ419 (COMPOUND 4C) 2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
2.7.7
3.1
5FRO CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) INTASOME IN COMPLEX WITH MAGNESIUM AND THE INSTI XZ446 (COMPOUND 4F) 2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
2.7.7
3.1
5FSH CRYSTAL STRUCTURE OF THERMUS THERMOPHILUS CSM6 3.1
5FSJ STRUCTURE OF THERMOLYSIN PREPARED BY THE 'SOAK-AND-FREEZE' METHOD UNDER 45 BAR OF OXYGEN PRESSURE 3.4.24.27
5FSO MTH1 SUBSTRATE RECOGNITION: COMPLEX WITH A METHYLAMINOPYRIMIDINEDIONE. 3.6.1.55
3.6.1.56
5FSP STRUCTURE OF THERMOLYSIN PREPARED BY THE 'SOAK-AND-FREEZE' METHOD UNDER 100 BAR OF KRYPTON PRESSURE 3.4.24.27
5FSS STRUCTURE OF THERMOLYSIN PREPARED BY THE 'SOAK-AND-FREEZE' METHOD UNDER 40 BAR OF KRYPTON PRESSURE 3.4.24.27
5FST STRUCTURE OF LYSOZYME PREPARED BY THE 'SOAK-AND-FREEZE' METHOD UNDER 100 BAR OF KRYPTON PRESSURE 3.2.1.17
5FT9 ARABIDOPSIS THALIANA NUCLEAR PROTEIN-ONLY RNASE P 2 (PRORP2) 3.1.26.5
5FTB CRYSTAL STRUCTURE OF PIF1 HELICASE FROM BACTEROIDES IN COMPLEX WITH AMPPNP 3.6.4.12
5FTC CRYSTAL STRUCTURE OF PIF1 HELICASE FROM BACTEROIDES IN COMPLEX WITH ADP 3.6.4.12
5FTD CRYSTAL STRUCTURE OF PIF1 HELICASE FROM BACTEROIDES APO FORM 3.6.4.12
5FTE CRYSTAL STRUCTURE OF PIF1 HELICASE FROM BACTEROIDES IN COMPLEX WITH ADP-ALF3 AND SSDNA 3.6.4.12
5FTF CRYSTAL STRUCTURE OF PIF1 HELICASE FROM BACTEROIDES DOUBLE MUTANT L95C-I339C 3.6.4.12
5FUD OCEANOBACILLUS IHEYENSIS MACRODOMAIN WITH MES BOUND 3.2.2
3.5.1
5FUI CRYSTAL STRUCTURE OF THE C-TERMINAL CBM6 OF LAMC A MARINE LAMINARIANSE FROM ZOBELLIA GALACTANIVORANS 3.2.1.39
5FUM MUS MUSCULUS ACETYLCHOLINESTERASE IN COMPLEX WITH AL200 3.1.1.7
5FV4 PIG LIVER ESTERASE 5 (PLE5) 3.1.1.1
5FWQ APO STRUCTURE OF HUMAN LEUKOTRIENE A4 HYDROLASE 3.3.2.6
3.4.11.4
5G0M BETA-GLUCURONIDASE WITH AN ACTIVITY-BASED PROBE (N-ACYL CYCLOPHELLITOL AZIRIDINE) BOUND 3.2.1.31
5G0Q BETA-GLUCURONIDASE WITH AN ACTIVITY-BASED PROBE (N-ALKYL CYCLOPHELLITOL AZIRIDINE) BOUND 3.2.1.31
5G0X PSEUDOMONAS AERUGINOSA HDAH BOUND TO ACETATE. 3.5.1
5G0Y PSEUDOMONAS AERUGINOSA HDAH UNLIGANDED. 3.5.1
5G10 PSEUDOMONAS AERUGINOSA HDAH BOUND TO 9,9,9 TRIFLUORO-8,8-DIHYDROY-N-PHENYLNONANAMIDE 3.5.1
5G11 PSEUDOMONAS AERUGINOSA HDAH BOUND TO PFSAHA. 3.5.1
5G12 PSEUDOMONAS AERUGINOSA HDAH (Y313F) UNLIGANDED. 3.5.1
5G13 PSEUDOMONAS AERUGINOSA HDAH (H143A) UNLIGANDED. 3.5.1
5G17 BORDETELLA ALCALIGENES HDAH (T101A) BOUND TO 9,9,9-TRIFLUORO-8,8- DIHYDROXY-N-PHENYLNONANAMIDE. 3.5.1.4
3.5.1
5G18 DIRECT OBSERVATION OF ACTIVE-SITE PROTONATION STATES IN A CLASS A BETA LACTAMASE WITH A MONOBACTAM SUBSTRATE 3.5.2.6
5G1A BORDETELLA ALCALIGENES HDAH BOUND TO PFSAHA 3.5.1.4
3.5.1
5G1B BORDETELLA ALCALIGENES HDAH NATIVE 3.5.1.4
3.5.1
5G1C STRUCTURE OF HDAC LIKE PROTEIN FROM BORDETELLA ALCALIGENES BOUND THE PHOTOSWITCHABLE PYRAZOLE INHIBITOR CEW395 3.5.1.4
3.5.1
5G1M CRYSTAL STRUCTURE OF NAGZ FROM PSEUDOMONAS AERUGINOSA 3.2.1.52
5G1R OPEN CONFORMATION OF FRANCISELLA TULARENSIS CLPP AT 1.9 A 3.4.21.92
5G27 STRUCTURE OF SPIN-LABELLED T4 LYSOZYME MUTANT L118C-R1 AT ROOM TEMPERATURE 3.2.1.17
5G2B CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-008 3.1.4
5G2M CRYSTAL STRUCTURE OF NAGZ FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH N-ACETYLGLUCOSAMINE 3.2.1.52
5G2U STRUCTURE OF BT1596,A 2-O GAG SULFATASE 3.1.6.18
3.1.6
5G2V STRUCTURE OF BT4656 IN COMPLEX WITH ITS SUBSTRATE D-GLUCOSAMINE-2-N, 6-O-DISULFATE. 3.1.6.14
3.1.6
5G3M DISCOVERY OF A NOVEL SECRETED PHOSPHOLIPASE A2 (SPLA2) INHIBITOR. 3.1.1.4
5G3N DISCOVERY OF A NOVEL SECRETED PHOSPHOLIPASE A2 (SPLA2) INHIBITOR. 3.1.1.4
5G3O BACILLUS CEREUS FORMAMIDASE (BCEAMIF) INHIBITED WITH UREA. 3.5.1.49
5G3P BACILLUS CEREUS FORMAMIDASE (BCEAMIF) ACETYLATED AT THE ACTIVE SITE. 3.5.1.49
5G3R CRYSTAL STRUCTURE OF NAGZ FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH N-ACETYLGLUCOSAMINE AND L-ALA-1,6-ANHYDROMURNAC 3.2.1.52
5G3W STRUCTURE OF HDAC LIKE PROTEIN FROM BORDETELLA ALCALIGENES IN COMPLEX WITH THE PHOTOSWITCHABLE INHIBITOR CEW65 3.5.1
5G4C HUMAN SIRT2 CATALYSE SHORT CHAIN FATTY ACYL LYSINE 3.5.1
2.3.1.286
5G4H 1.50 A RESOLUTION CATECHOL (1,2-DIHYDROXYBENZENE) INHIBITED SPOROSARCINA PASTEURII UREASE 3.5.1.5
5G57 CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-001 3.1.4
5G5K CRYSTAL STRUCTURE OF NAGZ FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH THE INHIBITOR 2-ACETAMIDO-1,2-DIDEOXYNOJIRIMYCIN 3.2.1.52
5G5R CBS DOMAIN TANDEM OF SITE-2 PROTEASE FROM ARCHAEOGLOBUS FULGIDUS IN COMPLEX WITH LLAMA NANOBODY - APO FORM 3.4.24.85
5G5S STRUCTURE OF THE ARGONAUTE PROTEIN FROM METHANOCALDCOCCUS JANASCHII 3.1.25
5G5T STRUCTURE OF THE ARGONAUTE PROTEIN FROM METHANOCALDCOCCUS JANASCHII IN COMPLEX WITH GUIDE DNA 3.1.25
5G5U CRYSTAL STRUCTURE OF NAGZ H174A MUTANT FROM PSEUDOMONAS AERUGINOSA 3.2.1.52
5G5V CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-038 3.1.4
5G5X CBS DOMAIN TANDEM OF SITE-2 PROTEASE FROM ARCHAEOGLOBUS FULGIDUS IN COMPLEX WITH LLAMA NANOBODY - NUCLEOTIDE-BOUND FORM 3.4.24.85
5G6T CRYSTAL STRUCTURE OF ZN-CONTAINING NAGZ H174A MUTANT FROM PSEUDOMONAS AERUGINOSA 3.2.1.52
5GCH CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN 3.4.21.1
5GDS HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX 3.4.21.5
5GG4 CRYSTAL STRUCTURE OF USP7 WITH RNF169 PEPTIDE 3.4.19.12
5GG5 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 3.6.1.69
3.6.1.58
3.6.1.61
5GG6 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH 8-OXO-DGTP 3.6.1.69
3.6.1.58
3.6.1.61
5GG7 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH 8-OXO-DGTP, 8-OXO-DGMP AND PYROPHOSPHATE (I) 3.6.1.69
3.6.1.58
3.6.1.61
5GG8 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH 8-OXO-DGTP, 8-OXO-DGMP AND PYROPHOSPHATE (II) 3.6.1.69
3.6.1.58
3.6.1.61
5GG9 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH 8-OXO-GTP, 8-OXO-GMP AND PYROPHOSPHATE 3.6.1.69
3.6.1.58
3.6.1.61
5GGA CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH 8-OXO-GDP, 8-OXO-GMP AND PYROPHOSPHATE 3.6.1.69
3.6.1.58
3.6.1.61
5GGB CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH 8-OXO-DGDP 3.6.1.69
3.6.1.58
3.6.1.61
5GGC CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH PHOSPHATE AND MAGNESIUM IONS (EXCESS MAGNESIUM, I) 3.6.1.69
3.6.1.58
3.6.1.61
5GGD CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH PHOSPHATE AND MAGNESIUM IONS (EXCESS MAGNESIUM, II) 3.6.1.69
3.6.1.58
3.6.1.61
5GGW CRYSTAL STRUCTURE OF CLASS C BETA-LACTAMASE 3.5.2.6
5GHI CRYSTAL STRUCTURE OF HUMAN MTH1(G2K MUTANT) IN COMPLEX WITH 8-OXO-DGTP 3.6.1.55
3.6.1.56
5GHJ CRYSTAL STRUCTURE OF HUMAN MTH1(G2K MUTANT) IN COMPLEX WITH 2-OXO-DATP 3.6.1.55
3.6.1.56
5GHL CRYSTAL STRUCTURE ANALYSIS OF THE STARCH-BINDING DOMAIN OF GLUCOAMYLASE FROM ASPERGILLUS NIGER 3.2.1.3
5GHM CRYSTAL STRUCTURE OF HUMAN MTH1(G2K/D120N MUTANT) IN COMPLEX WITH 8-OXO-DGTP AT PH 7.0 3.6.1.55
3.6.1.56
5GHN CRYSTAL STRUCTURE OF HUMAN MTH1(G2K/D120N MUTANT) IN COMPLEX WITH 2-OXO-DATP 3.6.1.55
3.6.1.56
5GHO CRYSTAL STRUCTURE OF HUMAN MTH1(G2K/D120A MUTANT) IN COMPLEX WITH 8-OXO-DGTP 3.6.1.55
3.6.1.56
5GHP CRYSTAL STRUCTURE OF HUMAN MTH1(G2K/D120A MUTANT) IN COMPLEX WITH 2-OXO-DATP 3.6.1.55
3.6.1.56
5GHQ CRYSTAL STRUCTURE OF HUMAN MTH1(G2K/D120A MUTANT) IN COMPLEX WITH 2-OXO-DATP UNDER HIGH CONCENTRATIONS OF 2-OXO-DATP 3.6.1.55
3.6.1.56
5GHX CRYSTAL STRUCTURE OF BETA-LACTAMASE PENP MUTANT-E166H 3.5.2.6
5GHY CRYSTAL STRUCTURE OF BETA-LACTAMASE PENP MUTANT-E166H IN COMPLEX WITH CEPHALORIDINE AS POST-ACYLATION" INTERMEDIATE" 3.5.2.6
5GHZ CRYSTAL STRUCTURE OF BETA-LACTAMASE PENP MUTANT-E166H IN COMPLEX WITH CEPHALORIDINE AS PRE-DEACYLATION" INTERMEDIATE" 3.5.2.6
5GI4 DEAD-BOX RNA HELICASE 3.6.4.13
5GIM CRYSTAL STRUCTURE OF THROMBIN-AVATHRIN COMPLEX 3.4.21.5
5GJ4 STRUCTURE OF NS2B-NS3 PROTEASE FROM ZIKA VIRUS CAUGHT AFTER SELF-CLEAVAGE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5GJU DEAD-BOX RNA HELICASE 3.6.4.13
5GKA CRYO-EM STRUCTURE OF HUMAN AICHI VIRUS 3.6.4.13
3.4.22.28
2.7.7.48
5GKC THE CRYSTAL STRUCTURE OF THE CPS-6 H148A/F122A 3.1.30
5GKE STRUCTURE OF ENDOMS-DSDNA1 COMPLEX 3.1
5GKF STRUCTURE OF ENDOMS-DSDNA1' COMPLEX 3.1
5GKG STRUCTURE OF ENDOMS-DSDNA1'' COMPLEX 3.1
5GKH STRUCTURE OF ENDOMS-DSDNA2 COMPLEX 3.1
5GKI STRUCTURE OF ENDOMS-DSDNA3 COMPLEX 3.1
5GKJ STRUCTURE OF ENDOMS IN APO FORM 3.1
5GKO CRYSTAL STRUCTURE OF TRIPARTITE-TYPE ABC TRANSPORTER, MACB FROM ACINETOBACTER BAUMANNII 3.6.3
7.6.2
5GKP CRYSTAL STRUCTURE OF THE ENDOG WORM HOMOLOGUE CPS-6 H148A/F122A IN COMPLEX WITH DNA 3.1.30
5GKW CRYSTAL STRUCTURE OF SZ529 COMPLEX WITH (R,R)-CYCLOPENTANEDIOL 3.3.2.8
5GL8 THE CRYSTAL STRUCTURE OF NATTOKINASE FRAGMENTS 3.4.21.62
5GL9 CRYSTAL STRUCTURE OF THE CLASS A BETA-LACTAMASE PENL 3.5.2.6
5GLA CRYSTAL STRUCTURE OF THE CLASS A BETA-LACTAMASE PENL-TTR10 CONTAINING 10 RESIDUES INSERTION IN OMEGA-LOOP 3.5.2.6
5GLB CRYSTAL STRUCTURE OF THE CLASS A BETA-LACTAMASE PENL-TTR10 IN COMPLEX WITH CBA 3.5.2.6
5GLC CRYSTAL STRUCTURE OF THE CLASS A BETA-LACTAMASE PENL-TTR11 CONTAINING 20 RESIDUES INSERTION IN OMEGA-LOOP 3.5.2.6
5GLD CRYSTAL STRUCTURE OF THE CLASS A BETA-LACTAMASE PENL-TTR11 IN COMPLEX WITH CBA 3.5.2.6
5GLE THE STRUCTURE OF VIBRIO ANGUILLARUM775 ANGB-ICL 3.3.2.1
5GLF STRUCTURAL INSIGHTS INTO THE INTERACTION OF P97 N-TERMINAL DOMAIN AND SHP MOTIF IN DERLIN-1 RHOMBOID PSEUDOPROTEASE 3.6.4.6
5GLH HUMAN ENDOTHELIN RECEPTOR TYPE-B IN COMPLEX WITH ET-1 3.2.1.17
5GLI HUMAN ENDOTHELIN RECEPTOR TYPE-B IN THE LIGAND-FREE FORM 3.2.1.17
5GLJ CRYSTAL STRUCTURE OF PDZ1 DOMAIN OF HUMAN PROTEIN TYROSINE PHOSPHATASE PTP-BAS 3.1.3.48
5GLX CRYSTAL STRUCTURE OF A GLYCOSIDE HYDROLASE FROM THIELAVIA TERRESTRIS NRRL 8126 3.2.1.4
5GLY CRYSTAL STRUCTURE OF A GLYCOSIDE HYDROLASE IN COMPLEX WITH CELLOTETROSE FROM THIELAVIA TERRESTRIS NRRL 8126 3.2.1.4
5GM3 CRYSTAL STRUCTURE OF FI-CMCASE FROM ASPERGILLUS ACULEATUS F-50 3.2.1.4
5GM4 CRYSTAL STRUCTURE OF FI-CMCASE FROM ASPERGILLUS ACULEATUS F-50 IN COMPLEX WITH CELLOTETROSE 3.2.1.4
5GM5 CRYSTAL STRUCTURE OF FI-CMCASE FROM ASPERGILLUS ACULEATUS F-50 IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5GM9 CRYSTAL STRUCTURE OF A GLYCOSIDE HYDROLASE IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5GMA CRYSTAL STRUCTURE OF THE P228A VARIANT OF THERMOTOGA MARITIMA ACETYL ESTERASE 3.1.1.41
3.1.1.72
5GMX CRYSTAL STRUCTURE OF A FAMILY VIII CARBOXYLESTERASE 3.1.1.1
5GN1 CRYSTAL STRUCTURE OF THE C-TERMINAL PART OF FUN30 ATPASE DOMAIN 3.6.4.12
5GNQ CRYSTAL STRUCTURE OF REPLISOMAL DIMER OF DNA POLYMERASE FROM BACTERIOPHAGE RB69 WITH DNA DUPLEXES 2.7.7.7
3.1.11
5GNR THE STRUCTURE OF MINI-MFN1 K88A IN COMPLEX WITH GDP 3.6.5
5GNS STRUCTURES OF HUMAN MITOFUSIN 1 PROVIDE INSIGHT INTO MITOCHONDRIAL TETHERING 3.6.5
5GNT BDLP-LIKE FOLDING OF MITOFUSIN 1 3.6.5
5GNU THE STRUCTURE OF MINI-MFN1 APO 3.6.5
5GNX THE E171Q MUTANT STRUCTURE OF BGL6 3.2.1.21
5GNY THE STRUCTURE OF WT BGL6 3.2.1.21
5GNZ THE M3 MUTANT STRUCTURE OF BGL6 3.2.1.21
5GO4 TRUNCATED MITOFUSIN-1, NUCLEOTIDE-FREE 3.6.5
5GOE TRUNCATED MITOFUSIN-1, GDP-BOUND 3.6.5
5GOF TRUNCATED MITOFUSIN-1, GTP-BOUND 3.6.5
5GOM TRUNCATED MITOFUSIN-1, TRANSITION-LIKE STATE 3.6.5
5GOO CRYSTAL STRUCTURE OF ALKALINE INVERTASE INVA FROM ANABAENA SP. PCC 7120 COMPLEXED WITH FRUCTOSE 3.2.1.26
5GOP CRYSTAL STRUCTURE OF ALKALINE INVERTASE INVA FROM ANABAENA SP. PCC 7120 COMPLEXED WITH SUCROSE 3.2.1.26
5GOQ CRYSTAL STRUCTURE OF ALKALINE INVERTASE INVA FROM ANABAENA SP. PCC 7120 COMPLEXED WITH GLUCOSE 3.2.1.26
5GOR CRYSTAL STRUCTURE OF ALKALINE INVERTASE INVA FROM ANABAENA SP. PCC 7120 3.2.1.26
5GOT CRYSTAL STRUCTURE OF SP-PTP, LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE FROM STREPTOCOCCUS PYOGENES 3.1.3.48
5GOX EUKARYOTIC RAD50 FUNCTIONS AS A ROD-SHAPED DIMER 3.6
5GOZ CRYSTAL STRUCTURE OF ZIKV NS5 METHYLTRANSFERASE IN COMPLEX WITH GTP AND SAH 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5GP0 CRYSTAL STRUCTURE OF GERANIOL-NUDX1 COMPLEX 3.6.1.55
3.6.1.67
3.6.1.22
5GP1 CRYSTAL STRUCTURE OF ZIKV NS5 METHYLTRANSFERASE IN COMPLEX WITH GTP AND SAH 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5GPI CRYSTAL STRUCTURES OF UNLINKED NS2B-NS3 PROTEASE FROM ZIKA VIRUS AND ITS COMPLEX WITH A REVERSE PEPTIDE INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5GPJ CRYSTAL STRUCTURE OF PROTON-PUMPING PYROPHOSPHATASE 3.6.1.1
7.1.3.1
5GQ1 CRYSTAL STRUCTURE OF 2C HELICASE FROM ENTEROVIRUS 71 (EV71) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5GQC CRYSTAL STRUCTURE OF LACTO-N-BIOSIDASE LNBX FROM BIFIDOBACTERIUM LONGUM SUBSP. LONGUM, LIGAND-FREE FORM 3.2.1.140
5GQD CRYSTAL STRUCTURE OF COVALENT GLYCOSYL-ENZYME INTERMEDIATE OF XYLANASE MUTANT (T82A, N127S, AND E128H) FROM STREPTOMYCES OLIVACEOVIRIDIS E-86 3.2.1.8
5GQE CRYSTAL STRUCTURE OF MICHAELIS COMPLEX OF XYLANASE MUTANT (T82A, N127S, AND E128H) FROM STREPTOMYCES OLIVACEOVIRIDIS E-86 3.2.1.8
5GQF CRYSTAL STRUCTURE OF LACTO-N-BIOSIDASE LNBX FROM BIFIDOBACTERIUM LONGUM SUBSP. LONGUM, LACTO-N-BIOSE COMPLEX 3.2.1.140
5GQG CRYSTAL STRUCTURE OF LACTO-N-BIOSIDASE LNBX FROM BIFIDOBACTERIUM LONGUM SUBSP. LONGUM, GALACTO-N-BIOSE COMPLEX 3.2.1.140
5GQH CRYO-EM STRUCTURE OF PAECAS3-ACRF3 COMPLEX 3.1
3.6.4
5GS6 FULL-LENGTH NS1 STRUCTURE OF ZIKA VIRUS FROM 2015 BRAZIL STRAIN 3.4.21.91
3.6.1.15
3.6.4.13
5GS7 CRYSTAL STRUCTURE DETERMINATION OF CYS2ALA MUTANT OF BILE SALT HYDROLASE FROM ENTEROCOCCUS FEACALIS 3.5.1.24
5GS8 CRYSTAL STRUCTURE OF TLA-3 EXTENDED-SPECTRUM BETA-LACTAMASE 3.5.2.6
5GSC CRYSTAL STRUCTURE OF A CLASS C BETA LACTAMASE OF APO FORM 3.5.2.6
5GSL GLYCOSIDE HYDROLASE A 3.2.1
5GSM GLYCOSIDE HYDROLASE B WITH PRODUCT 3.2.1
5GSP RIBONUCLEASE T1/3'-GMP, 9 WEEKS 3.1.27.3
4.6.1.24
5GTJ CRYSTAL STRUCTURE OF CATALYTICALLY ACTIVE FORM OF HUMAN DUSP26 3.1.3.16
3.1.3.48
5GU4 RRNA N-GLYCOSYLASE RTA 3.2.2.22
5GUH CRYSTAL STRUCTURE OF SILKWORM PIWI-CLADE ARGONAUTE SIWI BOUND TO PIRNA 3.1.26
5GV1 CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE WILD TYPE 3.2.1.8
5GV5 CRYSTAL STRUCTURE OF CANDIDA ANTARCTICA LIPASE B WITH ACTIVE SER105 MODIFIED WITH A PHOSPHONATE INHIBITOR 3.1.1.3
5GVR CRYSTAL STRUCTURE OF THE DDX41 DEAD DOMAIN IN AN APO CLOSED FORM 3.6.4.13
5GVS CRYSTAL STRUCTURE OF THE DDX41 DEAD DOMAIN IN AN APO OPEN FORM 3.6.4.13
5GVT CRYSTAL STRUCTURES OF THE SERINE PROTEASE DOMAIN OF MURINE PLASMA KALLIKREIN 3.4.21.34
5GVX STRUCTURAL INSIGHT INTO DEPHOSPHORYLATION BY TREHALOSE 6-PHOSPHATE PHOSPHATASE (OTSB2) FROM MYCOBACTERIUM TUBERCULOSIS 3.1.3.12
5GVZ CRYSTAL STRUCTURE OF PEPTIDYL-TRNA HYDROLASE FROM VIBRIO CHOLERAE IN SPACE GROUP C2221 AT RESOLUTION 1.75A. 3.1.1.29
5GW7 CRYSTAL STRUCTURE OF THE GLYCOSYNTHASE MUTANT E727A OF ESCHERICHIA COLI GH63 GLYCOSIDASE IN COMPLEX WITH GLUCOSE AND LACTOSE 3.2.1
5GWA CRYSTAL STRUCTURE OF TLA-3 EXTENDED-SPECTRUM BETA-LACTAMASE IN A COMPLEX WITH AVIBACTAM 3.5.2.6
5GWB HEN EGG WHITE LYSOZYME NATIVE CRYSTALS SOAKED FOR 2 HOURS IN PRECIPITANT SOLUTION CONTAINING 1 M GUANIDINE HYDROCHLORIDE AND 25% GLYCEROL, BEFORE DATA COLLECTION 3.2.1.17
5GWO CRYSTAL STRUCTURE OF RCAR3:PP2C S265F/I267M WITH (+)-ABA 3.1.3.16
5GWP CRYSTAL STRUCTURE OF RCAR3:PP2C WILD-TYPE WITH (+)-ABA 3.1.3.16
5GWY STRUCTURE OF MAIN PROTEASE FROM HUMAN CORONAVIRUS NL63: INSIGHTS FOR WIDE SPECTRUM ANTI-CORONAVIRUS DRUG DESIGN 3.4.22
3.4.19.12
5GWZ THE STRUCTURE OF PORCINE EPIDEMIC DIARRHEA VIRUS MAIN PROTEASE IN COMPLEX WITH AN INHIBITOR 3.4.22
3.4.19.12
5GXJ ZIKA VIRUS NS2B-NS3 PROTEASE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5GXP CATIONIC TRYPSIN WITH GOL/PGE AS DIMER AT PH 4.6 3.4.21.4
5GXX CRYSTAL STRUCTURE OF ENDOGLUCANASE CELQ FROM CLOSTRIDIUM THERMOCELLUM COMPLEXED WITH TRIS 3.2.1
5GXY CRYSTAL STRUCTURE OF ENDOGLUCANASE CELQ FROM CLOSTRIDIUM THERMOCELLUM COMPLEXED WITH CELLOBIOSE AND TRIS 3.2.1
5GXZ CRYSTAL STRUCTURE OF ENDOGLUCANASE CELQ FROM CLOSTRIDIUM THERMOCELLUM COMPLEXED WITH CELLOBIOSE AND CELLOTRIOSE 3.2.1
5GY0 CRYSTAL STRUCTURE OF ENDOGLUCANASE CELQ FROM CLOSTRIDIUM THERMOCELLUM COMPLEXED WITH CELLOTETRAOSE 3.2.1
5GY1 CRYSTAL STRUCTURE OF ENDOGLUCANASE CELQ FROM CLOSTRIDIUM THERMOCELLUM COMPLEXED WITH CELLOTRIOSE 3.2.1
5GY3 THE CRYSTAL STRUCTURE OF ENDOGLUCANASE CEL10, A FAMILY 8 GLYCOSYL HYDROLASE FROM KLEBSIELLA PNEUMONIAE 3.2.1
5GY6 RIBONUCLEASE FROM HERICIUM ERINACEUS (RNASE HE1) 3.1.27.3
5GY8 CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE T28C+T60C MUTANT 3.2.1.8
5GY9 CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE A74C+G84C MUTANT 3.2.1.8
5GYA CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE V5N+V6N+K7R+K223R+K227R MUTANT 3.2.1.8
5GYB CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE V5N+V6N+K7R+K223R+K227R AND T28C+T60C MUTANT 3.2.1.8
5GYC CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE K73R+K185R AND T28C+T60C MUTANT 3.2.1.8
5GYE CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE T28C+T60C AND T77C+E249C MUTANT 3.2.1.8
5GYF CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE T28C+T60C+L59F MUTANT 3.2.1.8
5GYG CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE T28C+T60C MUTANT WITH THREE N-TEMINAL RESIDUE TRUNCATION 3.2.1.8
5GYH CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE T28C+T60C+T48F+L59F MUTANT 3.2.1.8
5GYI CRYSTAL STRUCTURE OF ENZBLEACH XYLANASE V176C+E220C MUTANT 3.2.1.8
5GYN CRYSTAL STRUCTURE OF HUMAN PYRIDOXAL 5'-PHOSPHATE PHOSPHATASE (CHRONOPHIN) MUTANT - C221S 3.1.3.3
3.1.3.74
5GZ4 CRYSTAL STRUCTURE OF SNAKE VENOM PHOSPHODIESTERASE (PDE) FROM TAIWAN COBRA (NAJA ATRA ATRA) 3.6.1
5GZ5 CRYSTAL STRUCTURE OF SNAKE VENOM PHOSPHODIESTERASE (PDE) FROM TAIWAN COBRA (NAJA ATRA ATRA) IN COMPLEX WITH AMP 3.6.1
5GZ7 CRYSTAL STRUCTURE OF THE COMPLEX OF RIBOSOME INACTIVATING PROTEIN WITH 1,2-ETHANEDIOL AT 1.95 ANGSTROM RESOLUTION 3.2.2.22
5GZR ZIKA VIRUS E PROTEIN COMPLEXED WITH A NEUTRALIZING ANTIBODY Z23-FAB 3.4.21.91
3.6.1.15
3.6.4.13
5GZW CRYSTAL STRUCTURE OF AMPC BER 3.5.2.6
5GZX THE COMPLEX STRUCTURE OF D-2-HALOACID DEHALOGENASE MUTANT WITH D-2-CPA 3.8.1.9
5GZY THE COMPLEX STRUCTURE OF D-2-HALOACID DEHALOGENASE WITH L-LA 3.8.1.9
5H00 THE CRYSTAL STRUCTURE OF D-2-HALOACID DEHALOGENASE 3.8.1.9
5H01 THE CRYSTAL STRUCTURE OF D-2-HALACID DEHALOGENASE MUTANT 3.8.1.9
5H08 HUMAN PTPRZ D1 DOMAIN COMPLEXED WITH NAZ2329 3.1.3.48
5H0I NAME TO BE RELEASED WHEN PUBLISHED 3.4.22.34
5H0U CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF MEMBRANE TYPE 1 MATRIX METALLOPROTEINASE 3.4.24.80
5H12 CRYSTAL STRUCTURE OF DEEP VENT DNA POLYMERASE 2.7.7.7
3.1
5H1O CRISPR-ASSOCIATED PROTEIN 3.1
5H1P CRISPR-ASSOCIATED PROTEIN 3.1
5H1Y CRYSTAL STRUCTURE OF THE DDX41 DEAD DOMAIN IN COMPLEX WITH SO42- AND MG2+ 3.6.4.13
5H23 CRYSTAL STRUCTURE OF CHIKUNGUNYA VIRUS CAPSID PROTEIN 3.4.21.90
5H2Q CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 13E 3.1.4
5H2R CRYSTAL STRUCTURE OF T BRUCEI PHOSPHODIESTERASE B2 BOUND TO COMPOUND 15B 3.1.4
5H31 STRUCTURAL BASIS FOR DIMERIZATION OF THE DEATH EFFECTOR DOMAINS OF CASPASE-8 3.4.22.61
5H33 STRUCTURAL BASIS FOR DIMERIZATION OF THE DEATH EFFECTOR DOMAINS OF CASPASE-8 3.4.22.61
5H3B CRYSTAL STRUCTURE OF SEMET-BIOG FROM HAEMOPHILUS INFLUENZAE AT 1.49 ANGSTROMS RESOLUTION 3.1.1.1
5H3C CRYSTAL STRUCTURE OF ARABIDOPSIS SNC1 TIR DOMAIN 3.2.2.6
5H4D CRYSTAL STRUCTURE OF HSIRT3 IN COMPLEX WITH A SPECIFIC AGONIST AMIODARONE HYDROCHLORIDE 3.5.1
2.3.1.286
5H4F STRUCTURE OF INORGANIC PYROPHOSPHATASE CRYSTALLISED AS A CONTAMINANT 3.6.1.1
5H4G STRUCTURE OF PIN-DOMAIN PROTEIN (VAPC4 TOXIN) FROM PYROCOCCUS HORIKOSHII DETERMINED AT 1.77 A RESOLUTION 3.1
5H4H STRUCTURE OF PIN-DOMAIN PROTEIN (VAPC4 TOXIN) FROM PYROCOCCUS HORIKOSHII DETERMINED AT 2.2 A RESOLUTION 3.1
5H4I UNLINKED NS2B-NS3 PROTEASE FROM ZIKA VIRUS IN COMPLEX WITH A COMPOUND FRAGMENT 3.4.21.91
3.6.1.15
3.6.4.13
5H4J CRYSTAL STRUCTURE OF HUMAN DUTPASE IN COMPLEX WITH N-[(1R)-1-[3-(CYCLOPENTYLOXY)-PHENYL]-ETHYL]-3-[(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)METHOXY]-1-PROPANESULFONAMIDE 3.6.1.23
5H4U CRYSTAL STRUCTURE OF CELLULASE FROM ANTARCTIC SPRINGTAIL, CRYPTOPYGUS ANTARCTICUS 3.2.1.4
5H5P CRYSTAL STRUCTURE OF MYELIN-GENE REGULATORY FACTOR DNA BINDING DOMAIN 3.4
5H6B CRYSTAL STRUCTURE OF A THERMOSTABLE LIPASE FROM MARINE STREPTOMYCES 3.1.1.3
5H6V STRUCTURE OF ZIKA VIRUS PROTEASE IN COMPLEX WITH A DIPEPTIDE INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
5H7E CRYSTAL STRUCTURE OF NATIVE DRCPDASE 3.1.4
3.1.4.58
5H7F CRYSTAL STRUCTURE OF MN-DERIVATIVE DRCPDASE 3.1.4
3.1.4.58
5H7T A GH19 CHITINASE DOMAIN FROM THE CRYPTOMERIA JAPNONICA POLLEN (CJP-4) ALLERGEN 3.2.1.14
5H7W CRYSTAL STRUCTURE OF 5'-NUCLEOTIDASE FROM VENOM OF NAJA ATRA 3.1.3.5
5H8C TRUNCATED XPD 3.6.4.12
5H8W XPD MECHANISM 3.6.4.12
5H8X CRYSTAL STRUCTURE OF THE COMPLEX MMP-8/BF471 (CATECHOL INHIBITOR) 3.4.24.34
5H9X CRYSTAL STRUCTURE OF GH FAMILY 64 LAMINARIPENTAOSE-PRODUCING BETA-1,3-GLUCANASE FROM PAENIBACILLUS BARENGOLTZII 3.2.1.39
5H9Y CRYSTAL STRUCTURE OF GH FAMILY 64 LAMINARIPENTAOSE-PRODUCING BETA-1,3-GLUCANASE FROM PAENIBACILLUS BARENGOLTZII COMPLEXED WITH LAMINARIHEXAOSE. 3.2.1.39
5HAA CRYSTAL STRUCTURE OF MPY-RNASE J, AN ARCHAEAL RNASE J FROM METHANOLOBUS PSYCHROPHILUS R15 3.1
5HAB CRYSTAL STRUCTURE OF MPY-RNASE J (MUTANT H84A), AN ARCHAEAL RNASE J FROM METHANOLOBUS PSYCHROPHILUS R15, COMPLEX WITH RNA 3.1
5HAI P99 BETA-LACTAMASE MUTANT - S64G 3.5.2.6
5HAP OXA-48 BETA-LACTAMASE - S70A MUTANT 3.5.2.6
5HAQ OXA-48 BETA-LACTAMASE MUTANT - S70G 3.5.2.6
5HAR OXA-163 BETA-LACTAMASE - S70G MUTANT 3.5.2.6
5HBC INTERMEDIATE STRUCTURE OF IRON-SATURATED C-LOBE OF BOVINE LACTOFERRIN AT 2.79 ANGSTROM RESOLUTION INDICATES THE SOFTENING OF IRON COORDINATION 3.4.21
5HBM CRYSTAL STRUCTURE OF A DIHYDROXYCOUMARIN RNASE H ACTIVE-SITE INHIBITOR IN COMPLEX WITH HIV-1 REVERSE TRANSCRIPTASE 2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
3.4.23.16
2.7.7
3.1
5HBZ STRUCTURE OF EAV NSP11 K170A MUTANT AT 3.10A 3.4.22
3.4.19.12
3.4.21
2.7.7.48
3.6.4.12
3.6.4.13
5HC0 STRUCTURE OF ESTERASE EST22 WITH P-NITROPHENOL 3.1.1
5HC1 STRUCTURE OF EAV NSP11 H141A MUTANT AT 3.10A 3.4.22
3.4.19.12
3.4.21
2.7.7.48
3.6.4.12
3.6.4.13
5HC2 STRUCTURE OF ESTERASE EST22 MUTANT-S188A WITH P-NITROPHENOL 3.1.1
5HC3 THE STRUCTURE OF ESTERASE EST22 3.1.1
5HC4 STRUCTURE OF ESTERASE EST22 3.1.1
5HC5 THE STRUCTURE OF ESTERASE EST22 MUTANT-S188A 3.1.1
5HCI GPN-LOOP GTPASE NPA3 IN COMPLEX WITH GDP 3.6.5
5HCN GPN-LOOP GTPASE NPA3 IN COMPLEX WITH GMPPCP 3.6.5
5HCO ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE 3.4.23.22
5HCU CRYSTAL STRUCTURE OF MOUSE ACETYLCHOINESTERASE INHIBITED BY DFP 3.1.1.7
5HDE CRYSTAL STRUCTURE OF PTPN12 CATALYTIC DOMAIN 3.1.3.48
5HF7 TDG ENZYME-SUBSTRATE COMPLEX 3.2.2.29
5HFO CRYSTAL STRUCTURE OF OXA-232 BETA-LACTAMASE 3.5.2.6
5HGT CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS L25K/I92T AT CRYOGENIC TEMPERATURE 3.1.31.1
5HGW CRYSTAL STRUCTURE OF A PEPTIDE DEFORMYLASE FROM BURKHOLDERIA AMBIFARIA 3.5.1.88
5HH4 CRYSTAL STRUCTURE OF METALLO-BETA-LACTAMASE IMP-1 IN COMPLEX WITH A PHOSPHONATE-BASED INHIBITOR 3.5.2.6
5HH5 CRYSTAL STRUCTURE OF B3 METALLO-BETA-LACTAMASE L1 COMPLEXED WITH A PHOSPHONATE-BASED INHIBITOR 3.5.2.6
5HH6 CRYSTAL STRUCTURE OF B3 METALLO-BETA-LACTAMASE L1 IN COMPLEX WITH A PHOSPHONATE-BASED INHIBITOR 3.5.2.6
5HIF CRYSTAL STRUCTURE OF A RECONSTRUCTED LACTONASE ANCESTOR, ANC1-MPH, OF THE BACTERIAL METHYL PARATHION HYDROLASE, MPH. 3.1.1.35
5HIH CRYSTAL STRUCTURE OF THE MACRO DOMAIN IN MIDDLE-EAST RESPIRATORY SYNDROME CORONAVIRUS 3.4.19.12
3.4.22.69
3.4.22
5HIY CRYSTAL STRUCTURE OF PEDV NSP9 MUTANT-C59A 3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5HIZ THE STRUCTURE OF PEDV NSP9 3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5HJ5 CRYSTAL STRUCTURE OF TERTIARY COMPLEX OF GLUCOSAMINE-6-PHOSPHATE DEAMINASE FROM VIBRIO CHOLERAE WITH BETA-D-GLUCOSE-6-PHOSPHATE AND FRUCTOSE-6-PHOSPHATE 3.5.99.6
5HJZ STRUCTURE OF M. TUBERCULOSIS MAZF-MT1 (RV2801C) IN COMPLEX WITH RNA 3.1
5HK0 CRYSTAL STRUCTURE OF M. TUBERCULOSIS MAZF-MT3 (RV1991C) IN COMPLEX WITH RNA 3.1.27
5HK3 CRYSTAL STRUCTURE OF M. TUBERCULOSIS MAZF-MT3 T52D-F62D MUTANT IN COMPLEX WITH DNA 3.1.27
5HKC CRYSTAL STRUCTURE OF M. TUBERCULOSIS MAZF-MT3 T52D-F62D MUTANT IN COMPLEX WITH 8-MER RNA 3.1.27
5HKK CALDALAKLIBACILLUS THERMARUM F1-ATPASE (WILD TYPE) 3.6.3.14
7.1.2.2
5HKO CRYSTAL STRUCTURE OF ABC TRANSPORTER SOLUTE BINDING PROTEIN MSMEG_3598 FROM MYCOBACTERIUM SMEGMATIS STR. MC2 155, TARGET EFI-510969, IN COMPLEX WITH L-SORBITOL 3.6.3.17
5HKQ CRYSTAL STRUCTURE OF CDI COMPLEX FROM ESCHERICHIA COLI STEC_O31 3.1
5HLB E. COLI PBP1B IN COMPLEX WITH ACYL-AZTREONAM AND MOENOMYCIN 2.4.1.129
3.4
3.4.16.4
5HLD E. COLI PBP1B IN COMPLEX WITH ACYL-CENTA AND MOENOMYCIN 2.4.1.129
3.4
3.4.16.4
5HLF STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH A 38-MER HAIRPIN TEMPLATE-PRIMER DNA APTAMER AND AN ALPHA-CARBOXYPHOSPHONATE INHIBITOR 2.7.7.49
3.4.23.16
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5HLK CRYSTAL STRUCTURE OF THE TERNARY ECORV-DNA-LU COMPLEX WITH CLEAVED DNA SUBSTRATE. 3.1.21.4
5HLL RE-REFINEMENT OF 4G4A: ROOM-TEMPERATURE X-RAY DIFFRACTION STUDY OF CISPLATIN AND ITS BINDING TO HIS15 OF HEWL AFTER 14 MONTHS CHEMICAL EXPOSURE IN THE PRESENCE OF DMSO. 3.2.1.17
5HMD CRYSTAL STRUCTURE OF TRIAZINE HYDROLASE VARIANT (Y215H/E241Q) 3.8.1.8
5HME CRYSTAL STRUCTURE OF TRIAZINE HYDROLASE VARIANT (P214T/Y215H) 3.8.1.8
5HMF CRYSTAL STRUCTURE OF TRIAZINE HYDROLASE VARIANT (P214T/Y215H/E241Q) 3.8.1.8
5HMJ RE-REFINEMENT OF 4XAN: HEN LYSOZYME WITH CARBOPLATIN IN SODIUM BROMIDE SOLUTION 3.2.1.17
5HOH RIBONUCLEASE T1 (ASN9ALA/THR93ALA DOUBLEMUTANT) COMPLEXED WITH 2'GMP 3.1.27.3
4.6.1.24
5HOL THE CRYSTAL STRUCTURE OF THE MERS-COV MACRO DOMAIN WITH ADP-RIBOSE 3.4.19.12
3.4.22.69
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
2.1.1
3.1.13
3.1
5HP7 CRYSTAL STRUCTURES OF RIDA IN THE APO FORM 3.5.99.10
5HP8 CRYSTAL STRUCTURES OF RIDA IN COMPLEX WITH PYRUVATE 3.5.99.10
5HPG STRUCTURE AND LIGAND DETERMINANTS OF THE RECOMBINANT KRINGLE 5 DOMAIN OF HUMAN PLASMINOGEN 3.4.21.7
5HQD ACOUSTIC INJECTORS FOR DROP-ON-DEMAND SERIAL FEMTOSECOND CRYSTALLOGRAPHY 3.4.24
5HR5 BOVINE HEART 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE (PFKFB2) 2.7.1.105
3.1.3.46
5HRN HIV INTEGRASE CATALYTIC DOMAIN CONTAINING F185K MUTATION COMPLEXED WITH GSK0002 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5HRP HIV INTEGRASE CATALYTIC DOMAIN CONTAINING F185K + A124T MUTATIONS COMPLEXED WITH GSK0002 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5HRR HIV INTEGRASE CATALYTIC DOMAIN CONTAINING F185K + A124N + T125S MUTATIONS COMPLEXED WITH GSK0002 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5HRS HIV INTEGRASE CATALYTIC DOMAIN CONTAINING F185K + A124N + T125A MUTATIONS COMPLEXED WITH GSK0002 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5HSW KSHV SOX RNA COMPLEX 3.1
5HTK HUMAN HEART 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE (PFKFB2) 2.7.1.105
3.1.3.46
5HTZ BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-2,5-DIMETHYL-1,2,4-THIADIAZINAN-3-IMINIUM 1,1-DIOXIDE 3.4.23.46
5HU0 BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5-OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM 3.4.23.46
5HU1 BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5-FLUOROPICOLINAMIDE 3.4.23.46
5HU4 CYSTAL STRUCTURE OF LISTERIA MONOCYTOGENES SORTASE A 3.4.22
5HUR CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS L25T/I92K AT CRYOGENIC TEMPERATURE 3.1.31.1
5HVI CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE 3.5.2.6
5HVP CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN AT 2.0-ANGSTROMS RESOLUTION 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5HW1 CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE IN THE PRESENCE OF 1.2 MPA XENON 3.5.2.6
5HW3 CRYSTAL STRUCTURE OF A BETA LACTAMASE FROM BURKHOLDERIA VIETNAMIENSIS 3.5.2.6
5HW5 CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE IN THE PRESENCE OF 2.0 MPA XENON 3.5.2.6
5HWA CRYSTAL STRUCTURE OF MH-K1 CHITOSANASE IN SUBSTRATE-BOUND FORM 3.2.1.132
5HWE HIGH RESOLUTION STRUCTURE OF BARBITURASE 3.5.2.1
5HX9 CRYSTAL STRUCTURE OF BETA-LACTAMASE FROM BURKHOLDERIA VIETNAMIENSIS 3.5.2.6
5HXD CRYSTAL STRUCTURE OF MUREIN-TRIPEPTIDE AMIDASE MPAA FROM ESCHERICHIA COLI O157 3.4.17
5HXM CYCLOALTERNAN-FORMING ENZYME FROM LISTERIA MONOCYTOGENES IN COMPLEX WITH PANOSE 3.2.1.177
5HXU STRUCTURE-FUNCTION ANALYSIS OF FUNCTIONALLY DIVERSE MEMBERS OF THE CYCLIC AMIDE HYDROLASE FAMILY OF TOBLERONE FOLD ENZYMES 3.5.2.1
5HXZ STRUCTURE-FUNCTION ANALYSIS OF FUNCTIONALLY DIVERSE MEMBERS OF THE CYCLIC AMIDE HYDROLASE FAMILY OF TOBLERONE FOLD ENZYMES 3.5.2.1
5HY0 OROTIC ACID HYDROLASE 3.5.2.15
3.5.2
5HY1 HIGH RESOLUTION STRUCTURE OF BARBITURASE 3.5.2.1
5HY2 STRUCTURE-FUNCTION ANALYSIS OF FUNCTIONALLY DIVERSE MEMBERS OF THE CYCLIC AMIDE HYDROLASE FAMILY OF TOBLERONE FOLD ENZYMES 3.5.2.15
3.5.2
5HZH CRYSTAL STRUCTURE OF PHOTOINHIBITABLE RAC1 CONTAINING C450A MUTANT LOV2 DOMAIN 3.6.5.2
5HZK CRYSTAL STRUCTURE OF PHOTOINHIBITABLE INTERSECTIN1 CONTAINING WILDTYPE LOV2 DOMAIN IN COMPLEX WITH CDC42 3.6.5.2
5I0A RECA MINI INTEIN IN COMPLEX WITH CISPLATIN 3.1
5I13 ENDONUCLEASE INHIBITOR 2 BOUND TO INFLUENZA STRAIN H1N1 POLYMERASE ACIDIC SUBUNIT N-TERMINAL REGION AT PH 7.0 3.1
5I14 TRUNCATED AND MUTATED T4 LYSOZYME 3.2.1.17
5I3D SULFOLOBUS SOLFATARICUS BETA-GLYCOSIDASE - E387Y MUTANT 3.2.1.23
5I3E CRYSTAL STRUCTURE OF PUTATIVE PUTATIVE DEOXYRIBONUCLEASE-2 FROM BURKHOLDERIA THAILANDENSIS, E264 3.1
5I4M CRYSTAL STRUCTURE OF AMIDASE, HYDANTOINASE/CARBAMOYLASE FAMILY FROM BURKHOLDERIA VIETNAMIENSIS 3.5.1.87
5I4Q CONTACT-DEPENDENT INHIBITION SYSTEM FROM ESCHERICHIA COLI NC101 - TERNARY CDIA/CDII/EF-TU COMPLEX (DOMAINS 2 AND 3) 3.1
5I4R CONTACT-DEPENDENT INHIBITION SYSTEM FROM ESCHERICHIA COLI NC101 - TERNARY CDIA/CDII/EF-TU COMPLEX (TRYPSIN-MODIFIED) 3.1
5I4W EXPLORING THE ONSET OF LYSOZYME DENATURATION BY UREA 3.2.1.17
5I4X EXPLORING ONSET OF LYSOZYME DENATURATION BY UREA - SOAK PERIOD 2 HOURS 3.2.1.17
5I4Y EXPLORING ONSET OF LYSOZYME DENATURATION BY UREA: SOAK PERIOD 10 HOURS. 3.2.1.17
5I52 CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE MUTANT I263N 3.5.2.6
5I53 EXPLORING ONSET OF LYSOZYME DENATURATION BY UREA - SOAK PERIOD 7 HOURS 3.2.1.17
5I54 EXPLORING ONSET OF LYSOZYME DENATURATION BY UREA - SOAK PERIOD 4 HOURS 3.2.1.17
5I63 CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE MUTANT I263N IN THE PRESENCE OF 1.2 MPA XENON 3.5.2.6
5I6W CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS A58D AT CRYOGENIC TEMPERATURE 3.1.31.1
5I6Y CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS A90E AT CRYOGENIC TEMPERATURE 3.1.31.1
5I77 CRYSTAL STRUCTURE OF A BETA-1,4-ENDOGLUCANASE FROM ASPERGILLUS NIGER 3.2.1.4
5I78 CRYSTAL STRUCTURE OF A BETA-1,4-ENDOGLUCANASE FROM ASPERGILLUS NIGER 3.2.1.4
5I79 CRYSTAL STRUCTURE OF A BETA-1,4-ENDOGLUCANASE MUTANT FROM ASPERGILLUS NIGER IN COMPLEX WITH SUGAR 3.2.1.4
5I81 ASMASE WITH ZINC 3.1.4.12
5I85 ASMASE WITH ZINC AND PHOSPHOCHOLINE 3.1.4.12
5I8L CRYSTAL STRUCTURE OF THE FULL-LENGTH CELL WALL-BINDING MODULE OF CPL7 MUTANT R223A 3.2.1.17
5I8Q S. CEREVISIAE PRP43 IN COMPLEX WITH RNA AND ADPNP 3.6.4.13
5I8R ASMASE WITH ZINC 3.1.4.12
5I8U CRYSTAL STRUCTURE OF THE RV1700 (MT ADPRASE) E142Q MUTANT 3.6.1.13
3.6.1.58
5I9B CASPASE 3 V266A 3.4.22.56
5I9T CASPASE 3 V266C 3.4.22.56
5IAB CASPASE 3 V266D 3.4.22.56
5IAE CASPASE 3 V266F 3.4.22.56
5IAG CASPASE 3 V266Q 3.4.22.56
5IAJ CASPASE 3 V266L 3.4.22.56
5IAK CASPASE 3 V266S 3.4.22.56
5IAN CASPASE 3 V266N 3.4.22.56
5IAR CASPASE 3 V266W 3.4.22.56
5IAS CASPASE 3 V266Y 3.4.22.56
5IBC CASPASE 3 V266I 3.4.22.56
5IBP CASPASE 3 V266M 3.4.22.56
5IBR CASPASE 3 V266K 3.4.22.56
5IDI STRUCTURE OF BETA GLUCOSIDASE 1A FROM THERMOTOGA NEAPOLITANA, MUTANT E349A 3.2.1.74
3.2.1.21
5IDK CRYSTAL STRUCTURE OF WEST NILE VIRUS NS2B-NS3 PROTEASE IN COMPLEX WITH A CAPPED DIPEPTIDE BORONATE INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5IDV STRUCTURE OF THE NUCLEOTIDE BINDING DOMAIN OF AN ABC TRANSPORTER MSBA FROM ACINETOBACTER BAUMANNII 3.6.3
5IEL STRUCTURE OF LYSOZYME LABELED WITH FLUORESCEIN ISOTHIOCYANATE (FITC) AT 1.15 ANGSTROMS RESOLUTION 3.2.1.17
5IEQ CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FRAGMENT HIT EBSI-747 1-(4-CHLOROPHENYL)-1H-IMIDAZOLE 3.1
5IF2 CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FRAGMENT HIT EBSI-576 (5,6-DICHLORO-1H-1,3-BENZODIAZOL-2-YL)METHANOL 3.1
5IF5 CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO EBSI-39 (2,3-DICHLOROPHENYL)METHANOL 3.1
5IF7 CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FRAGMENT HIT EBSI-279 N-[(4-CHLOROPHENYL)METHYL]-1-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 3.1
5IF8 CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FRAGMENT HIT EBSI-2643 5-[(4-CHLOROPHENYL)METHYL]-1,3,4-OXADIAZOL-2-AMINE 3.1
5IFB CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FOLLOW ON FRAGMENT EBSI-4719 5-CHLORO-2-(1H-IMIDAZOL-1-YL)ANILINE 3.1
5IFC CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FOLLOW ON FRAGMENT EBSI-4720 1-(4-BROMOPHENYL)-1H-IMIDAZOLE 3.1
5IFD CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FOLLOW ON FRAGMENT EBSI-4721 1-(4-FLUOROPHENYL)-1H-IMIDAZOLE 3.1
5IFG CRYSTAL STRUCTURE OF HIGA-HIGB COMPLEX FROM E. COLI 3.1
5IFP STRUCTURE OF BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER 3.2.1.23
5IFT STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 3-B-GALACTOPYRANOSYL GLUCOSE 3.2.1.23
5IH7 ACETYLCHOLINESTERASE OF TORPEDO CALIFORNICA IN COMPLEX WITH THE N-METHYL-INDOXYLACETATE HYDROLYSIS PRODUCTS 3.1.1.7
5IHG THE X-RAY STRUCTURE OF THE ADDUCT FORMED IN THE REACTION BETWEEN HEN EGG WHITE LYSOZYME A COMPOUND I, A PLATIN(II) COMPOUND CONTAINING A O, S BIDENTATE LIGAND 3.2.1.17
5IHR STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH ALLOLACTOSE 3.2.1.23
5II3 THE X-RAY STRUCTURE OF THE ADDUCT FORMED IN THE REACTION BETWEEN HEN EGG WHITE LYSOZYME AND COMPOUND 3, A PLATIN(II) COMPOUND CONTAINING A O, S BIDENTATE LIGAND 3.2.1.17
5IKE CRYSTAL STRUCTURE OF MUTANT-D97N OF PEPTIDYL-TRNA HYDROLASE FROM VIBRIO CHOLERAE 3.1.1.29
5IKU CRYSTAL STRUCTURE OF THE HATHEWAYA HISTOLYTICA COLG TANDEM COLLAGEN-BINDING DOMAIN S3AS3B IN THE PRESENCE OF CALCIUM AT 1.9 ANGSTROM RESOLUTION 3.4.24.3
5IL9 CRYSTAL STRUCTURE OF DEG9 3.4.21
5ILA DEG9 PROTEASE DOMAIN 3.4.21
5ILB CRYSTAL STRUCTURE OF PROTEASE DOMAIN OF DEG2 LINKED WITH THE PDZ DOMAIN OF DEG9 3.4.21
5ILC THE X-RAY STRUCTURE OF THE ADDUCT FORMED IN THE REACTION BETWEEN HEN EGG WHITE LYSOZYME A COMPOUND 2, A PLATIN(II) COMPOUND CONTAINING A O, S BIDENTATE LIGAND 3.2.1.17
5ILF THE X-RAY STRUCTURE OF THE ADDUCT FORMED IN THE REACTION BETWEEN HEN EGG WHITE LYSOZYME AND COMPOUND 4, A PLATIN(II) COMPOUND CONTAINING A O, S BIDENTATE LIGAND 3.2.1.17
5IMB CRYSTAL STRUCTURE OF PEPTIDYL-TRNA HYDROLASE MUTANT-N14D FROM VIBRIO CHOLERAE 3.1.1.29
5INB REPOMAN-PP1G (PROTEIN PHOSPHATASE 1, GAMMA ISOFORM) HOLOENZYME COMPLEX 3.1.3.16
5INH CRYSTAL STRUCTURE OF AUTOTAXIN/ENPP2 WITH A COVALENT FRAGMENT 3.1.4.39
5IOH REPOMAN-PP1A (PROTEIN PHOSPHATASE 1, ALPHA ISOFORM) HOLOENZYME COMPLEX 3.1.3.16
5IP5 HUMAN DJ-1 COMPLEXED WITH NA-K-TARTRATE 3.1.2
3.5.1
3.5.1.124
5IPB HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT 3
5IPC HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT NUCLEOSIDE THIOPHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5IPD HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) NUCLEOSIDE THIOPHOSPHORAMIDATE COVALENT INTERMEDIATE COMPLEX 3
5IPE HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) NUCLEOSIDE THIOPHOSPHORAMIDATE CATALYTIC PRODUCT COMPLEX 3
5IPP STRUCTURE OF BACILLUS NANORNASE A ACTIVE SITE MUTANT BOUND TO A MONONUCLEOTIDE 3.1.3.7
3.1
5IQ5 NMR SOLUTION STRUCTURE OF MAYARO VIRUS MACRO DOMAIN 2.1.1
2.7.7
3.1.3.33
3.4.22
3.6.1.15
3.6.4.13
2.7.7.48
3.1.3.84
2.7.7.19
5IQ6 CRYSTAL STRUCTURE OF DENGUE VIRUS SEROTYPE 3 RNA DEPENDENT RNA POLYMERASE BOUND TO HEE1-2TYR, A NEW PYRIDOBENZOTHIZOLE INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5IQ8 CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE MUTANT A224C/G283C DISULFIDE 3.5.2.6
5IS4 ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL BROMINATED PRIMARY AMINE FRAGMENT 3.4.23.22
5ISJ ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL CHLORINATED PRIMARY AMINE FRAGMENT 3.4.23.22
5ISK ENDOTHIAPEPSIN IN COMPLEX WITH FLUORINATED PRIMARY AMINE FRAGMENT 3.4.23.22
5ISN NMR SOLUTION STRUCTURE OF MACRO DOMAIN FROM VENEZUELAN EQUINE ENCEPHALITIS VIRUS 2.1.1
2.7.7
3.1.3.33
3.4.22
3.6.1.15
3.6.4.13
2.7.7.48
3.1.3.84
2.7.7.19
5ISY CRYSTAL STRUCTURE OF NUDIX FAMILY PROTEIN WITH NAD 3.6.1.22
3.6.1
5IUF BACILLUS NANORNASE A ACTIVE SITE MUTANT BOUND TO PAP 3.1.3.7
3.1
5IVL CSHA HELICASE 3.6.4.13
5IVP CRYSTAL STRUCTURE OF THE PEPTIDYL-TRNA HYDROLASE FROM VIBRIO CHOLERAE IN THE C121 SPACE GROUP AT PH 6.5 3.1.1.29
5IYT COMPLEX STRUCTURE OF EV-B93 MAIN PROTEASE 3C WITH N-ETHYL 4-((1-CYCLOHEPTYL-1,2-DIHYDROPYRAZOL-3-ONE-5-YL)-AMINO)-4-OXO-2Z-BUTENAMIDE 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5IZO BACILLUS NANORNASE A (H103A) + 2 DIVALENT CATIONS + PO4 AT THE ACTIVE SITE 3.1
3.1.3.7
5J1Q CARBOXYPEPTIDASE B WITH SULPHAMOIL PHENYLALANINE 3.4.17.2
5J21 STRUCTURE OF BACILLUS NANORNASE A (WT) 3.1.3.7
3.1
5J25 ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158 3.4.23.22
5J28 KI67-PP1G (PROTEIN PHOSPHATASE 1, GAMMA ISOFORM) HOLOENZYME COMPLEX 3.1.3.16
5J3J CRYSTAL STRUCTURE OF HUMAN DPP-IV IN COMPLEX WITH HL1 3.4.14.5
5J3N C-TERMINAL DOMAIN OF ECOR124I HSDR SUBUNIT FUSED WITH THE PH-SENSITIVE GFP VARIANT RATIOMETRIC PHLUORIN 3.1.21.3
5J44 CRYSTAL STRUCTURE OF THE SECRETED EXTRACELLULAR PROTEIN A (SEPA) FROM SHIGELLA FLEXNERI 3.4.21
5J4Q ALPHA-CHYMOTRYPSIN FROM BOVINE PANCREAS IN COMPLEX WITH BOWMAN-BIRK INHIBITOR FROM SOYBEAN 3.4.21.1
5J4S ALPHA-CHYMOTRYPSIN FROM BOVINE PANCREAS IN COMPLEX WITH A MODIFIED BOWMAN-BIRK INHIBITOR FROM SOYBEAN 3.4.21.1
5J56 RTA-V1C7 3.2.2.22
5J57 V5E1-RTA COMPLEX 3.2.2.22
5J5E CRYSTAL STRUCTURE OF ANTIGEN-ERAP1 DOMAIN COMPLEX 3.4.11
5J61 D-AMINOACYL-TRNA DEACYLASE (DTD) FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH GLYCYL-3'-AMINOADENOSINE AT 2.10 ANGSTROM RESOLUTION 3.1
3.1.1.96
5J6S CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2 (ERAP2) IN COMPLEX WITH A HYDROXAMIC DERIVATIVE LIGAND 3.4.11
5J70 THE CHD1 DNA-BINDING DOMAIN IN COMPLEX WITH 17MER DNA DUPLEX 3.6.4
5J72 CWP6 FROM CLOSTRIDIUM DIFFICILE 3.5.1.28
5J8J A HISTONE DEACETYLASE FROM SACCHAROMYCES CEREVISIAE 3.5.1.98
5J8T NMR STRUCTURE OF EXCALIBUR DOMAIN OF CBPL 3.2.1.96
5J9R STRUCTURE OF PENICILLIN V ACYLASE FROM AGROBACTERIUM TUMEFACIENS 3.5.1.24
5JA7 HUMAN CATHEPSIN K MUTANT C25S IN COMPLEX WITH THE ALLOSTERIC EFFECTOR NSC94914 3.4.22.38
5JAW STRUCTURE OF A BETA GALACTOSIDASE WITH INHIBITOR 3.2.1.23
5JBL STRUCTURE OF THE BACTERIOPHAGE T4 CAPSID ASSEMBLY PROTEASE, GP21. 3.4.99
3.4
5JBT MESOTRYPSIN IN COMPLEX WITH CLEAVED AMYLOID PRECURSOR LIKE PROTEIN 2 INHIBITOR (APLP2) 3.4.21.4
5JC6 CARBOXYPEPTIDASE B WITH 2-ND ZINC AND ACETATE ION 3.4.17.2
5JDT STRUCTURE OF SPIN-LABELLED T4 LYSOZYME MUTANT L118C-R1 AT 100K 3.2.1.17
5JEX CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE, CRYSTALLIZED IN IMIDAZOLE BUFFER 3.5.1.88
5JEY CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE, CRYSTALLIZED IN CACODYLATE BUFFER 3.5.1.88
5JEZ CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH TRIPEPTIDE MET-ALA-SER 3.5.1.88
5JF0 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH TRIPEPTIDE MET-ALA-ARG 3.5.1.88
5JF1 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH ACTINONIN 3.5.1.88
5JF2 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR AT002 3.5.1.88
5JF3 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR AT018 3.5.1.88
5JF4 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR AT019 3.5.1.88
5JF5 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR AT020 3.5.1.88
5JF6 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR 6B (AB47) 3.5.1.88
5JF7 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR SMP289 3.5.1.88
5JF8 CRYSTAL STRUCTURE OF TYPE 2 PDF FROM STREPTOCOCCUS AGALACTIAE IN COMPLEX WITH INHIBITOR RAS358 (21) 3.5.1.88
5JFD THROMBIN IN COMPLEX WITH (S)-N-(2-(AMINOMETHYL)-5-CHLOROBENZYL)-1-((BENZYLSULFONYL)-D-ARGINYL)PYRROLIDINE-2-CARBOXAMIDE 3.4.21.5
5JFP HIV-1 WILD TYPE PROTEASE WITH GRL-097-13A (A ADAMANTANE P1-LIGAND WITH BIS-THF IN P2 AND ISOBUTYLAMINE IN P1') 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5JFU HIV-1 WILD TYPE PROTEASE WITH GRL-007-14A (A ADAMANTANE P1-LIGAND WITH BIS-THF IN P2 AND BENZYLAMINE IN P1') 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5JG1 HIV-1 WILD TYPE PROTEASE WITH GRL-031-14A (A ADAMANTANE P1-LIGAND WITH TETRAHYDROPYRANO-TETRAHYDROFURAN IN P2 AND ISOBUTYLAMINE IN P1') 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5JGN SPIN-LABELED T4 LYSOZYME CONSTRUCT I9V1 3.2.1.17
5JGR SPIN-LABELED T4 LYSOZYME CONSTRUCT K43V1 3.2.1.17
5JGU SPIN-LABELED T4 LYSOZYME CONSTRUCT R119V1 3.2.1.17
5JGV SPIN-LABELED T4 LYSOZYME CONSTRUCT A73V1 3.2.1.17
5JGX SPIN-LABELED T4 LYSOZYME CONSTRUCT V131V1 3.2.1.17
5JGZ SPIN-LABELED T4 LYSOZYME CONSTRUCT T151V1 3.2.1.17
5JH3 HUMAN CATHEPSIN K MUTANT C25S 3.4.22.38
5JI2 HSLU L199Q IN HSLUV COMPLEX 3.4.25.2
5JI3 HSLUV COMPLEX 3.4.25.2
5JIB CRYSTAL STRUCTURE OF THE THERMOTOGA MARITIMA ACETYL ESTERASE (TM0077) COMPLEX WITH A SUBSTRATE ANALOG 3.1.1.41
3.1.1.72
5JIG CRYTSAL STRUCTURE OF WSS1 FROM S. POMBE 3.4.24
5JJI RHO TRANSCRIPTION TERMINATION FACTOR BOUND TO RU7 AND 6 ADP-BEF3 MOLECULES 3.6.4
5JJK RHO TRANSCRIPTION TERMINATION FACTOR BOUND TO RA7 AND 6 ADP-BEF3 MOLECULES 3.6.4
5JJL RHO TRANSCRIPTION TERMINATION FACTOR BOUND TO RU8 AND 5 ADP-BEF3 MOLECULES 3.6.4
5JJT CRYSTAL STRUCTURE OF A TYPE 5 SERINE/THREONINE PROTEIN PHOSPHATASE FROM ARABIDOPSIS THALIANA 3.1.3.16
5JKI CRYSTAL STRUCTURE OF THE FIRST TRANSMEMBRANE PAP2 TYPE PHOSPHATIDYLGLYCEROLPHOSPHATE PHOSPHATASE FROM BACILLUS SUBTILIS 3.1.3
3.1.3.27
5JKR VACCINIA VIRUS D4/A20(1-50)W43A MUTANT 3.2.2.27
5JKS VACCINIA VIRUS D4 R167A MUTANT /A20(1-50) 3.2.2.27
5JKT VACCINIA VIRUS D4 P173G MUTANT /A20(1-50) 3.2.2.27
5JL4 INHIBITOR RESISTANT MUTANT CATALYTIC CORE DOMAIN OF HIV-1 INTEGRASE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5JLP CRYSTAL STRUCTURE OF MYCOBACTERIUM AVIUM SERB2 IN COMPLEX WITH SERINE AT ACT DOMAIN 3.1.3.3
5JLR CRYSTAL STRUCTURE OF MYCOBACTERIUM AVIUM SERB2 WITH SERINE PRESENT AT SLIGHTLY DIFFERENT POSITION NEAR ACT DOMAIN 3.1.3.3
5JMA CRYSTAL STRUCTURE OF MYCOBACTERIUM AVIUM SERB2 IN COMPLEX WITH SERINE AT CATALYTIC (PSP) DOMAIN 3.1.3.3
5JMO X-RAY STRUCTURE OF FURIN IN COMPLEX WITH THE INHIBITORY ANTIBODY NB14 3.4.21.75
5JMX CRYSTAL STRUCTURE OF BCII METALLO-BETA-LACTAMASE IN COMPLEX WITH DZ-305 3.5.2.6
5JNR CRYSTAL STRUCTURE OF HUMAN LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) TYPE A 3.1.3.48
3.1.3.2
5JNS CRYSTAL STRUCTURE OF HUMAN LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) TYPE A COMPLEXED WITH PHOSPHATE 3.1.3.48
3.1.3.2
5JNT CRYSTAL STRUCTURE OF HUMAN LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) TYPE A COMPLEXED WITH MES 3.1.3.48
3.1.3.2
5JNU CRYSTAL STRUCTURE OF MOUSE LOW-MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE TYPE A (LMPTP-A) COMPLEXED WITH PHOSPHATE 3.1.3.48
3.1.3.2
5JNV CRYSTAL STRUCTURE OF BOVINE LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) MUTANT (W49Y N50E) COMPLEXED WITH HEPES 3.1.3.48
3.1.3.2
5JNW CRYSTAL STRUCTURE OF BOVINE LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) MUTANT (W49Y N50E) COMPLEXED WITH VANADATE AND UNCOMPETITIVE INHIBITOR 3.1.3.48
3.1.3.2
5JO3 PDE5A FOR NAV1.7 3.1.4.35
5JOC CRYSTAL STRUCTURE OF THE S61A MUTANT OF AMPC BER 3.5.2.6
5JOG CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5I-3 3.4
5JOH CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5I-1B 3.4
5JPC JOINT X-RAY/NEUTRON STRUCTURE OF MTAN COMPLEX WITH FORMYCIN A 3.2.2.30
3.2.2.9
5JPS STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE DOMAIN 3.6.4.13
3.4.21.91
3.6.1.15
2.1.1.56
2.1.1.57
2.7.7.48
5JPT CRYSTAL STRUCTURE OF THE PRP43P DEAH-BOX RNA HELICASE IN COMPLEX WITH CDP 3.6.4.13
5JQE CRYSTAL STRUCTURE OF CASPASE8 TDED 3.4.22.61
5JQJ DIRECTED EVOLUTIONARY CHANGES IN MBL SUPER FAMILY - NDM-1 ROUND 10 CRYSTAL-1 3.5.2.6
5JRM CRYSTAL STRUCTURE OF A XYLANASE AT 1.56 ANGSTROEM RESOLUTION 3.2.1.8
5JRN CRYSTAL STRUCTURE OF A XYLANASE IN COMPLEX WITH A MONOSACCHARIDE AT 2.84 ANGSTROEM RESOLUTION 3.2.1.8
5JS3 THERMOLYSIN IN COMPLEX WITH JC114. 3.4.24.27
5JSS THERMOLYSIN IN COMPLEX WITH JC149. 3.4.24.27
5JT8 STRUCTURAL BASIS FOR THE LIMITED ANTIBODY CROSS REACTIVITY BETWEEN THE MITE ALLERGENS BLO T 1 AND DER P 1 3.4.22
5JT9 THERMOLYSIN IN COMPLEX WITH JC106. 3.4.24.27
5JTA NEUTRAL TREHALASE NTH1 FROM SACCHAROMYCES CEREVISIAE 3.2.1.28
5JTS STRUCTURE OF A BETA-1,4-MANNANASE, SSGH134. 3.2.1.78
5JTV USP7CD-UBL45 IN COMPLEX WITH UBIQUITIN 3.4.19.12
5JU9 STRUCTURE OF A BETA-1,4-MANNANASE, SSGH134, IN COMPLEX WITH MAN3. 3.2.1.78
5JUG STRUCTURE OF AN INACTIVE (E45Q) VARIANT OF A BETA-1,4-MANNANASE, SSGH134, IN COMPLEX WITH MAN5 3.2.1.78
5JUV STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 6-B-GALACTOPYRANOSYL GALACTOSE 3.2.1.23
5JVI THERMOLYSIN IN COMPLEX WITH JC148. 3.4.24.27
5JWF CRYSTAL STRUCTURE OF PORPHYROMONAS GINGIVALIS DPP11 3.4.14
5JWG CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP 3.4.14
5JWH APO STRUCTURE 3.4.21.91
3.6.1.15
3.6.4.13
5JWI CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH DIPEPTIDE ARG-GLU 3.4.14
5JWS T4 LYSOZYME L99A WITH 1-HYDRO-2-ETHYL-1,2-AZABORINE BOUND 3.2.1.17
5JWT T4 LYSOZYME L99A/M102Q WITH BENZENE BOUND 3.2.1.17
5JWU T4 LYSOZYME L99A/M102Q WITH 1,2-DIHYDRO-1,2-AZABORINE BOUND 3.2.1.17
5JWV T4 LYSOZYME L99A/M102Q WITH ETHYLBENZENE BOUND 3.2.1.17
5JWW T4 LYSOZYME L99A/M102Q WITH 1-HYDRO-2-ETHYL-1,2-AZABORINE BOUND 3.2.1.17
5JX0 TEMPERATURE SENSITIVE D4 MUTANT L110F 3.2.2.27
5JX5 GH6 ORPINOMYCES SP. Y102 ENZYME 3.2.1
5JX8 NEW IMPROVED STRUCTURE OF D4 IN TRIGONAL SPACE GROUP 3.2.2.27
5JXG STRUCTURE OF THE UNLIGANDED FORM OF THE PROPROTEIN CONVERTASE FURIN. 3.4.21.75
5JXH STRUCTURE THE PROPROTEIN CONVERTASE FURIN IN COMPLEX WITH META-GUANIDINOMETHYL-PHAC-RVR-AMBA AT 2.0 ANGSTROM RESOLUTION. 3.4.21.75
5JXI STRUCTURE OF THE UNLIGANDED FORM OF THE PROPROTEIN CONVERTASE FURIN IN PRESENCE OF EDTA. 3.4.21.75
5JXJ STRUCTURE OF THE PROPROTEIN CONVERTASE FURIN COMPLEXED TO META-GUANIDINOMETHYL-PHAC-RVR-AMBA IN PRESENCE OF EDTA 3.4.21.75
5JXK CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 3.4.14
5JXN THERMOLYSIN IN COMPLEX WITH JC240. 3.4.24.27
5JXP CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN ALTERNATE CONFORMATION 3.4.14
5JXY ENZYME-SUBSTRATE COMPLEX OF TDG CATALYTIC DOMAIN BOUND TO A G/U ANALOG 3.2.2.29
5JY0 CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH SUBSTRATE 3.4.14
5JY7 COMPLEX OF MYCOBACTERIUM SMEGMATIS TREHALOSE SYNTHASE WITH MALTOKINASE 3.2.1.1
5.4.99.16
5JYK DEG9 CRYSTAL UNDER 289K 3.4.21
5JZ9 CRYSTAL STRUCTURE OF HSAD BOUND TO 3,5-DICHLORO-4-HYDROXYBENZENESULPHONIC ACID 3.7.1.17
3.7.1.8
5JZB CRYSTAL STRUCTURE OF HSAD BOUND TO 3,5-DICHLOROBENZENE SULPHONAMIDE 3.7.1.17
3.7.1.8
5JZS HSAD BOUND TO 3,5-DICHLORO-4-HYDROXYBENZOIC ACID 3.7.1.8
3.7.1.17
5JZY THROMBIN IN COMPLEX WITH (S)-1-((R)-2-AMINO-3-CYCLOHEXYLPROPANOYL)-N-(4-CARBAMIMIDOYLBENZYL)PYRROLIDINE-2-CARBOXAMIDE 3.4.21.5
5K08 RECA MINI INTEIN-ZEISE'S SALT COMPLEX 3.1
5K1D CRYSTAL STRUCTURE OF A CLASS C BETA LACTAMASE/COMPOUND1 COMPLEX 3.5.2.6
5K1F CRYSTAL STRUCTURE OF A CLASS C BETA LACTAMASE/COMPOUND2 COMPLEX 3.5.2.6
5K1V CRYSTAL STRUCTURE OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2 (ERAP2) IN COMPLEX WITH A DIAMINOBENZOIC ACID DERIVATIVE LIGAND. 3.4.11
5K1Z JOINT X-RAY/NEUTRON STRUCTURE OF MTAN COMPLEX WITH P-CLPH-THIO-DADME-IMMA 3.2.2.30
3.2.2.9
5K20 CASPASE-7 S239E PHOSPHOMIMETIC 3.4.22.60
5K22 CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN HUMAN PRL-2 PHOSPHATASE IN REDUCED STATE AND BATEMAN DOMAIN OF HUMAN CNNM3 3.1.3.48
5K23 CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN HUMAN PHOSPHATASE PRL-2 IN THE OXIDIZED STATE WITH THE BATEMAN DOMAIN OF HUMAN MAGNESIUM TRANSPORTER CNNM3 3.1.3.48
5K24 CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PHOSPHATASE PRL-2 IN THE OXIDIZED STATE WITH THE BATEMAN DOMAIN OF MURINE MAGNESIUM TRANSPORTER CNNM3 3.1.3.48
5K25 CRYSTAL STRUCTURE OF HUMAN PHOSPHATASE PRL-2 IN COMPLEX WITH THE ADP-BOUND BATEMAN DOMAIN OF HUMAN MAGNESIUM TRANSPORTER CNNM3 3.1.3.48
5K2K CRYSTAL STRUCTURE OF LYSOZYME 3.2.1.17
5K2N LYSOZYME WITH NANO PARTICLES 3.2.1.17
5K2P CRYSTAL STRUCTURE OF LYSOZYME 3.2.1.17
5K2Q LYSOZYME WITH NANO PARTICLES 3.2.1.17
5K2R CRYSTAL STRUCTURE OF LYSOZYME 3.2.1.17
5K2S LYSOZYME WITH NANO PARTICLES 3.2.1.17
5K32 PDE4D CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR 3.1.4.53
5K3A CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - HIS280ASN/FLUOROACETATE - COCRYSTALLIZED - BOTH PROTOMERS REACTED WITH LIGAND 3.8.1.3
5K3B CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - ASP110ASN/CHLOROACETATE - COCRYSTALLIZED 3.8.1.3
5K3C CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - WT/5-FLUOROTRYPTOPHAN 3.8.1.3
5K3D CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - WT/APO - NO HALIDE 3.8.1.3
5K3E CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - ASP110ASN/GLYCOLATE - COCRYSTALLIZED 3.8.1.3
5K3F CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - HIS280ASN/FLUOROACETATE - COCRYSTALLIZED - SINGLE PROTOMER REACTED WITH LIGAND 3.8.1.3
5K3O WOLINELLA SUCCINOGENES L-ASPARAGINASE P121 AND L-ASPARTIC ACID 3.5.1.1
5K45 WOLINELLA SUCCINOGENES L-ASPARAGINASE P121 + L-GLUTAMIC ACID 3.5.1.1
5K4G WOLINELLA SUCCINOGENES L-ASPARAGINASE S121 + L-ASPARTIC ACID, OPEN CONFORMATION 3.5.1.1
5K4M DIRECTED EVOLUTIONARY CHANGES IN MBL SUPER FAMILY - NDM-1 ROUND 10 CRYSTAL-3 3.5.2.6
5K54 HUMAN MUSCLE FRUCTOSE-1,6-BISPHOSPHATASE E69Q MUTANT IN ACTIVE R-STATE 3.1.3.11
5K55 HUMAN MUSCLE FRUCTOSE-1,6-BISPHOSPHATASE E69Q MUTANT IN ACTIVE R-STATE IN COMPLEX WITH FRUCTOSE-6-PHOSPHATE 3.1.3.11
5K56 HUMAN MUSCLE FRUCTOSE-1,6-BISPHOSPHATASE IN ACTIVE R-STATE IN COMPLEX WITH FRUCTOSE-1,6-BISPHOSPHATE 3.1.3.11
5K6J HUMAN PHOSPODIESTERASE 4B IN COMPLEX WITH PYRIDYLOXY-BENZOXABOROLE BASED INHIBITOR 3.1.4.53
5K6L STRUCTURE OF A GH3 B-GLUCOSIDASE FROM COW RUMEN METAGENOME 3.2.1.21
5K6M STRUCTURE OF A GH3 B-GLICOSIDASE FROM COW RUMEN METAGENOME IN COMPLEX WITH GLUCOSE 3.2.1.21
5K6O STRUCTURE OF A GH3 B-GLUCOSIDASE FROM COW RUMEN METAGENOME IN COMPLEX WITH GALACTOSE 3.2.1.21
5K7Y CRYSTAL STRUCTURE OF ENZYME IN PURINE METABOLISM 3.1.3.5
5K8I APO STRUCTURE 3.4.21.91
3.6.1.15
3.6.4.13
5K8L APO STRUCTURE 3.4.21.91
3.6.1.15
3.6.4.13
5K8M APO 5-NITROANTHRANILATE AMINOHYDROLASE 3.5.99.8
5K8T CRYSTAL STRUCTURE OF ZIKV NS3 HELICASE IN COMPLEX WITH GTP-GAMMAR S AND AN MAGNESIUM ION 3.4.21.91
3.6.1.15
3.6.4.13
5K8U APO STRUCTURE 3.4.21.91
3.6.1.15
3.6.4.13
5K95 CRYSTAL STRUCTURE OF GTP CYCLOHYDROLASE-IB WITH 8-OXO-GTP 3.5.4.16
5K9G CRYSTAL STRUCTURE OF GTP CYCLOHYDROLASE-IB WITH TRIS 3.5.4.16
5K9V PROTEIN TYROSINE PHOSPHATASE 1B (1-301), OPEN STATE 3.1.3.48
5K9W PROTEIN TYROSINE PHOSPHATASE 1B (1-301) IN COMPLEX WITH TCS401, CLOSED STATE 3.1.3.48
5K9Y CRYSTAL STRUCTURE OF A THERMOPHILIC XYLANASE A FROM BACILLUS SUBTILIS 1A1 QUADRUPLE MUTANT Q7H/G13R/S22P/S179C 3.2.1.8
5KA0 PROTEIN TYROSINE PHOSPHATASE 1B DELTA HELIX 7, OPEN STATE 3.1.3.48
5KA1 PROTEIN TYROSINE PHOSPHATASE 1B DELTA HELIX 7 MUTANT IN COMPLEX WITH TCS401, CLOSED STATE 3.1.3.48
5KA2 PROTEIN TYROSINE PHOSPHATASE 1B YAYA (Y152A, Y153A) MUTANT, OPEN STATE 3.1.3.48
5KA3 PROTEIN TYROSINE PHOSPHATASE 1B YAYA (Y152A, Y153A) MUTANT IN COMPLEX WITH TCS401, CLOSED STATE 3.1.3.48
5KA4 PROTEIN TYROSINE PHOSPHATASE 1B T178A MUTANT, OPEN STATE 3.1.3.48
5KA7 PROTEIN TYROSINE PHOSPHATASE 1B T178A MUTANT IN COMPLEX WITH TCS401, CLOSED STATE 3.1.3.48
5KA8 PROTEIN TYROSINE PHOSPHATASE 1B L192A MUTANT, OPEN STATE 3.1.3.48
5KA9 PROTEIN TYROSINE PHOSPHATASE 1B L192A MUTANT IN COMPLEX WITH TCS401, OPEN STATE 3.1.3.48
5KAA PROTEIN TYROSINE PHOSPHATASE 1B DELTA HELIX 7, P185G MUTANT, OPEN STATE 3.1.3.48
5KAB PROTEIN TYROSINE PHOSPHATASE 1B DELTA HELIX 7, P185G MUTANT IN COMPLEX WITH TCS401, OPEN STATE 3.1.3.48
5KAC PROTEIN TYROSINE PHOSPHATASE 1B P185G MUTANT, OPEN STATE 3.1.3.48
5KAD PROTEIN TYROSINE PHOSPHATASE 1B N193A MUTANT IN COMPLEX WITH TCS401, CLOSED STATE 3.1.3.48
5KAR MURINE ACID SPHINGOMYELINASE-LIKE PHOSPHODIESTERASE 3B (SMPDL3B) 3.1.4
5KAS MURINE ACID SPHINGOMYELINASE-LIKE PHOSPHODIESTERASE 3B (SMPDL3B) WITH PHOSPHOCHOLINE 3.1.4
5KB3 1.4 A RESOLUTION STRUCTURE OF HELICOBACTER PYLORI MTAN IN COMPLEXED WITH P-CLPH-DADME-IMMA 3.2.2.30
3.2.2.9
5KDE INORGANIC PYROPHOSPHATASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH INHIBITOR 1 AND INORGANIC PYROPHOSPHATE 3.6.1.1
5KDF INORGANIC PYROPHOSPHATASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH INHIBITOR 6 AND INORGANIC PYROPHOSPHATE 3.6.1.1
5KDG CRYSTAL STRUCTURE OF SALMONELLA TYPHIMURIUM EFFECTOR GTGE 3.4.22.2
5KDV IMPA METALLOPEPTIDASE FROM PSEUDOMONAS AERUGINOSA 3.4.24
5KDW IMPA METALLOPEPTIDASE FROM PSEUDOMONAS AERUGINOSA 3.4.24
5KDX IMPA METALLOPEPTIDASE IN COMPLEX WITH T-ANTIGEN 3.4.24
5KEG CRYSTAL STRUCTURE OF APOBEC3A IN COMPLEX WITH A SINGLE-STRANDED DNA 3.5.4
3.5.4.38
5KES SOLUTION STRUCTURE OF THE YEAST DDI1 HDD DOMAIN 3.4.23
5KEZ SELECTIVE AND POTENT INHIBITION OF THE GLYCOSIDASE HUMAN AMYLASE BY THE SHORT AND EXTREMELY COMPACT PEPTIDE PIHA FROM MRNA DISPLAY 3.2.1.1
5KGR SPIN-LABELED T4 LYSOZYME CONSTRUCT I9V1/V131V1 (30 DAYS) 3.2.1.17
5KGW HIV1 CATALYTIC CORE DOMAIN IN COMPLEX WITH INHIBITOR: (2~{S})-2-[3-(3,4-DIHYDRO-2~{H}-CHROMEN-6-YL)-1-METHYL-INDOL-2-YL]-2-[(2-METHYLPROPAN-2-YL)OXY]ETHANOIC ACID 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5KGX HIV1 CATALYTIC CORE DOMAIN IN COMPLEX WITH AN INHIBITOR (2~{S})-2-[3-(3,4-DIHYDRO-2~{H}-CHROMEN-6-YL)-1-METHYL-INDOL-2-YL]-2-[(2-METHYLPROPAN-2-YL)OXY]ETHANOIC ACID 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5KHZ PSEUDO T4 LYSOZYME 3.2.1.17
5KI1 PSEUDO T4 LYSOZYME MUTANT - Y18F 3.2.1.17
5KI2 PSEUDO T4 LYSOZYME MUTANT - Y18PHE-METHYL 3.2.1.17
5KI3 PSEUDO T4 LYSOZYME MUTANT - Y18PHE-BR 3.2.1.17
5KI8 PSEUDO T4 LYSOZYME MUTANT - Y88PHE-BR 3.2.1.17
5KIG PSEUDO T4 LYSOZYME MUTANT - Y88F 3.2.1.17
5KII PSEUDO T4 LYSOZYME MUTANT - Y88PHE-METHYL 3.2.1.17
5KIJ CRYSTAL STRUCTURE OF THE CLASS I HUMAN ENDOPLASMIC RETICULUM 1,2-ALPHA-MANNOSIDASE AND MAN9GLCNAC2-PA COMPLEX 3.2.1.113
5KIM PSEUDO T4 LYSOZYME MUTANT - Y88PHE-I 3.2.1.17
5KIO PSEUDO T4 LYSOZYME MUTANT - Y18PHE-I 3.2.1.17
5KIW P97 ND1-L198W IN COMPLEX WITH VIMP 3.6.4.6
5KIY P97 ND1-A232E IN COMPLEX WITH VIMP 3.6.4.6
5KK7 CRYSTAL STRUCTURE OF THE CLASS I HUMAN ENDOPLASMIC RETICULUM 1,2-ALPHA-MANNOSIDASE T688A MUTANT AND THIO-DISACCHARIDE SUBSTRATE ANALOG COMPLEX 3.2.1.113
5KKB STRUCTURE OF MOUSE GOLGI ALPHA-1,2-MANNOSIDASE IA AND MAN9GLCNAC2-PA COMPLEX 3.2.1.113
5KKF CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE MUTANT I263L 3.5.2.6
5KKI 1.7-ANGSTROM IN SITU MYLAR STRUCTURE OF HEN EGG-WHITE LYSOZYME (HEWL) AT 100 K 3.2.1.17
5KKJ 2.0-ANGSTROM IN SITU MYLAR STRUCTURE OF HEN EGG-WHITE LYSOZYME (HEWL) AT 293 K 3.2.1.17
5KKY STRUCTURE OF STREPTOCOCCUS PNEUMONIA NANA BOUND WITH INHIBITOR 9N3NEU5AC2EN 3.2.1.18
5KLY HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT ADENOSINE NUCLEOSIDE PHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5KLZ HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) AMP CATALYTIC PRODUCT COMPLEX 3
5KM0 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT) IMP COMPLEX 3
5KM1 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) GMP CATALYTIC PRODUCT COMPLEX 3
5KM2 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) CMP CATALYTIC PRODUCT COMPLEX 3
5KM3 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) UMP CATALYTIC PRODUCT COMPLEX 3
5KM4 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1)-5-IODO-UMP COMPLEX 3
5KM5 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 2 (HHINT2) TRICIRIBINE 5'-MONOPOSPHATE CATALYTIC PRODUCT COMPLEX 3
5KM6 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT ARA-A NUCLEOSIDE PHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5KM8 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 2 (HHINT2) CIDOFOVIR COMPLEX 3
5KM9 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 2 (HHINT2) ADENOSINE COMPLEX 3
5KMA HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT NUCLEOSIDE D-TRP PHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5KMB HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT NUCLEOSIDE L-TRP PHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5KMC HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) NON-NUCLEOTIDIC COVALENT INTERMEDIATE COMPLEX 3
5KMT CTX-M9 MUTANT L48A 3.5.2.6
5KMU CTX-M-9 BETA LACTAMASE MUTANT - T165W 3.5.2.6
5KMW TOHO1 BETA LACTAMASE MUTANT E166A/R274N/R276N -BENZYL PENICILLIN COMPLEX 3.5.2.6
5KN8 MUTY N-TERMINAL DOMAIN IN COMPLEX WITH UNDAMAGED DNA 3.2.2
3.2.2.31
5KN9 MUTY N-TERMINAL DOMAIN IN COMPLEX WITH DNA CONTAINING AN INTRAHELICAL OXOG:A BASE-PAIR 3.2.2
3.2.2.31
5KNB CRYSTAL STRUCTURE OF THE 2 ADP-BOUND V1 COMPLEX 3.6.3.15
7.2.2.1
5KND CRYSTAL STRUCTURE OF THE PI-BOUND V1 COMPLEX 3.6.3.15
7.2.2.1
5KO2 MOUSE PGP 34 LINKER DELETED MUTANT HG DERIVATIVE 3.6.3.44
7.6.2.2
7.6.2.1
5KO3 STRUCTURE OF A CORE PAPAIN-LIKE PROTEASE OF MERS CORONAVIRUS WITH UTILITY FOR STRUCTURE-BASED DRUG DESIGN 3.4.19.12
3.4.22.69
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
2.1.1
3.1.13
3.1
5KOQ DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN-HIBITOR 3.4.23.15
5KOS DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN-HIBITOR 3.4.23.15
5KOT DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN-HIBITOR 3.4.23.15
5KOY MOUSE PGP 34 LINKER DELETED BOUND WITH ATP 3.6.3.44
7.6.2.2
7.6.2.1
5KPD MOUSE PGP 34 LINKER DELETED DOUBLE EQ MUTANT 3.6.3.44
7.6.2.2
7.6.2.1
5KPI MOUSE NATIVE PGP 3.6.3.44
7.6.2.2
7.6.2.1
5KPJ MOUSE PGP METHYLATED PROTEIN 3.6.3.44
7.6.2.2
7.6.2.1
5KPU CRYSTAL STRUCTURE OF TEM1 BETA-LACTAMASE MUTANT I263L IN THE PRESENCE OF 1.2 MPA XENON 3.5.2.6
5KQB IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF LYTU 3.4.24.75
5KQC IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF LYTU 3.4.24.75
5KQF (4~{S},6~{S})-4-[2,4-BIS(FLUORANYL)PHENYL]-4-METHYL-6-PYRIMIDIN-5-YL-5,6-DIHYDRO-1,3-THIAZIN-2-AMINE (COMPOUND 12) BOUND TO BACE1 3.4.23.46
5KQG CO-CRYSTAL STRUCTURE OF LMW-PTP IN COMPLEX WITH 2-(BENZOTHIAZOL-2-YLAMINO)-2-OXO-1-PHENYLETHANESULFONIC ACID 3.1.3.48
3.1.3.2
5KQL CO-CRYSTAL STRUCTURE OF LMW-PTP IN COMPLEX WITH 2-OXO-1-PHENYL-2-(PHENYLAMINO)ETHANESULFONIC ACID 3.1.3.48
3.1.3.2
5KQM CO-CRYSTAL STRUCTURE OF LMW-PTP IN COMPLEX WITH MES 3.1.3.48
3.1.3.2
5KQP CRYSTAL STRUCTURE OF APO-FORM LMW-PTP 3.1.3.48
3.1.3.2
5KQR STRUCTURE OF NS5 METHYLTRANSFERASE FROM ZIKA VIRUS BOUND TO S-ADENOSYLMETHIONINE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5KQS STRUCTURE OF NS5 METHYLTRANSFERASE FROM ZIKA VIRUS BOUND TO S-ADENOSYLMETHIONINE AND 7-METHYL-GUANOSINE-5'-DIPHOSPHATE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5KR8 (4~{S},6~{S})-4-[2,4-BIS(FLUORANYL)PHENYL]-6-(3,5-DIMETHYL-1,2-OXAZOL-4-YL)-4-METHYL-5,6-DIHYDRO-1,3-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1 3.4.23.46
5KRS HIV-1 INTEGRASE CATALYTIC CORE DOMAIN IN COMPLEX WITH AN ALLOSTERIC INHIBITOR, 3-(1H-PYRROL-1-YL)-2-THIOPHENECARBOXYLIC ACID 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5KRT HIV-1 INTEGRASE CATALYTIC CORE DOMAIN (CCD) IN COMPLEX WITH A FRAGMENT-DERIVED ALLOSTERIC INHIBITOR 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5KSE FLAP ENDONUCLEASE 1 (FEN1) R100A WITH 5'-FLAP SUBSTRATE DNA AND SM3+ 3.1
5KSH CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 2 FROM NEISSERIA GONORRHOEAE CONTAINING AN A501T MUTATION ASSOCIATED WITH CEPHALOSPORIN RESISTANCE 3.4.16.4
5KSO HMIRO1 C-DOMAIN GDP-PI COMPLEX P3121 CRYSTAL FORM 3.6.5
5KSP HMIRO1 C-DOMAIN GDP COMPLEX C2221 CRYSTAL FORM 3.6.5
5KSQ STATIONARY PHASE SURVIVAL PROTEIN E (SURE) FROM XYLELLA FASTIDIOSA 3.1.3.5
5KSR STATIONARY PHASE SURVIVAL PROTEIN E (SURE) FROM XYLELLA FASTIDIOSA - XFSURE-TB (TETRAMER BIGGER). 3.1.3.5
5KSS STATIONARY PHASE SURVIVAL PROTEIN E (SURE) FROM XYLELLA FASTIDIOSA - XFSURE-DS (DIMER SMALLER) 3.1.3.5
5KST STATIONARY PHASE SURVIVAL PROTEIN E (SURE) FROM XYLELLA FASTIDIOSA- XFSURE-TSAMP (TETRAMER SMALLER - CRYSTALLIZATION WITH 3'AMP). 3.1.3.5
5KSY HMIRO1 C-DOMAIN GDP COMPLEX P41212 CRYSTAL FORM 3.6.5
5KSZ HMIRO EF HAND AND CGTPASE DOMAINS IN THE GMPPCP-BOUND STATE 3.6.5
5KTY HMIRO EF HAND AND CGTPASE DOMAINS, GDP AND CA2+ BOUND STATE 3.6.5
5KTZ EXPANDED POLIOVIRUS IN COMPLEX WITH VHH 12B 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5KU0 EXPANDED POLIOVIRUS IN COMPLEX WITH VHH 17B 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5KU1 HMIRO1 EF HAND AND CGTPASE DOMAINS IN THE GDP-BOUND STATE 3.6.5
5KU2 EXPANDED POLIOVIRUS IN COMPLEX WITH VHH 7A 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5KU7 CRYSTAL STRUCTURE OF THE TIR DOMAIN FROM THE MUSCADINIA ROTUNDIFOLIA DISEASE RESISTANCE PROTEIN RPV1 3.2.2.6
5KU9 CRYSTAL STRUCTURE OF MCL1 WITH COMPOUND 1 3.6.1.11
5KUB BACILLUS CEREUS DNA GLYCOSYLASE ALKD BOUND TO 7-METHYLGUANINE NUCLEOBASE AND DNA CONTAINING AN OXOCARBENIUM-INTERMEDIATE ANALOG 3.2.2
5KUT HMIRO2 C-TERMINAL GTPASE DOMAIN, GDP-BOUND 3.6.5
5KV8 CRYSTAL STRUCTURE OF A HPIV HAEMAGGLUTININ-NEURAMINIDASE-INHIBITOR COMPLEX 3.2.1.18
5KV9 CRYSTAL STRUCTURE OF A HPIV HAEMAGGLUTININ-NEURAMINIDASE-INHIBITOR COMPLEX 3.2.1.18
5KW2 THE EXTRA-HELICAL BINDING SITE OF GPR40 AND THE STRUCTURAL BASIS FOR ALLOSTERIC AGONISM AND INCRETIN STIMULATION 3.2.1.17
5KWL EXPANDED POLIOVIRUS IN COMPLEX WITH VHH 10E 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5KXA SELECTIVE INHIBITION OF AUTOTAXIN IS EFFECTIVE IN MOUSE MODELS OF LIVER FIBROSIS 3.1.4.39
5KXK HEN EGG WHITE LYSOZYME AT 100K, DATA SET 1 3.2.1.17
5KXL HEN EGG WHITE LYSOZYME AT 100K, DATA SET 2 3.2.1.17
5KXM HEN EGG WHITE LYSOZYME AT 100K, DATA SET 3 3.2.1.17
5KXN HEN EGG WHITE LYSOZYME AT 100K, DATA SET 4 3.2.1.17
5KXO HEN EGG WHITE LYSOZYME AT 278K, DATA SET 1 3.2.1.17
5KXP HEN EGG WHITE LYSOZYME AT 278K, DATA SET 2 3.2.1.17
5KXR HEN EGG WHITE LYSOZYME AT 278K, DATA SET 3 3.2.1.17
5KXS HEN EGG WHITE LYSOZYME AT 278K, DATA SET 4 3.2.1.17
5KXT HEN EGG WHITE LYSOZYME AT 278K, DATA SET 5 3.2.1.17
5KXU STRUCTURE PROTEINASE K DETERMINED BY SACLA 3.4.21.64
5KXV STRUCTURE PROTEINASE K AT 0.98 ANGSTROMS 3.4.21.64
5KXW HEN EGG WHITE LYSOZYME AT 278K, DATA SET 6 3.2.1.17
5KXX HEN EGG WHITE LYSOZYME AT 278K, DATA SET 7 3.2.1.17
5KXY HEN EGG WHITE LYSOZYME AT 278K, DATA SET 8 3.2.1.17
5KXZ HEN EGG WHITE LYSOZYME AT 278K, DATA SET 9 3.2.1.17
5KY1 HEN EGG WHITE LYSOZYME AT 278K, DATA SET 10 3.2.1.17
5KYB CRYSTAL STRUCTURE OF THE APO-FORM OF USP7 CATALYTIC DOMAIN [V302K] MUTANT 3.4.19.12
5KYC CRYSTAL STRUCTURE OF USP7 CATALYTIC DOMAIN [V302K] MUTANT IN COMPLEX WITH UBIQUITIN (MALONATE BOUND) 3.4.19.12
5KYD CRYSTAL STRUCTURE OF USP7 CATALYTIC DOMAIN [V302K] MUTANT IN COMPLEX WITH UBIQUITIN 3.4.19.12
5KYE CRYSTAL STRUCTURE OF USP7 CATALYTIC DOMAIN [H294E] MUTANT IN COMPLEX WITH UBIQUITIN 3.4.19.12
5KYF CRYSTAL STRUCTURE OF USP7 CATALYTIC DOMAIN [L299A] MUTANT IN COMPLEX WITH UBIQUITIN 3.4.19.12
5KYK COVALENT GTP-COMPETITIVE INHIBITORS OF KRAS G12C: GUANOSINE BISPHOSPHONATE ANALOGS 3.6.5.2
5KZ9 CRYSTAL STRUCTURE OF THE ROUS SARCOMA VIRUS MATRIX PROTEIN. 3.4.23
2.7.7.49
2.7.7.7
3.1.26.4
2.7.7
3.1
5KZA CRYSTAL STRUCTURE OF THE ROUS SARCOMA VIRUS MATRIX PROTEIN (AA 2-102). SPACE GROUP I41 3.4.23
2.7.7.49
2.7.7.7
3.1.26.4
2.7.7
3.1
5KZB CRYSTAL STRUCTURE OF THE ROUS SARCOMA VIRUS MATRIX PROTEIN (AA 2-102). SPACE GROUP I4122 3.4.23
2.7.7.49
2.7.7.7
3.1.26.4
2.7.7
3.1
5KZP STRUCTURE OF THE HCV1-C1 ANTIBODY-ANTIGEN COMPLEX 3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5KZW CRYSTAL STRUCTURE OF HUMAN GAA 3.2.1.20
5KZX CRYSTAL STRUCTURE OF HUMAN GAA 3.2.1.20
5L08 CRYO-EM STRUCTURE OF CASP-8 TDED FILAMENT 3.4.22.61
5L0A HUMAN MUSCLE FRUCTOSE-1,6-BISPHOSPHATASE E69Q MUTANT IN ACTIVE R-STATE IN COMPLEX WITH FRUCTOSE-1,6-BISPHOSPHATE 3.1.3.11
5L0Q CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN ADAM10 D+C DOMAIN AND A CONFORMATION SPECIFIC MAB 8C7. 3.4.24.81
5L14 THE CRYSTAL STRUCTURE OF NEURAMINIDASE FROM A/SHANGHAI/2/2013 (H7N9) INFLUENZA VIRUS 3.2.1.18
5L15 THE CRYSTAL STRUCTURE OF NEURAMINIDASE IN COMPLEX WITH OSELTAMIVIR FROM A/SHANGHAI/2/2013 (H7N9) INFLUENZA VIRUS 3.2.1.18
5L17 THE CRYSTAL STRUCTURE OF NEURAMINIDASE IN COMPLEX WITH ZANAMIVIR FROM A/SHANGHAI/2/2013 (H7N9) INFLUENZA VIRUS 3.2.1.18
5L18 THE CRYSTAL STRUCTURE OF NEURAMINIDASE IN COMPLEX WITH SIALIC ACID FROM A/SHANGHAI/2/2013 (H7N9) INFLUENZA VIRUS 3.2.1.18
5L21 CRYSTAL STRUCTURE OF BONT/A RECEPTOR BINDING DOMAIN IN COMPLEX WITH VHH C2 3.4.24.69
5L2P STRUCTURE OF ARYLESTERASE 3.1.1.2
3.1.8.1
5L2Y FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 1-[(2R,15R)-2-[(1-AMINO-4-FLUOROISOQUINOLIN-6-YL)AMINO]-4,15,20-TRIMETHYL-3,12-DIOXO-13-OXA-4,11-DIAZATRICYCLO[14.2.2.1~6,10~]HENICOSA-1(18),6,8,10(21),16,19-HEXAEN-7-YL] CYCLOBUTANE-1-CARBOXYLIC ACID 3.4.21.21
5L2Z FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 1-[(2R,15R)-2-[(1-AMINO-4-FLUOROISOQUINOLIN-6-YL)AMINO]-4,15,17-TRIMETHYL-3,12-DIOXO-13-OXA-4,11-DIAZATRICYCLO[14.2.2.1~6,10~]HENICOSA-1(18),6(21),7,9,16,19-HEXAEN-7-YL]CYCLOHEXANE-1-CARBOXYLIC ACID 3.4.21.21
5L30 FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R,15R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-4,15,17-TRIMETHYL-7-[1-(1H-TETRAZOL-5-YL)CYCLOPROPYL]-13-OXA-4,11-DIAZATRICYCLO[14.2.2.1~6,10~]HENICOSA-1(18),6(21),7,9,16,19-HEXAENE-3,12-DIONE 3.4.21.21
5L3U THERMOLYSIN IN COMPLEX WITH JC149 (MPD CRYO PROTECTANT) 3.4.24.27
5L41 THERMOLYSIN IN COMPLEX WITH JC148 (MPD CRYO PROTECTANT) 3.4.24.27
5L4Z CRYSTAL STRUCTURE OF ENZYME IN PURINE METABOLISM 3.1.3.5
5L50 CRYSTAL STRUCTURE OF ENZYME IN PURINE METABOLISM 3.1.3.5
5L6N DISULFATED MADANIN-THROMBIN COMPLEX 3.4.21.5
5L6Z CRYSTAL STRUCTURE OF D62A MUTANT OF THERMOTOGA MARITIMA TMPEP1050 AMINOPEPTIDASE 3.2.1.4
5L79 CRYSTAL STRUCTURE OF MMP12 IN COMPLEX WITH RXP470.1 CONJUGATED WITH FLUOROPHORE CY5,5 IN SPACE GROUP P21212. 3.4.24.65
5L7F CRYSTAL STRUCTURE OF MMP12 MUTANT K421A IN COMPLEX WITH RXP470.1 CONJUGATED WITH FLUOROPHORE CY5,5 IN SPACE GROUP P21. 3.4.24.65
5L8C CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-039 3.1.4
5L8H STRUCTURE OF USP46-UBVME 3.4.19.12
5L8P THERMOLYSIN IN COMPLEX WITH JC114 (PEG400 CRYO PROTECTANT) 3.4.24.27
5L8W STRUCTURE OF USP12-UB-PRG/UAF1 3.4.19.12
5L8Y CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-937 3.1.4
5L9H CRYSTAL STRUCTURE OF T. BRUCEI PDE-B1 CATALYTIC DOMAIN WITH INHIBITOR NPD-340 3.1.4
5L9Y CRYSTAL STRUCTURE OF HUMAN HEPARANASE, IN COMPLEX WITH GLUCURONIC ACID CONFIGURED AZIRIDINE PROBE JJB355 3.2.1.166
5L9Z CRYSTAL STRUCTURE OF HUMAN HEPARANASE NUCLEOPHILE MUTANT (E343Q), IN COMPLEX WITH UNREACTED GLUCURONIC ACID CONFIGURED AZIRIDINE PROBE JJB355 3.2.1.166
5LA4 CRYSTAL STRUCTURE OF APO HUMAN PROHEPARANASE 3.2.1.166
5LA5 ROOM TEMPERATURE X-RAY DIFFRACTION OF TETRAGONAL HEWL. SECOND DATA SET (0.62 MGY) 3.2.1.17
5LA7 CRYSTAL STRUCTURE OF HUMAN PROHEPARANASE, IN COMPLEX WITH GLUCURONIC ACID CONFIGURED AZIRIDINE PROBE JJB355 3.2.1.166
5LA8 ROOM TEMPERATURE X-RAY DIFFRACTION OF TETRAGONAL HEWL. THIRD DATA SET (0.93 MGY) 3.2.1.17
5LAF ROOM TEMPERATURE X-RAY DIFFRACTION OF TETRAGONAL HEWL WITH 1M OF URIDINE. FIRST DATA SET (0.31 MGY) 3.2.1.17
5LAG ROOM TEMPERATURE X-RAY DIFFRACTION OF TETRAGONAL HEWL WITH 1M OF URIDINE. SECOND DATA SET (0.62 MGY) 3.2.1.17
5LAN ROOM TEMPERATURE X-RAY DIFFRACTION OF TETRAGONAL HEWL WITH 1M OF URIDINE. THIRD DATA SET (0.93 MGY) 3.2.1.17
5LAQ CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN WITH INHIBITOR NPD-001 3.1.4.53
5LBD CRYSTAL STRUCTURE OF THE N-DOMAIN OF HMA6, A COPPER-TRANSPORTING P-TYPE ATPASE 3.6.3.54
7.2.2.8
5LBK CRYSTAL STRUCTURE OF THE N-DOMAIN OF HMA8, A COPPER-TRANSPORTING P-TYPE ATPASE 3.6.3.4
7.2.2.9
5LBO CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D2 CATALYTIC DOMAIN WITH INHIBITOR NPD-001 3.1.4.53
5LCE THROMBIN IN COMPLEX WITH (S)-1-((R)-2-AMINO-3-CYCLOHEXYLPROPANOYL)-N-(5-CHLORO-2-(HYDROXYMETHYL)BENZY L)PYRROLIDINE-2-CARBOXAMIDE 3.4.21.5
5LD2 CRYO-EM STRUCTURE OF RECBCD+DNA COMPLEX REVEALING ACTIVATED NUCLEASE DOMAIN 3.1.11.5
5LD9 STRUCTURE OF DEUBIQUITINATING ENZYME HOMOLOG, PYROCOCCUS FURIOSUS JAMM1. 3.4.19.15
5LDA STRUCTURE OF DEUBIQUITINATING ENZYME HOMOLOG (PYROCOCCUS FURIOSUS JAMM1) IN COMPLEX WITH UBIQUITIN-LIKE SAMP2. 3.4.19.15
5LDI CRYSTAL STRUCTURE OF E.COLI LIGT IN APO FORM 3.1.4
3.1.4.58
5LDJ CRYSTAL STRUCTURE OF E.COLI LIGT COMPLEXED WITH PHOSPHATE 3.1.4
3.1.4.58
5LDK CRYSTAL STRUCTURE OF E.COLI LIGT COMPLEXED WITH ATP 3.1.4
3.1.4.58
5LDM CRYSTAL STRUCTURE OF E.COLI LIGT COMPLEXED WITH 2'-AMP 3.1.4
3.1.4.58
5LDO CRYSTAL STRUCTURE OF E.COLI LIGT COMPLEXED WITH 3'-AMP 3.1.4
3.1.4.58
5LDP CRYSTAL STRUCTURE OF E.COLI LIGT COMPLEXED WITH ATP 3.1.4
3.1.4.58
5LDQ CRYSTAL STRUCTURE OF E.COLI LIGT COMPLEXED WITH NADP+ 3.1.4
3.1.4.58
5LDR CRYSTAL STRUCTURE OF A COLD-ADAPTED DIMERIC BETA-D-GALACTOSIDASE FROM PARACOCCUS SP. 32D STRAIN IN COMPLEX WITH GALACTOSE 3.2.1.23
5LDS STRUCTURE OF THE PORCINE AMINOPEPTIDASE N ECTODOMAIN 3.4.11.2
5LDZ QUADRUPLE SPACE GROUP AMBIGUITY DUE TO ROTATIONAL AND TRANSLATIONAL NON-CRYSTALLOGRAPHIC SYMMETRY IN HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 3.1.3.11
5LEO COMPLEX STRUCTURE OF LYSOSTAPHIN SH3B DOMAIN WITH PEPTIDOGLYCAN FRAGMENT 3.4.24.75
5LF8 HUMAN NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 17 (NUDT17) 3.6.1
5LF9 CRYSTAL STRUCTURE OF HUMAN NUDT22 3.6.1.45
5LG6 STRUCTURE OF THE DEGLYCOSYLATED PORCINE AMINOPEPTIDASE N ECTODOMAIN 3.4.11.2
5LH4 TRYPSIN INHIBITORS FOR THE TREATMENT OF PANCREATITIS - CPD 1 3.4.21.4
5LHB POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00017262 3.2.1.143
5LHD STRUCTURE OF GLYCOSYLATED HUMAN AMINOPEPTIDASE N 3.4.11.2
5LHJ BOTTROMYCIN MATURATION ENZYME BOTP 3.4.11
3.4.11.1
5LHK BOTTROMYCIN MATURATION ENZYME BOTP IN COMPLEX WITH MN 3.4.11
3.4.11.1
5LHN THE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ALLOSTERIC INHIBITORY NANOBODY NB7 3.4.21.73
5LHP THE P-AMINOBENZAMIDINE ACTIVE SITE INHIBITED CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ALLOSTERIC INHIBITORY NANOBODY NB7 3.4.21.73
5LHQ THE EGR-CMK ACTIVE SITE INHIBITED CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ALLOSTERIC INHIBITORY NANOBODY NB7 3.4.21.73
5LHR THE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ACTIVE SITE BINDING INHIBITORY NANOBODY NB22 3.4.21.73
5LHS THE LIGAND FREE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR 3.4.21.73
5LI3 CRYSTAL STRUCTURE OF HDAC-LIKE PROTEIN FROM P. AERUGINOSA IN COMPLEX WITH A PHOTO-SWITCHABLE INHIBITOR. 3.5.1
5LIA CRYSTAL STRUCTURE OF MURINE AUTOTAXIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR 3.1.4.39
5LIF THERMOLYSIN IN COMPLEX WITH INHIBITOR 3.4.24.27
5LIL STRUCTURE OF AGGREGATIBACTER ACTINOMYCETEMCOMITANS MACB BOUND TO ATPYS (P21) 3.6.3
7.6.2
5LIP PSEUDOMONAS LIPASE COMPLEXED WITH RC-(RP, SP)-1,2-DIOCTYLCARBAMOYLGLYCERO-3-O-OCTYLPHOSPHONATE 3.1.1.3
5LJ6 STRUCTURE OF AGGREGATIBACTER ACTINOMYCETEMCOMITANS MACB BOUND TO ATPYS (P6522) 3.6.3
7.6.2
5LJ7 STRUCTURE OF AGGREGATIBACTER ACTINOMYCETEMCOMITANS MACB BOUND TO ATP (P21) 3.6.3
7.6.2
5LJ8 STRUCTURE OF THE E. COLI MACB PERIPLASMIC DOMAIN (P21) 3.6.3
7.6.2
5LJ9 STRUCTURE OF THE E. COLI MACB ABC DOMAIN (C2221) 3.6.3
7.6.2
5LJA STRUCTURE OF THE E. COLI MACB ABC DOMAIN (P6122) 3.6.3
7.6.2
5LJF CRYSTAL STRUCTURE OF THE ENDO-1,4-GLUCANASE RBCEL1 E135A WITH CELLOTRIOSE 3.2.1.4
5LJV MAMK DOUBLE HELICAL FILAMENT 3.6.1
5LJW MAMK NON-POLYMERISING A278D MUTANT BOUND TO AMPPNP 3.6.1
5LKA CRYSTAL STRUCTURE OF HALOALKANE DEHALOGENASE LINB 140A+143L+177W+211L MUTANT (LINB86) FROM SPHINGOBIUM JAPONICUM UT26 AT 1.3 A RESOLUTION 3.8.1.5
5LKQ PROTEASE DOMAIN OF RADA 3.6.4
5LKR HUMAN BUTYRYLCHOLINESTERASE COMPLEXED WITH N-PROPARGYLIPERIDINES 3.1.1.8
5LL7 CRYSTAL STRUCTURE OF KPC-2 CARBAPENEMASE IN COMPLEX WITH A PHENYL BORONIC INHIBITOR. 3.5.2.6
5LLJ MAEDI-VISNA VIRUS (MVV) INTEGRASE C-TERMINAL DOMAIN (RESIDUES 220-276) 3.4.23
2.7.7.49
3.1.26.13
3.1.13.2
3.6.1.23
2.7.7
3.1
2.7.7.7
3.1.26.4
5LLS PORCINE DIPEPTIDYL PEPTIDASE IV IN COMPLEX WITH 8-(3-AMINOPIPERIDIN-1-YL)-7-[(2-BROMOPHENYL)METHYL]-1,3-DIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE 3.4.14.5
5LM1 CRYSTAL STRUCTURE OF HD-PTP PHOSPHATASE IN COMPLEX WITH UBAP1 3.1.3.48
5LN3 THE HUMAN 26S PROTEASOME AT 6.8 ANG. 3.4.25.1
5LN5 CRYSTAL STRUCTURE OF THE WSS1 E203Q MUTANT FROM S. POMBE 3.4.24
5LNB CRYSTAL STRUCTURE OF THE DE-SUMOYLATING PROTEASE 3.4.22.68
3.4.22
5LOR HUMAN NUDT22 3.6.1.45
5LOU HUMAN NUDT22 3.6.1.45
5LP1 CRYSTAL STRUCTURE OF HUMAN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN COMPLEX WITH A [1.1.1]BICYCLOPENTANE-CONTAINING INHIBITOR AT 1.91A RESOLUTION. 3.1.1.47
5LP3 THREE TETRAMERIC RINGS OF ISOASPARTYL DIPEPTIDASE FITTED IN AN EM VOLUME. 3.4.19
5LPD THROMBIN IN COMPLEX WITH (S)-1-((R)-2-AMINO-3-CYCLOHEXYLPROPANOYL)-N-(2-(AMINOMETHYL)-5-CHLOROBENZYL) PYRROLIDINE-2-CARBOXAMIDE 3.4.21.5
5LPE KALLIKREIN-RELATED PEPTIDASE 10 COMPLEX WITH ZN2+ 3.4.21
5LPF KALLIKREIN-RELATED PEPTIDASE 10 3.4.21
5LPR STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS 3.4.21.12
5LQQ STRUCTURE OF AUTOTAXIN (ENPP2) WITH LM350 3.1.4.39
5LR0 BINDING DOMAIN OF BOTULINUM NEUROTOXIN DC IN COMPLEX WITH SIALYLT 3.4.24.69
5LRG CRYSTAL STRUCTURE OF THE PORCINE CARBOXYPEPTIDASE B - ANABAENOPEPTIN B COMPLEX 3.4.17.2
5LRJ CRYSTAL STRUCTURE OF THE PORCINE CARBOXYPEPTIDASE B - ANABAENOPEPTIN C COMPLEX 3.4.17.2
5LRK CRYSTAL STRUCTURE OF THE PORCINE CARBOXYPEPTIDASE B - ANABAENOPEPTIN F COMPLEX 3.4.17.2
5LRP MOPEIA VIRUS EXONUCLEASE DOMAIN COMPLEXED WITH MAGNESIUM 3.1.13
5LRT STRUCTURE OF THE DEAMIDASE-DEPUPYLASE DOP OF THE PROKARYOTIC UBIQUITIN-LIKE MODIFICATION PATHWAY IN COMPLEX WITH ADP AND PHOSPHATE 3.4
5LRU STRUCTURE OF CEZANNE/OTUD7B OTU DOMAIN 3.4.19.12
5LRV STRUCTURE OF CEZANNE/OTUD7B OTU DOMAIN BOUND TO LYS11-LINKED DIUBIQUITIN 3.4.19.12
5LRW STRUCTURE OF CEZANNE/OTUD7B OTU DOMAIN BOUND TO UBIQUITIN 3.4.19.12
5LRX STRUCTURE OF A20 OTU DOMAIN BOUND TO UBIQUITIN 3.4.19.12
6.3.2
2.3.2
5LS0 CRYSTAL STRUCTURE OF INORGANIC PYROPHOSPHATASE PPA1 FROM ARABIDOPSIS THALIANA 3.6.1.1
5LS3 CRYSTAL STRUCTURE OF METALLO-BETA-LACTAMASE SPM-1 WITH Y58C MUTATION 3.5.2.6
5LS4 MOPEIA VIRUS EXONUCLEASE DOMAIN COMPLEXED WITH CALCIUM 3.1.13
5LSH HUMAN LYSOZYME IN COMPLEX WITH A TETRASACCHARIDE FRAGMENT OF THE O-CHAIN OF LPS FROM KLEBSIELLA PNEUMONIAE 3.2.1.17
5LST CRYSTAL STRUCTURE OF THE HUMAN RECQL4 HELICASE. 3.6.4.12
5LTA CRYSTAL STRUCTURE OF THE PRP43-ADP-BEF3-U7-RNA COMPLEX 3.6.4.13
5LTF CRYSTAL STRUCTURE OF LYMPHOCYTIC CHORIOMENINGITIS MAMMARENAVIRUS ENDONUCLEASE COMPLEXED WITH CATALYTIC IONS 2.7.7.48
3.1
5LTN CRYSTAL STRUCTURE OF LYMPHOCYTIC CHORIOMENINGITIS MAMMARENAVIRUS ENDONUCLEASE COMPLEXED WITH DPBA 2.7.7.48
3.1
5LTS CRYSTAL STRUCTURE OF LYMPHOCYTIC CHORIOMENINGITIS MAMMARENAVIRUS ENDONUCLEASE MUTANT D118A 2.7.7.48
3.1
5LTU CRYSTAL STRUCTURE OF NUDT4A- DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE 2 3.6.1.52
3.6.1
5LU8 CRYSTAL STRUCTURE OF YVAD-CMK BOUND HUMAN LEGUMAIN (AEP) IN COMPLEX WITH COMPOUND 11B 3.4.22.34
5LU9 CRYSTAL STRUCTURE OF YVAD-CMK BOUND HUMAN LEGUMAIN (AEP) IN COMPLEX WITH COMPOUND 11 3.4.22.34
5LUA CRYSTAL STRUCTURE OF HUMAN LEGUMAIN (AEP) IN COMPLEX WITH COMPOUND 11B 3.4.22.34
5LUB CRYSTAL STRUCTURE OF HUMAN LEGUMAIN (AEP) IN COMPLEX WITH COMPOUND 11 3.4.22.34
5LUP STRUCTURES OF DHBN DOMAIN OF HUMAN BLM HELICASE 3.6.4.12
5LUS STRUCTURES OF DHBN DOMAIN OF PELECANUS CRISPUS BLM HELICASE 3.6.4.12
5LUT STRUCTURES OF DHBN DOMAIN OF GALLUS GALLUS BLM HELICASE 3.6.4.12
5LUZ STRUCTURE OF HUMAN NEUROLYSIN (E475Q) IN COMPLEX WITH NEUROTENSIN PEPTIDE PRODUCTS 3.4.24.16
5LV0 STRUCTURE OF HUMAN NEUROLYSIN (E475Q) IN COMPLEX WITH AMYLOID-BETA 35-40 PEPTIDE PRODUCT 3.4.24.16
5LVC AICHI VIRUS 1: EMPTY PARTICLE 3.6.4.13
3.4.22.28
2.7.7.48
5LVD THERMOLYSIN IN COMPLEX WITH INHIBITOR (JC67) 3.4.24.27
5LVG HEN EGG WHITE LYSOZYME SOAKED WITH CIS-RU(DMSO)4CL2 3.2.1.17
5LVH HEN EGG WHITE LYSOZYME SOAKED WITH TRANS-RU(DMSO)4CL2 3.2.1.17
5LVI HEN EGG WHITE LYSOZYME SOAKED WITH [HISQ][TRANS-RUCL4(DMSO)(ISQ)] 3.2.1.17
5LVJ HEN EGG WHITE LYSOZYME SOAKED WITH [H2IND][TRANS-RUCL4(DMSO)(HIND)] 3.2.1.17
5LVK HUMAN LYSOZYME SOAKED WITH [H2IND][TRANS-RUCL4(DMSO)(HIND)] 3.2.1.17
5LW5 TURNIP YELLOW MOSAIC VIRUS PROTEASE/DEUBIQUITINASE DOMAIN, DELTAC5 MUTANT 2.1.1
3.4.22
3.6.4
2.7.7.48
5LWA TURNIP YELLOW MOSAIC VIRUS PROTEASE/DEUBIQUITINASE DOMAIN, I847A MUTANT 2.1.1
3.4.22
3.6.4
2.7.7.48
5LWD THERMOLYSIN IN COMPLEX WITH INHIBITOR (JC96) 3.4.24.27
5LWF STRUCTURE OF A SINGLE DOMAIN CAMELID ANTIBODY FRAGMENT CAB-G10S IN COMPLEX WITH THE BLAP BETA-LACTAMASE FROM BACILLUS LICHENIFORMIS 3.5.2.6
5LWO STRUCTURE OF SPIN-LABELLED T4 LYSOZYME MUTANT L115C-R119C-R1 AT 100K 3.2.1.17
5LWR ENDOTHIAPEPSIN IN COMPLEX WITH A DERIVATIVE OF FRAGMENT 177 3.4.23.22
5LWS ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 177 AND A DERIVATIVE THEREOF 3.4.23.22
5LWT ENDOTHIAPEPSIN IN COMPLEX WITH A METHOXYLATED DERIVATIVE OF FRAGMENT 177 3.4.23.22
5LWU STRUCTURE RESULTING FROM AN ENDOTHIAPEPSIN CRYSTAL SOAKED WITH A DIMERIC DERIVATIVE OF FRAGMENT 177 3.4.23.22
5LWZ CYS-GLY DIPEPTIDASE GLIJ (SPACE GROUP C2) 3.4.13.19
5LX0 CYS-GLY DIPEPTIDASE GLIJ (SPACE GROUP P3221) 3.4.13.19
5LX1 CYS-GLY DIPEPTIDASE GLIJ MUTANT D304A 3.4.13.19
5LX4 CYS-GLY DIPEPTIDASE GLIJ MUTANT D38H 3.4.13.19
5LX7 CYS-GLY DIPEPTIDASE GLIJ MUTANT D38N 3.4.13.19
5LXW ATOMIC RESOLUTION X-RAY CRYSTAL STRUCTURE OF CISPLATIN BOUND TO HEN EGG WHITE LYSOZYME STORED FOR 5 YEARS ON THE SHELF 3.2.1.17
5LY7 CRYSTAL STRUCTURE OF NAGZ H174A MUTANT FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH THE INHIBITOR 2-ACETAMIDO-1,2-DIDEOXYNOJIRIMYCIN 3.2.1.52
5LYD CRYSTAL STRUCTURE OF 1 IN COMPLEX WITH TAFCPB 3.4.17.2
5LYF CRYSTAL STRUCTURE OF 1 IN COMPLEX WITH TAFCPB 3.4.17.2
5LYI CRYSTAL STRUCTURE OF 1 IN COMPLEX WITH TAFCPB 3.4.17.2
5LYL CRYSTAL STRUCTURE OF 1 IN COMPLEX WITH TAFCPB 3.4.17.2
5LYM STUDIES OF MONOCLINIC HEN EGG WHITE LYSOZYME. IV. X-RAY REFINEMENT AT 1.8 ANGSTROM RESOLUTION AND A COMPARISON OF THE VARIABLE REGIONS IN THE POLYMORPHIC FORMS 3.2.1.17
5LYO CRYSTAL STRUCTURE OF THE ZYMOGEN MATRIPTASE CATALYTIC DOMAIN 3.4.21.109
5LYT COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES 3.2.1.17
5LYW CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 6-((R)-2-O-TOLYLOXYMETHYL-PYRROLIDIN-1-YL)-9H-PURINE 3.4.11.18
5LYX CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 5-((R)-1-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL-PYRROLIDIN-2-YLMETHOXY)-ISOQUINOLINE 3.4.11.18
5LYY FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LYZ REAL-SPACE REFINEMENT OF THE STRUCTURE OF HEN EGG-WHITE LYSOZYME 3.2.1.17
5LZ2 FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LZ4 FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LZ5 FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LZ7 FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LZ8 FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LZ9 FRAGMENT-BASED INHIBITORS OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 3.1.1.47
5LZM COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS 3.2.1.17
5LZP BINDING OF THE C-TERMINAL GQYL MOTIF OF THE BACTERIAL PROTEASOME ACTIVATOR BPA TO THE 20S PROTEASOME 3.4.25.1
5LZQ CRYSTAL STRUCTURE OF THERMOTOGA MARITIMA SODIUM PUMPING MEMBRANE INTEGRAL PYROPHOSPHATASE IN COMPLEX WITH IMIDODIPHOSPHATE AND MAGNESIUM, AND WITH BOUND SODIUM ION 3.6.1.1
5LZR CRYSTAL STRUCTURE OF THERMOTOGA MARITIMA SODIUM PUMPING MEMBRANE INTEGRAL PYROPHOSPHATASE IN COMPLEX WITH TUNGSTATE AND MAGNESIUM 3.6.1.1
5M04 STRUCTURE OF OBGE FROM ESCHERICHIA COLI 3.6.5
5M0D STRUCTURE-BASED EVOLUTION OF A HYBRID STEROID SERIES OF AUTOTAXIN INHIBITORS 3.1.4.39
5M0E STRUCTURE-BASED EVOLUTION OF A HYBRID STEROID SERIES OF AUTOTAXIN INHIBITORS 3.1.4.39
5M0K CRYSTAL STRUCTURE OF ENDO-1,4-BETA-XYLANASE FROM CELLULOMONAS FLAVIGENA 3.2.1.8
5M0M STRUCTURE-BASED EVOLUTION OF A HYBRID STEROID SERIES OF AUTOTAXIN INHIBITORS 3.1.4.39
5M0Q CRYO-EM RECONSTRUCTION OF THE MAEDI-VISNA VIRUS (MVV) INTASOME 3.4.23
2.7.7.49
3.1.26.13
3.1.13.2
3.6.1.23
2.7.7
3.1
2.7.7.7
3.1.26.4
5M0R CRYO-EM RECONSTRUCTION OF THE MAEDI-VISNA VIRUS (MVV) STRAND TRANSFER COMPLEX 3.4.23
2.7.7.49
3.1.26.13
3.1.13.2
3.6.1.23
2.7.7
3.1
2.7.7.7
3.1.26.4
5M0S STRUCTURE-BASED EVOLUTION OF A HYBRID STEROID SERIES OF AUTOTAXIN INHIBITORS 3.1.4.39
5M0X STRUCTURE OF APO STRUCTURE OF GH36 ALPHA-GALACTOSIDASE FROM THERMOTOGA MARITIMA 3.2.1.22
5M12 STRUCTURE OF GH36 ALPHA-GALACTOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH INTACT CYCLOPROPYL-CARBASUGAR. 3.2.1.22
5M16 STRUCTURE OF GH36 ALPHA-GALACTOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH A HYDROLYSED CYCLOPROPYL CARBASUGAR. 3.2.1.22
5M1F CRYSTAL STRUCTURE OF THE LARGE TERMINASE NUCLEASE FROM THERMOPHILIC PHAGE G20C 3.6.4
3.1.21
5M1I STRUCTURE OF GH36 ALPHA-GALACTOSIDASE FROM THERMOTOGA MARITIMA IN A COVALENT COMPLEX WITH A CYCLOPROPYL CARBASUGAR. 3.2.1.22
5M1K CRYSTAL STRUCTURE OF THE LARGE TERMINASE NUCLEASE FROM THERMOPHILIC PHAGE G20C WITH BOUND MAGNESIUM 3.6.4
3.1.21
5M1N CRYSTAL STRUCTURE OF THE LARGE TERMINASE NUCLEASE FROM THERMOPHILIC PHAGE G20C WITH BOUND MANGANESE 3.6.4
3.1.21
5M1O CRYSTAL STRUCTURE OF THE LARGE TERMINASE NUCLEASE FROM THERMOPHILIC PHAGE G20C WITH BOUND COBALT 3.6.4
3.1.21
5M1P CRYSTAL STRUCTURE OF THE LARGE TERMINASE NUCLEASE FROM THERMOPHILIC PHAGE G20C WITH BOUND CALCIUM 3.6.4
3.1.21
5M1Q CRYSTAL STRUCTURE OF THE LARGE TERMINASE NUCLEASE FROM THERMOPHILIC PHAGE G20C WITH BOUND ZINC 3.6.4
3.1.21
5M1Y THE CASE OF 1LKR HELD AT THE PDB AND ITS VARIABLE AMINO ACID OCCUPANCIES; RE REFINEMENT OF 4OW9 TO CORRECT THIS 3.2.1.17
5M1Z STRUCTURE OF THE ALPHA-L-ARABINOFURANOSIDASE ARB93A FROM FUSARIUM GRAMINEARUM IN COMPLEX WITH AN HYDROXIMOLACTONE INHIBITOR 3.2.1.55
5M2G PCE REDUCTIVE DEHALOGENASE FROM S. MULTIVORANS IN COMPLEX WITH 2,4,6-TRIBROMOPHENOL 3.8.1
5M2Z CRYSTAL STRUCTURE OF THE FULL-LENGTH ZIKA VIRUS NS5 PROTEIN (HUMAN ISOLATE Z1106033) 3.4.21.91
3.6.1.15
3.6.4.13
5M32 HUMAN 26S PROTEASOME IN COMPLEX WITH OPROZOMIB 3.4.25.1
5M3J INFLUENZA B POLYMERASE BOUND TO FOUR HEPTAD REPEATS OF SERINE 5 PHOSPHORYLATED POL II CTD 3.1
5M3N HTRA2 WILD-TYPE STRUCTURE 3.4.21.108
5M3O HTRA2 A141S MUTANT STRUCTURE 3.4.21.108
5M4A NEUTRAL TREHALASE NTH1 FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH TREHALOSE 3.2.1.28
5M4G CRYSTAL STRUCTURE OF WILD-TYPE HUMAN PROLIDASE WITH MN IONS 3.4.13.9
5M4J CRYSTAL STRUCTURE OF WILD-TYPE HUMAN PROLIDASE WITH GLYPRO LIGAND 3.4.13.9
5M4L CRYSTAL STRUCTURE OF WILD-TYPE HUMAN PROLIDASE WITH MG IONS AND LEUPRO LIGAND 3.4.13.9
5M4Q CRYSTAL STRUCTURE OF WILD-TYPE HUMAN PROLIDASE WITH MN IONS AND PRO LIGAND 3.4.13.9
5M5B CRYSTAL STRUCTURE OF ZIKA VIRUS NS5 METHYLTRANSFERASE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5M5F THERMOLYSIN IN COMPLEX WITH INHIBITOR AND KRYPTON 3.4.24.27
5M5K S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM BRADYRHIZOBIUM ELKANII IN COMPLEX WITH ADENOSINE AND CORDYCEPIN 3.3.1.1
5M5Q COPS5(2-257) IN COMPLEX WITH A AZAINDOLE (COMPOUND 4) 3.4
5M65 CRYSTAL STRUCTURE OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM BRADYRHIZOBIUM ELKANII IN COMPLEX WITH ADENINE 3.3.1.1
5M66 CRYSTAL STRUCTURE OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM BRADYRHIZOBIUM ELKANII IN COMPLEX WITH ADENOSINE 3.3.1.1
5M67 CRYSTAL STRUCTURE OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM BRADYRHIZOBIUM ELKANII IN COMPLEX WITH ADENINE AND 2'-DEOXYADENOSINE 3.3.1.1
5M69 THERMOLYSIN IN COMPLEX WITH INHIBITOR AND XENON 3.4.24.27
5M6G CRYSTAL STRUCTURE GLUCAN 1,4-BETA-GLUCOSIDASE FROM SACCHAROPOLYSPORA ERYTHRAEA 3.2.1.74
5M7M NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES WITH POTENT AUTOTAXIN/ENPP2 INHIBITOR ACTIVITY 3.1.4.39
5M7R STRUCTURE OF HUMAN O-GLCNAC HYDROLASE 3.2.1.169
3.2.1
5M7S STRUCTURE OF HUMAN O-GLCNAC HYDROLASE WITH BOUND TRANSITION STATE ANALOG THIAMETG 3.2.1.169
3.2.1
5M7T STRUCTURE OF HUMAN O-GLCNAC HYDROLASE WITH PUGNAC TYPE INHIBITOR 3.2.1.169
3.2.1
5M7U STRUCTURE OF HUMAN O-GLCNAC HYDROLASE WITH NEW IMINOCYCLITOL TYPE INHIBITOR 3.2.1.169
3.2.1
5M8B CRYSTAL STRUCTURE OF ALPHA-L-ARABINOFURANOSIDASE FROM LACTOBACILLUS BREVIS 3.2.1.55
5M8E CRYSTAL STRUCTURE OF A GH43 ARABONOFURANOSIDASE FROM WEISSELLA SP. STRAIN 142 3.2.1.55
5M8U PCE REDUCTIVE DEHALOGENASE FROM S. MULTIVORANS IN COMPLEX WITH 4-BROMOPHENOL 3.8.1
5M8W PCE REDUCTIVE DEHALOGENASE FROM S. MULTIVORANS IN COMPLEX WITH 4-CHLOROPHENOL 3.8.1
5M99 FUNCTIONAL CHARACTERIZATION AND CRYSTAL STRUCTURE OF THERMOSTABLE AMYLASE FROM THERMOTOGA PETROPHILA, REVEALS HIGH THERMOSTABILITY AND AN ARCHAIC FORM OF DIMERIZATION 3.2.1.1
5M9A HUMAN ANGIOGENIN PD VARIANT H13R 3.1.27
5M9C HUMAN ANGIOGENIN ALS VARIANT K40R 3.1.27
5M9G HUMAN ANGIOGENIN PD VARIANT K54R 3.1.27
5M9J HUMAN ANGIOGENIN PD VARIANT K60E 3.1.27
5M9M HUMAN ANGIOGENIN PD VARIANT Q77P 3.1.27
5M9O CRYSTAL STRUCTURE OF HUMAN SND1 EXTENDED TUDOR DOMAIN IN COMPLEX WITH A SYMMETRICALLY DIMETHYLATED E2F PEPTIDE 3.1.31.1
5M9P HUMAN ANGIOGENIN ALS VARIANT T80S 3.1.27
5M9Q HUMAN ANGIOGENIN PD VARIANT R95Q 3.1.27
5M9R HUMAN ANGIOGENIN ALS VARIANT F100I 3.1.27
5M9S HUMAN ANGIOGENIN ALS VARIANT V103I 3.1.27
5M9T HUMAN ANGIOGENIN ALS VARIANT H114R 3.1.27
5M9V HUMAN ANGIOGENIN PD/ALS VARIANT R121C 3.1.27
5M9W EXPERIMENTAL MAD PHASED STRUCTURE OF THERMOLYSIN IN COMPLEX WITH INHIBITOR JC65. 3.4.24.27
5MA2 PCE REDUCTIVE DEHALOGENASE FROM S. MULTIVORANS IN COMPLEX WITH 4-IODOPHENOL 3.8.1
5MA7 STRUCTURE OF THERMOLYSIN IN COMPLEX WITH INHIBITOR (JC306). 3.4.24.27
5MAE CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-CHLORO-4-METHOXY-BENZENESULFONYL)-1-[3-(5-CHLORO-PYRIDIN-2-YL)-AZETIDINE-3-CARBONYL]-PYRROLIDINE-2-CAR BOXYLIC ACID (1-CYANO-CYCLOPROPYL)-AMIDE 3.4.22.15
5MAJ CATHEPSIN L IN COMPLEX WITH 4-[CYCLOPENTYL(IMIDAZO[1,2-A]PYRIDIN-2-YLMETHYL)AMINO]-6-MORPHOLINO-1,3,5-TRIAZINE-2-CARBONITRILE 3.4.22.15
5MAL CRYSTAL STRUCTURE OF EXTRACELULAR LIPASE FROM STREPTOMYCES RIMOSUS AT 1.7A RESOLUTION 3.1.1.3
3.1.1
3.1.2.2
5MAR STRUCTURE OF HUMAN SIRT2 IN COMPLEX WITH 1,2,4-OXADIAZOLE INHIBITOR AND ADP RIBOSE. 3.5.1
2.3.1.286
5MAT STRUCTURE OF HUMAN SIRTUIN 2 IN COMPLEX WITH A SELECTIVE THIENOPYRIMIDINONE BASED INHIBITOR 3.5.1
2.3.1.286
5MB0 COCKTAIL EXPERIMENT A: FRAGMENTS 63, 267, AND 291 IN COMPLEX WITH ENDOTHIAPEPSIN 3.4.23.22
5MB3 FRAGMENT 333 AT A CONCENTRATION OF 50MM IN COMPLEX WITH ENDOTHIAPEPSIN 3.4.23.22
5MB5 COCKTAIL EXPERIMENT C: FRAGMENTS 103 AND 171 IN COMPLEX WITH ENDOTHIAPEPSIN 3.4.23.22
5MB6 COCKTAIL EXPERIMENT D: FRAGMENTS 308 AND 333 AT 50MM CONCENTRATION 3.4.23.22
5MB7 COCKTAIL EXPERIMENT B: FRAGMENTS 224 AND 236 AT 50MM CONCENTRATION 3.4.23.22
5MBL CATHEPSIN B IN COMPLEX WITH DARPIN 81 3.4.22.1
5MBM CATHEPSIN B IN COMPLEX WITH DARPIN 8H6 3.4.22.1
5MBW CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH PEP#3 3.4.23.46
5MBY CRYSTAL STRUCTURE OF ARG184GLN MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MBZ CRYSTAL STRUCTURE OF SER202PHE MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MC0 CRYSTAL STRUCTURE OF DELTYR231 MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MC1 CRYSTAL STRUCTURE OF ASP276ASN MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MC2 CRYSTAL STRUCTURE OF GLY278ASP MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MC3 CRYSTAL STRUCTURE OF GLU412LYS MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MC4 CRYSTAL STRUCTURE OF GLY448ARG MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MC5 CRYSTAL STRUCTURE OF DELGLU452 MUTANT OF HUMAN PROLIDASE WITH MN IONS AND GLYPRO LIGAND 3.4.13.9
5MCC RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 1.11 MGY 3.2.1.91
5MCD RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 3.27 MGY 3.2.1.91
5MCE RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 5.43 MGY 3.2.1.91
5MCF RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 7.59 MGY 3.2.1.91
5MCH RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 9.75 MGY 3.2.1.91
5MCI RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 11.9 MGY 3.2.1.91
5MCJ RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 14.1 MGY 3.2.1.91
5MCK RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 16.2 MGY 3.2.1.91
5MCL RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 18.4 MGY 3.2.1.91
5MCM RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 20.6 MGY 3.2.1.91
5MCN RADIATION DAMAGE TO GH7 FAMILY CELLOBIOHYDROLASE FROM DAPHNIA PULEX: DOSE (DWD) 22.7 MGY 3.2.1.91
5MCO CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL-8234 AND EXOSITE PEPTIDE 3.4.23.46
5MCQ CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR 3.4.23.46
5MEH CRYSTAL STRUCTURE OF ALPHA-1,2-MANNOSIDASE FROM CAULOBACTER K31 STRAIN IN COMPLEX WITH 1-DEOXYMANNOJIRIMYCIN 3.2.1.113
5MF5 PA3825-EAL MG-CDG STRUCTURE 3.1.4.52
5MF6 HUMAN SIRT6 IN COMPLEX WITH ACTIVATOR UBCS039 3.5.1
2.3.1.286
5MFP HUMAN SIRT6 IN COMPLEX WITH ACTIVATOR UBCS58 3.5.1
2.3.1.286
5MFR THE CRYSTAL STRUCTURE OF E. COLI AMINOPEPTIDASE N IN COMPLEX WITH 7-AMINO-5,7,8,9-TETRAHYDROBENZOCYCLOHEPTEN-6-ONE 3.4.11.2
5MFS THE CRYSTAL STRUCTURE OF E. COLI AMINOPEPTIDASE N IN COMPLEX WITH 7-AMINO-4-PHENYL-5,7,8,9-TETRAHYDROBENZOCYCLOHEPTEN-6-ONE 3.4.11.2
5MFT THE CRYSTAL STRUCTURE OF E. COLI AMINOPEPTIDASE N IN COMPLEX WITH 7-AMINO-1-BROMO-4-PHENYL-5,7,8,9-TETRAHYDROBENZOCYCLOHEPTEN-6-ONE 3.4.11.2
5MFU PA3825-EAL MN-PGPG STRUCTURE 3.1.4.52
5MFX ZIKA NS3 HELICASE:RNA COMPLEX 3.4.21.91
3.6.1.15
3.6.4.13
5MFZ HUMAN SIRT6 IN COMPLEX WITH SMALL MOLECULE UBCS40 3.5.1
2.3.1.286
5MGA STRUCTURE OF THE CPF1 ENDONUCLEASE R-LOOP COMPLEX AFTER DNA CLEAVAGE 3.1
3.1.21.1
4.6.1.22
5MGC STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 4-GALACTOSYL-LACTOSE 3.2.1.23
5MGD STRUCTURE OF E298Q-BETA-GALACTOSIDASE FROM ASPERGILLUS NIGER IN COMPLEX WITH 6-GALACTOSYL-LACTOSE 3.2.1.23
5MGI CRYSTAL STRUCTURE OF KPC-2 CARBAPENEMASE IN COMPLEX WITH A PHENYL BORONIC INHIBITOR. 3.5.2.6
5MGN HUMAN SIRT6 IN COMPLEX WITH ACTIVATOR UBCS38 3.5.1
2.3.1.286
5MHF MURINE ENDOPLASMIC RETICULUM ALPHA-GLUCOSIDASE I WITH N-9'-METHOXYNONYL-1-DEOXYNOJIRIMYCIN 3.2.1.106
5MHP NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES WITH POTENT AUTOTAXIN/ENPP2 INHIBITOR ACTIVITY 3.1.4.39
5MI4 BTGH84 MUTANT WITH COVALENT MODIFICATION BY MA3 3.2.1.169
3.2.1.52
5MI5 BTGH84 MUTANT WITH COVALENT MODIFICATION BY MA3 IN COMPLEX WITH PUGNAC 3.2.1.169
3.2.1.52
5MI6 BTGH84 MUTANT WITH COVALENT MODIFICATION BY MA3 IN COMPLEX WITH THIAMET G 3.2.1.169
3.2.1.52
5MI7 BTGH84 MUTANT WITH COVALENT MODIFICATION BY MA4 IN COMPLEX WITH PUGNAC 3.2.1.169
3.2.1.52
5MIM XRAY STRUCTURE OF HUMAN FURIN BOUND WITH THE 2,5-DIDEOXYSTREPTAMINE DERIVED SMALL MOLECULE INHIBITOR 1N 3.4.21.75
5MJJ SINGLE-SHOT PINK BEAM SERIAL CRYSTALLOGRAPHY: LYSOZYME 3.2.1.17
5MJL SINGLE-SHOT PINK BEAM SERIAL CRYSTALLOGRAPHY: PROTEINASE K 3.4.21.64
5MJV REBUILD AND RE-REFINED MODEL FOR HUMAN PARECHOVIRUS 1 3.6.1.15
3.4.22.28
2.7.7.48
3.4.22.29
5MJY CRYSTAL STRUCTURE OF THE HIS DOMAIN PROTEIN TYROSINE PHOSPHATASE (HD-PTP/PTPN23) BRO1 DOMAIN (SARA COMPLEX STRUCTURE) 3.1.3.48
5MJZ CRYSTAL STRUCTURE OF THE HIS DOMAIN PROTEIN TYROSINE PHOSPHATASE (HD-PTP/PTPN23) BRO1 DOMAIN (APO STRUCTURE) 3.1.3.48
5MK0 CRYSTAL STRUCTURE OF THE HIS DOMAIN PROTEIN TYROSINE PHOSPHATASE (HD-PTP/PTPN23) BRO1 DOMAIN (ENDOFIN PEPTIDE COMPLEX) 3.1.3.48
5MK1 CRYSTAL STRUCTURE OF THE HIS DOMAIN PROTEIN TYROSINE PHOSPHATASE (HD-PTP/PTPN23) BRO1 DOMAIN (CHMP4A PEPTIDE COMPLEX STRUCTURE) 3.1.3.48
5MK2 CRYSTAL STRUCTURE OF THE HIS DOMAIN PROTEIN TYROSINE PHOSPHATASE (HD-PTP/PTPN23) BRO1 DOMAIN (CHMP4B PEPTIDE COMPLEX STRUCTURE) 3.1.3.48
5MK5 STRUCTURES OF DHBN DOMAIN OF HUMAN BLM HELICASE 3.6.4.12
5MK6 CRYSTAL STRUCTURE OF THE RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A1 (CRYSTAL FORM 1) 3.4.24.69
5MK7 CRYSTAL STRUCTURE OF THE RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A1 (CRYSTAL FORM 2) 3.4.24.69
5MKT CRYSTAL STRUCTURE OF MOUSE PRORENIN 3.4.23.15
5MKW CRYSTAL STRUCTURE OF THE HUMAN ZRANB3 HNH DOMAIN 3.6.4
3.1
5MLA CRYSTAL STRUCTURE OF HUMAN RAS IN COMPLEX WITH DARPIN K55 3.6.5.2
5MLG CRYSTAL STRUCTURE OF RAT PRORENIN 3.4.23.15
5MM6 THROMBIN MUTANT A190S IN COMPLEX WITH (S)-1-(D-PHENYLALANYL)-N-(4-CARBAMIMIDOYLBENZYL)PYRROLIDINE-2-CARBOXAMIDE 3.4.21.5
5MM8 ATOMIC RESOLUTION STRUCTURE OF SPLE PROTEASE FROM STAPHYLOCOCCUS AUREUS 3.4.21
5MMA CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) INTASOME IN COMPLEX WITH MAGNESIUM AND THE INSTI XZ379 (COMPOUND 5'G) 2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
2.7.7
3.1
5MMB CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) INTASOME IN COMPLEX WITH MAGNESIUM AND THE INSTI XZ434 (COMPOUND 6P) 2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
2.7.7
3.1
5MMV CRYSTAL STRUCTURE OF HUMAN CASPASE-1 WITH 2-((2-NAPHTHOYL)-L-VALYL)-4-HYDROXY-N-((3S)-2-HYDROXY-5-OXOTETRAHYDROFURAN-3-YL)-2-AZABICYCLO[2.2.2]OCTANE-3-CARBOXAMIDE (COMPOUND 1) 3.4.22.36
5MMY CRYSTAL STRUCTURE OF OXA10 WITH HEPES 3.5.2.6
5MN1 CATIONIC TRYPSIN IN COMPLEX WITH 2-AMINOPYRIDINE (DEUTERATED SAMPLE AT 100 K) 3.4.21.4
5MNA CATIONIC TRYPSIN IN COMPLEX WITH ANILINE (DEUTERATED SAMPLE AT 295 K) 3.4.21.4
5MNB CATIONIC TRYPSIN IN COMPLEX WITH 2-AMINOPYRIDINE (DEUTERATED SAMPLE AT 295 K) 3.4.21.4
5MNC CATIONIC TRYPSIN IN COMPLEX WITH ANILINE (DEUTERATED SAMPLE AT 100 K) 3.4.21.4
5MNE CATIONIC TRYPSIN IN ITS APO FORM (DEUTERATED SAMPLE AT 100 K) 3.4.21.4
5MNF CATIONIC TRYPSIN IN ITS APO FORM (DEUTERATED SAMPLE AT 295 K) 3.4.21.4
5MNG CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE (DEUTERATED SAMPLE AT 100 K) 3.4.21.4
5MNH CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE (DEUTERATED SAMPLE AT 295 K) 3.4.21.4
5MNK CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE (DEUTERATED SAMPLE AT 100 K) 3.4.21.4
5MNL CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE (DEUTERATED SAMPLE AT 295 K) 3.4.21.4
5MNM CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE (AT 295 K) 3.4.21.4
5MNN CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE (DEUTERATED SAMPLE AT 100 K) 3.4.21.4
5MNO CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE (DEUTERATED SAMPLE AT 295 K) 3.4.21.4
5MNP CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE (AT 295 K) 3.4.21.4
5MNQ CATIONIC TRYPSIN IN COMPLEX WITH A DERIVATIVE OF N-AMIDINOPIPERIDINE 3.4.21.4
5MNR THERMOLYSIN IN COMPLEX WITH INHIBITOR JC256 3.4.24.27
5MNU OXA-10 AVIBACTAM COMPLEX WITH BOUND BROMIDE 3.5.2.6
5MON JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH 2-AMINOPYRIDINE 3.4.21.4
5MOO JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH ANILINE 3.4.21.4
5MOP JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN ITS APO FORM 3.4.21.4
5MOQ JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE 3.4.21.4
5MOR JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE 3.4.21.4
5MOS JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE 3.4.21.4
5MOX OXA-10 AVIBACTAM COMPLEX WITH BOUND CO2 3.5.2.6
5MOY CRYSTAL STRUCTURE OF THE BONT/A2 RECEPTOR-BINDING DOMAIN IN COMPLEX WITH THE LUMINAL DOMAIN OF ITS NEURONAL RECEPTOR SV2C 3.4.24.69
5MOZ OXA-10 AVIBACTAM COMPLEX WITH BOUND IODIDE 3.5.2.6
5MP0 HUMAN M7GPPPN-MRNA HYDROLASE (DCP2, NUDT20) CATALYTIC DOMAIN 3.6.1.62
5MP9 26S PROTEASOME IN PRESENCE OF ATP (S1) 3.4.25.1
5MPA 26S PROTEASOME IN PRESENCE OF ATP (S2) 3.4.25.1
5MPM SERCA2A FROM PIG HEART 3.6.3.8
7.2.2.10
5MQ5 A PROTEASE-RESISTANT N24S ESCHERICHIA COLI ASPARAGINASE MUTANT WITH OUTSTANDING STABILITY AND ENHANCED ANTI-LEUKAEMIC ACTIVITY 3.5.1.1
5MQH STRUCTURE OF THE PHOSPHATASE DOMAIN OF THE CELL FATE DETERMINANT SPOIIE FROM BACILLUS SUBTILIS IN A CRYSTAL FORM WITHOUT DOMAIN SWAPPING 3.1.3.16
5MQO GLYCOSIDE HYDROLASE BT_1003 3.2.1.185
5MQR SIALIDASE BT_1020 3.2.1.187
5MQX NMR SOLUTION STRUCTURE OF MACRO DOMAIN FROM VENEZUELAN EQUINE ENCEPHALITIS VIRUS(VEEV) IN COMPLEX WITH ADP-RIBOSE 2.1.1
2.7.7
3.1.3.33
3.4.22
3.6.1.15
3.6.4.13
2.7.7.48
3.1.3.84
2.7.7.19
5MQY CATHEPSIN L IN COMPLEX WITH 4-[1,3-BENZODIOXOL-5-YLMETHYL(2-PHENOXYETHYL)AMINO]-5-FLUOROPYRIMIDINE-2-CARBONITRILE 3.4.22.15
5MRJ CRYSTAL STRUCTURE OF ENDO-1,4-BETA-XYLANASE-LIKE PROTEIN FROM ACREMONIUM CHRYSOGENUM 3.2.1.8
5MRK STRUCTURAL BASIS OF ZIKA VIRUS METHYLTRANSFERASE INHIBITION BY SINEFUNGIN 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5MRV CRYSTAL STRUCTURE OF HUMAN CARBOXYPEPTIDASE O IN COMPLEX WITH NVCI 3.4.17
5MS3 KALLIKREIN-RELATED PEPTIDASE 8 CALCIUM COMPLEX 3.4.21.118
5MS4 KALLIKREIN-RELATED PEPTIDASE 8 LEUPEPTIN INHIBITOR COMPLEX 3.4.21.118
5MSG INFLUENZA B POLYMERASE BOUND TO VRNA PROMOTER AND CAPPED RNA PRIMER 3.1
5MT0 COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR 3.4.21.46
5MT4 COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR 3.4.21.46
5MT6 STRUCTURE OF E.COLI GLPG IN COMPLEX WITH PEPTIDE DERIVED INHIBITOR AC-RVRHA-PHENYLETHYL-KETOAMIDE 3.4.21.105
5MT7 STRUCTURE OF E.COLI GLPG IN COMPLEX WITH PEPTIDE DERIVED INHIBITOR AC-VRHA-CMK 3.4.21.105
5MT8 STRUCTURE OF E.COLI GLPG IN COMPLEX WITH PEPTIDE DERIVED INHIBITOR AC-RVRHA-CMK 3.4.21.105
5MTF A MODULAR ROUTE TO NOVEL POTENT AND SELECTIVE INHIBITORS OF RHOMBOID INTRAMEMBRANE PROTEASES 3.4.21.105
5MTK CRYSTAL STRUCTURE OF HUMAN CASPASE-1 WITH (3S,6S,10AS)-N-((2S,3S)-2-HYDROXY-5-OXOTETRAHYDROFURAN-3-YL)-6-(ISOQUINOLINE-1-CARBOXAMIDO)-5-OXODECAHYDROPYRROLO[1,2-A]AZOCINE-3-CARBOXAMIDE (PGE-3935199) 3.4.22.36
5MTZ CRYSTAL STRUCTURE OF A LONG FORM RNASE Z FROM YEAST 3.1.26.11
5MUF CRYSTAL STRUCTURE OF HUMAN PHOSPHOGLYCERATE MUTASE FAMILY MEMBER 5 (PGAM5) IN ITS ENZYMATICALLY ACTIVE DODECAMERIC FORM INDUCED BY THE PRESENCE OF THE N-TERMINAL WDPNWD MOTIF 3.1.3.16
5MUN STRUCTURAL INSIGHT INTO ZYMOGENIC LATENCY OF GINGIPAIN K FROM PORPHYROMONAS GINGIVALIS. 3.4.22.47
5MUV ATOMIC STRUCTURE FITTED INTO A LOCALIZED RECONSTRUCTION OF BACTERIOPHAGE PHI6 PACKAGING HEXAMER P4 3.6.1.15
5MUW ATOMIC STRUCTURE OF P4 PACKAGING ENZYME FITTED INTO A LOCALIZED RECONSTRUCTION OF BACTERIOPHAGE PHI6 VERTEX 3.6.1.15
5MV1 CRYSTAL STRUCTURE OF THE E PROTEIN OF THE JAPANESE ENCEPHALITIS VIRULENT VIRUS 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5MV2 CRYSTAL STRUCTURE OF THE E PROTEIN OF THE JAPANESE ENCEPHALITIS LIVE ATTENUATED VACCINE VIRUS 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5MWA HUMAN SEH PHOSPHATASE IN COMPLEX WITH 3-4-3,4-DICHLOROPHENYL-5-PHENYL-1,3-OXAZOL-2-YL-BENZOIC-ACID 3.3.2.10
3.1.3.76
5MXB CRYSTAL STRUCTURE OF YELLOW LUPIN LLPR-10.2B PROTEIN IN COMPLEX WITH MELATONIN 3.1.27
5MXP HALOALKANE DEHALOGENASE DMXA FROM MARINOBACTER SP. ELB17 POSSESSING A UNIQUE CATALYTIC RESIDUE 3.8.1.5
5MXW CRYSTAL STRUCTURE OF YELLOW LUPIN LLPR-10.2B PROTEIN IN COMPLEX WITH MELATONIN AND TRANS-ZEATIN. 3.1.27
5MYD CONVERGENT EVOLUTION INVOLVING DIMERIC AND TRIMERIC DUTPASES IN SIGNALLING. 3.6.1.23
5MYF CONVERGENT EVOLUTION INVOLVING DIMERIC AND TRIMERIC DUTPASES IN SIGNALLING. 3.6.1.23
5MYI CONVERGENT EVOLUTION INVOLVING DIMERIC AND TRIMERIC DUTPASES IN SIGNALLING. 3.6.1.23
5MYY HEN EGG-WHITE LYSOZYME (HEWL) COCRYSTALLIZED IN THE PRESENCE OF CADMIUM SULPHATE 3.2.1.17
5MZ4 CRYSTAL STRUCTURE OF FULL-LENGH CSFV NS3/4A 3.4.22
3.4.21.113
3.6.1.15
3.6.4.13
2.7.7.48
5MZ6 CRYO-EM STRUCTURE OF A SEPARASE-SECURIN COMPLEX FROM CAENORHABDITIS ELEGANS AT 3.8 A RESOLUTION 3.4.22.49
5MZE CRYSTAL STRUCTURE OF MOUSE MTH1 WITH 8-OXO-DGTP 3.6.1.55
3.6.1.56
5MZF CRYSTAL STRUCTURE OF DOG MTH1 PROTEIN 3.6.1.55
3.6.1.56
5MZG CRYSTAL STRUCTURE OF MOUSE MTH1 IN COMPLEX WITH TH588 3.6.1.55
3.6.1.56
5MZN HELICASE SEN1 3.6.4
5N0B CRYSTAL STRUCTURE OF THE TETANUS NEUROTOXIN IN COMPLEX WITH GD1A 3.4.24.68
5N0C CRYSTAL STRUCTURE OF THE TETANUS NEUROTOXIN IN COMPLEX WITH GM1A 3.4.24.68
5N0H CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH HYDROLYZED MEROPENEM - NEW REFINEMENT 3.5.2.6
5N0I CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH BETA-MERCAPTOETHANOL - NEW REFINEMENT 3.5.2.6
5N0M HPAD4 CRYSTAL COMPLEX WITH BB-F-AMIDINE 3.5.3.15
5N0Y HPAD4 CRYSTAL COMPLEX WITH AFM-30A 3.5.3.15
5N0Z HPAD4 CRYSTAL COMPLEX WITH AFM-41A 3.5.3.15
5N11 CRYSTAL STRUCTURE OF HUMAN BETA1-CORONAVIRUS OC43 NL/A/2005 HEMAGGLUTININ-ESTERASE 3.1.1.53
5N19 STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE IN COMPLEX WITH THE ALPHA-KETOAMIDE (S)-N-BENZYL-3-((S)-2-CINNAMAMIDO-3-PHENYLPROPANAMIDO)-2-OXO-4-((S)-2-OXOPYRROLIDIN-3-YL)BUTANAMIDE 3.4.19.12
3.4.22.69
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
2.1.1
3.1.13
3.1
5N1B HPAD4 CRYSTAL COMPLEX WITH AFM-14A 3.5.3.15
5N1J CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS 3.5.1
3.5.1.104
5N1P CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS IN COMPLEX WITH N-HYDROXYNAPHTHALENE-1-CARBOXAMIDE 3.5.1
3.5.1.104
5N2E STRUCTURE OF THE E9 DNA POLYMERASE FROM VACCINIA VIRUS 2.7.7.7
3.1.11
5N2G STRUCTURE OF THE E9 DNA POLYMERASE FROM VACCINIA VIRUS IN COMPLEX WITH MANGANESE 2.7.7.7
3.1.11
5N2H STRUCTURE OF THE E9 DNA POLYMERASE EXONUCLEASE DEFICIENT MUTANT (D166A+E168A) FROM VACCINIA VIRUS 2.7.7.7
3.1.11
5N2T THERMOLYSIN IN COMPLEX WITH INHIBITOR JC287 3.4.24.27
5N2X THERMOLYSIN IN COMPLEX WITH INHIBITOR JC272 3.4.24.27
5N2Z THERMOLYSIN IN COMPLEX WITH INHIBITOR JC286 3.4.24.27
5N31 THERMOLYSIN IN COMPLEX WITH INHIBITOR JC277 3.4.24.27
5N34 THERMOLYSIN IN COMPLEX WITH INHIBITOR JC276 3.4.24.27
5N3V THERMOLYSIN IN COMPLEX WITH INHIBITOR JC292 3.4.24.27
5N3W CRYSTAL STRUCTURE OF LTA4H BOUND TO A SELECTIVE INHIBITOR AGAINST LTB4 GENERATION 3.3.2.6
3.4.11.4
5N3Y THERMOLYSIN IN COMPLEX WITH INHIBITOR JC267 3.4.24.27
5N4B PROLYL OLIGOPEPTIDASE B FROM GALERINA MARGINATA BOUND TO 25MER MACROCYCLIZATION SUBSTRATE - S577A MUTANT 3.4.21.26
5N4C PROLYL OLIGOPEPTIDASE B FROM GALERINA MARGINATA BOUND TO 35MER HYDROLYSIS AND MACROCYCLIZATION SUBSTRATE - S577A MUTANT 3.4.21.26
5N4D PROLYL OLIGOPEPTIDASE B FROM GALERINA MARGINATA BOUND TO 25MER MACROCYCLIZATION SUBSTRATE - D661A MUTANT 3.4.21.26
5N4E PROLYL OLIGOPEPTIDASE B FROM GALERINA MARGINATA BOUND TO 35MER HYDROLYSIS AND MACROCYCLIZATION SUBSTRATE - H698A MUTANT 3.4.21.26
5N4F PROLYL OLIGOPEPTIDASE B FROM GALERINA MARGINATA - APO PROTEIN 3.4.21.26
5N5J HUMAN MMP12 IN COMPLEX WITH 3-(5-(1,2-DITHIOLAN-3-YL)PENTANAMIDO)PROPANE-1-SULFONATE 3.4.24.65
5N5K HUMAN CATALYTIC MMP-12 IN COMPLEX WITH 5-(1,2-DITHIOLAN-3-YL)-N-(3-HYDROXYPROPYL)PENTANAMIDE 3.4.24.65
5N5O STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE IN COMPLEX WITH THE ALPHA-KETOAMIDE (S)-N-BENZYL-3-((S)-2-CINNAMAMIDO-3-CYCLOPROPYLPROPANAMIDO)-2-OXO-4-((S)-2-OXOPYRROLIDIN-3-YL)BUTANAMIDE (CINNAMOYL-CYCLOPROPYLALANINE-GLNLACTAM-CO-CO-NH-BENZYL) 3.4.19.12
3.4.22.69
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
2.1.1
3.1.13
3.1
5N6O WILD TYPE HUMAN RAC1-GDP 3.6.5.2
5N6S THERMOTOGA MARITIMA FAMILY 1 GLYCOSIDE HYDROLASE COMPLEXED WITH CARBA-CYCLOPHELLITOL TRANSITION STATE MIMIC 3.2.1.21
5N6T THERMOTOGA MARITIMA FAMILY 1 GLYCOSIDE HYDROLASE COMPLEXED WITH A CYCLOPHELLITOL ANALOGUE TRANSITION STATE MIMIC 3.2.1.21
5N6U CRYSTAL STRUCTURE OF BETA-D-MANNOSIDASE FROM DICTYOGLOMUS THERMOPHILUM. 3.2.1.25
5N8C CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA LPXC COMPLEXED WITH INHIBITOR 3.5.1.108
5N8O CRYO EM STRUCTURE OF THE CONJUGATIVE RELAXASE TRAI OF THE F/R1 PLASMID SYSTEM 5.6.2.1
3.6.4.12
5N8R CRYSTAL STRUCTURE OF DROSOPHILIA DHX36 HELICASE IN COMPLEX WITH GAGCACTGC 3.6.1.3
3.6.4.12
3.6.4.13
5N8S CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH POLYT 3.6.1.3
3.6.4.12
3.6.4.13
5N8U CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH CTCTCCT 3.6.1.3
3.6.4.12
3.6.4.13
5N8X TRIGONAL STRUCTURE OF MUTANT V173I OF 3D POLYMERASE FROM FOOT-AND-MOUTH DISEASE VIRUS 3.4.22.46
3.6.1.15
3.4.22.28
2.7.7.48
5N8Z CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH CTCTCCCTT 3.6.1.3
3.6.4.12
3.6.4.13
5N90 CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH TTGTGGTGT 3.6.1.3
3.6.4.12
3.6.4.13
5N94 CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH POLYU 3.6.1.3
3.6.4.12
3.6.4.13
5N95 TETRAGONAL STRUCTURE OF MUTANT V173I OF 3D POLYMERASE FROM FOOT-AND-MOUTH DISEASE VIRUS 3.4.22.46
3.6.1.15
3.4.22.28
2.7.7.48
5N96 CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH AGGGTTTTTT 3.6.1.3
3.6.4.12
3.6.4.13
5N98 CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH TAGGGTTTT 3.6.1.3
3.6.4.12
3.6.4.13
5N9A CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH GTTAGGGTT 3.6.1.3
3.6.4.12
3.6.4.13
5N9D CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH GGGTTAGGGT 3.6.1.3
3.6.4.12
3.6.4.13
5N9E CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH TGGGGATTT 3.6.1.3
3.6.4.12
3.6.4.13
5N9F CRYSTAL STRUCTURE OF DROSOPHILA DHX36 HELICASE IN COMPLEX WITH SSDNA CPG_A 3.6.1.3
3.6.4.12
3.6.4.13
5N9M CRYSTAL STRUCTURE OF GATD - A GLUTAMINE AMIDOTRANSFERASE FROM STAPHYLOCOCCUS AUREUS INVOLVED IN PEPTIDOGLYCAN AMIDATION 6.3.5.13
3.5.1.2
5N9R CRYSTAL STRUCTURE OF USP7 IN COMPLEX WITH A POTENT, SELECTIVE AND REVERSIBLE SMALL-MOLECULE INHIBITOR 3.4.19.12
5N9T CRYSTAL STRUCTURE OF USP7 IN COMPLEX WITH A POTENT, SELECTIVE AND REVERSIBLE SMALL-MOLECULE INHIBITOR 3.4.19.12
5NA6 STRUCTURE OF CYS-NULL SE-MET DPP III FROM BACTEROIDES THETAIOTAOMICRON 3.4.14.4
5NA7 STRUCTURE OF DPP III FROM BACTEROIDES THETAIOTAOMICRON 3.4.14.4
5NA8 STRUCTURE OF DPP III FROM BACTEROIDES THETAIOTAOMICRON IN CLOSED FORM 3.4.14.4
5NA9 THE X-RAY STRUCTURE OF BOVINE PANCREATIC RIBONUCLEASE INCUBATED IN THE PRESENCE OF AN EXCESS OF CARBOPLATIN (1:10 RATIO) 3.1.27.5
4.6.1.18
5NAM NMR STRUCTURE OF TLR4 TRANSMEMBRANE DOMAIN (624-670) IN DMPG/DHPC BICELLES 3.2.2.6
5NAO NMR STRUCTURE OF TLR4 TRANSMEMBRANE DOMAIN (624-657) IN DPC MICELLES 3.2.2.6
5NAP TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IN COMPLEX WITH A NON-CHIRAL DONEPEZIL-LIKE INHIBITOR 17 3.1.1.7
5NAQ CRYSTAL STRUCTURE OF NATIVE 6-PHOSPHO-GLUCOSIDASE LPBGL FROM LACTOBACILLUS PLANTARUM 3.2.1.21
5NAR COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] 3.4.21.46
5NAT COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-[(1-METHYL-1H-INDOL-3-YL)-AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] 3.4.21.46
5NAU TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IN COMPLEX WITH A NON-CHIRAL DONEPEZIL-LIKE COMPOUND 20 3.1.1.7
5NAW COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (1R,3S,5R)-2-AZA-BICYCLO[3.1.0]HEXANE-2,3-DICARBOXYLIC ACID 2-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 3-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] 3.4.21.46
5NB6 COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (2S,4S)-4-AMINO-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] 3.4.21.46
5NB7 COMPLEMENT FACTOR D 3.4.21.46
5NBA COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (2S,4R)-4-FLUORO-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE] 3.4.21.46
5NBJ DLS TETRAGONAL - REHEWL 3.2.1.17
5NBK NDM-1 METALLO-BETA-LACTAMASE: A PARSIMONIOUS INTERPRETATION OF THE DIFFRACTION DATA 3.5.2.6
5NBS STRUCTURAL STUDIES OF A GLYCOSIDE HYDROLASE FAMILY 3 BETA-GLUCOSIDASE FROM THE MODEL FUNGUS NEUROSPORA CRASSA 3.2.1.21
5NC6 CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS IN COMPLEX WITH (E)-N-HYDROXY-3-(NAPHTHALEN-1-YL)PROP-2-ENAMIDE 3.5.1.104
5NC9 CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS IN COMPLEX WITH (2S)-2,6-DIAMINO-N-HYDROXYHEXANAMIDE 3.5.1
3.5.1.104
5NCD CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS IN COMPLEX WITH (2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)-N-HYDROXYPENTANAMIDE 3.5.1.104
5NCQ STRUCTURE OF THE (SR) CA2+-ATPASE BOUND TO A TETRAHYDROCARBAZOLE AND TNP-ATP 3.6.3.8
7.2.2.10
5NCR OH1 FROM THE ORF VIRUS: A TYROSINE PHOSPHATASE THAT DISPLAYS DISTINCT STRUCTURAL FEATURES AND TRIPLE SUBSTRATE SPECIFICITY 3.1.3
5NCX CRYSTAL STRUCTURE OF THERMOANAEROBACTERIUM XYLOLYTICUM GH116 BETA-GLUCOSIDASE WITH AN COVALENT INHIBITOR 3.2.1.45
5NDB CRYSTAL STRUCTURE OF METALLO-BETA-LACTAMASE SPM-1 COMPLEXED WITH CYCLOBUTANONE INHIBITOR 3.5.2.6
5NDD CRYSTAL STRUCTURE OF A THERMOSTABILISED HUMAN PROTEASE-ACTIVATED RECEPTOR-2 (PAR2) IN COMPLEX WITH AZ8838 AT 2.8 ANGSTROM RESOLUTION 3.2.1.17
5NDE CRYSTAL STRUCTURE OF METALLO-BETA-LACTAMASE SPM-1 IN SPACE GROUP P4222 3.5.2.6
5NDZ CRYSTAL STRUCTURE OF A THERMOSTABILISED HUMAN PROTEASE-ACTIVATED RECEPTOR-2 (PAR2) IN COMPLEX WITH AZ3451 AT 3.6 ANGSTROM RESOLUTION 3.2.1.17
5NE0 ROOM TEMPERATURE IN-SITU STRUCTURE OF HEN EGG-WHITE LYSOZYME FROM CRYSTALS ENCLOSED BETWEEN ULTRATHIN SILICON NITRIDE MEMBRANES 3.2.1.17
5NE1 L2 CLASS A SERINE-BETA-LACTAMASE IN COMPLEX WITH CYCLIC BORONATE 2 3.5.2.6
5NE2 L2 CLASS A SERINE-BETA-LACTAMASE 3.5.2.6
5NE3 L2 CLASS A SERINE-BETA-LACTAMASE COMPLEXED WITH AVIBACTAM 3.5.2.6
5NE5 CRYSTAL STRUCTURE OF FAMILY 47 ALPHA-1,2-MANNOSIDASE FROM CAULOBACTER K31 STRAIN IN COMPLEX WITH KIFUNENSINE 3.2.1.113
5NE6 CRYSTAL STRUCTURE OF DIMERIC TMPEP1050 AMINOPEPTIDASE 3.4.11.1
5NE7 CRYSTAL STRUCTURE OF H60A MUTANT OF THERMOTOGA MARITIMA TMPEP1050 AMINOPEPTIDASE 3.4.11.1
5NE8 CRYSTAL STRUCTURE OF H307A MUTANT OF THERMOTOGA MARITIMA TMPEP1050 AMINOPEPTIDASE 3.4.11.1
5NE9 CRYSTAL STRUCTURE OF H60A H307A MUTANT OF THERMOTOGA MARITIMA TMPEP1050 AMINOPEPTIDASE 3.4.11.1
5NEJ CRYOEM STRUCTURE OF FOOT AND MOUTH DISEASE VIRUS O1 MANISA 2.7.7.48
3.4.22.28
3.4.22.46
3.6.1.15
5NEK CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS IN COMPLEX WITH ACETAZOLAMIDE 3.5.1
3.5.1.104
5NEL CRYSTAL STRUCTURE OF THE POLYSACCHARIDE DEACETYLASE BC1974 FROM BACILLUS CEREUS IN COMPLEX WITH THIAMETG 3.5.1
3.5.1.104
5NET LOCALISED RECONSTRUCTION OF INTEGRIN ALPHA V BETA 6 BOUND TO FOOT AND MOUTH DISEASE VIRUS O1 MANISA - POSE A. 2.7.7.48
3.4.22.28
3.4.22.46
3.6.1.15
5NEU LOCALISED RECONSTRUCTION OF INTEGRIN ALPHA V BETA 6 BOUND TO FOOT AND MOUTH DISEASE VIRUS O1 MANISA - POSE B. 2.7.7.48
3.4.22.28
3.4.22.46
3.6.1.15
5NFG STRUCTURE OF RECOMBINANT CARDOSIN B FROM CYNARA CARDUNCULUS 3.4.23
5NFO HUMAN JMJD7 IN COMPLEX WITH MN AND 2OG IN THE P21212 FORM 1.14.11.63
3.4
5NFQ NOVEL EPOXIDE HYDROLASES BELONGING TO THE ALPHA/BETA HYDROLASES SUPERFAMILY IN METAGENOMES FROM HOT ENVIRONMENTS 3.3.2.10
5NFS STRUCTURE OF COXSACKIEVIRUS B3 3C PROTEASE IN COMPLEX WITH THE ALPHA-KETOAMIDE (S)-N-BENZYL-3-((S)-2-CINNAMAMIDO-3-PHENYLPROPANAMIDO)-2-OXO-4-((S)-2-OXOPYRROLIDIN-3-YL)BUTANAMIDE (CINNAMOYL-PHENYLALANINE-GLNLACTAM-CO-CO-NH-BENZYL) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5NFV CRYSTAL STRUCTURE OF CATALYTICALLY INACTIVE FNCAS12 MUTANT BOUND TO AN R-LOOP STRUCTURE CONTAINING A PRE-CRRNA MIMIC AND FULL-LENGTH DNA TARGET 3.1
3.1.21.1
4.6.1.22
5NFY SARS-COV NSP10/NSP14 DYNAMIC COMPLEX 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5NG7 NOVEL EPOXIDE HYDROLASES BELONGING TO THE ALPHA/BETA HYDROLASES SUPERFAMILY IN METAGENOMES FROM HOT ENVIRONMENTS 3.3.2.10
5NGE CRYSTAL STRUCTURE OF USP7 IN COMPLEX WITH THE NON-COVALENT INHIBITOR, FT671 3.4.19.12
5NGF CRYSTAL STRUCTURE OF USP7 IN COMPLEX WITH THE COVALENT INHIBITOR, FT827 3.4.19.12
5NGR CRYSTAL STRUCTURE OF HUMAN MTH1 IN COMPLEX WITH FRAGMENT INHIBITOR 8-(METHYLSULFANYL)-7H-PURIN-6-AMINE 3.6.1.55
3.6.1.56
5NGS CRYSTAL STRUCTURE OF HUMAN MTH1 IN COMPLEX WITH INHIBITOR 6-[(2-PHENYLETHYL)SULFANYL]-7H-PURIN-2-AMINE 3.6.1.55
3.6.1.56
5NGT CRYSTAL STRUCTURE OF HUMAN MTH1 IN COMPLEX WITH INHIBITOR 7-(FURAN-2-YL)-5-METHYL-1,3-BENZOXAZOL-2-AMINE 3.6.1.55
3.6.1.56
5NH0 STRUCTURE OF HUMAN CORONAVIRUS NL63 MAIN PROTEASE IN COMPLEX WITH THE ALPHA-KETOAMIDE TERT-BUTYL ((S)-4-(BENZYLAMINO)-3,4-DIOXO-1-((S)-2-OXOPYRROLIDIN-3-YL)B- UTAN-2-YL)CARBAMATE (TERT-BUTYL -GLNLACTAM-CO-CO-NH-BENZYL) 3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5NHU HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE CE5 ANTICOAGULANT 3.4.21.5
5NHY BAY-707 IN COMPLEX WITH MTH1 3.6.1.55
3.6.1.56
5NI2 CRYSTAL STRUCTURE OF HUMAN LTA4H MUTANT E271A IN COMPLEX WITH LTA4 (CRYSTAL FORM I) 3.3.2.6
3.4.11.4
5NI4 CRYSTAL STRUCTURE OF HUMAN LTA4H MUTANT E271A IN COMPLEX WITH LTA4 (CRYSTAL FORM II) 3.3.2.6
3.4.11.4
5NI6 CRYSTAL STRUCTURE OF HUMAN LTA4H MUTANT D375N IN COMPLEX WITH LTA4 3.3.2.6
3.4.11.4
5NIA CRYSTAL STRUCTURE OF HUMAN LTA4H MUTANT D375N IN OPEN CONFORMATION (CRYSTAL FORM I) 3.3.2.6
3.4.11.4
5NID CRYSTAL STRUCTURE OF HUMAN LTA4H MUTANT D375N IN OPEN CONFORMATION (CRYSTAL FORM II) 3.3.2.6
3.4.11.4
5NIE CRYSTAL STRUCTURE OF HUMAN LTA4H MUTANT R563A IN OPEN CONFORMATION 3.3.2.6
3.4.11.4
5NIF YEAST 20S PROTEASOME IN COMPLEX WITH BLM-PEP ACTIVATOR 3.4.25.1
5NIJ CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA LEGUMAIN ISOFORM GAMMA IN TWO-CHAIN ACTIVATION STATE 3.4.22.34
5NIS NEUTRAL TREHALASE NTH1 FROM SACCHAROMYCES CEREVISIAE 3.2.1.28
5NJ1 THE X-RAY STRUCTURE OF THE ADDUCT FORMED IN THE REACTION BETWEEN HEN EGG WHITE LYSOZYME AND ARSENOPLATIN-1 3.2.1.17
5NJ2 CRYSTAL STRUCTURE OF BLAC FROM MYCOBACTERIUM TUBERCULOSIS BOUND TO PHOSPHATE 3.5.2.6
5NJ5 E. COLI MICROCIN-PROCESSING METALLOPROTEASE TLDD/E WITH PHOSPHATE BOUND 3.4
5NJ7 THE X-RAY STRUCTURE OF THE ADDUCT FORMED IN THE REACTION BETWEEN BOVINE PANCREATIC RIBONUCLEASE AND ARSENOPLATIN-1 3.1.27.5
4.6.1.18
5NJ9 E. COLI MICROCIN-PROCESSING METALLOPROTEASE TLDD/E WITH DRVY ANGIOTENSIN FRAGMENT BOUND 3.4
5NJA E. COLI MICROCIN-PROCESSING METALLOPROTEASE TLDD/E WITH ANGIOTENSIN ANALOGUE BOUND 3.4
5NJB E. COLI MICROCIN-PROCESSING METALLOPROTEASE TLDD/E WITH ACTINONIN BOUND 3.4
5NJC E. COLI MICROCIN-PROCESSING METALLOPROTEASE TLDD/E (TLDD E263A MUTANT) WITH HEXAPEPTIDE BOUND 3.4
5NJF E. COLI MICROCIN-PROCESSING METALLOPROTEASE TLDD/E (TLDD H262A MUTANT) WITH PENTAPEPTIDE BOUND 3.4
5NJM LYSOZYME ROOM-TEMPERATURE STRUCTURE DETERMINED BY SERIAL MILLISECOND CRYSTALLOGRAPHY 3.2.1.17
5NJP MIX-AND-DIFFUSE SERIAL SYNCHROTRON CRYSTALLOGRAPHY: STRUCTURE OF N,N',N''-TRIACETYLCHITOTRIOSE BOUND TO LYSOZYME WITH 1S TIME-DELAY, PHASED WITH 1HEW 3.2.1.17
5NJQ MIX-AND-DIFFUSE SERIAL SYNCHROTRON CRYSTALLOGRAPHY: STRUCTURE OF N,N',N''-TRIACETYLCHITOTRIOSE BOUND TO LYSOZYME WITH 1S TIME-DELAY, PHASED WITH 4ET8 3.2.1.17
5NJR MIX-AND-DIFFUSE SERIAL SYNCHROTRON CRYSTALLOGRAPHY: STRUCTURE OF N,N',N''-TRIACETYLCHITOTRIOSE BOUND TO LYSOZYME WITH 50S TIME-DELAY, PHASED WITH 4ET8 3.2.1.17
5NJS MIX-AND-DIFFUSE SERIAL SYNCHROTRON CRYSTALLOGRAPHY: STRUCTURE OF N,N',N''-TRIACETYLCHITOTRIOSE BOUND TO LYSOZYME WITH 50S TIME-DELAY, PHASED WITH 1HEW 3.2.1.17
5NJU FLAVIVIRUS NS5 DOMAIN 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5NJV FLAVIVIRUS NS5 DOMAIN 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5NMY NMR SOLUTION STRUCTURE OF LYSOSTAPHIN 3.4.24.75
5NN0 CRYSTAL STRUCTURE OF HUBCHE WITH N-((1-(2,3-DIHYDRO-1H-INDEN-2-YL)PIPERIDIN-3-YL)METHYL)-N-(2-(DIMETHYLAMINO)ETHYL)-2-NAPHTHAMIDE. 3.1.1.8
5NN3 CRYSTAL STRUCTURE OF HUMAN LYSOSOMAL ACID-ALPHA-GLUCOSIDASE, GAA 3.2.1.20
5NN4 CRYSTAL STRUCTURE OF HUMAN LYSOSOMAL ACID-ALPHA-GLUCOSIDASE, GAA, IN COMPLEX WITH N-ACETYL-CYSTEINE 3.2.1.20
5NN5 CRYSTAL STRUCTURE OF HUMAN LYSOSOMAL ACID-ALPHA-GLUCOSIDASE, GAA, IN COMPLEX WITH 1-DEOXYNOJIRIMYCIN 3.2.1.20
5NN6 CRYSTAL STRUCTURE OF HUMAN LYSOSOMAL ACID-ALPHA-GLUCOSIDASE, GAA, IN COMPLEX WITH N-HYDROXYETHYL-1-DEOXYNOJIRIMYCIN 3.2.1.20
5NN7 KSHV URACIL-DNA GLYCOSYLASE, APO FORM 3.2.2.27
5NN8 CRYSTAL STRUCTURE OF HUMAN LYSOSOMAL ACID-ALPHA-GLUCOSIDASE, GAA, IN COMPLEX WITH ACARBOSE 3.2.1.20
5NN9 REFINED ATOMIC STRUCTURES OF N9 SUBTYPE INFLUENZA VIRUS NEURAMINIDASE AND ESCAPE MUTANTS 3.2.1.18
5NNH KSHV URACIL-DNA GLYCOSYLASE, APO FORM 3.2.2.27
5NNU KSHV URACIL-DNA GLYCOSYLASE, PRODUCT COMPLEX WITH DSDNA EXHIBITING DUPLEX NUCLEOTIDE FLIPPING 3.2.2.27
5NO1 CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS (PFV) INTASOME IN COMPLEX WITH MAGNESIUM AND THE INSTI XZ407 (COMPOUND 5G) 2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
2.7.7
3.1
5NOA POLYSACCHARIDE LYASE BACCELL_00875 3.2.1.172
5NPF CRYSTAL STRUCTURE OF TXGH116 (BETA-GLUCOSIDASE FROM THERMOANAEROBACTERIUM XYLOLYTICUM) IN COMPLEX WITH BETA CYCLOPHELLITOL CYCLOSULFATE PROBE ME594 3.2.1.45
5NPH STRUCTURE OF THE HEPATITIS C VIRUS STRAIN J4 GLYCOPROTEIN E2 ANTIGENIC REGION 532-540 BOUND TO THE FAB FRAGMENT OF THE NON-NEUTRALIZING ANTIBODY DAO5 3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5NPO PROMISCUOUS PROTEIN SELF-ASSEMBLY AS A FUNCTION OF PROTEIN STABILITY 3.5.2.6
5NQR POTENT INHIBITORS OF NUDT5 SILENCE HORMONE SIGNALING IN BREAST CANCER 3.6.1.13
3.6.1.58
2.7.7.96
5NR8 CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE-1 (HCHIT) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 7A 3.2.1.14
5NRA CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE-1 (HCHIT) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 7G 3.2.1.14
5NRF CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE-1 (HCHIT) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 7I 3.2.1.14
5NRK CRYSTAL STRUCTURE OF THE SIXTH COHESIN FROM ACETIVIBRIO CELLULOLYTICUS' SCAFFOLDIN B IN COMPLEX WITH CEL5 DOCKERIN S15I, I16N MUTANT 3.2.1.4
5NRM CRYSTAL STRUCTURE OF THE SIXTH COHESIN FROM ACETIVIBRIO CELLULOLYTICUS' SCAFFOLDIN B IN COMPLEX WITH CEL5 DOCKERIN S51I, L52N MUTANT 3.2.1.4
5NRT CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH CA2+ 3.4.13.19
5NRU CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH ZN2+ 3.4.13.19
5NRX CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH FE2+ 3.4.13.19
5NRY CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH FE3+ 3.4.13.19
5NRZ CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH MN2+ 3.4.13.19
5NS1 CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH NI2+ 3.4.13.19
5NS2 CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH CO2+ 3.4.13.19
5NS5 CYS-GLY DIPEPTIDASE GLIJ IN COMPLEX WITH CU2+ AND ZN2+ 3.4.13.19
5NS6 CRYSTAL STRUCTURE OF BETA-GLUCOSIDASE BGLM-G1 FROM MARINE METAGENOME 3.2.1.21
5NS7 CRYSTAL STRUCTURE OF BETA-GLUCOSIDASE BGLM-G1 MUTANT H75R FROM MARINE METAGENOME 3.2.1.21
5NS8 CRYSTAL STRUCTURE OF BETA-GLUCOSIDASE BGLM-G1 MUTANT H75R FROM MARINE METAGENOME IN COMPLEX WITH INHIBITOR 1-DEOXYNOJIRIMYCIN 3.2.1.21
5NTH STRUCTURE OF LEUCYL AMINOPEPTIDASE FROM LEISHMANIA MAJOR IN COMPLEX WITH ACTINONIN 3.4.11
5NUC STAPHYLOCOCCAL NUCLEASE, 1-N-PENTANE THIOL DISULFIDE TO V23C VARIANT 3.1.31.1
5NUU TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IN COMPLEX WITH A CHLOROTACRINE-TRYPTOPHAN HYBRID INHIBITOR 3.1.1.7
5NW9 CRYSTAL STRUCTURE OF THE COMPLEX OF TDP1 WITH DUPLEX DNA 3.1.4
5NWA CRYSTAL STRUCTURE OF THE COMPLEX OF TDP1 WITH DUPLEX DNA 3.1.4
5NWE COMPLEX OF H275Y MUTANT VARIANT OF NEURAMINIDASE FROM H1N1 INFLUENZA VIRUS WITH OSELTAMIVIR 3.2.1.18
5NWH POTENT INHIBITORS OF NUDT5 SILENCE HORMONE SIGNALING IN BREAST CANCER 3.6.1.13
3.6.1.58
2.7.7.96
5NX0 STRUCTURE OF SPIN-LABELLED T4 LYSOZYME MUTANT L115C-R119C-R1 AT ROOM TEMPERATURE 3.2.1.17
5NX1 COMBINATORIAL ENGINEERING OF PROTEOLYTICALLY RESISTANT APPI VARIANTS THAT SELECTIVELY INHIBIT HUMAN KALLIKREIN 6 FOR CANCER THERAPY 3.4.21
5NX3 COMBINATORIAL ENGINEERING OF PROTEOLYTICALLY RESISTANT APPI VARIANTS THAT SELECTIVELY INHIBIT HUMAN KALLIKREIN 6 FOR CANCER THERAPY 3.4.21
5NXB MOUSE GALACTOCEREBROSIDASE IN COMPLEX WITH SAPOSIN A 3.2.1.46
5NXZ A C145A MUTANT OF NESTERENKONIA AN1 AMIDASE FROM THE NITRILASE SUPERFAMILY 3.5.1.4
5NY2 A C145A MUTANT OF NESTERENKONIA AN1 AMIDASE FROM THE NITRILASE SUPERFAMILY 3.5.1.4
5NY7 A C145A MUTANT OF NESTERENKONIA AN1 AMIDASE BOUND TO NICOTINAMIDE 3.5.1.4
5NYB A C145A MUTANT OF NESTERENKONIA AN1 AMIDASE BOUND TO ADIPAMIDE 3.5.1.4
5NYC A C145A MUTANT OF NESTERENKONIA AN1 AMIDASE BOUND TO PROPIONITRILE 3.5.1.4
5NYE A C145A MUTANT OF NESTERENKONIA AN1 AMIDASE BOUND TO PROPIONAMIDE 3.5.1.4
5NYV CRYSTAL STRUCTURE DETERMINATION FROM PICOSECOND INFRARED LASER ABLATED PROTEIN CRYSTALS BY SERIAL SYNCHROTRON CRYSTALLOGRAPHY 3.8.1.3
5NYZ TWIST AND INDUCE: DISSECTING THE LINK BETWEEN THE ENZYMATIC ACTIVITY AND THE SAPI INDUCING CAPACITY OF THE PHAGE 80 DUTPASE. D95E MUTANT FROM DUTPASE 80ALPHA PHAGE. 3.6.1.23
5NZ2 TWIST AND INDUCE: DISSECTING THE LINK BETWEEN THE ENZYMATIC ACTIVITY AND THE SAPI INDUCING CAPACITY OF THE PHAGE 80 DUTPASE. D95E MUTANT FROM DUTPASE 80ALPHA PHAGE. 3.6.1.23
5NZ4 COMPLEX OF I223V MUTANT VARIANT OF NEURAMINIDASE FROM H1N1 INFLUENZA VIRUS WITH OSELTAMIVIR 3.2.1.18
5NZ5 A C145S MUTANT OF NESTERENKONIA AN1 AMIDASE FROM THE NITRILASE SUPERFAMILY 3.5.1.4
5NZE COMPLEX OF S247N MUTANT VARIANT OF NEURAMINIDASE FROM H1N1 INFLUENZA VIRUS WITH OSELTAMIVIR 3.2.1.18
5NZF COMPLEX OF H275Y/I223V MUTANT VARIANT OF NEURAMINIDASE FROM H1N1 INFLUENZA VIRUS WITH OSELTAMIVIR 3.2.1.18
5NZN COMPLEX OF H275Y/S247N MUTANT VARIANT OF NEURAMINIDASE FROM H1N1 INFLUENZA VIRUS WITH OSELTAMIVIR 3.2.1.18
5O0S CRYSTAL STRUCTURE OF TXGH116 (BETA-GLUCOSIDASE FROM THERMOANAEROBACTERIUM XYLOLYTICUM) IN COMPLEX WITH UNREACTED BETA CYCLOPHELLITOL CYCLOSULFATE PROBE ME711 3.2.1.45
5O19 JAPANESE ENCEPHALITIS VIRUS NON-STRUCTURAL PROTEIN 1 C-TERMINAL DOMAIN 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5O22 E. COLI FOLD IN COMPLEX WITH CAROLACTON 1.5.1.5
3.5.4.9
5O28 E. COLI FOLD APO 1.5.1.5
3.5.4.9
5O2A FOLD Q98H 1.5.1.5
3.5.4.9
5O2E CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH HYDROLYZED CEFUROXIME - NEW REFINEMENT 3.5.2.6
5O2F CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH HYDROLYZED AMPICILLIN - NEW REFINEMENT 3.5.2.6
5O2G CRYSTAL STRUCTURE DETERMINATION FROM PICOSECOND INFRARED LASER ABLATED PROTEIN CRYSTALS BY SERIAL SYNCHROTRON CRYSTALLOGRAPHY 3.8.1.3
5O2I AN EFFICIENT SETUP FOR FIXED-TARGET, TIME-RESOLVED SERIAL CRYSTALLOGRAPHY WITH OPTICAL EXCITATION 3.8.1.3
5O2P P130CAS SH3 DOMAIN PTP-PEST PEPTIDE CHIMERA 3.1.3.48
5O2T HUMAN KRAS IN COMPLEX WITH DARPIN K27 3.6.5.2
5O33 A STRUCTURE OF THE GEF KALIRIN DH1 DOMAIN IN COMPLEX WITH THE SMALL GTPASE RAC1 3.6.5.2
5O3V STRUCTURAL CHARACTERIZATION OF THE FAST AND PROMISCUOUS MACROCYCLASE FROM PLANT - PCY1-S562A BOUND TO PRESEGETALIN B1 3.4.21.26
5O3X STRUCTURAL CHARACTERIZATION OF THE FAST AND PROMISCUOUS MACROCYCLASE FROM PLANT - APO PCY1 3.4.21.26
5O4P CRYSTAL STRUCTURE OF AMPYLATED GRP78 3.6.4.10
5O59 CELLOBIOHYDROLASE CEL7A FROM T. ATROVIRIDE 3.2.1
5O5D CELLOBIOHYDROLASE CEL7A FROM T. ATROVIRIDE 3.2.1
5O5R X-RAY STRUCTURE OF HUMAN GLUTAMATE CARBOXYPEPTIDASE II (GCPII) IN COMPLEX WITH A UREA BASED INHIBITOR PSMA 1023 3.4.17.21
5O5T X-RAY STRUCTURE OF HUMAN GLUTAMATE CARBOXYPEPTIDASE II (GCPII) IN COMPLEX WITH A UREA BASED INHIBITOR PSMA 1007 3.4.17.21
5O5U X-RAY STRUCTURE OF HUMAN GLUTAMATE CARBOXYPEPTIDASE II (GCPII) IN COMPLEX WITH A UREA BASED INHIBITOR PSMA 1027 3.4.17.21
5O63 CRYSTAL STRUCTURE OF UBALAI RESTRICTION ENDONUCLEASE B3 DOMAIN DOMAIN (MUTANT L24M L53M L95M) WITH COGNATE DNA 3.1.21.4
5O6A THE CRYO-EM STRUCTURE OF TICK-BORNE ENCEPHALITIS VIRUS MATURE PARTICLE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5O6B STRUCTURE OF SCPIF1 IN COMPLEX WITH GGGTTTT AND ADP-ALF4 3.6.4.12
5O6D STRUCTURE OF SCPIF1 IN COMPLEX WITH POLYDT AND ATPGS 3.6.4.12
5O6E STRUCTURE OF SCPIF1 IN COMPLEX WITH TTTGGGTT AND ADP-ALF4 3.6.4.12
5O6I STRUCTURES AND DYNAMICS OF MESOPHILIC VARIANTS FROM THE HOMING ENDONUCLEASE I-DMOI 3.1
5O6Q HIGH PRESSURE FLASH COOLED HEN EGG WHITE LYSOZYME 3.2.1.17
5O6V THE CRYO-EM STRUCTURE OF TICK-BORNE ENCEPHALITIS VIRUS COMPLEXED WITH FAB FRAGMENT OF NEUTRALIZING ANTIBODY 19/1786 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5O6Y CRYSTAL STRUCTURE OF THE BC1960 PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE IN COMPLEX WITH 4-NAPHTHALEN-1-YL-~{N}-OXIDANYL-BENZAMIDE 3.5.1
3.5.1.104
5O71 CRYSTAL STRUCTURE OF HUMAN USP25 3.4.19.12
5O7B CRYSTAL STRUCTURE OF THE SLR0328 TYROSINE PHOSPHATASE WZB FROM SYNECHOCYSTIS SP. PCC 6803 3.1.3.48
5O7E CRYSTAL STRUCTURE OF THE PEPTIDASE DOMAIN OF COLLAGENASE H FROM CLOSTRIDIUM HISTOLYTICUM IN COMPLEX WITH N-ARYL MERCAPTOACETAMIDE-BASED INHIBITOR 3.4.24.3
5O8I CRYSTAL STRUCTURE OF HUMAN HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 1 (HHINT1) CRYSTALLIZED AT P212121 SPACE GROUP, AND REFINED TO 1.27 A 3
5O8N STRUCTURE OF THERMOLYSIN AT ROOM TEMPERATURE VIA A METHOD OF ACOUSTICALLY INDUCED ROTATION. 3.4.24.27
5O9J CRYSTAL STRUCTURE OF TRANSCRIPTION FACTOR IIB MJA MINI-INTEIN 3.1
5OA5 CELLOBIOHYDROLASE I (CEL7A) FROM HYPOCREA JECORINA WITH IMPROVED THERMAL STABILITY 3.2.1.91
5OAB A NOVEL CRYSTAL FORM OF HUMAN RNASE6 AT ATOMIC RESOLUTION 3.1.27
5OAF HUMAN RVB1/RVB2 HETEROHEXAMER IN INO80 COMPLEX 3.6.4.12
5OAR CRYSTAL STRUCTURE OF NATIVE BETA-N-ACETYLHEXOSAMINIDASE ISOLATED FROM ASPERGILLUS ORYZAE 3.2.1.52
5OB6 X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF LYSOZYME WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-IM), IM=IMIDAZOLE 3.2.1.17
5OB7 X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF LYSOZYME WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-IM), IM=IMIDAZOLE (CRYSTAL 2) 3.2.1.17
5OB8 X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF LYSOZYME WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-MIM), MIM=METHYL-IMIDAZOLE (CRYSTALS GROWN USING NACL) 3.2.1.17
5OB9 X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF LYSOZYME WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-MIM), MIM=METHYL-IMIDAZOLE (CRYSTALS GROWN USING ETHYLENE GLYCOL 3.2.1.17
5OBC X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF RIBONUCLEASE A WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-IM), IM=IMIDAZOLE 3.1.27.5
4.6.1.18
5OBD X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF RIBONUCLEASE A WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-MIM), MIM=METHYL-IMIDAZOLE 3.1.27.5
4.6.1.18
5OBE X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF RIBONUCLEASE A WITH THE COMPOUND FAC-[RUII(CO)3CL2(N3-MBI), MBI=METHYL-BENZIMIDAZOLE 3.1.27.5
4.6.1.18
5OBL X-RAY STRUCTURE OF THE PHOSPHATASE PAPP5 FROM ARABIDOPSIS THALIANA 3.1.3.16
5OBP PCE REDUCTIVE DEHALOGENASE FROM S. MULTIVORANS WITH 6-HYDROXYBENZIMIDAZOLYL NORCOBAMIDE COFACTOR 3.8.1
5OBT FULLY ACTIVATED A. THALIANA LEGUMAIN ISOFORM GAMMA IN COMPLEX WITH AC-YVAD-CMK 3.4.22.34
5OCA PCSK9:FAB COMPLEX WITH DEXTRAN SULFATE 3.4.21
5OCG DISCOVERY OF SMALL MOLECULES BINDING TO KRAS VIA HIGH AFFINITY ANTIBODY FRAGMENT COMPETITION METHOD. 3.6.5.2
5OCO DISCOVERY OF SMALL MOLECULES BINDING TO KRAS VIA HIGH AFFINITY ANTIBODY FRAGMENT COMPETITION METHOD. 3.6.5.2
5OCQ CRYSTAL STRUCTURE OF THE COMPLEX OF THE KAPPA-CARRAGEENASE FROM PSEUDOALTEROMONAS CARRAGEENOVORA WITH AN OLIGOTETRASACCHARIDE OF KAPPA-CARRAGEENAN 3.2.1.83
5OCR CRYSTAL STRUCTURE OF THE KAPPA-CARRAGEENASE ZOBELLIA_236 FROM ZOBELLIA GALACTANIVORANS 3.2.1.83
5OCT DISCOVERY OF SMALL MOLECULES BINDING TO KRAS VIA HIGH AFFINITY ANTIBODY FRAGMENT COMPETITION METHOD. 3.6.5.2
5ODZ CRYSTAL STRUCTURE OF THE BETA-LACTAMASE OXA-163 3.5.2.6
5OE0 CRYSTAL STRUCTURE OF THE BETA-LACTAMASE OXA-181 3.5.2.6
5OE2 CRYSTAL STRUCTURE OF THE BETA-LACTAMASE OXA-245 3.5.2.6
5OE7 STRUCTURE OF OTULIN BOUND TO THE MET1-LINKED DIUBIQUITIN ACTIVITY PROBE 3.4.19.12
5OER HEN EGG-WHITE LYSOZYME REFINED AGAINST 5000 9 KEV DIFFRACTION PATTERNS 3.2.1.17
5OEY CRYSTAL STRUCTURE OF LEISHMANIA MAJOR FRUCTOSE-1,6-BISPHOSPHATASE IN HOLO FORM. 3.1.3.11
5OEZ CRYSTAL STRUCTURE OF LEISHMANIA MAJOR FRUCTOSE-1,6-BISPHOSPHATASE IN APO FORM. 3.1.3.11
5OF0 X-RAY STRUCTURE OF HUMAN GLUTAMATE CARBOXYPEPTIDASE II (GCPII), THE E424M INACTIVE MUTANT, IN COMPLEX WITH A INHIBITOR CFBZOG 3.4.17.21
5OF4 THE CRYO-EM STRUCTURE OF HUMAN TFIIH 3.6.4.12
5OF9 CRYSTAL STRUCTURE OF HUMAN MORC2 (RESIDUES 1-603) 3.6.1
5OFA CRYSTAL STRUCTURE OF HUMAN MORC2 (RESIDUES 1-603) WITH SPINAL MUSCULAR ATROPHY MUTATION T424R 3.6.1
5OFB CRYSTAL STRUCTURE OF HUMAN MORC2 (RESIDUES 1-603) WITH SPINAL MUSCULAR ATROPHY MUTATION S87L 3.6.1
5OFT STRUCTURAL BASIS FOR OXA-48 DIMERIZATION 3.5.2.6
5OFU CRYSTAL STRUCTURE OF LEISHMANIA MAJOR FRUCTOSE-1,6-BISPHOSPHATASE IN T-STATE. 3.1.3.11
5OG7 ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE FRAGMENT 3.4.23.22
5OGH STRUCTURE OF RNASE A AT HIGH RESOLUTION (1.16 A) IN COMPLEX WITH 3'-CMP AND SULPHATE IONS 3.1.27.5
4.6.1.18
5OGZ CRYSTAL STRUCTURE OF RUMINICLOSTRIDIUM THERMOCELLUM BETA-GLUCOSIDASE A 3.2.1.21
5OHC CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) IN COMPLEX WITH GLYCEROL 3.2.1.208
5OHI CRYSTAL STRUCTURE OF AUTOTAXIN IN COMPLEX WITH BI-2545 3.1.4.39
5OHJ HUMAN PHOSPHODIESTERASE 4B CATALYTIC DOMAIN IN COMPLEX WITH A PYRROLIDINYL INHIBITOR. 3.1.4.53
5OHK CRYSTAL STRUCTURE OF USP30 IN COVALENT COMPLEX WITH UBIQUITIN PROPARGYLAMIDE (HIGH RESOLUTION) 3.4.19.12
5OHN CRYSTAL STRUCTURE OF USP30 IN COVALENT COMPLEX WITH UBIQUITIN PROPARGYLAMIDE (LOW RESOLUTION) 3.4.19.12
5OHP CRYSTAL STRUCTURE OF USP30 (C77A) IN COMPLEX WITH LYS6-LINKED DIUBIQUITIN 3.4.19.12
5OHY A GH31 FAMILY SULFOQUINOVOSIDASE IN COMPLEX WITH AZA-SUGAR INHIBITOR IFGSQ 3.2.1.20
5OHZ CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) - SEMET DERIVATIVE 3.2.1.208
5OI0 CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) IN COMPLEX WITH SERINE AND GLYCEROL 3.2.1.208
5OI2 DISSOCIATION OF BIOCHEMICAL AND ANTIRETROVIRAL ACTIVITIES OF INTEGRASE-LEDGF ALLOSTERIC INHIBITORS REVEALED BY RESISTANCE OF A125 POLYMORPHIC HIV-1 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5OI3 DISSOCIATION OF BIOCHEMICAL AND ANTIRETROVIRAL ACTIVITIES OF INTEGRASE-LEDGF ALLOSTERIC INHIBITORS REVEALED BY RESISTANCE OF A125 POLYMORPHIC HIV-1 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5OI5 DISSOCIATION OF BIOCHEMICAL AND ANTIRETROVIRAL ACTIVITIES OF INTEGRASE-LEDGF ALLOSTERIC INHIBITORS REVEALED BY RESISTANCE OF A125 POLYMORPHIC HIV-1 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5OI8 DISSOCIATION OF BIOCHEMICAL AND ANTIRETROVIRAL ACTIVITIES OF INTEGRASE-LEDGF ALLOSTERIC INHIBITORS REVEALED BY RESISTANCE OF A125 POLYMORPHIC HIV-1 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5OIA DISSOCIATION OF BIOCHEMICAL AND ANTIRETROVIRAL ACTIVITIES OF INTEGRASE-LEDGF ALLOSTERIC INHIBITORS REVEALED BY RESISTANCE OF A125 POLYMORPHIC HIV-1 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5OIE CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) E419A VARIANT IN COMPLEX WITH SERINE AND GLYCEROL 3.2.1.208
5OIV CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) D43A VARIANT IN COMPLEX WITH SERINE AND GLYCEROL 3.2.1.208
5OIW CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) D182A VARIANT IN COMPLEX WITH GLUCOSYLGLYCERATE 3.2.1.208
5OJ4 CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) D182A VARIANT IN COMPLEX WITH MANNOSYLGLYCERATE 3.2.1.208
5OJ7 SIRTUIN 4 ORTHOLOGUE FROM XENOPUS TROPICALIS IN COMPLEX WITH ADP-RIBOSE 3.5.1
2.3.1
5OJE ENDOTHIAPEPSIN WITH LIGAND VSK-B24 3.4.23.22
5OJN SIRTUIN 4 FROM XENOPUS TROPICALIS IN COMPLEX WITH THIOACETYL-ADP-RIBOSE 3.5.1
2.3.1
5OJO SIRTUIN 5 FROM DANIO RERIO IN COMPLEX WITH 3-HYDROXY-3-METHYLGLUTARYL-CPS1 PEPTIDE 3.5.1
2.3.1
5OJU CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) E419A VARIANT IN COMPLEX WITH GLUCOSYLGLYCERATE 3.2.1.208
5OJV CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) E419A VARIANT IN COMPLEX WITH MANNOSYLGLYCERATE 3.2.1.208
5OK6 UBIQUITIN SPECIFIC PROTEASE 11 USP11 - PEPTIDE F COMPLEX 3.4.19.12
5OKB HIGH RESOLUTION STRUCTURE OF NATIVE GAN1D, A PUTATIVE 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS 3.2.1.85
5OKH CONSERVATIVELY REFINED STRUCTURE OF GAN1D-WT, A PUTATIVE 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS, IN THE C2 SPACEGROUP 3.2.1.85
5OKI CRYSTAL STRUCTURE OF THE CTF18-1-8 MODULE FROM CTF18-RFC IN COMPLEX WITH A 63 KDA FRAGMENT OF DNA POLYMERASE EPSILON 2.7.7.7
3.1.11
5OKJ NON-CONSERVATIVELY REFINED STRUCTURE OF GAN1D-WT, A PUTATIVE 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS, IN THE C2 SPACEGROUP 3.2.1.85
5OKK CONSERVATIVELY REFINED STRUCTURE OF GAN1D-WT, A PUTATIVE 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS, IN COMPLEX WITH 6-PHOSPHO-BETA-GALACTOSE 3.2.1.85
5OKM CRYSTAL STRUCTURE OF HUMAN SHIP2 PHOSPHATASE-C2 3.1.3.86
5OKN CRYSTAL STRUCTURE OF HUMAN SHIP2 PHOSPHATASE-C2 D607A MUTANT 3.1.3.86
5OKO CRYSTAL STRUCTURE OF HUMAN SHIP2 PHOSPHATASE-C2 DOUBLE MUTANT F593D/L597D 3.1.3.86
5OKP CRYSTAL STRUCTURE OF HUMAN SHIP2 PHOSPHATASE-C2 DOUBLE MUTANT F593D/L597D 3.1.3.86
5OKQ NON-CONSERVATIVELY REFINED STRUCTURE OF GAN1D-WT, A PUTATIVE 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS, IN COMPLEX WITH 6-PHOSPHO-BETA-GALACTOSE 3.2.1.85
5OKR CONSERVATIVELY REFINED STRUCTURE OF GAN1D-WT, A PUTATIVE 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS, IN COMPLEX WITH 6-PHOSPHO-BETA-GLUCOSE 3.2.1.85
5OKS NON-CONSERVATIVELY REFINED STRUCTURE OF GAN1D, A 6-PHOSPHO-BETA-GALACTOSIDASE FROM GEOBACILLUS STEAROTHERMOPHILUS, IN COMPLEX WITH 6-PHOSPHO-BETA-GLUCOSE 3.2.1.85
5OL4 1.28 A RESOLUTION OF SPOROSARCINA PASTEURII UREASE INHIBITED IN THE PRESENCE OF NBPT 3.5.1.5
5OLB CRYSTAL STRUCTURE OF AUTOTAXIN IN COMPLEX WITH PF-8380 3.1.4.39
5OLD X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF RIBONUCLEASE A WITH A TETRANUCLEAR PT-THIOSEMICARBAZONE COMPOUND 3.1.27.5
4.6.1.18
5OLE X-RAY STRUCTURE OF THE ADDUCT FORMED UPON REACTION OF HEN EGG WHITE LYSOZYME WITH A TETRANUCLEAR PT-THIOSEMICARBAZONE COMPOUND 3.2.1.17
5OM9 CRYSTAL STRUCTURE OF THE HUMAN CARBOXYPEPTIDASE A1 IN COMPLEX WITH A THIIRANE MECHANISM-BASED INHIBITOR 3.4.17.1
5OMF CLOSED, TERNARY STRUCTURE OF KOD DNA POLYMERASE 2.7.7.7
3.1
5OMZ SOLUTION STRUCTURE OF DOMAIN III (DIII)OF ZIKA VIRUS ENVELOPE PROTEIN 3.4.21.91
3.6.1.15
3.6.4.13
5ONP ALZHEIMER'S AMYLOID-BETA PEPTIDE FRAGMENT 1-40 IN COMPLEX WITH CD-SUBSTITUTED THERMOLYSIN 3.4.24.27
5ONQ ALZHEIMER'S AMYLOID-BETA PEPTIDE FRAGMENT 29-40 IN COMPLEX WITH CD-SUBSTITUTED THERMOLYSIN 3.4.24.27
5ONR ALZHEIMER'S AMYLOID-BETA PEPTIDE FRAGMENT 1-40 IN COMPLEX WITH THERMOLYSIN 3.4.24.27
5ONT CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE(MHGGH) E419A VARIANT IN COMPLEX WITH GLUCOSYLGLYCEROL 3.2.1.208
5ONZ CRYSTAL STRUCTURE OF MYCOLICIBACTERIUM HASSIACUM GLUCOSYLGLYCERATE HYDROLASE (MHGGH) D182A VARIANT IN COMPLEX WITH GLUCOSYLGLYCOLATE 3.2.1.208
5OON STRUCTURE OF UNDECAPRENYL-PYROPHOSPHATE PHOSPHATASE, BACA 3.6.1.27
5OOQ STRUCTURE OF THE MTR4 NOP53 COMPLEX 3.6.4.13
5OPK CRYSTAL STRUCTURE OF D52N/R367Q CN-II MUTANT BOUND TO DATP AND FREE PHOSPHATE 3.1.3.5
5OPL CRYSTAL STRUCTURE OF K25E CN-II MUTANT 3.1.3.5
5OPM CRYSTAL STRUCTURE OF D52N/R238W CN-II MUTANT BOUND TO DATP AND FREE PHOSPHATE 3.1.3.5
5OPN CRYSTAL STRUCTURE OF R39Q CN-II MUTANT 3.1.3.5
5OPO CRYSTAL STRUCTURE OF R238G CN-II MUTANT 3.1.3.5
5OPP CRYSTAL STRUCTURE OF S408R CN-II MUTANT 3.1.3.5
5OQ2 SE-SAD STRUCTURE OF THE FUNCTIONAL REGION OF CWP19 FROM CLOSTRIDIUM DIFFICILE 3.5.1.28
5OQ3 HIGH RESOLUTION STRUCTURE OF THE FUNCTIONAL REGION OF CWP19 FROM CLOSTRIDIUM DIFFICILE 3.5.1.28
5OQJ STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH 3.6.4.12
5OQM STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH AND CORE MEDIATOR 3.6.4.12
5OSS BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH GLUCO-1H-IMIDAZOLE 3.2.1.21
5OST BETA-GLUCOSIDASE FROM THERMOANAEROBACTERIUM XYLOLYTICUM GH116 IN COMPLEX WITH GLUCO-1H-IMIDAZOLE 3.2.1.45
5OSY HUMAN DECAPPING SCAVENGER ENZYME (HDCPS) IN COMPLEX WITH M7G(5'S)PPSP(5'S)G MRNA 5' CAP ANALOG 3.6.1.59
5OT0 THE THERMOSTABLE L-ASPARAGINASE FROM THERMOCOCCUS KODAKARENSIS 3.5.1.1
5OTM CRYSTAL STRUCTURE OF HUMAN MTH1 IN COMPLEX WITH O6-METHYL-DGMP 3.6.1.55
3.6.1.56
5OUN NMR SOLUTION STRUCTURE OF THE EXTERNAL DII DOMAIN OF RVB2 FROM SACCHAROMYCES CEREVISIAE 3.6.4.12
5OV9 CRYSTAL STRUCTURE OF ACETYLCHOLINESTERASE IN COMPLEX WITH CRYSTAL VIOLET 3.1.1.7
5OVN CRYSTAL STRUCTURE OF FIV REVERSE TRANSCRIPTASE 3.4.23
2.7.7.49
3.1.26.13
3.1.13.2
3.6.1.23
2.7.7
3.1
5OVO STRUCTURE OF DRAG-GLNZ-DELTA42-54 COMPLEX FROM AZOSPIRILLUM BRASILENSE 3.2.2.24
5OVR X-RAY CHARACTERIZATION OF STRIATAL-ENRICHED PROTEIN TYROSINE PHOSPHATASE INHIBITORS 3.1.3.48
5OVX X-RAY CHARACTERIZATION OF STRIATAL-ENRICHED PROTEIN TYROSINE PHOSPHATASE INHIBITORS 3.1.3.48
5OW1 X-RAY CHARACTERIZATION OF STRIATAL-ENRICHED PROTEIN TYROSINE PHOSPHATASE INHIBITORS 3.1.3.48
5OW2 JAPANESE ENCEPHALITIS VIRUS CAPSID PROTEIN 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5OW8 INDOLE-2 CARBOXAMIDES AS SELECTIVE SECRETED PHOSPHOLIPASE A2 TYPE X (SPLA2-X) INHIBITORS 3.1.1.4
5OWC INDOLE-2 CARBOXAMIDES AS SELECTIVE SECRETED PHOSPHOLIPASE A2 TYPE X (SPLA2-X) INHIBITORS 3.1.1.4
5OWX INSIDE-OUT FMDV A10 CAPSID 3.4.22.46
3.6.1.15
3.4.22.28
2.7.7.48
5OX2 CRYSTAL STRUCTURE OF THYMOLIGASE, A SUBSTRATE-TAILORED PEPTILIGASE VARIANT 3.4.21.62
5OXD COMPLEX OF A C. PERFRINGENS O-GLCNACASE WITH A FRAGMENT HIT 3.2.1.169
3.2.1.52
5OYC GH5 ENDO-XYLOGLUCANASE FROM CELLVIBRIO JAPONICUS 3.2.1.151
3.2.1.4
5OYD GH5 ENDO-XYLOGLUCANASE FROM CELLVIBRIO JAPONICUS 3.2.1.151
3.2.1.4
5OYE GH5 ENDO-XYLOGLUCANASE FROM CELLVIBRIO JAPONICUS 3.2.1.151
3.2.1.4
5OYI FMDV A10 DISSOCIATED PENTAMER 3.4.22.46
3.6.1.15
3.4.22.28
2.7.7.48
5OYO CRYSTAL STRUCTURE OF BLAC FROM MYCOBACTERIUM TUBERCULOSIS 3.5.2.6
5P21 REFINED CRYSTAL STRUCTURE OF THE TRIPHOSPHATE CONFORMATION OF H-RAS P21 AT 1.35 ANGSTROMS RESOLUTION: IMPLICATIONS FOR THE MECHANISM OF GTP HYDROLYSIS 3.6.5.2
5P2P X-RAY STRUCTURE OF PHOSPHOLIPASE A2 COMPLEXED WITH A SUBSTRATE-DERIVED INHIBITOR 3.1.1.4
5PA8 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH CYCLOHEXANAMINE 3.4.21.21
5PA9 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH PHENYLMETHANAMINE;HYDROCHLORIDE 3.4.21.21
5PAA CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH CYCLOHEXYLMETHANAMINE 3.4.21.21
5PAB CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-[[3-[2-HYDROXY-3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PHENYL]PHENYL]METHYL]-3-PHENYLUREA 3.4.21.21
5PAC HUMAN FACTOR VIIA IN COMPLEX WITH 5-HYDROXY-N-(4-OXO-3H-QUINAZOLIN-6-YL)-1-[3-[(PHENYLCARBAMOYLAMINO)METHYL]PHENYL]PYRAZOLE-4-CARBOXAMIDE AT 1.50A 3.4.21.21
5PAD BINDING OF CHLOROMETHYL KETONE SUBSTRATE ANALOGUES TO CRYSTALLINE PAPAIN 3.4.22.2
5PAE CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2S)-2-HYDROXY-N-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]PROPANAMIDE 3.4.21.21
5PAF CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H-BENZIMIDAZOL-5-YL)-2-[3-[(2-AMINO-2-OXOETHYL)-METHYLSULFONYLAMINO]-5-CHLOROPHENYL]ACETAMIDE;2,2,2-TRIFLUOROACETIC ACID 3.4.21.21
5PAG CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2R)-2-HYDROXY-N-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-METHYLBUTANAMIDE;HYDROBROMIDE 3.4.21.21
5PAI HUMAN FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H-BENZIMIDAZOL-5-YL)-1-[3-[[(3,5-DIMETHYL-1,2-OXAZOL-4-YL)CARBAMOYLAMINO]METHYL]PHENYL]-5-HYDROXYPYRAZOLE-4-CARBOXAMIDE AT 1.73A 3.4.21.21
5PAJ CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-(1-AMINOISOQUINOLIN-6-YL)-3-BENZYLUREA 3.4.21.21
5PAK CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-[[4-(AMINOMETHYL)-2-(2-AMINO-2-OXOETHOXY)PHENYL]METHYL]-2-(4-HYDROXYPHENYL)-2-METHOXYACETAMIDE;HYDROCHLORIDE 3.4.21.21
5PAM CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-(5-ETHOXY-2-FLUOROPHENYL)-1-(2-PHENYLPYRROLIDIN-1-YL)ETHANONE 3.4.21.21
5PAN CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 5-HYDROXY-N-(3-OXO-1,2-DIHYDROISOINDOL-5-YL)-1-[3-[(PHENYLCARBAMOYLAMINO)METHYL]PHENYL]PYRAZOLE-4-CARBOXAMIDE 3.4.21.21
5PAO CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2S)-2,3-DIHYDROXY-N-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]PROPANAMIDE;HYDROBROMIDE 3.4.21.21
5PAQ CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-(3-ETHOXY-4-PROPAN-2-YLOXYPHENYL)-1-(2-PHENYLPYRROLIDIN-1-YL)ETHANONE 3.4.21.21
5PAR CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1H-BENZIMIDAZOL-2-AMINE 3.4.21.21
5PAS CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2S)-2-HYDROXY-N-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLPROPANAMIDE 3.4.21.21
5PAT CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H-BENZIMIDAZOL-5-YL)-2-(3-CHLOROPHENYL)ACETAMIDE 3.4.21.21
5PAU CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H-BENZIMIDAZOL-5-YL)-2-[3-[(2-AMINO-2-OXOETHYL)-METHYLSULFONYLAMINO]PHENYL]ACETAMIDE;2,2,2-TRIFLUOROACETIC ACID 3.4.21.21
5PAV CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(6-AMINOPYRIDIN-3-YL)-5-HYDROXY-1-PHENYLPYRAZOLE-4-CARBOXAMIDE 3.4.21.21
5PAW CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH ISOQUINOLINE-1,6-DIAMINE 3.4.21.21
5PAX CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-(2,6-DIFLUOROPHENYL)-3-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]UREA 3.4.21.21
5PAY CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLUREA 3.4.21.21
5PB0 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-(4-ETHOXY-3-METHOXYPHENYL)-2-(ISOQUINOLIN-6-YLAMINO)ACETIC ACID 3.4.21.21
5PB1 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH BENZENECARBOXIMIDAMIDE 3.4.21.21
5PB2 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-PHENYL-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-3-OL 3.4.21.21
5PB3 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-[[3-[4-(5-AMINO-1H-PYRROLO[3,2-B]PYRIDIN-2-YL)-5-HYDROXYPYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLUREA 3.4.21.21
5PB4 HUMAN FACTOR VIIA IN COMPLEX WITH 1-[[3-[5-HYDROXY-3-METHYL-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLUREA AT 2.43A 3.4.21.21
5PB5 HUMAN FACTOR VIIA IN COMPLEX WITH 1-[[3-[5-HYDROXY-4-(7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLUREA AT 1.84A 3.4.21.21
5PB6 CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-[[3-[5-HYDROXY-4-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]PENTANAMIDE 3.4.21.21
5PEP X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION 3.4.23.1
5PNT CRYSTAL STRUCTURE OF A HUMAN LOW MOLECULAR WEIGHT PHOSPHOTYROSYL PHOSPHATASE. IMPLICATIONS FOR SUBSTRATE SPECIFICITY 3.1.3.2
3.1.3.48
5PTD PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT H32A 3.1.4.10
4.6.1.13
5PTP STRUCTURE OF HYDROLASE (SERINE PROTEINASE) 3.4.21.4
5PZK CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-(4-FLUOROPHENYL)-N-METHYL-6-[(METHYLSULFONYL)AMINO]-5-(PROPAN-2-YLOXY)-1-BENZOFURAN-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5PZL CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-({3-[1-(2-CYCLOPROPYLETHYL)-6-FLUORO-4-HYDROXY-2-OXO-1,2-DIHYDROQUINOLIN-3-YL]-1,1-DIOXO-1,4-DIHYDRO-1LAMBDA~6~,2,4-BENZOTHIADIAZIN-7-YL}OXY)ACETAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5PZM CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 3-[2-(4-FLUOROPHENYL)-3-(METHYLCARBAMOYL)-1-BENZOFURAN-5-YL]BENZOIC ACID 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5PZN CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 5-[3-(TERT-BUTYLCARBAMOYL)PHENYL]-2-(4-FLUOROPHENYL)-N-METHYL-1-BENZOFURAN-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5PZO CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE C316N IN COMPLEX WITH 2-(4-FLUOROPHENYL)-N-METHYL-5-[3-({2-METHYL-1-OXO-1-[(1,3,4-THIADIAZOL-2-YL)AMINO]PROPAN-2-YL}CARBAMOYL)PHENYL]-1-BENZOFURAN-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5PZP CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 4-FLUORO-2-(4-FLUOROPHENYL)-N-METHYL-5-(2-METHYL-5-{[1-(PYRIMIDIN-2-YL)CYCLOPROPYL]CARBAMOYL}PHENYL)-1-BENZOFURAN-3-CARBOXAMIDE (BMS-929075) 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5PZQ HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 2-(4-METHOXYPHENYL)FURAN-3,4-DICARBOXYLIC ACID 3.1.3.11
5PZR HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(3-CHLOROPHENYL)SULFONYL-3-[3-[3-[(3-CHLOROPHENYL)SULFONYLCARBAMOYLAMINO]PROPOXY]PROPYL]UREA 3.1.3.11
5PZS HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(3-CHLOROPHENYL)SULFONYL-3-[6-[(3-CHLOROPHENYL)SULFONYLCARBAMOYLAMINO]HEXYL]UREA 3.1.3.11
5PZT HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-(3-ETHYL-4-PHENYLPHENYL)SULFONYLUREA 3.1.3.11
5PZU HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR [5-[2-AMINO-5-(2-METHYLPROPYL)-1,3-THIAZOL-4-YL]FURAN-2-YL]PHOSPHONIC ACID 3.1.3.11
5PZV HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(4-BROMOPYRIDIN-2-YL)-3-(4-CHLOROPHENYL)SULFONYLUREA 3.1.3.11
5PZW HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(3-CHLOROPHENYL)SULFONYL-3-[5-[(3-CHLOROPHENYL)SULFONYLCARBAMOYLAMINO]PENTYL]UREA 3.1.3.11
5PZX HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[4-METHOXY-3-(2-METHYLPROPYL)PHENYL]SULFONYLUREA 3.1.3.11
5PZY HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-(2-CHLOROPHENYL)SULFONYLUREA 3.1.3.11
5PZZ HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-(3,4-DICHLOROPHENYL)SULFONYLUREA 3.1.3.11
5Q00 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 2-[3-[(5-BROMO-1,3-THIAZOL-2-YL)CARBAMOYLSULFAMOYL]-1-METHYLINDOL-7-YL]OXYACETAMIDE 3.1.3.11
5Q01 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[4-(4,5-DICHLORO-2-METHYLPYRAZOL-3-YL)OXYPHENYL]SULFONYLUREA 3.1.3.11
5Q02 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[5-(1,2-OXAZOL-3-YL)THIOPHEN-2-YL]SULFONYLUREA 3.1.3.11
5Q03 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[5-(2-METHYLPROPYL)THIOPHEN-2-YL]SULFONYLUREA 3.1.3.11
5Q04 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(4-BROMO-5-CHLOROTHIOPHEN-2-YL)SULFONYL-3-(5-BROMO-1,3-THIAZOL-2-YL)UREA 3.1.3.11
5Q05 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[5-(2-METHOXYETHYL)-4-METHYLTHIOPHEN-2-YL]SULFONYLUREA 3.1.3.11
5Q06 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[4-(2-METHYL-1,3-THIAZOL-4-YL)PHENYL]SULFONYLUREA 3.1.3.11
5Q07 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(4-BROMO-6-MORPHOLIN-4-YLPYRIDIN-2-YL)-3-[5-(2-METHOXYETHYL)-4-METHYLTHIOPHEN-2-YL]SULFONYLUREA 3.1.3.11
5Q08 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(1-BENZOTHIOPHEN-3-YLSULFONYL)-3-(5-BROMO-1,3-THIAZOL-2-YL)UREA 3.1.3.11
5Q09 HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-[4-BROMO-6-(CARBAMOYLAMINO)PYRIDIN-2-YL]-3-[5-(2-METHOXYETHYL)-4-METHYLTHIOPHEN-2-YL]SULFONYLUREA 3.1.3.11
5Q0A HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-CYANOPYRAZIN-2-YL)-3-[3-(DIFLUOROMETHOXY)PHENYL]SULFONYLUREA 3.1.3.11
5Q0B HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(4-BROMO-3-METHYL-1,2-THIAZOL-5-YL)-3-(3-METHYLPHENYL)SULFONYLUREA 3.1.3.11
5Q0C HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE 1 (FRUCTOSE 1,6-BISPHOSPHATE 1-PHOSPHATASE, E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR 1-(5-BROMO-1,3-THIAZOL-2-YL)-3-[5-(4-METHOXYPHENYL)THIOPHEN-2-YL]SULFONYLUREA AND WITH FRUCTOSE-2,6-DIPHOSPHATE 3.1.3.11
5Q0D FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-2-OXO-1,2,3,4,5,6,7,9-OCTAHYDRO-11,8-(AZENO)-1,9-BENZODIAZACYCLOTRIDECIN-14-YL]CARBAMATE 3.4.21.27
5Q0E FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(4S,8S)-8-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-4-METHYL-2-OXO-1,3,4,5,6,7,8,10-OCTAHYDRO-2H-12,9-(AZENO)-1,10-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5Q0F FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(4R,5E,8S)-8-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-4-METHYL-2-OXO-1,3,4,7,8,10-HEXAHYDRO-2H-12,9-(AZENO)-1,10-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5Q0G FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(3R,7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-3-ETHYL-2-OXO-1,2,3,4,5,6,7,9-OCTAHYDRO-11,8-(AZENO)-1,9-BENZODIAZACYCLOTRIDECIN-14-YL]CARBAMATE 3.4.21.27
5Q0H FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(4R,5E,8S)-11-CHLORO-8-[(2,6-DIFLUORO-4-METHYLBENZENE-1-CARBONYL)AMINO]-4-METHYL-2-OXO-1,3,4,7,8,10-HEXAHYDRO-2H-12,9-(AZENO)-1,10-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5QA4 OXA-48 IN COMPLEX WITH COMPOUND 3A 3.5.2.6
5QA5 OXA-48 IN COMPLEX WITH COMPOUND 3B 3.5.2.6
5QA6 OXA-48 IN COMPLEX WITH COMPOUND 4A 3.5.2.6
5QA7 OXA-48 IN COMPLEX WITH COMPOUND 4B 3.5.2.6
5QA8 OXA-48 IN COMPLEX WITH COMPOUND 4C 3.5.2.6
5QA9 OXA-48 IN COMPLEX WITH COMPOUND 5 3.5.2.6
5QAA OXA-48 IN COMPLEX WITH COMPOUND 6A 3.5.2.6
5QAB OXA-48 IN COMPLEX WITH COMPOUND 6B 3.5.2.6
5QAC OXA-48 IN COMPLEX WITH COMPOUND 6C 3.5.2.6
5QAD OXA-48 IN COMPLEX WITH COMPOUND 8A 3.5.2.6
5QAE OXA-48 IN COMPLEX WITH COMPOUND 8B 3.5.2.6
5QAF OXA-48 IN COMPLEX WITH COMPOUND 8C 3.5.2.6
5QAG OXA-48 IN COMPLEX WITH COMPOUND 9A 3.5.2.6
5QAH OXA-48 IN COMPLEX WITH COMPOUND 9B 3.5.2.6
5QAI OXA-48 IN COMPLEX WITH COMPOUND 12A 3.5.2.6
5QAJ OXA-48 IN COMPLEX WITH COMPOUND 13 3.5.2.6
5QAK OXA-48 IN COMPLEX WITH COMPOUND 14 3.5.2.6
5QAL OXA-48 IN COMPLEX WITH COMPOUND 11B 3.5.2.6
5QAM OXA-48 IN COMPLEX WITH COMPOUND 17 3.5.2.6
5QAN OXA-48 IN COMPLEX WITH COMPOUND 19A 3.5.2.6
5QAO OXA-48 IN COMPLEX WITH COMPOUND 19B 3.5.2.6
5QAP OXA-48 IN COMPLEX WITH COMPOUND 21A 3.5.2.6
5QAQ OXA-48 IN COMPLEX WITH COMPOUND 21B 3.5.2.6
5QAR OXA-48 IN COMPLEX WITH COMPOUND 23A 3.5.2.6
5QAS OXA-48 IN COMPLEX WITH COMPOUND 23B 3.5.2.6
5QAT OXA-48 IN COMPLEX WITH COMPOUND 24 3.5.2.6
5QAU OXA-48 IN COMPLEX WITH COMPOUND 26A 3.5.2.6
5QAV OXA-48 IN COMPLEX WITH COMPOUND 26B 3.5.2.6
5QAW OXA-48 IN COMPLEX WITH COMPOUND 27 3.5.2.6
5QAZ OXA-48 IN COMPLEX WITH COMPOUND 34 3.5.2.6
5QB0 OXA-48 IN COMPLEX WITH COMPOUND 35 3.5.2.6
5QB1 OXA-48 IN COMPLEX WITH COMPOUND 36 3.5.2.6
5QB2 OXA-48 IN COMPLEX WITH COMPOUND 38 3.5.2.6
5QB3 OXA-48 IN COMPLEX WITH COMPOUND 40 3.5.2.6
5QB4 OXA-48 IN COMPLEX WITH SUBSTRATE IMIPENEM 3.5.2.6
5QB5 CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG056 COMPLEX 3.4.23.22
5QB6 CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG062 COMPLEX 3.4.23.22
5QB7 CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG075 COMPLEX 3.4.23.22
5QB8 CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG080 COMPLEX 3.4.23.22
5QB9 CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG081 COMPLEX 3.4.23.22
5QBA CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG134 COMPLEX 3.4.23.22
5QBB CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG140 COMPLEX 3.4.23.22
5QBC CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG164 COMPLEX 3.4.23.22
5QBD CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG166 COMPLEX 3.4.23.22
5QBE CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG175 COMPLEX 3.4.23.22
5QBF CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG203 COMPLEX 3.4.23.22
5QBG CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG245 COMPLEX 3.4.23.22
5QBH CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG270 COMPLEX 3.4.23.22
5QBI CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG274 COMPLEX 3.4.23.22
5QBJ CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-FRG283 COMPLEX 3.4.23.22
5QBK CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-347144 COMPLEX 3.4.23.22
5QBL CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-347147 COMPLEX 3.4.23.22
5QBM CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-347151 COMPLEX 3.4.23.22
5QBN CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT14-350193 COMPLEX 3.4.23.22
5QBO CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-347283 COMPLEX 3.4.23.22
5QBP CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-347290A COMPLEX 3.4.23.22
5QBQ CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN 3.4.23.22
5QBR CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN 3.4.23.22
5QBS CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-346976 COMPLEX 3.4.23.22
5QBT CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN-NAT17-346985 COMPLEX 3.4.23.22
5QBU CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QBW CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QBX CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QBZ CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC0 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC1 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC2 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC3 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC4 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC5 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC6 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC7 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC8 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QC9 CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCA CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCB CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCC CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCD CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCE CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCF CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCG CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCH CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCI CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCJ CRYSTAL STRUCTURE OF HUMAN CATHEPSIN-S WITH BOUND LIGAND 3.4.22.27
5QCK FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-CHLORANYL-2-(1,2,3,4-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-3-PHENYL-PYRROLIDIN-2-YL]CARBONYLAMINO]BENZOIC ACID 3.4.21.27
5QCL FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-CHLORANYL-2-(1,2,3,4-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-3,4-DIHYDRO-1~{H}-ISOQUINOLIN-1-YL]CARBONYLAMINO]BENZOIC ACID 3.4.21.27
5QCM FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-CHLORANYL-2-FLUORANYL-6-(1,2,3,4-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-3,4-DIHYDRO-1~{H}-ISOQUINOLIN-1-YL]CARBONYLAMINO]PHENYL]CARBAMATE 3.4.21.27
5QCN FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-CHLORANYL-2-(1,2,3,4-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-5-[(3~{S})-3-ETHOXYCARBONYLPIPERIDIN-1-YL]CARBONYL-3,4-DIHYDRO-1~{H}-ISOQUINOLIN-1-YL]CARBONYLAMINO]BENZOIC ACID 3.4.21.27
5QCO CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC016 3.4.23.46
5QCP CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC018 3.4.23.46
5QCQ CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC025 3.4.23.46
5QCR CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC026 3.4.23.46
5QCS CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC024 3.4.23.46
5QCT CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC001 3.4.23.46
5QCU CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC022 3.4.23.46
5QCV CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC023 3.4.23.46
5QCW CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC021 3.4.23.46
5QCX CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC007 3.4.23.46
5QCY CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC008 3.4.23.46
5QCZ CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC015 3.4.23.46
5QD0 CRYSTAL STRUCTURE OF BACE COMPLEX WITHBMC006 3.4.23.46
5QD1 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC011 3.4.23.46
5QD2 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC017 3.4.23.46
5QD3 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC010 3.4.23.46
5QD4 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC023 3.4.23.46
5QD5 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC009 3.4.23.46
5QD6 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC004 3.4.23.46
5QD7 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC014 3.4.23.46
5QD8 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC003 3.4.23.46
5QD9 CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC005 3.4.23.46
5QDA CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC013 3.4.23.46
5QDB CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC002 3.4.23.46
5QDC CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC019 HYDROLYZED 3.4.23.46
5QDD CRYSTAL STRUCTURE OF BACE COMPLEX WITH BMC020 HYDROLYZED 3.4.23.46
5QDE PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000740A 3.1.3.48
5QDF PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000295A 3.1.3.48
5QDG PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000294A 3.1.3.48
5QDH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000004A 3.1.3.48
5QDJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000211A 3.1.3.48
5QDK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000069A 3.1.3.48
5QDL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000072A 3.1.3.48
5QDN PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000163A 3.1.3.48
5QDP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000207A 3.1.3.48
5QDQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_XST00000847B 3.1.3.48
5QDU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000466A 3.1.3.48
5QDZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000435A 3.1.3.48
5QE1 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000645A 3.1.3.48
5QE6 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000608A 3.1.3.48
5QE7 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000601A 3.1.3.48
5QE9 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000232A 3.1.3.48
5QEB PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000639A 3.1.3.48
5QEC PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000270A 3.1.3.48
5QED PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000538A 3.1.3.48
5QEE PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000240A 3.1.3.48
5QEF PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000134A 3.1.3.48
5QEH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000323A 3.1.3.48
5QEI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_PKTTA024495B 3.1.3.48
5QEL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000675B 3.1.3.48
5QER PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000847B 3.1.3.48
5QES PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000141A 3.1.3.48
5QET PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000017A 3.1.3.48
5QEV PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_XST00000603B 3.1.3.48
5QEW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000470B 3.1.3.48
5QEY PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000708A 3.1.3.48
5QEZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_XST00000713B 3.1.3.48
5QF0 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_XST00000216B 3.1.3.48
5QF2 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000187A 3.1.3.48
5QF3 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000194A 3.1.3.48
5QF4 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000144A 3.1.3.48
5QF5 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA001440B 3.1.3.48
5QF6 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000281B 3.1.3.48
5QF7 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000951B 3.1.3.48
5QF9 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000242A 3.1.3.48
5QFA PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_XST00000752B 3.1.3.48
5QFD PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000505A 3.1.3.48
5QFF PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000515A 3.1.3.48
5QFG PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000523A 3.1.3.48
5QFI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000531A 3.1.3.48
5QFJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000814B 3.1.3.48
5QFL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOMB000206A 3.1.3.48
5QFQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000491A 3.1.3.48
5QFT PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000683B 3.1.3.48
5QFU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000487A 3.1.3.48
5QFW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000497A 3.1.3.48
5QFX PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA000953B 3.1.3.48
5QFZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000711A 3.1.3.48
5QG3 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000662A 3.1.3.48
5QG6 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMSOA001176B 3.1.3.48
5QG7 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000611A 3.1.3.48
5QG8 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000555A 3.1.3.48
5QGC PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000650A 3.1.3.48
5QGD PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOOA000611A 3.1.3.48
5QGE PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF PTP1B IN COMPLEX WITH COMPOUND_FMOPL000619A 3.1.3.48
5QGG PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000693A 3.6.1
5QGH PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000420A 3.6.1
5QGI PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000710A 3.6.1
5QGJ PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000706A 3.6.1
5QGK PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000679A 3.6.1
5QGL PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000275A 3.6.1
5QGM PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH OX-160 3.6.1
5QGN PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH OX-210 3.6.1
5QGO PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH OX-220 3.6.1
5QGP PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH OX-221 3.6.1
5QGQ PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH OX-65 3.6.1
5QGR PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000022A 3.6.1
5QGS PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000476A 3.6.1
5QGT PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000609A 3.6.1
5QGU PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH FMOPL000747A 3.6.1
5QGV PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH UNUYB062989 3.6.1
5QGW PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000154 3.6.1
5QGX PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000155 3.6.1
5QGY PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000158 3.6.1
5QGZ PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000161 3.6.1
5QH0 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000180 3.6.1
5QH1 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000181 3.6.1
5QH2 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000188 3.6.1
5QH3 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000191 3.6.1
5QH4 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000220A 3.6.1
5QH5 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000224A 3.6.1
5QH6 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000259A 3.6.1
5QH7 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000194A 3.6.1
5QH8 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH PCM-0102558 3.6.1
5QH9 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH PCM-0102716 3.6.1
5QHA PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH PCM-0102951 3.6.1
5QHB PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH RK4-332 3.6.1
5QHC PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH RK4-337 3.6.1
5QHE PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH RK4-350 3.6.1
5QHF PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NUOOA000301A 3.6.1
5QHG PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NU000442A 3.6.1
5QHH PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT7 IN COMPLEX WITH NU000443A 3.6.1
5QIO COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH P11 3.4.19.12
5QIP COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102153 3.4.19.12
5QIQ COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0103050 3.4.19.12
5QIR COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102305 3.4.19.12
5QIS COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102500 3.4.19.12
5QIT COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102821 3.4.19.12
5QIU COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0103011 3.4.19.12
5QIV COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102998 3.4.19.12
5QIW COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102660 3.4.19.12
5QIX COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0103007 3.4.19.12
5QIY COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0102954 3.4.19.12
5QIZ COVALENT FRAGMENT GROUP DEPOSITION -- CRYSTAL STRUCTURE OF OUTB2 IN COMPLEX WITH PCM-0103080 3.4.19.12
5QJ0 CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS GENOTYPE 2A STRAIN JFH1 NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 6-[ETHYL(METHYLSULFONYL)AMINO]-2-(4-FLUOROPHENYL)-N-METHYL-5-(3-{[1-(PYRIMIDIN-2-YL)CYCLOPROPYL]CARBAMOYL}PHENYL)-1-BENZOFURAN-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5QJ1 CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS GENOTYPE 2A STRAIN JFH1 L30S NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 6-(ETHYLAMINO)-2-(4-FLUOROPHENYL)-5-(3-{[1-(5-FLUOROPYRIMIDIN-2-YL)CYCLOPROPYL]CARBAMOYL}-4-METHOXYPHENYL)-N-METHYL-1-BENZOFURAN-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5QJ4 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1827602749 3.6.1.13
3.6.1.58
2.7.7.96
5QJ5 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z44592329 3.6.1.13
3.6.1.58
2.7.7.96
5QJ6 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1614545742 3.6.1.13
3.6.1.58
2.7.7.96
5QJ7 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z32327641 3.6.1.13
3.6.1.58
2.7.7.96
5QJ8 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z2856434829 3.6.1.13
3.6.1.58
2.7.7.96
5QJ9 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z768399682 3.6.1.13
3.6.1.58
2.7.7.96
5QJA PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1497321453 3.6.1.13
3.6.1.58
2.7.7.96
5QJB PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1787627869 3.6.1.13
3.6.1.58
2.7.7.96
5QJC PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z755044716 3.6.1.13
3.6.1.58
2.7.7.96
5QJD PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z240297434 3.6.1.13
3.6.1.58
2.7.7.96
5QJE PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z275181224 3.6.1.13
3.6.1.58
2.7.7.96
5QJF PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z52425517 3.6.1.13
3.6.1.58
2.7.7.96
5QJG PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z44567722 3.6.1.13
3.6.1.58
2.7.7.96
5QJH PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z375990520 3.6.1.13
3.6.1.58
2.7.7.96
5QJI PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1899842917 3.6.1.13
3.6.1.58
2.7.7.96
5QJJ PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z24758179 3.6.1.13
3.6.1.58
2.7.7.96
5QJK PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z373221060 3.6.1.13
3.6.1.58
2.7.7.96
5QJL PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z56983806 3.6.1.13
3.6.1.58
2.7.7.96
5QJM PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z328695024 3.6.1.13
3.6.1.58
2.7.7.96
5QJN PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1439422127 3.6.1.13
3.6.1.58
2.7.7.96
5QJO PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z57292369 3.6.1.13
3.6.1.58
2.7.7.96
5QJP PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1578665941 3.6.1.13
3.6.1.58
2.7.7.96
5QJQ PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z56791867 3.6.1.13
3.6.1.58
2.7.7.96
5QJR PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z220816104 3.6.1.13
3.6.1.58
2.7.7.96
5QJS PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z979145504 3.6.1.13
3.6.1.58
2.7.7.96
5QJT PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z969560582 3.6.1.13
3.6.1.58
2.7.7.96
5QJU PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z906021418 3.6.1.13
3.6.1.58
2.7.7.96
5QJV PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z281802060 3.6.1.13
3.6.1.58
2.7.7.96
5QJW PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z198194396 3.6.1.13
3.6.1.58
2.7.7.96
5QJX PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z2856434778 3.6.1.13
3.6.1.58
2.7.7.96
5QJY PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z94597856 3.6.1.13
3.6.1.58
2.7.7.96
5QJZ PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1696822287 3.6.1.13
3.6.1.58
2.7.7.96
5QK0 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1270312110 3.6.1.13
3.6.1.58
2.7.7.96
5QK1 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z2027049478 3.6.1.13
3.6.1.58
2.7.7.96
5QK2 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z54628578 3.6.1.13
3.6.1.58
2.7.7.96
5QK3 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z239136710 3.6.1.13
3.6.1.58
2.7.7.96
5QK4 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z44590919 3.6.1.13
3.6.1.58
2.7.7.96
5QK5 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1267773786 3.6.1.13
3.6.1.58
2.7.7.96
5QK6 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1343633025 3.6.1.13
3.6.1.58
2.7.7.96
5QK7 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1918536193 3.6.1.13
3.6.1.58
2.7.7.96
5QK8 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z1271660837 3.6.1.13
3.6.1.58
2.7.7.96
5QK9 PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z102895082 3.6.1.13
3.6.1.58
2.7.7.96
5QKA PANDDA ANALYSIS GROUP DEPOSITION OF MODELS WITH MODELLED EVENTS (E.G. BOUND LIGANDS) -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH Z2377835233 3.6.1.13
3.6.1.58
2.7.7.96
5QKB GROUND-STATE MODEL OF NUDT5 AND CORRESPONDING APO DATASETS FOR PANDDA ANALYSIS 3.6.1.13
3.6.1.58
2.7.7.96
5QOH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH XST00000847B 3.6.1.62
5QOI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000213A 3.6.1.62
5QOJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOCR000171B 3.6.1.62
5QOK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000294A 3.6.1.62
5QOL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000435A 3.6.1.62
5QOM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000576A 3.6.1.62
5QON PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000446A 3.6.1.62
5QOO PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000144A 3.6.1.62
5QOP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH NUOOA000023A 3.6.1.62
5QOQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z2895259680 3.6.1.62
5QOR PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1203490773 3.6.1.62
5QOS PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1187701032 3.6.1.62
5QOT PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1592710382 3.6.1.62
5QOU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z296300542 3.6.1.62
5QOV PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1699011516 3.6.1.62
5QOW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z2895259675 3.6.1.62
5QOX PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z2212124043 3.6.1.62
5QOY PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH YW-FY-378 3.6.1.62
5QOZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH PB1787571279 3.6.1.62
5QP0 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z454376544 3.6.1.62
5QP1 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1190363272 3.6.1.62
5QP2 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1170065264 3.6.1.62
5QP3 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1494850193 3.6.1.62
5QP4 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z450133538 3.6.1.62
5QP5 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z2895259681 3.6.1.62
5QP6 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z1662802141 3.6.1.62
5QP7 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH PB1230873739 3.6.1.62
5QP8 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH PB1787571279 3.6.1.62
5QP9 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH Z100435060 3.6.1.62
5QPA PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000449A 3.6.1.62
5QPB PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF DCP2 (NUDT20) IN COMPLEX WITH FMOPL000701A 3.6.1.62
5QPC CRYSTAL STRUCTURE OF DCP2 (NUDT20) AFTER INITIAL REFINEMENT WITH NO LIGAND MODELLED (STRUCTURE $N) 3.6.1.62
5QQD PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH Z56880342 3.6.5.2
5QQE PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-531-494 3.6.5.2
5QQF PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-004-412-710 3.6.5.2
5QQG PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-541-216 3.6.5.2
5QQH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-020-096-465 3.6.5.2
5QQI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-178-994 3.6.5.2
5QQJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-587-558 3.6.5.2
5QQK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-359-835 3.6.5.2
5QQL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-565-301 3.6.5.2
5QQM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-009-565-325 3.6.5.2
5QQN PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF KALIRIN/RAC1 IN COMPLEX WITH MOLPORT-010-382-606 3.6.5.2
5QQO FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(5E,8S)-8-[(6R)-6-(3-CHLOROPHENYL)-2-OXO-1,3-OXAZINAN-3-YL]-2-OXO-1,3,4,7,8,10-HEXAHYDRO-2H-12,9-(AZENO)-1,10-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5QQP FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(5E,8S)-8-[(4S)-4-(3-CHLOROPHENYL)-2-OXOPIPERIDIN-1-YL]-2-OXO-1,3,4,7,8,10-HEXAHYDRO-2H-12,9-(AZENO)-1,10-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5QTL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH GB-0804 3.6.1.13
3.6.1.58
2.7.7.96
5QTM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH FS-2639 3.6.1.13
3.6.1.58
2.7.7.96
5QTN PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH SS-4432 3.6.1.13
3.6.1.58
2.7.7.96
5QTO PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH 1R-0641 3.6.1.13
3.6.1.58
2.7.7.96
5QTP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH AE-0227 3.6.1.13
3.6.1.58
2.7.7.96
5QTQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH FS-1169 3.6.1.13
3.6.1.58
2.7.7.96
5QTR PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH FS-3764 3.6.1.13
3.6.1.58
2.7.7.96
5QTS PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF NUDT5 IN COMPLEX WITH 8J-537S 3.6.1.13
3.6.1.58
2.7.7.96
5QTT FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(3R,7S)-7-{[5-AMINO-1-(3-CHLORO-2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBONYL]AMINO}-3-METHYL-2-OXO-2,3,4,5,6,7-HEXAHYDRO-1H-12,8-(METHENO)-1,9-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5QTU FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(3R,7S)-7-{[1-(3-CHLORO-2-FLUOROPHENYL)-5-METHYL-1H-IMIDAZOLE-4-CARBONYL]AMINO}-3-METHYL-2-OXO-2,3,4,5,6,7-HEXAHYDRO-1H-12,8-(METHENO)-1,9-BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE 3.4.21.27
5QTV FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(2R,7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-2-(TRIFLUOROMETHYL)-2,3,4,5,6,7-HEXAHYDRO-1H-8,11-EPIMINO-1,9-BENZODIAZACYCLOTRIDECIN-14-YL]CARBAMATE 3.4.21.27
5QTW FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL (2R,7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-14-[(METHOXYCARBONYL)AMINO]-2,3,4,5,6,7-HEXAHYDRO-1H-8,11-EPIMINO-1,9-BENZODIAZACYCLOTRIDECINE-2-CARBOXYLATE 3.4.21.27
5QTX FACTOR XIA IN COMPLEX WITH THE INHIBITOR ETHYL (2R,7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-14-[(METHOXYCARBONYL)AMINO]-1,2,3,4,5,6,7,9-OCTAHYDRO-11,8-(AZENO)-1,9-BENZODIAZACYCLOTRIDECINE-2-CARBOXYLATE 3.4.21.27
5QTY FACTOR XIA IN COMPLEX WITH THE INHIBITOR ETHYL (2R,7S)-7-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-15-[(METHOXYCARBONYL)AMINO]-2,3,4,5,6,7-HEXAHYDRO-1H-12,8-(METHENO)-1,9-BENZODIAZACYCLOTETRADECINE-2-CARBOXYLATE 3.4.21.27
5QU9 PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF KALIRIN/RAC1 SCREENED AGAINST A CUSTOMIZED UREA FRAGMENT LIBRARY BY X-RAY CRYSTALLOGRAPHY AT THE XCHEM FACILITY OF DIAMOND LIGHT SOURCE BEAMLINE I04-1 3.6.5.2
5QXI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH PC587 3.6.1.3
3.6.1
5QXJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH PC578 3.6.1.3
3.6.1
5QXK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH PC581 3.6.1.3
3.6.1
5QXL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF776 3.6.1.3
3.6.1
5QXM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF789 3.6.1.3
3.6.1
5QXN PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF826 3.6.1.3
3.6.1
5QXO PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF848 3.6.1.3
3.6.1
5QXP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH TCJ732 3.6.1.3
3.6.1
5QXQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH TCJ779 3.6.1.3
3.6.1
5QXR PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF849 3.6.1.3
3.6.1
5QXS PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF852 3.6.1.3
3.6.1
5QXT PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH JKH47 3.6.1.3
3.6.1
5QXU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH RZ373 3.6.1.3
3.6.1
5QXV PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH PC631 3.6.1.3
3.6.1
5QXW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH RZ189 3.6.1.3
3.6.1
5QXX PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH RZ99 3.6.1.3
3.6.1
5QXY PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH JKH93A 3.6.1.3
3.6.1
5QXZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH DF853 3.6.1.3
3.6.1
5QY0 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH PC591 3.6.1.3
3.6.1
5R1T PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY A07, DMSO-FREE 3.4.23.22
5R1U PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY B03, DMSO-FREE 3.4.23.22
5R1V PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY C04, DMSO-FREE 3.4.23.22
5R1W PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY C11, DMSO-FREE 3.4.23.22
5R1X PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY D04, DMSO-FREE 3.4.23.22
5R1Y PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY D10, DMSO-FREE 3.4.23.22
5R1Z PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY D11, DMSO-FREE 3.4.23.22
5R20 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY E06, DMSO-FREE 3.4.23.22
5R21 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY E07, DMSO-FREE 3.4.23.22
5R22 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY E11, DMSO-FREE 3.4.23.22
5R23 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY F03, DMSO-FREE 3.4.23.22
5R24 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY F04, DMSO-FREE 3.4.23.22
5R25 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY F08, DMSO-FREE 3.4.23.22
5R26 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY G02, DMSO-FREE 3.4.23.22
5R27 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY G03, DMSO-FREE 3.4.23.22
5R28 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY G08, DMSO-FREE 3.4.23.22
5R29 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY G09, DMSO-FREE 3.4.23.22
5R2A PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY H02, DMSO-FREE 3.4.23.22
5R2B PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY H03, DMSO-FREE 3.4.23.22
5R2C PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY H05, DMSO-FREE 3.4.23.22
5R2D PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT F2X-ENTRY H11, DMSO-FREE 3.4.23.22
5R2E PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 01, DMSO-FREE 3.4.23.22
5R2F PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 02, DMSO-FREE 3.4.23.22
5R2G PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 03, DMSO-FREE 3.4.23.22
5R2H PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 04, DMSO-FREE 3.4.23.22
5R2I PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 05, DMSO-FREE 3.4.23.22
5R2J PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 06, DMSO-FREE 3.4.23.22
5R2K PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 07, DMSO-FREE 3.4.23.22
5R2L PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 09, DMSO-FREE 3.4.23.22
5R2M PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 10, DMSO-FREE 3.4.23.22
5R2N PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 11, DMSO-FREE 3.4.23.22
5R2O PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 12, DMSO-FREE 3.4.23.22
5R2P PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 13, DMSO-FREE 3.4.23.22
5R2Q PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 14, DMSO-FREE 3.4.23.22
5R2R PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 15, DMSO-FREE 3.4.23.22
5R2S PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 16, DMSO-FREE 3.4.23.22
5R2T PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 17, DMSO-FREE 3.4.23.22
5R2U PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 18, DMSO-FREE 3.4.23.22
5R2V PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 19, DMSO-FREE 3.4.23.22
5R2W PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 20, DMSO-FREE 3.4.23.22
5R2X PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 21, DMSO-FREE 3.4.23.22
5R2Y PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 22, DMSO-FREE 3.4.23.22
5R2Z PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 23, DMSO-FREE 3.4.23.22
5R30 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 24, DMSO-FREE 3.4.23.22
5R31 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 25, DMSO-FREE 3.4.23.22
5R32 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 26, DMSO-FREE 3.4.23.22
5R33 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 27, DMSO-FREE 3.4.23.22
5R34 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 28, DMSO-FREE 3.4.23.22
5R35 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 29, DMSO-FREE 3.4.23.22
5R36 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 30, DMSO-FREE 3.4.23.22
5R37 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 31, DMSO-FREE 3.4.23.22
5R38 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 32, DMSO-FREE 3.4.23.22
5R39 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 33, DMSO-FREE 3.4.23.22
5R3A PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 34, DMSO-FREE 3.4.23.22
5R3B PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 35, DMSO-FREE 3.4.23.22
5R3C PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 36, DMSO-FREE 3.4.23.22
5R3D PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 37, DMSO-FREE 3.4.23.22
5R3E PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 38, DMSO-FREE 3.4.23.22
5R3F PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 39, DMSO-FREE 3.4.23.22
5R3G PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 40, DMSO-FREE 3.4.23.22
5R3H PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 41, DMSO-FREE 3.4.23.22
5R3I PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 42, DMSO-FREE 3.4.23.22
5R3J PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 43, DMSO-FREE 3.4.23.22
5R3K PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 44, DMSO-FREE 3.4.23.22
5R3L PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 45, DMSO-FREE 3.4.23.22
5R3M PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 46, DMSO-FREE 3.4.23.22
5R3N PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 47, DMSO-FREE 3.4.23.22
5R3O PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 48, DMSO-FREE 3.4.23.22
5R3P PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 49, DMSO-FREE 3.4.23.22
5R3Q PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 50, DMSO-FREE 3.4.23.22
5R3R PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 51, DMSO-FREE 3.4.23.22
5R3S PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 52, DMSO-FREE 3.4.23.22
5R3T PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 53, DMSO-FREE 3.4.23.22
5R3U PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 54, DMSO-FREE 3.4.23.22
5R3V PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 55, DMSO-FREE 3.4.23.22
5R3W PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 56, DMSO-FREE 3.4.23.22
5R3X PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 57, DMSO-FREE 3.4.23.22
5R3Y PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 58, DMSO-FREE 3.4.23.22
5R3Z PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 59, DMSO-FREE 3.4.23.22
5R40 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 60, DMSO-FREE 3.4.23.22
5R41 PANDDA ANALYSIS GROUP DEPOSITION -- AUTO-REFINED DATA OF ENDOTHIAPEPSIN FOR GROUND STATE MODEL 61, DMSO-FREE 3.4.23.22
5R4E PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ATAD2 IN COMPLEX WITH RZ201 3.6.1.3
3.6.1
5R4F PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF ATAD2 3.6.1.3
3.6.1
5R4V XCHEM FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 IN COMPLEX WITH N13475A 3.6.1.3
3.6.1
5R4W XCHEM FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 IN COMPLEX WITH N13501A 3.6.1.3
3.6.1
5R4X XCHEM FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 IN COMPLEX WITH N13413A 3.6.1.3
3.6.1
5R4Y XCHEM FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 IN COMPLEX WITH N13612A 3.6.1.3
3.6.1
5R4Z XCHEM FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 IN COMPLEX WITH N13605A 3.6.1.3
3.6.1
5R50 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13371A 3.6.1.45
5R51 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N14003A 3.6.1.45
5R52 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N14004A 3.6.1.45
5R53 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13854A 3.6.1.45
5R54 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13582A 3.6.1.45
5R55 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13369A 3.6.1.45
5R56 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13688A 3.6.1.45
5R57 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N08253B 3.6.1.45
5R58 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13542A 3.6.1.45
5R59 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13441A 3.6.1.45
5R5A PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13663A 3.6.1.45
5R5B PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13725A 3.6.1.45
5R5C PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13956A 3.6.1.45
5R5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13564A 3.6.1.45
5R5E PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13848A 3.6.1.45
5R5F PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13793A 3.6.1.45
5R5G PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13707A 3.6.1.45
5R5H PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13706A 3.6.1.45
5R5I PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N06325B 3.6.1.45
5R5J PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13964A 3.6.1.45
5R5K PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13960A 3.6.1.45
5R5L PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13589A 3.6.1.45
5R5M PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N14123A 3.6.1.45
5R5N PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13595A 3.6.1.45
5R5O PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N14027A 3.6.1.45
5R5P PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13910A 3.6.1.45
5R5Q PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13920A 3.6.1.45
5R5R PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N14078A 3.6.1.45
5R5S PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF HUMAN NUDT22 IN COMPLEX WITH N13775A 3.6.1.45
5R7Y PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH Z45617795 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R7Z PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1220452176 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R80 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z18197050 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R81 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH Z1367324110 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R82 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH Z219104216 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R83 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z44592329 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R84 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH Z31792168 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5R8T PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF SARS-COV-2 MAIN PROTEASE SCREENED AGAINST DSI POISED (ENAMINE), FRAGLITES AND PEPLITES (NEWCASTLE UNIVERSITY), MINI FRAGS (ASTEX), YORK 3D (YORK UNIVERSITY), ELECTROPHILE CYSTEINE COVALENT (WEIZMAN INSTITUTE) FRAGMENT LIBRARIES 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RAT EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K 3.1.27.5
4.6.1.18
5RBO PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY A07A 3.4.23.22
5RBP PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY B03A 3.4.23.22
5RBQ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY B06B 3.4.23.22
5RBR PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY C04A 3.4.23.22
5RBS PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY C08A 3.4.23.22
5RBT PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY C11B 3.4.23.22
5RBU PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY D01A 3.4.23.22
5RBV PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY D04A 3.4.23.22
5RBW PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY D06B 3.4.23.22
5RBX PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY D10A 3.4.23.22
5RBY PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY D11B 3.4.23.22
5RBZ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY E05A 3.4.23.22
5RC0 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY E06A 3.4.23.22
5RC1 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY E07A 3.4.23.22
5RC2 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY E11B 3.4.23.22
5RC3 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY F03A 3.4.23.22
5RC4 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY F04A 3.4.23.22
5RC5 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY F06B 3.4.23.22
5RC6 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY F08B 3.4.23.22
5RC7 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY F11A 3.4.23.22
5RC8 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY G02A 3.4.23.22
5RC9 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY G03B 3.4.23.22
5RCA PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY G08B 3.4.23.22
5RCB PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY G09A 3.4.23.22
5RCC PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY H02B 3.4.23.22
5RCD PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY H03A 3.4.23.22
5RCE PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY H05A 3.4.23.22
5RCF PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY H10B 3.4.23.22
5RCG PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN CHANGED STATE MODEL FOR FRAGMENT F2X-ENTRY LIBRARY H11A 3.4.23.22
5RCH PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 02 3.4.23.22
5RCI PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 03 3.4.23.22
5RCJ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 04 3.4.23.22
5RCK PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 05 3.4.23.22
5RCL PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 06 3.4.23.22
5RCM PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 07 3.4.23.22
5RCN PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 08 3.4.23.22
5RCO PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 09 3.4.23.22
5RCP PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 10 3.4.23.22
5RCQ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 11 3.4.23.22
5RCR PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 13 3.4.23.22
5RCS PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 14 3.4.23.22
5RCT PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 15 3.4.23.22
5RCU PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 16 3.4.23.22
5RCV PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 17 3.4.23.22
5RCW PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 18 3.4.23.22
5RCX PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 19 3.4.23.22
5RCY PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 20 3.4.23.22
5RCZ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 21 3.4.23.22
5RD0 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 22 3.4.23.22
5RD1 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 23 3.4.23.22
5RD2 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 24 3.4.23.22
5RD3 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 25 3.4.23.22
5RD4 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 26 3.4.23.22
5RD5 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 27 3.4.23.22
5RD6 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 28 3.4.23.22
5RD7 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 29 3.4.23.22
5RD8 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 30 3.4.23.22
5RD9 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 31 3.4.23.22
5RDA PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 32 3.4.23.22
5RDB PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 33 3.4.23.22
5RDC PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 34 3.4.23.22
5RDD PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 35 3.4.23.22
5RDE PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 36 3.4.23.22
5RDF PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 37 3.4.23.22
5RDG PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 38 3.4.23.22
5RDH PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 39 3.4.23.22
5RDI PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 40 3.4.23.22
5RDJ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 43 3.4.23.22
5RDK PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 44 3.4.23.22
5RDL PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 45 3.4.23.22
5RDM PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 46 3.4.23.22
5RDN PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 47 3.4.23.22
5RDO PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 01 3.4.23.22
5RDP PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 41 3.4.23.22
5RDQ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 42 3.4.23.22
5RDR PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 48 3.4.23.22
5RDS PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 49 3.4.23.22
5RDT PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 50 3.4.23.22
5RDU PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 51 3.4.23.22
5RDV PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 52 3.4.23.22
5RDW PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 53 3.4.23.22
5RDX PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 54 3.4.23.22
5RDY PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 55 3.4.23.22
5RDZ PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 56 3.4.23.22
5RE0 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 57 3.4.23.22
5RE1 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 58 3.4.23.22
5RE2 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 59 3.4.23.22
5RE3 PANDDA ANALYSIS GROUP DEPOSITION -- ENDOTHIAPEPSIN GROUND STATE MODEL 12 3.4.23.22
5RE4 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1129283193 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RE5 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z33545544 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RE6 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z54571979 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RE7 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z30932204 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RE8 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2737076969 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RE9 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2856434836 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REA PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z31432226 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REB PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2856434899 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REC PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1587220559 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RED PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2856434865 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REE PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2217052426 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REF PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z24758179 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REG PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1545313172 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z111507846 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2856434856 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102241 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102327 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102340 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0103016 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REN PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102425 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REO PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102578 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102201 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RER PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102615 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RES PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102281 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RET PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102269 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102395 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REV PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0103072 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102275 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REX PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102287 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REY PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102911 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5REZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH POB0129 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF0 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH POB0073 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF1 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH NCL-00023830 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF2 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1741969146 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF3 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1741970824 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF4 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1741982125 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF5 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z3241250482 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF6 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1348371854 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF7 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z316425948_MINOR 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF8 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z271004858 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RF9 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z217038356 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFA PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2643472210 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFB PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1271660837 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFC PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z979145504 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFD PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z126932614 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFE PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z509756472 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFF PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102704 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFG PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102372 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102277 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102353 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0103067 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102575 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102389 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102539 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFN PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102868 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFO PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102972 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102190 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102179 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFR PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102169 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFS PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102739 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFT PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102432 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102121 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFV PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102306 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102243 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFX PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102254 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFY PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102974 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RFZ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102274 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RG0 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102535 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RG1 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH NCL-00024905 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RG2 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH NCL-00025058 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RG3 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH NCL-00025412 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RG4 CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3 IN UNBOUND STATE, 277K 3.2.1.8
5RG5 CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.3B IN UNBOUND STATE, 277K 3.2.1.8
5RG6 CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.7 IN UNBOUND STATE, 277K 3.2.1.8
5RG7 CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.14 IN UNBOUND STATE, 277K 3.2.1.8
5RG8 CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.17 IN UNBOUND STATE, 277K 3.2.1.8
5RG9 CRYSTAL STRUCTURE OF KEMP ELIMINASE HG4 IN UNBOUND STATE, 277K 3.2.1.8
5RGA CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3 WITH BOUND TRANSITION STATE ANALOGUE, 277K 3.2.1.8
5RGB CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.3B WITH BOUND TRANSITION STATE ANALOGUE, 277K 3.2.1.8
5RGC CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.7 WITH BOUND TRANSITION STATE ANALOGUE, 277K 3.2.1.8
5RGD CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.14 WITH BOUND TRANSITION STATE ANALOGUE, 277K 3.2.1.8
5RGE CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.17 WITH BOUND TRANSITION STATE ANALOG, 277K 3.2.1.8
5RGF CRYSTAL STRUCTURE OF KEMP ELIMINASE HG4 WITH BOUND TRANSITION STATE ANALOGUE, 277K 3.2.1.8
5RGG PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2856434890 (MPRO-X0165) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGH PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1619978933 (MPRO-X0395) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGI PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z369936976 (MPRO-X0397) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGJ PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1401276297 (MPRO-X0425) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGK PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1310876699 (MPRO-X0426) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGL PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102962 (MPRO-X0705) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGM PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102142 (MPRO-X0708) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGN PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102759 (MPRO-X0731) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGO PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102248 (MPRO-X0736) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGP PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PCM-0102628 (MPRO-X0771) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGQ PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1849009686 (MPRO-X1086) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGR PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z328695024 (MPRO-X1101) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGS PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1259086950 (MPRO-X1163) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGT PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4439011607 (MPRO-X2540) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGU PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4444622180 (MPRO-X2562) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGV PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4444622066 (MPRO-X2563) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGW PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4444621910 (MPRO-X2569) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGX PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1344037997 (MPRO-X2572) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGY PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1535580916 (MPRO-X2581) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RGZ PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1343543528 (MPRO-X2600) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH0 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1286870272 (MPRO-X2608) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH1 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z2010253653 (MPRO-X2643) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH2 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1129289650 (MPRO-X2646) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH3 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1264525706 (MPRO-X2649) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH4 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z1530425063 (MPRO-X2659) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH5 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4439011520 (MPRO-X2694) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH6 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4439011588 (MPRO-X2703) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH7 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4439011584 (MPRO-X2705) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH8 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4444621965 (MPRO-X2764) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RH9 PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z4438424255 (MPRO-X2776) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHA PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z147647874 (MPRO-X2779) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHB PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH COV_HETLIB030 (MPRO-X2097) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHC PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH COV_HETLIB053 (MPRO-X2119) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHD PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH SF013 (MPRO-X2193) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHE PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PG-COV-42 (MPRO-X2052) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHF PANDDA ANALYSIS GROUP DEPOSITION SARS-COV-2 MAIN PROTEASE FRAGMENT SCREEN -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH PG-COV-34 (MPRO-X2754) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RHG PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z235341991 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHH PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z1515654336 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHI PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z198194396 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHJ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z126932614 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHK PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z87615031 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHL PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z425387594 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHM PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z1454310449 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHN HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN (HINT) FROM RABBIT COMPLEXED WITH 8-BR-AMP 3
5RHO PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z1444783243 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHP PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z2856434938 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHQ PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z235449082 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHR PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z1348559502 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHS PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z274555794 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHT PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z291279160 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHU PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z1703168683 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHV PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z62645406 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHW PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z31222641 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHX PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 HELICASE IN COMPLEX WITH Z1324080698 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RHY PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF ZIKA VIRUS NS3 HELICASE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5RKZ PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF HUMAN NUDT22 SCREENED AGAINST THE DSPL FRAGMENT LIBRARY BY X-RAY CRYSTALLOGRAPHY 3.6.1.45
5RL0 PANDDA ANALYSIS GROUP DEPOSITION OF COMPUTATIONAL DESIGNS OF SARS-COV-2 MAIN PROTEASE COVALENT INHIBITORS -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LON-WEI-ADC59DF6-2 (MPRO-X3110) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RL1 PANDDA ANALYSIS GROUP DEPOSITION OF COMPUTATIONAL DESIGNS OF SARS-COV-2 MAIN PROTEASE COVALENT INHIBITORS -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LON-WEI-ADC59DF6-27 (MPRO-X3113) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RL2 PANDDA ANALYSIS GROUP DEPOSITION OF COMPUTATIONAL DESIGNS OF SARS-COV-2 MAIN PROTEASE COVALENT INHIBITORS -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LON-WEI-ADC59DF6-26 (MPRO-X3115) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RL3 PANDDA ANALYSIS GROUP DEPOSITION OF COMPUTATIONAL DESIGNS OF SARS-COV-2 MAIN PROTEASE COVALENT INHIBITORS -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LON-WEI-ADC59DF6-39 (MPRO-X3117) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RL4 PANDDA ANALYSIS GROUP DEPOSITION OF COMPUTATIONAL DESIGNS OF SARS-COV-2 MAIN PROTEASE COVALENT INHIBITORS -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LON-WEI-ADC59DF6-3 (MPRO-X3124) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RL5 PANDDA ANALYSIS GROUP DEPOSITION OF COMPUTATIONAL DESIGNS OF SARS-COV-2 MAIN PROTEASE COVALENT INHIBITORS -- CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LON-WEI-ADC59DF6-30 (MPRO-X3359) 3.4.22.69
3.4.19.12
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RLA ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION 3.5.3.1
5RNT X-RAY ANALYSIS OF CUBIC CRYSTALS OF THE COMPLEX FORMED BETWEEN RIBONUCLEASE T1 AND GUANOSINE-3',5'-BISPHOSPHATE 3.1.27.3
4.6.1.24
5RS7 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000034618676 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RS8 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000001601 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RS9 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000007636250 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSA COMPARISON OF TWO INDEPENDENTLY REFINED MODELS OF RIBONUCLEASE-A 3.1.27.5
4.6.1.18
5RSB CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001674697 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSC CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000003888754 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSD CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000331945 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSE CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000336438345 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSF CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000026180281 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSG CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000263392672 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSH CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000274438208 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSI CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000374420934 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSJ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000089254160_N3 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSK CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000901381520_N3 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSL CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000365052868 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSM CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000001099 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSN CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000064576 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSO CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000000226 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSP CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002560357 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSQ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000158490 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSR CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000158650 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSS CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000006691828 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RST CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000332673 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSU CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000002055 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSV CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000340465 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSW CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000337835 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSX CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388262 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSY CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000004787230 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RSZ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000004218283 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT0 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002582714 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT1 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000039810 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT2 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000008652361 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT3 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000039281982 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT4 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000051581 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT5 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000058111 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT6 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000156509 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT7 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000015442276 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT8 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000161908 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RT9 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388280 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTA CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000332540 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTB CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000006534965 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTC CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000006490906 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTD CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000157108 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTE CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000013283576 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTF CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002047514 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTG CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000395673 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTH CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000156863 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTI CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000004219237 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTJ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000332752 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTK CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000164504 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTL CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388056 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTM CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000002005 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTN CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000013514509 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTO CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388302 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTP CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001679336 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTQ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000019015078 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTR CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000018169763 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTS CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000159004 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTT CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000873830 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTU CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000159056 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTV CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001698894 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTW CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000164777 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTX CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000090873 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTY CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000157088 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RTZ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000404062 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU0 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388514 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU1 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000034687 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU2 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000331715 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU3 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000161696 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU4 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001688638 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU5 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000098208711 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU6 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001442764 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU7 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000003591110 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU8 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000154817 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RU9 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000165882 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUA CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000033986325 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUC CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000005878 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUD CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000008615114 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUE CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000000922 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUF CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000016989831 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUG CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000038389 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUH CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000123600 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUI CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000332651 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUJ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000404314 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUK CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000161692 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUL CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000163774 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUM CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000008861082 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUN CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000194295 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUO CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001683100 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUP CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000004976927 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUQ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000032199226 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUR CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000017744334 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUS CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388081 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUT CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000161958 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUU CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000438614 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUV CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000019015194 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUW CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000045014941 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUX CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002020050 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUY CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000013517187 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RUZ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000019685960 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV0 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000039994 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV1 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000251609 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV2 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000311783 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV3 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000057162 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV4 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000039224 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV5 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000008578948 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV6 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000158540 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV7 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000003954002 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV8 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000039575 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RV9 CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000388150 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVA CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000016343276 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVB CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000014419577 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVC CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000933940912 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVD CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000263980802 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVE CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000736709772 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVF CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000082473428_N3 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVG CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000400552187_N3 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVH CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000265642 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVI CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000084843283 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVJ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000001612349 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVK CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002977810 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVL CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000149580 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVM CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000157088 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVN CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000332748 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVO CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000013514509 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVP CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000154817 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVQ CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002508153 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVR CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000016052862 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVS CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000000159004 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVT CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002582714 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVU CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000002506130 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RVV CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ZINC000020269197 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5RW2 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2737076969 3.1.3.86
3.1.3.56
3.1.3.36
5RW3 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2064898339 3.1.3.86
3.1.3.56
3.1.3.36
5RW4 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z19735192 3.1.3.86
3.1.3.56
3.1.3.36
5RW5 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z69092635 3.1.3.86
3.1.3.56
3.1.3.36
5RW6 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434816 3.1.3.86
3.1.3.56
3.1.3.36
5RW7 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z86622311 3.1.3.86
3.1.3.56
3.1.3.36
5RW8 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z28290384 3.1.3.86
3.1.3.56
3.1.3.36
5RW9 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z203581214 3.1.3.86
3.1.3.56
3.1.3.36
5RWA INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434812 3.1.3.86
3.1.3.56
3.1.3.36
5RWB INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434899 3.1.3.86
3.1.3.56
3.1.3.36
5RWC INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434879 3.1.3.86
3.1.3.56
3.1.3.36
5RWD INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1675346324 3.1.3.86
3.1.3.56
3.1.3.36
5RWE INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434865 3.1.3.86
3.1.3.56
3.1.3.36
5RWF INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1983897532 3.1.3.86
3.1.3.56
3.1.3.36
5RWG INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z17497990 3.1.3.86
3.1.3.56
3.1.3.36
5RWH INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1152242726 3.1.3.86
3.1.3.56
3.1.3.36
5RWI INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434926 3.1.3.86
3.1.3.56
3.1.3.36
5RWJ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434824 3.1.3.86
3.1.3.56
3.1.3.36
5RWK INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1267881672 3.1.3.86
3.1.3.56
3.1.3.36
5RWL INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1348371854 3.1.3.86
3.1.3.56
3.1.3.36
5RWM INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z136583524 3.1.3.86
3.1.3.56
3.1.3.36
5RWN INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1310876699 3.1.3.86
3.1.3.56
3.1.3.36
5RWO INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434898 3.1.3.86
3.1.3.56
3.1.3.36
5RWP INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z915492990 3.1.3.86
3.1.3.56
3.1.3.36
5RWQ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z44592329 3.1.3.86
3.1.3.56
3.1.3.36
5RWR INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434783 3.1.3.86
3.1.3.56
3.1.3.36
5RWS INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1478435544 3.1.3.86
3.1.3.56
3.1.3.36
5RWT INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z32327641 3.1.3.86
3.1.3.56
3.1.3.36
5RWU INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z57778470 3.1.3.86
3.1.3.56
3.1.3.36
5RWV INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1103351268 3.1.3.86
3.1.3.56
3.1.3.36
5RWW INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2241115980 3.1.3.86
3.1.3.56
3.1.3.36
5RWX INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z44567722 3.1.3.86
3.1.3.56
3.1.3.36
5RWY INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1259335913 3.1.3.86
3.1.3.56
3.1.3.36
5RWZ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z57299529 3.1.3.86
3.1.3.56
3.1.3.36
5RX0 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z57258487 3.1.3.86
3.1.3.56
3.1.3.36
5RX1 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2466069494 3.1.3.86
3.1.3.56
3.1.3.36
5RX2 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1827898537 3.1.3.86
3.1.3.56
3.1.3.36
5RX3 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1262327505 3.1.3.86
3.1.3.56
3.1.3.36
5RX4 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1593306637 3.1.3.86
3.1.3.56
3.1.3.36
5RX5 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2443429438 3.1.3.86
3.1.3.56
3.1.3.36
5RX6 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z30620520 3.1.3.86
3.1.3.56
3.1.3.36
5RX7 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1545196403 3.1.3.86
3.1.3.56
3.1.3.36
5RX8 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434884 3.1.3.86
3.1.3.56
3.1.3.36
5RX9 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z54226095 3.1.3.86
3.1.3.56
3.1.3.36
5RXA INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434829 3.1.3.86
3.1.3.56
3.1.3.36
5RXB INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434821 3.1.3.86
3.1.3.56
3.1.3.36
5RXC INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434868 3.1.3.86
3.1.3.56
3.1.3.36
5RXD INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z111810692 3.1.3.86
3.1.3.56
3.1.3.36
5RXE INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z240654968 3.1.3.86
3.1.3.56
3.1.3.36
5RXF INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2074076908 3.1.3.86
3.1.3.56
3.1.3.36
5RXG INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434909 3.1.3.86
3.1.3.56
3.1.3.36
5RXH INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z939944666 3.1.3.86
3.1.3.56
3.1.3.36
5RXI INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2447286438 3.1.3.86
3.1.3.56
3.1.3.36
5RXJ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1722836661 3.1.3.86
3.1.3.56
3.1.3.36
5RXK INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434840 3.1.3.86
3.1.3.56
3.1.3.36
5RXL INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1673618163 3.1.3.86
3.1.3.56
3.1.3.36
5RXM INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434894 3.1.3.86
3.1.3.56
3.1.3.36
5RXO INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z68299550 3.1.3.86
3.1.3.56
3.1.3.36
5RXP INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434944 3.1.3.86
3.1.3.56
3.1.3.36
5RXQ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z26548083 3.1.3.86
3.1.3.56
3.1.3.36
5RXR INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1148747945 3.1.3.86
3.1.3.56
3.1.3.36
5RXS INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1818332938 3.1.3.86
3.1.3.56
3.1.3.36
5RXT INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z319545618 3.1.3.86
3.1.3.56
3.1.3.36
5RXU INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434858 3.1.3.86
3.1.3.56
3.1.3.36
5RXV INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z45527714 3.1.3.86
3.1.3.56
3.1.3.36
5RXW INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2856434856 3.1.3.86
3.1.3.56
3.1.3.36
5RXX INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1275599911 3.1.3.86
3.1.3.56
3.1.3.36
5RXY INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z32014663 3.1.3.86
3.1.3.56
3.1.3.36
5RXZ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z19739650 3.1.3.86
3.1.3.56
3.1.3.36
5RY0 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z275165822 3.1.3.86
3.1.3.56
3.1.3.36
5RY1 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2940170964 3.1.3.86
3.1.3.56
3.1.3.36
5RY2 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z19727416 3.1.3.86
3.1.3.56
3.1.3.36
5RY3 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2027158783 3.1.3.86
3.1.3.56
3.1.3.36
5RY4 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z300245038 3.1.3.86
3.1.3.56
3.1.3.36
5RY5 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z166605480 3.1.3.86
3.1.3.56
3.1.3.36
5RY6 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z198194394 3.1.3.86
3.1.3.56
3.1.3.36
5RY7 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1267773591 3.1.3.86
3.1.3.56
3.1.3.36
5RY8 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1374778753 3.1.3.86
3.1.3.56
3.1.3.36
5RY9 INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z274575916 3.1.3.86
3.1.3.56
3.1.3.36
5RYA INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1741973467 3.1.3.86
3.1.3.56
3.1.3.36
5RYB INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z927400026 3.1.3.86
3.1.3.56
3.1.3.36
5RYC INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z18197050 3.1.3.86
3.1.3.56
3.1.3.36
5RYD INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z955369596 3.1.3.86
3.1.3.56
3.1.3.36
5RYE INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z33545544 3.1.3.86
3.1.3.56
3.1.3.36
5RYF INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1266823232 3.1.3.86
3.1.3.56
3.1.3.36
5RYG INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z168883358 3.1.3.86
3.1.3.56
3.1.3.36
5RYH INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1212984951 3.1.3.86
3.1.3.56
3.1.3.36
5RYI INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z274555794 3.1.3.86
3.1.3.56
3.1.3.36
5RYJ INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z2177153697 3.1.3.86
3.1.3.56
3.1.3.36
5RYK INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1346370629 3.1.3.86
3.1.3.56
3.1.3.36
5RYL INPP5D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF THE PHOSPHATASE AND C2 DOMAINS OF SHIP1 IN COMPLEX WITH Z1745658474 3.1.3.86
3.1.3.56
3.1.3.36
5S18 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-321461 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1A PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-43406 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1C PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z3034471507 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1E PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH AB-601_30915014 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1G PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-108952 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1I PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-301084 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1K PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-105873 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1M PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH STK497968 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1O PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH STL414928 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1Q PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-17035 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1S PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1613477500 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1U PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-52144 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1W PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z838838708 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S1Y PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH STK346965 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S20 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH PB1827975385 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S22 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z145120524 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S24 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH EN300-697611 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S26 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z605596346 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S27 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1262398530 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S28 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z409974522 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S29 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z199959602 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2A PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1263529624 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2B PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z373769142 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2C PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z45612755 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z369936976 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2E PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1152242726 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2F PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z44592329 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2G PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z321318226 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2H PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2856434920 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2I PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z57299529 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2J PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z509756472 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2K PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z445856640 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2L PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2234920345 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2M PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z56827661 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2N PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1787627869 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2O PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z645232558 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2P PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z927746322 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2Q PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z26781952 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2R PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z57292369 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2S PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2856434894 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2T PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z26781964 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2U PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z85956652 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2V PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1186029914 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2W PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1407672867 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2X PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1139246057 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2Y PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z19727416 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S2Z PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z126932614 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S30 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z65532537 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S31 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1741959530 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S32 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z26781943 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S33 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z906021418 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S34 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2856434941 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S35 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z68404778 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S36 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2856434938 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S37 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1954800564 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S38 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1745658474 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S39 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z165170770 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3A PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1562205518 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3B PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1741966151 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3C PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2856434937 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z30820160 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3E PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z274553586 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3F PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z57446103 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3G PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z384468096 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3H PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2856434892 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3I PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z50145861 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3J PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1324853681 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3K PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z219104216 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3L PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z54628578 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3M PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z45656995 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3N PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z287484230 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3O PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z102768020 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3P PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1238477790 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3Q PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0013 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3R PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0014 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3S PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0103 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3T PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0128 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3U PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0041 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3V PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0120 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3W PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0135 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3X PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0136 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3Y PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0012 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S3Z PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH POB0140 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S40 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH NCL-00023824 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S41 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH NCL-00023825 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S42 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH NCL-00023833 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S43 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH NCL-00024661 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S44 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH NCL-00024890 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S45 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH NCL-00024773 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S46 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z57131035 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S47 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z940713508 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S48 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1741982125 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S49 PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z56866006 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4A PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z955123498 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4B PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z3219959731 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4C PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1954800348 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4D PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z1741982441 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4E PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH Z2301685688 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4F PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH SF003 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4G PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH SF005 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4H PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH SF048 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4I PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH SF051 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4J PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH SF054 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S4K PANDDA ANALYSIS GROUP DEPOSITION -- CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH FMOOA000509A 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S73 PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF SARS-COV-2 NSP3 MACRODOMAIN 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5S74 PANDDA ANALYSIS GROUP DEPOSITION OF GROUND-STATE MODEL OF SARS-COV-2 NSP3 MACRODOMAIN 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
3.1.13
3.1
2.1.1
5SGA STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS 3.4.21.80
5SIC MOLECULAR RECOGNITION AT THE ACTIVE SITE OF SUBTILISIN BPN': CRYSTALLOGRAPHIC STUDIES USING GENETICALLY ENGINEERED PROTEINACEOUS INHIBITOR SSI (STREPTOMYCES SUBTILISIN INHIBITOR) 3.4.21.62
5SUP STRUCTURE OF MRNA EXPORT FACTORS 3.6.4.13
5SV2 TOXIN VAPC21 FROM MYCOBACTERIUM TUBERCULOSIS 3.1
5SVE STRUCTURE OF CALCINEURIN IN COMPLEX WITH NFATC1 LXVP PEPTIDE 3.1.3.16
5SWJ CRYSTAL STRUCTURE OF ATPASE DELTA1-79 SPA47 3.6.3.14
7.1.2.2
5SWL CRYSTAL STRUCTURE OF ATPASE DELTA1-79 SPA47 E188A 3.6.3.14
7.1.2.2
5SWM BACILLUS HALODURANS RNASE H MUTANT D132N IN COMPLEX WITH 12-MER FRNA/DNA HYBRID 3.1.26.4
5SWN CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - ASP110ASN/FLUOROACETATE - COCRYSTALLIZED 3.8.1.3
5SWW CRYSTAL STRUCTURE OF HUMAN APOBEC3A COMPLEXED WITH SSDNA 3.5.4
3.5.4.38
5SXG CRYSTAL STRUCTURE OF THE CANCER GENOMIC DNA MUTATOR APOBEC3B 3.5.4
3.5.4.38
5SXH CRYSTAL STRUCTURE OF THE CANCER GENOMIC DNA MUTATOR APOBEC3B 3.5.4
3.5.4.38
5SXN STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE-5-CARBOXAMIDES AS RENIN INHIBITORS 3.4.23.15
5SY2 STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE-5-CARBOXAMIDES AS RENIN INHIBITORS 3.4.23.15
5SY3 STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE-5-CARBOXAMIDES AS RENIN INHIBITORS 3.4.23.15
5SY4 ATOMIC RESOLUTION STRUCTURE OF REDUCED E. COLI YAJL 3.1.2
3.5.1
3.5.1.124
5SY6 ATOMIC RESOLUTION STRUCTURE OF HUMAN DJ-1, DTT BOUND 3.1.2
3.5.1
3.5.1.124
5SY9 ATOMIC RESOLUTION STRUCTURE OF E15Q MUTANT HUMAN DJ-1 3.1.2
3.5.1
3.5.1.124
5SYA ATOMIC RESOLUTION STRUCTURE OF D24N MUTANT HUMAN DJ-1 3.1.2
3.5.1
3.5.1.124
5SYM COCRYSTAL STRUCTURE OF THE HUMAN ACYL PROTEIN THIOESTERASE 1 WITH AN ISOFORM-SELECTIVE INHIBITOR, ML348 3.1.2
5SYN COCRYSTAL STRUCTURE OF THE HUMAN ACYL PROTEIN THIOESTERASE 2 WITH AN ISOFORM-SELECTIVE INHIBITOR, ML349 3.1.2
5SYP CRYSTAL STRUCTURE OF ATPASE DELTA1-79 SPA47 K165A 3.6.3.14
7.1.2.2
5SYR CRYSTAL STRUCTURE OF ATPASE DELTA1-79 SPA47 R350A 3.6.3.14
7.1.2.2
5SZ9 STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE-5-CARBOXAMIDES AS RENIN INHIBITORS 3.4.23.15
5SZU NOVEL STRUCTURAL INSIGHTS INTO GDP-MEDIATED REGULATION OF ACYL-COA THIOESTERASES 3.1.2
5SZV NOVEL STRUCTURAL INSIGHTS INTO GDP-MEDIATED REGULATION OF ACYL-COA THIOESTERASES 3.1.2
5SZY NOVEL STRUCTURAL INSIGHTS INTO GDP-MEDIATED REGULATION OF ACYL-COA THIOESTERASES 3.1.2
5SZZ NOVEL STRUCTURAL INSIGHTS INTO GDP-MEDIATED REGULATION OF ACYL-COA THIOESTERASES 3.1.2
5T02 STRUCTURAL CHARACTERISATION OF MUTANT ASP39ALA OF THIOESTERASE (NMACH) FROM NEISSERIA MENINGITIDIS 3.1.2
5T04 STRUCTURE OF CONSTITUTIVELY ACTIVE NEUROTENSIN RECEPTOR 3.2.1.17
5T06 CRYSTAL STRUCTURE OF A PUTATIVE ACYL-COA THIOESTERASE EC709/ECK0725 FROM ESCHERICHIA COLI IN COMPLEX WITH HEXANOYL-COA 3.1.2
5T07 CRYSTAL STRUCTURE OF A PUTATIVE ACYL-COA THIOESTERASE EC709/ECK0725 FROM ESCHERICHIA COLI IN COMPLEX WITH DECANOYL-COA 3.1.2
5T13 STRUCTURE OF THE CYANURIC ACID HYDROLASE TRZD REVEALS PRODUCT EXIT CHANNEL 3.5.2.15
5T16 CRYSTAL STRUCTURE OF YEAST RNASE III (RNT1P) COMPLEXED WITH A NON-HYDROLYZABLE RNA SUBSTRATE ANALOG 3.1.26.3
5T19 STRUCTURE OF PTP1B COMPLEXED WITH N-(3'-(1,1-DIOXIDO-4-OXO-1,2,5-THIADIAZOLIDIN-2-YL)-4'-METHYL-[1,1'-BIPHENYL]-4-YL)ACETAMIDE 3.1.3.48
5T1A STRUCTURE OF CC CHEMOKINE RECEPTOR 2 WITH ORTHOSTERIC AND ALLOSTERIC ANTAGONISTS 3.2.1.17
5T1U AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY 3.4.23.46
5T1V CRYSTAL STRUCTURE OF ZIKA VIRUS NS2B-NS3 PROTEASE IN APO-FORM. 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5T1W AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY 3.4.23.46
5T2T CRYSTAL STRUCTURE OF LYMPHOCYTIC CHORIOMENINGITIS MAMMARENAVIRUS ENDONUCLEASE BOUND TO COMPOUND L742001 2.7.7.48
3.1
5T2W STRUCTURE OF THYMINE DNA GLYCOSYLASE BOUND TO SUBSTRATE ANALOG 2'-F-5-FORMYL-DC 3.2.2.29
5T3A MAEDI-VISNA VIRUS (MVV) INTEGRASE CCD-CTD (RESIDUES 60-275) 3.4.23
2.7.7.49
2.7.7.7
3.1.26.4
3.1.13.2
3.6.1.23
2.7.7
3.1
5T3F HEN EGG-WHITE LYSOZYME SOAKED WITH SELENOUREA FOR 10 MIN 3.2.1.17
5T3H BOVINE TRYPSIN SOAKED WITH SELENOUREA FOR 5 MIN 3.4.21.4
5T3J HISTIDINOL PHOSPHATE PHOSPHATASE(HPP) SOAKED WITH SELENOUREA FOR 10 MIN 3.1.3.15
5T3P CRYSTAL STRUCTURE OF HUMAN PEROXISOMAL COENZYME A DIPHOSPHATASE NUDT7 3.6.1
5T3V A NOVEL DOMAIN IN HUMAN EXOG CONVERTS APOPTOTIC ENDONUCLEASE TO DNA-REPAIR ENZYME 3.1.30
5T40 A NOVEL DOMAIN IN HUMAN EXOG CONVERTS APOPTOTIC ENDONUCLEASE TO DNA-REPAIR ENZYME 3.1.30
5T41 CRYSTAL STRUCTURE OF MYCOBACTERIUM AVIUM SERB2 MUTANT S275A/R279A AT PH 6.6 WITH ETHYLENE GLYCOL BOUND AT ACT- I DOMAIN 3.1.3.3
5T49 CRYSTAL STRUCTURE OF SEMET DERIVATIVE BHGH81 3.2.1.6
5T4A CRYSTAL STRUCTURE OF BHGH81 IN COMPLEX WITH LAMINARO-HEXAOSE 3.2.1.6
5T4B HUMAN DPP4 IN COMPLEX WITH A LIGAND 34A 3.4.14.5
5T4C CRYSTAL STRUCTURE OF BHGH81 MUTANT IN COMPLEX WITH LAMINARO-HEXAOSE 3.2.1.6
5T4E HUMAN DPP4 IN COMPLEX WITH LIGAND 19A 3.4.14.5
5T4F HUMAN DPP4 IN COMPLEX WITH LIGAND 34P 3.4.14.5
5T4G CRYSTAL STRUCTURE OF BHGH81 IN COMPLEX WITH LAMINARIN 3.2.1.6
5T4H HUMAN DPP4 IN COMPLEX WITH LIGAND 34N 3.4.14.5
5T4I A NOVEL DOMAIN IN HUMAN EXOG CONVERTS APOPTOTIC ENDONUCLEASE TO DNA-REPAIR ENZYME 3.1.30
5T4O AUTOINHIBITED E. COLI ATP SYNTHASE STATE 1 3.6.3.14
7.1.2.2
5T4Q AUTOINHIBITED E. COLI ATP SYNTHASE STATE 3 3.6.3.14
7.1.2.2
5T4S NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS 3.4.23.15
5T4T CRYSTAL STRUCTURE OF THE FLUOROACETATE DEHALOGENASE RPA1163 - ASP110ASN - APO NO HALIDE 3.8.1.3
5T5C A NOVEL DOMAIN IN HUMAN EXOG CONVERTS APOPTOTIC ENDONUCLEASE TO DNA-REPAIR ENZYME 3.1.30
5T66 CRYSTAL STRUCTURE OF CTX-M-15 WITH 1C 3.5.2.6
5T6D 2.10 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7L (HEXAGONAL FORM) 3.6.1.15
3.4.22.66
2.7.7.48
5T6F 1.90 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7L (ORTHORHOMBIC P FORM) 3.6.1.15
3.4.22.66
2.7.7.48
5T6G 2.45 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7M (HEXAGONAL FORM) 3.6.1.15
3.4.22.66
2.7.7.48
5T6U CRYSTAL STRUCTURE OF MOUSE CATHEPSIN K AT 2.9 ANGSTROMS RESOLUTION. 3.4.22.38
5T7A CRYSTAL STRUCTURE OF BR DERIVATIVE BHCBM56 3.2.1.6
5T7B ARGONAUTE-2 - 5'-(E)-VINYLPHOSPHONATE 2'-O-METHYL-URIDINE MODIFIED MRTTR GUIDE RNA COMPLEX 3.1.26
5T82 HIV-1 REVERSE TRANSCRIPTASE THUMB SUBDOMAIN 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5T8K 1.95 ANGSTROM CRYSTAL STRUCTURE OF S-ADENOSYLHOMOCYSTEINASE FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH ADENINE AND NAD 3.3.1.1
5T8Z CRYSTAL STRUCTURE OF A PEPTIDE DEFORMYLASE FROM BURKHOLDERIA MULTIVORANS IN COMPLEX WITH ACTINONIN 3.5.1.88
5T91 CRYSTAL STRUCTURE OF B. SUBTILIS 168 GLPQ IN COMPLEX WITH BICINE 3.1.4.46
5T9B CRYSTAL STRUCTURE OF B. SUBTILIS 168 GLPQ IN COMPLEX WITH GLYCEROL-3-PHOSPHATE (5 MINUTE SOAK) 3.1.4.46
5T9C CRYSTAL STRUCTURE OF B. SUBTILIS 168 GLPQ IN COMPLEX WITH GLYCEROL-3-PHOSPHATE (1 HOUR SOAK) 3.1.4.46
5T9I CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5T9J CRYSTAL STRUCTURE OF HUMAN GEN1 IN COMPLEX WITH HOLLIDAY JUNCTION DNA IN THE UPPER INTERFACE 3.1
5T9K CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5T9Q CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAC CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAD CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAE CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAI CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAJ CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAK CONFORMATIONAL SAMPLING DIFFERENCES ACROSS THE ARRHENIUS PLOT BIPHASIC BREAK POINT AT AMBIENT TEMPERATURE IN THE ENZYME THERMOLYSIN 3.4.24.27
5TAR CRYSTAL STRUCTURE OF FARNESYLATED AND METHYLATED KRAS4B IN COMPLEX WITH PDE-DELTA (CRYSTAL FORM II - WITH ORDERED HYPERVARIABLE REGION) 3.6.5.2
5TB5 CRYSTAL STRUCTURE OF FULL-LENGTH FARNESYLATED AND METHYLATED KRAS4B IN COMPLEX WITH PDE-DELTA (CRYSTAL FORM I - WITH PARTIALLY DISORDERED HYPERVARIABLE REGION) 3.6.5.2
5TC2 C-TERMINAL DOMAIN OF HIV-1 INTEGRASE, CRYSTAL STRUCTURE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TC4 CRYSTAL STRUCTURE OF HUMAN MITOCHONDRIAL METHYLENETETRAHYDROFOLATE DEHYDROGENASE-CYCLOHYDROLASE (MTHFD2) IN COMPLEX WITH LY345899 AND COFACTORS 1.5.1.15
3.5.4.9
5TC9 WILD TYPE TRCEL7A CATALYTIC DOMAIN IN A CLOSED STATE 3.2.1
5TCA COMPLEMENT FACTOR D INHIBITED WITH JH3 3.4.21.46
5TCC COMPLEMENT FACTOR D INHIBITED WITH JH4 3.4.21.46
5TCD HUMAN ALKALINE SPHINGOMYELINASE (ENPP7) IN COMPLEX WITH PHOSPHOCHOLINE 3.1.4.12
5TD4 STARCH BINDING SITES ON THE HUMAN PANCREATIC ALPHA AMYLASE D300N VARIANT COMPLEXED WITH AN OCTAOSE SUBSTRATE. 3.2.1.1
5TD5 CRYSTAL STRUCTURE OF HUMAN APOBEC3B VARIANT COMPLEXED WITH SSDNA 3.5.4
3.5.4.38
5TD7 CRYSTAL STRUCTURE OF HISTONE DEACETYLASE 10 3.5.1.48
3.5.1.62
5TDI CRYSTAL STRUCTURE OF CATHEPSIN K WITH A COVALENTLY-LINKED INHIBITOR AT 1.4 ANGSTROM RESOLUTION. 3.4.22.38
5TEA CRYSTAL STRUCTURE OF AN INORGANIC PYROPHOSPHATASE FROM NEISSERIA GONORRHOEAE 3.6.1.1
5TEC CRYSTAL STRUCTURE OF THE TIR DOMAIN FROM THE ARABIDOPSIS THALIANA NLR PROTEIN SNC1 3.2.2.6
5TEO DIMER OF HIV-1 GAG CTD-SP1 FRAGMENT 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TER CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 5-CHLORO-7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-8-METHYL-2-NAPHTHONITRILE (JLJ651), A NON-NUCLEOSIDE INHIBITOR 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TF7 NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH ATP 3.6.3.49
5.6.1.6
5TF8 NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH DTTP 3.6.3.49
5.6.1.6
5TFA NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH DUTP 3.6.3.49
5.6.1.6
5TFB NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH 7-METHYL-GTP 3.6.3.49
5.6.1.6
5TFC NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH GTP 3.6.3.49
5.6.1.6
5TFD NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH CTP 3.6.3.49
5.6.1.6
5TFF NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH UTP 3.6.3.49
5.6.1.6
5TFG NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH 5-METHYL-UTP 3.6.3.49
5.6.1.6
5TFI NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH DGTP 3.6.3.49
5.6.1.6
5TFJ NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH DCTP 3.6.3.49
5.6.1.6
5TFN CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS2B-NS3 PROTEASE IN SUPER-OPEN CONFORMATION 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5TFO CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS2B-NS3 PROTEASE WITH A DELETION V76-L86 IN NS2B 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5TFQ CRYSTAL STRUCTURE OF A REPRESENTATIVE OF CLASS A BETA-LACTAMASE FROM BACTEROIDES CELLULOSILYTICUS DSM 14838 3.5.2.6
5TFR CRYSTAL STRUCTURE OF ZIKA VIRUS NS5 PROTEIN 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5TFV CRYSTAL STRUCTURE OF MT-I ISOLATED FROM BOTHROPS ASPER VENOM. 3.1.1.4
5TG1 1.40 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE A M-CHLOROPHENYL SUBSTITUTED MACROCYCLIC INHIBITOR (17-MER) 3.4.22.66
3.6.1.15
2.7.7.48
5TG2 1.75 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE A N-PENTYL SUBSTITUTED MACROCYCLIC INHIBITOR (17-MER) 3.4.22.66
3.6.1.15
2.7.7.48
5TG4 OXA-24/40 IN COMPLEX WITH BORONIC ACID BA16 3.5.2.6
5TG5 OXA-24/40 IN COMPLEX WITH BORONIC ACID BA8 3.5.2.6
5TG6 OXA-24/40 IN COMPLEX WITH BORONIC ACID BA4 3.5.2.6
5TG7 OXA-24/40 IN COMPLEX WITH BORONIC ACID BA3 3.5.2.6
5TGK NUCLEOTIDE-BINDING DOMAIN 1 OF THE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) WITH DATP 3.6.3.49
5.6.1.6
5TGL A MODEL FOR INTERFACIAL ACTIVATION IN LIPASES FROM THE STRUCTURE OF A FUNGAL LIPASE-INHIBITOR COMPLEX 3.1.1.3
5TH6 STRUCTURE DETERMINATION OF A POTENT, SELECTIVE ANTIBODY INHIBITOR OF HUMAN MMP9 (APO MMP9) 3.4.24.35
5TH9 STRUCTURE DETERMINATION OF A POTENT, SELECTIVE ANTIBODY INHIBITOR OF HUMAN MMP9 (GS-5745 BOUND TO MMP-9) 3.4.24.35
5THM ESTERASE-6 FROM DROSOPHILA MELANOGASTER 3.1.1.1
5THS CRYSTAL STRUCTURE OF G302A HDAC8 IN COMPLEX WITH M344 3.5.1.98
5THT CRYSTAL STRUCTURE OF G303A HDAC8 IN COMPLEX WITH M344 3.5.1.98
5THU CRYSTAL STRUCTURE OF G304A HDAC8 IN COMPLEX WITH M344 3.5.1.98
5THV CRYSTAL STRUCTURE OF G305A HDAC8 IN COMPLEX WITH M344 3.5.1.98
5THW CRYSTAL STRUCTURE OF AMIDASE, HYDANTOINASE/CARBAMOYLASE FAMILY FROM BURKHOLDERIA MULTIVORANS 3.5.1.87
5TI1 CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE FROM BURKHOLDERIA XENOVORANS LB400 3.7.1.2
5TIC X-RAY STRUCTURE OF WILD-TYPE E. COLI ACYL-COA THIOESTERASE I AT PH 5 3.1.2
3.1.1.5
3.1.2.2
3.1.1.2
3.1.2.14
3.4.21
5TID X-RAY STRUCTURE OF ACYL-COA THIOESTERASE I, TESA, MUTANT M141L/Y145K/L146K AT PH 5 IN COMPLEX WITH OCTANOIC ACID 3.1.2
3.1.1.5
3.1.2.2
3.1.1.2
3.1.2.14
3.4.21
5TIE X-RAY STRUCTURE OF ACYL-COA THIOESTERASE I, TESA, MUTANT M141L/Y145K/L146K AT PH 7.5 IN COMPLEX WITH OCTANOIC ACID 3.1.2
3.1.1.5
3.1.2.2
3.1.1.2
3.1.2.14
3.4.21
5TIF X-RAY STRUCTURE OF ACYL-COA THIOESTERASE I, TESA, TRIPLE MUTANT M141L/Y145K/L146K IN COMPLEX WITH OCTANOIC ACID 3.1.2
3.1.1.5
3.1.2.2
3.1.1.2
3.1.2.14
3.4.21
5TJ3 CRYSTAL STRUCTURE OF WILD TYPE ALKALINE PHOSPHATASE PAFA TO 1.7A RESOLUTION 3.1.3.1
5TJ9 2.6 ANGSTROM CRYSTAL STRUCTURE OF S-ADENOSYLHOMOCYSTEINASE FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH ARISTEROMYCIN AND NAD 3.3.1.1
5TJX STRUCTURE OF HUMAN PLASMA KALLIKREIN 3.4.21.34
5TK0 LYSOZYME STRUCTURE COLLECTED WITH 3D PRINTED POLYMER MOUNTS 3.2.1.17
5TKB CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND 3.1.4.53
5TKM CRYSTAL STRUCTURE OF HUMAN APOBEC3B N-TERMINAL DOMAIN 3.5.4
3.5.4.38
5TKS FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2- PROPENOYL)AMINO)-17,19-DIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE 3.4.21.27
5TKT FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,12,16(19)-HEXAEN-5-YL)CARBAMATE 3.4.21.27
5TKU FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE 3.4.21.27
5TKY CRYSTAL STRUCTURE OF THE CO-TRANSLATIONAL HSP70 CHAPERONE SSB IN THE ATP-BOUND, OPEN CONFORMATION 3.6.4.10
5TLI THERMOLYSIN (60% ISOPROPANOL SOAKED CRYSTALS) 3.4.24.27
5TLN BINDING OF HYDROXAMIC ACID INHIBITORS TO CRYSTALLINE THERMOLYSIN SUGGESTS A PENTACOORDINATE ZINC INTERMEDIATE IN CATALYSIS 3.4.24.27
5TLS 2.4 ANGSTROM CRYSTAL STRUCTURE OF S-ADENOSYLHOMOCYSTEINASE FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH DZ2002 AND NAD 3.3.1.1
5TMG OPTIMIZATION OF 3,5-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR 3.4.23.15
5TMH STRUCTURE OF ZIKA VIRUS NS5 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5TMK OPTIMIZATION OF 3,5-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR 3.4.23.15
5TMN SLOW-AND FAST-BINDING INHIBITORS OF THERMOLYSIN DISPLAY DIFFERENT MODES OF BINDING. CRYSTALLOGRAPHIC ANALYSIS OF EXTENDED PHOSPHONAMIDATE TRANSITION-STATE ANALOGUES 3.4.24.27
5TNO DISCOVERY OF NOVEL AMINOBENZISOXAZOLE DERIVATIVES AS ORALLY AVAILABLE FACTOR IXA INHIBITORS 3.4.21.22
5TNT DISCOVERY OF NOVEL AMINOBENZISOXAZOLE DERIVATIVES AS ORALLY AVAILABLE FACTOR IXA INHIBITORS 3.4.21.22
5TNW PHOSPHOLIPASE C GAMMA-1 C-TERMINAL SH2 DOMAIN 3.1.4.11
5TNY HTRA2 G399S MUTANT 3.4.21.108
5TNZ HTRA2 S142D MUTANT 3.4.21.108
5TO0 HTRA2 S276C MUTANT 3.4.21.108
5TO1 HTRA2 EXPOSED (L266R, F303A) MUTANT 3.4.21.108
5TO3 CRYSTAL STRUCTURE OF THROMBIN MUTANT W215A/E217A FUSED TO EGF456 OF THROMBOMODULIN VIA A 31-RESIDUE LINKER AND BOUND TO PPACK 3.4.21.5
5TO4 PHOSPHOLIPASE C GAMMA-1 C-TERMINAL SH2 DOMAIN, SPACEGROUP P212121 3.1.4.11
5TOL CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N-(3-((4AS,7AS)-2-AMINO-4,4A,5,6-TETRAHYDRO-7AH-FURO[2,3-D][1,3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE 3.4.23.46
5TOO CRYSTAL STRUCTURE OF ALKALINE PHOSPHATASE PAFA T79S, N100A, K162A, R164A MUTANT 3.1.3.1
5TOP ATOMIC RESOLUTION X-RAY CRYSTAL STRUCTURE OF A RUTHENOCENE CONJUGATED BETA-LACTAM ANTIBIOTIC IN COMPLEX WITH CTX-M-14 S70G BETA-LACTAMASE 3.5.2.6
5TOV CRYSTAL STRUCTURE OF THE INACTIVE FORM OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM THERMOTOGA MARITIMA IN BINARY COMPLEX WITH NADH 3.3.1.1
5TOW CRYSTAL STRUCTURE OF THE INACTIVE FORM OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM THERMOTOGA MARITIMA IN TERNARY COMPLEX WITH NADH AND ADENOSINE 3.3.1.1
5TOY X-RAY CRYSTAL STRUCTURE OF RUTHENOCENE CONJUGATED PENICILLOATE AND PENILLOATE PRODUCTS IN COMPLEX WITH CTX-M-14 E166A BETA-LACTAMASE 3.5.2.6
5TP0 HUMAN MESOTRYPSIN IN COMPLEX WITH DIMINAZENE 3.4.21.4
5TP4 CRYSTAL STRUCTURE OF A HYDANTOINASE/CARBAMOYLASE FAMILY AMIDASE FROM BURKHOLDERIA AMBIFARIA 3.5.1.87
5TPB BINDING DOMAIN OF BONT/A COMPLEXED WITH GANGLIOSIDE VARIANT 3.4.24.69
5TPC BINDING DOMAIN OF BONT/A COMPLEXED WITH GANGLIOSIDE 3.4.24.69
5TPQ E. COLI ALKALINE PHOSPHATASE D101A, D153A, R166S, E322A, K328A MUTANT 3.1.3.1
5TQ1 PHOSPHOLIPASE C GAMMA-1 C-TERMINAL SH2 DOMAIN BOUND TO A PHOSPHOPEPTIDE DERIVED FROM THE INSULIN RECEPTOR 3.1.4.11
5TQE FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (5R)-5-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-19-(CYCLOPROPYLSULFONYL)-3-METHYL-13-OXA-3,15-DIAZATRICYCLO[14.3.1.1~6,10~]HENICOSA-1(20),6(21),7,9,16,18-HEXAENE-4,14-DIONE 3.4.21.21
5TQF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (11R)-11-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-16-(CYCLOPROPYLSULFONYL)-13-METHYL-2,13-DIAZATRICYCLO[13.3.1.1~6,10~]ICOSA-1(19),6(20),7,9,15,17-HEXAENE-3,12-DIONE 3.4.21.21
5TQG FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (5R,11R)-11-[(1-AMINO-4-FLUOROISOQUINOLIN-6-YL)AMINO]-16-(CYCLOPROPYLSULFONYL)-7-(2,2-DIFLUOROETHOXY)-5,13-DIMETHYL-2,13-DIAZATRICYCLO[13.3.1.1~6,10~]ICOSA-1(19),6(20),7,9,15,17-HEXAENE-3,12-DIONE 3.4.21.21
5TQS PHOSPHOLIPASE C GAMMA-1 C-TERMINAL SH2 DOMAIN BOUND TO A PHOSPHOPEPTIDE DERIVED FROM THE RECEPTOR TYROSINE KINASE ERBB2 3.1.4.11
5TR7 CRYSTAL STRUCTURE OF A PUTATIVE D-ALANYL-D-ALANINE CARBOXYPEPTIDASE FROM VIBRIO CHOLERAE O1 BIOVAR ELTOR STR. N16961 3.4.16.4
5TRH CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-[(BENZENECARBONYL)AMINO]-3-[(4-CHLOROPHENYL)METHOXY]BENZOIC ACID 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5TRI CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 3-[(4-CHLOROPHENYL)METHOXY]-2-(1-OXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)BENZOIC ACID 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5TRJ CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 2-{[2-(CARBOXYMETHOXY)BENZENE-1-CARBONYL]AMINO}-3-[(4-CHLOROPHENYL)METHOXY]BENZOIC ACID 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5TRK CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA- DEPENDENT RNA POLYMERASE IN COMPLEX WITH N-{3-[(BENZENECARBONYL)AMINO]-4-[(4-CHLOROPHENYL)METHOXY]BENZENE-1-CARBONYL}GLYCINE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5TSN CRYSTAL STRUCTURES OF NORWALK VIRUS POLYMERASE BOUND TO AN RNA PRIMER-TEMPLATE DUPLEX 3.4.22.66
3.6.1.15
5TSQ CRYSTAL STRUCTURE OF IUNH FROM LEISHMANIA BRAZILIENSIS IN COMPLEX WITH D-RIBOSE 3.2.2.1
5TSR CRYSTAL STRUCTURE OF PRL-3 PHOSPHATASE IN COMPLEX WITH THE BATEMAN DOMAIN OF CNNM3 MAGNESIUM TRANSPORTER 3.1.3.48
5TTP CRYO-EM STRUCTURE OF MSBA-NANODISC WITH ADP-VANADATE 3.6.3
7.5.2.6
5TUN CRYSTAL STRUCTURE OF UNINHIBITED HUMAN CATHEPSIN K AT 1.62 ANGSTROM RESOLUTION 3.4.22.38
5TUQ CRYSTAL STRUCTURE OF A 6-CYCLOHEXYLMETHYL-3-HYDROXYPYRIMIDINE-2,4-DIONE INHIBITOR IN COMPLEX WITH HIV REVERSE TRANSCRIPTASE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TV4 3D CRYO-EM RECONSTRUCTION OF NUCLEOTIDE-FREE MSBA IN LIPID NANODISC 3.6.3
7.5.2.6
5TVP SUMO2 BOUND TO MOUSE TDP2 CATALYTIC DOMAIN WITH A 5'-PHOSPHORYLATED DNA TERNARY COMPLEX 3.1.4
5TVQ MOUSE TDP2 CATALYTIC DOMAIN BOUND TO SUMO2 3.1.4
5TVV COMPUTATIONALLY DESIGNED FENTANYL BINDER - FEN49* APO 3.2.1.8
5TVY COMPUTATIONALLY DESIGNED FENTANYL BINDER - FEN49 3.2.1.8
5TW3 CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 5-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)-4-FLUOROPHENOXY)-7-FLUORO-2-NAPHTHONITRILE (JLJ636), A NON-NUCLEOSIDE INHIBITOR 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TW6 CTX-M-14 P167S:E166A MUTANT WITH ACYLATED CEFTAZIDIME MOLECULE 3.5.2.6
5TWD CTX-M-14 P167S APOENZYME 3.5.2.6
5TWE CTX-M-14 P167S:S70G MUTANT ENZYME CRYSTALLIZED WITH CEFTAZIDIME 3.5.2.6
5TWM CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS GENOTYPE 2A STRAIN JFH1 L30S NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH 5-[3-(TERT-BUTYLCARBAMOYL)PHENYL]-6-(ETHYLAMINO)-2-(4-FLUOROPHENYL)-N-METHYLFURO[2,3-B]PYRIDINE-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5TWN CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA- DEPENDENT RNA POLYMERASE IN COMPLEX WITH 5-[3-(TERT-BUTYLCARBAMOYL)PHENYL]-6-(ETHYLAMINO)-2-(4-FLUOROPHENYL)-N-METHYLFURO[2,3-B]PYRIDINE-3-CARBOXAMIDE 2.7.7.48
3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
5TXC ATXE2 ISOPEPTIDASE - APO 3.4.21
3.4
5TXE ATXE2 ISOPEPTIDASE - S527A VARIANT WITH ASTEXIN3-DC4 BOUND 3.4
5TXF CRYSTAL STRUCTURE OF LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) IN A CLOSED CONFORMATION 2.3.1.43
3.1.1.47
5TXG CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE. 3.4.21.91
3.6.1.15
3.6.4.13
5TXK CRYSTAL STRUCTURE OF USP35 C450S IN COMPLEX WITH UBIQUITIN 3.4.19.12
5TXL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DATP 2.7.7.49
3.4.23.16
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TXM STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DDATP 2.7.7.49
3.4.23.16
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5TXN STRUCTURE OF Q151M MUTANT HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DATP 2.7.7.49
2.7.7.7
3.4.23.16
3.1.26.13
3.1.13.2
2.7.7
3.1
5TXO STRUCTURE OF Q151M COMPLEX (A62V, V75I, F77L, F116Y, Q151M) MUTANT HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DATP 2.7.7.49
2.7.7.7
3.4.23.16
3.1.26.13
3.1.13.2
2.7.7
3.1
5TXP STRUCTURE OF Q151M COMPLEX (A62V, V75I, F77L, F116Y, Q151M) MUTANT HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING DDATP 2.7.7.49
2.7.7.7
3.4.23.16
3.1.26.13
3.1.13.2
2.7.7
3.1
5TYJ ALPHA-ESTERASE-7 IN COMPLEX WITH (3-BROMO-5-PHENOXYLPHENYL)BORONIC ACID 3.1.1
5TYK ALPHA-ESTERASE-7 IN COMPLEX WITH 3-CHLORO-4-[(2-FLUOROPHENYL)METHOXY]PHENYLBORINIC ACID 3.1.1
5TYL ALPHA-ESTERASE-7 IN COMPLEX WITH NAPHTHALEN-2-YLBORONIC ACID 3.1.1
5TYM ALPHA-ESTERASE-7 IN COMPLEX WITH [3-BROMO-5-(PYRROLIDIN-1-YL)PHENYL]BORINIC ACID 3.1.1
5TYN ALPHA-ESTERASE-7 IN COMPLEX WITH [3-BROMO-5-(PYRROLIDIN-1-YL)PHENYL]BORINIC ACID 3.1.1
5TYO ALPHA-ESTERASE-7 IN COMPLEX WITH [3-(BENZYLOXY)-4-METHYLPHENYL]BORINIC ACID 3.1.1
5TYP ALPHA-ESTERASE-7 IN COMPLEX WITH (3-BROMO-4-METHYLPHENYL)BORONIC ACID 3.1.1
5TZ3 CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}-N-(NAPHTHALENE-2-YL)PIPERIDINE-3-CARBOXAMIDE 3.1.4.17
5TZA CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL-1-[(NAPHTHALENE-2-YL)CARBONYL]PIPERIDINE 3.1.4.17
5TZC CRYSTAL STRUCTURE OF HUMAN PDE2A IN COMPLEX WITH (5S)-1-[(3-BROMO-4-FLUOROPHENYL)CARBONYL]-3,3-DIFLUORO-5-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}PIPERIDINE 3.1.4.17
5TZH CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 3,3-DIFLUORO-1-[(4-FLUOROPHENYL)CARBONYL]-5-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}PIPERIDINE 3.1.4.17
5TZO COMPUTATIONALLY DESIGNED FENTANYL BINDER - FEN49*-COMPLEX 3.2.1.8
5TZR GPR40 IN COMPLEX WITH PARTIAL AGONIST MK-8666 3.2.1.17
5TZW CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3,4-DIFLUOROPHENYL)CARBONYL]-3,3-DIFLUORO-5-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}PIPERIDINE 3.1.4.17
5TZX CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3-CHLORO-4-FLUOROPHENYL)CARBONYL]-3,3-DIFLUORO-5-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}PIPERIDINE 3.1.4.17
5TZY GPR40 IN COMPLEX WITH AGOPAM AP8 AND PARTIAL AGONIST MK-8666 3.2.1.17
5TZZ CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3-BROMO-4-FLUOROPHENYL)CARBONYL]-3,3-DIFLUORO-5-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}PIPERIDINE 3.1.4.17
5U00 CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 3,3-DIFLUORO-1-[(4-FLUORO-3-IODOPHENYL)CARBONYL]-5-{5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}PIPERIDINE 3.1.4.17
5U04 CRYSTAL STRUCTURE OF ZIKA VIRUS NS5 RNA-DEPENDENT RNA POLYMERASE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5U0B STRUCTURE OF FULL-LENGTH ZIKA VIRUS NS5 2.1.1.56
2.1.1.57
2.7.7.48
3.4.21.91
3.6.1.15
3.6.4.13
5U0I C-TERMINAL ANKYRIN REPEATS FROM HUMAN KIDNEY-TYPE GLUTAMINASE (KGA) - TETRAGONAL CRYSTAL FORM 3.5.1.2
5U0J C-TERMINAL ANKYRIN REPEATS FROM HUMAN KIDNEY-TYPE GLUTAMINASE (KGA) - MONOCLINIC CRYSTAL FORM 3.5.1.2
5U0K C-TERMINAL ANKYRIN REPEATS FROM HUMAN LIVER-TYPE GLUTAMINASE (GAB/LGA) 3.5.1.2
5U1C STRUCTURE OF TETRAMERIC HIV-1 STRAND TRANSFER COMPLEX INTASOME 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5U1S CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SEPARASE-SECURIN COMPLEX AT 3.0 ANGSTROM RESOLUTION 3.4.22.49
5U1T CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SEPARASE-SECURIN COMPLEX AT 2.6 ANGSTROM RESOLUTION 3.4.22.49
5U2G 2.6 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF PENICILLIN-BINDING PROTEIN 1A FROM HAEMOPHILUS INFLUENZAE 2.4.2
3.4
2.4.1.129
3.4.16.4
5U30 CRYSTAL STRUCTURE OF AACC2C1-SGRNA-EXTENDED TARGET DNA TERNARY COMPLEX 3.1
5U31 CRYSTAL STRUCTURE OF AACC2C1-SGRNA-8MER SUBSTRATE DNA TERNARY COMPLEX 3.1
5U33 CRYSTAL STRUCTURE OF AACC2C1-SGRNA-EXTENDED NON-TARGET DNA TERNARY COMPLEX 3.1
5U34 CRYSTAL STRUCTURE OF AACC2C1-SGRNA BINARY COMPLEX 3.1
5U39 PSEUDOMONAS AERUGINOSA LPXC IN COMPLEX WITH CHIR-090 3.5.1.108
5U3A ULTRA HIGH RESOLUTION CRYSTAL STRUCTURE OF HUMAN PANCREATIC ALPHA AMYLASE 3.2.1.1
5U3B PSEUDOMONAS AERUGINOSA LPXC IN COMPLEX WITH NVS-LPXC-01 3.5.1.108
5U4L RTA-V1C7_G29R-HIGH-SALT 3.2.2.22
5U4M RTA-V1C7-G29R-NO_SALT 3.2.2.22
5U4W CRYO-EM STRUCTURE OF IMMATURE ZIKA VIRUS 3.4.21.91
3.6.1.15
3.6.4.13
5U53 CTX-M-14 E166A WITH ACYLATED CEFTAZIDIME MOLECULE 3.5.2.6
5U6J FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 3-{[(2R)-17-ETHYL-4-METHYL-3,12-DIOXO-7-[(PROPAN-2-YL)SULFONYL]-13-OXA-4,11-DIAZATRICYCLO[14.2.2.1~6,10~]HENICOSA-1(18),6(21),7,9,16,19-HEXAEN-2-YL]AMINO}BENZAMIDE 3.4.21.21
5U6Z CRYSTAL STRUCTURE OF XENOPUS LAEVIS APEX2 C-TERMINAL ZNF-GRF DOMAIN 4.2.99.18
3.1
5U7D PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS 3.1.4.17
5U7E APO DIHYDRONEOPTERIN TRIPHOSPHATE PYROPHOSPHOHYDROLASE FROM E. COLI 3.6.1.67
5U7F CO-BOUND DIHYDRONEOPTERIN TRIPHOSPHATE PYROPHOSPHOHYDROLASE FROM E. COLI 3.6.1.67
5U7H NI-BOUND DIHYDRONEOPTERIN TRIPHOSPHATE PYROPHOSPHOHYDROLASE FROM E. COLI 3.6.1.67
5U7I PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS 3.1.4.17
5U7J PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS 3.1.4.17
5U7K PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS 3.1.4.17
5U7L PDE2 CATALYTIC DOMAIN COMPLEXED WITH INHIBITORS 3.1.4.17
5U7P CRYSTAL STRUCTURE OF A NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE (NTPDASE) FROM THE LEGUME TRIFOLIUM REPENS 3.6.1.5
5U7V CRYSTAL STRUCTURE OF A NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE (NTPDASE) FROM THE LEGUME TRIFOLIUM REPENS IN COMPLEX WITH AMP 3.6.1.5
5U7W CRYSTAL STRUCTURE OF A NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE (NTPDASE) FROM THE LEGUME TRIFOLIUM REPENS IN COMPLEX WITH ADENINE AND PHOSPHATE 3.6.1.5
5U7Z HUMAN ACID CERAMIDASE (ASAH1, ACDASE) SELF-ACTIVATED 3.5.1.23
3.5.1
5U81 ACID CERAMIDASE (ASAH1, ACDASE) FROM NAKED MOLE RAT, CYS143ALA, UNCLEAVED 3.5.1.23
5U84 ACID CERAMIDASE (ASAH1, ACDASE) FROM COMMON MINKE WHALE, CYS143ALA, UNCLEAVED 3.5.1.23
3.5.1
5U86 STRUCTURE OF THE AQUIFEX AEOLICUS LPXC/LPC-069 COMPLEX 3.5.1.108
5U8S STRUCTURE OF EUKARYOTIC CMG HELICASE AT A REPLICATION FORK 3.6.4.12
5U8T STRUCTURE OF EUKARYOTIC CMG HELICASE AT A REPLICATION FORK AND IMPLICATIONS 3.6.4.12
5UAK DEPHOSPHORYLATED, ATP-FREE HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) 3.6.3.49
5.6.1.6
5UAR DEPHOSPHORYLATED, ATP-FREE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) FROM ZEBRAFISH 3.6.3.49
5.6.1.6
5UBJ STRUCTURE OF AN ALPHA-L-ARABINOFURANOSIDASE (GH62) FROM ASPERGILLUS NIDULANS 3.2.1.55
5UBK INACTIVE S1A/N269D-CPPVDQ MUTANT IN COMPLEX WITH THE PYOVERDINE PRECURSOR PVDIQ REVEALS A SPECIFIC BINDING POCKET FOR THE D-TYR OF THIS SUBSTRATE 3.5.1.97
5UBL A CIRCULARLY PERMUTED VERSION OF PVDQ (CPPVDQ) 3.5.1.97
5UBM CRYSTAL STRUCTURE OF HUMAN C1S IN COMPLEX WITH INHIBITOR GIGASTASIN 3.4.21.42
5UBW STRUCTURE OF CATALYTIC DOMAIN OF SSEL 3.4.22
5UCQ THE STRUCTURE OF ARCHAEAL INORGANIC PYROPHOSPHATASE IN COMPLEX WITH PYROPHOSPHATE 3.6.1.1
5UCT MYCOBACTERIUM TUBERCULOSIS TOXIN MAZF-MT6 3.1
5UDY HUMAN ALKALINE SPHINGOMYELINASE (ALK-SMASE, ENPP7, NPP7) 3.1.4.12
5UE1 CRYSTAL STRUCTURE OF 5'-METHYLTHIOADENOSINE/S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASE IN COMPLEX WITH ADENINE FROM VIBRIO FISCHERI ES114 3.2.2.9
5UE2 PROMMP-7 WITH HEPARIN OCTASACCHARIDE BRIDGING BETWEEN DOMAINS 3.4.24.23
5UE3 PROMMP-9DESFNII 3.4.24.35
5UE4 PROMMP-9DESFNII COMPLEXED TO JNJ0966 INHIBITOR 3.4.24.35
5UE5 PROMMP-7 WITH HEPARIN OCTASACCHARIDE BOUND TO THE CATALYTIC DOMAIN 3.4.24.23
5UEJ 1.30 A CRYSTAL STRUCTURE OF DAPE ENZYME FROM NEISSERIA MENINGITIDIS MC58 3.5.1.18
5UFE WILD-TYPE K-RAS(GNP)/R11.1.6 COMPLEX 3.6.5.2
5UFQ K-RASG12D(GNP)/R11.1.6 COMPLEX 3.6.5.2
5UFZ HIV-1 PROTEASE COMPLEXED WITH INHIBITOR: (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL [(1S,2S)-1-(1-{[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO}CYCLOPROPYL)-1-HYDROXY-3-PHENYLPROPAN-2-YL]CARBAMATE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5UGD PROTEASE INHIBITOR 3.4.21.7
5UGG PROTEASE INHIBITOR 3.4.21.7
5UGQ CRYSTAL STRUCTURE OF HIP1 (RV2224C) 3.1.1
5UHK CRYSTAL STRUCTURE OF THE CORE CATALYTIC DOMAIN OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5UHL CRYSTAL STRUCTURE OF THE CORE CATALYTIC DOMAIN OF HUMAN O-GLCNACASE COMPLEXED WITH THIAMET G 3.2.1.169
3.2.1
5UHO CRYSTAL STRUCTURE OF THE CORE CATALYTIC DOMAIN OF HUMAN O-GLCNACASE COMPLEXED WITH PUGNAC 3.2.1.169
3.2.1
5UHP CRYSTAL STRUCTURE OF THE CORE CATALYTIC DOMAIN OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5UHV WILD-TYPE NRAS BOUND TO GPPNHP 3.6.5.2
5UHY A HUMAN ANTIBODY AGAINST ZIKA VIRUS CROSSLINKS THE E PROTEIN TO PREVENT INFECTION 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5UI1 CRYSTAL STRUCTURE OF HUMAN PROTEIN PHOSPHATASE 5C (PP5C) IN COMPLEX WITH A TRIAZOLE INHIBITOR 3.1.3.16
5UJ0 STRUCTURE OF T4PNKP 3' PHOSPHATASE COVALENTLY BOUND TO BEF3 2.7.1.78
3.1.3.34
5UJ2 CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS AND DELTA8 NETA HAIRPOIN LOOP DELETION IN COMPLEX WITH GS-639476 (DIPHSOHATE VERSION OF GS-9813), MN2+ AND SYMMETRICAL PRIMER TEMPLATE 5'-AUAAAUUU 3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5UJ3 CRYSTAL STRUCTURE OF THE KPC-2 BETA-LACTAMASE COMPLEXED WITH HYDROLYZED CEFOTAXIME 3.5.2.6
5UJ4 CRYSTAL STRUCTURE OF THE KPC-2 BETA-LACTAMASE COMPLEXED WITH HYDROLYZED FAROPENEM 3.5.2.6
5UJO X-RAY CRYSTAL STRUCTURE OF RUTHENOCENYL-7-AMINODESACETOXYCEPHALOSPORANIC ACID COVALENT ACYL-ENYZME COMPLEX WITH CTX-M-14 E166A BETA-LACTAMASE 3.5.2.6
5UK9 WILD-TYPE K-RAS(GCP) PH 6.5 3.6.5.2
5UL5 CRYSTAL STRUCTURE OF RPE65 IN COMPLEX WITH MB-004 AND PALMITATE 3.1.1.64
5.3.3.22
5UL8 APO KPC-2 BETA-LACTAMASE CRYSTAL STRUCTURE AT 1.15 ANGSTROM RESOLUTION 3.5.2.6
5ULG CRYSTAL STRUCTURE OF RPE65 IN COMPLEX WITH MB-008 AND PALMITATE 3.1.1.64
5.3.3.22
5ULI CRYSTAL STRUCTURE OF MOUSE DXO IN COMPLEX WITH (3'-NADP)+ AND CALCIUM ION 3.1.13
3.6.1
5ULP STRUCTURE OF THE NS5 METHYLTRANSFERASE FROM ZIKA BOUND TO MS2042 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5ULT HIV-1 WILD TYPE PROTEASE WITH GRL-100-13A (A CROWN-LIKE OXOTRICYCLIC CORE AS THE P2-LIGAND WITH THE SULFONAMIDE ISOSTERE AS THE P2' GROUP) 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5UM9 FLAP ENDONUCLEASE 1 (FEN1) D86N WITH 5'-FLAP SUBSTRATE DNA AND SM3+ 3.1
5UN3 TETRAGONAL THERMOLYSIN (295 K) IN THE PRESENCE OF 50% XYLOSE 3.4.24.27
5UN8 CRYSTAL STRUCTURE OF HUMAN O-GLCNACASE IN COMPLEX WITH GLYCOPEPTIDE P53 3.2.1.169
3.2.1
5UN9 THE CRYSTAL STRUCTURE OF HUMAN O-GLCNACASE IN COMPLEX WITH THIAMET-G 3.2.1.169
3.2.1
5UNB CRYSTAL STRUCTURE OF PUTATIVE PUTATIVE DEOXYRIBONUCLEASE-2 FROM BURKHOLDERIA THAILANDENSIS IN COMPLEX WITH COPPER 3.1
5UNO CRYSTAL STRUCTURE OF HIP1 (RV2224C) 3.1.1
5UOH CRYSTAL STRUCTURE OF HIP1 (RV2224C) T466A MUTANT 3.1.1
5UOP CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS INTASOME WITH A 2- PYRIDINONE AMINAL INHIBITOR (COMPOUND 18) 2.7.7
2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
3.1
5UOQ CRYSTAL STRUCTURE OF THE PROTOTYPE FOAMY VIRUS INTASOME WITH A 2- PYRIDINONE AMINAL INHIBITOR (COMPOUND 31) 2.7.7
2.7.7.49
2.7.7.7
3.1.26.4
3.4.23
3.1
5UOV HIV-1 WILD TYPE PROTEASE WITH GRL-1118A , AN ISOPHTHALAMIDE-DERIVED P2-P3 LIGAND WITH THE SULFONAMIDE ISOSTERE AS THE P2' GROUP 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5UOY CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 16J (6-(4-METHOXYBENZYL)-9-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-8,9,10,11-TETRAHYDROPYRIDO[4',3':4,5]THIENO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5(6H)-ONE) 3.1.4.17
5UP0 CRYSTAL STRUCTURE OF HUMAN PDE1B CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 3 (6-(4-CHLOROBENZYL)-8,9,10,11-TETRAHYDROBENZO[4,5]THIENO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5(6H)-ONE) 3.1.4.17
5UPG CRYSTAL STRUCTURE OF LPXC FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH PF-5081090 3.5.1.108
5UPI CRYSTAL STRUCTURE OF BHGH81 MUTANT IN COMPLEX WITH LAMINARO-BIOSE 3.2.1.6
5UPJ HIV-2 PROTEASE/U99283 COMPLEX 3.4.23.16
3.4.23.47
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5UPM CRYSTAL STRUCTURE OF BHGH81 MUTANT IN COMPLEX WITH LAMINARO-TRIOSE 3.2.1.6
5UPN CRYSTAL STRUCTURE OF BHGH81 MUTANT IN COMPLEX WITH LAMINARO-TETRAOSE 3.2.1.6
5UPO CRYSTAL STRUCTURE OF BHGH81 MUTANT IN COMPLEX WITH LAMINARO-PENTAOSE 3.2.1.6
5UPZ HIV-1 WILD TYPE PROTEASE WITH GRL-0518A , AN ISOPHTHALAMIDE-DERIVED P2-P3 LIGAND WITH THE PARA-HYDOXYMETHYL SULFONAMIDE ISOSTERE AS THE P2' GROUP 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5UQ6 PIG PURPLE ACID PHOSPHATASE COMPLEXED WITH PHOSPHATE IN TWO COORDINATION MODES ALONG WITH A BRIDGING HYDROXIDE ION 3.1.3.2
5UQJ STRUCTURE OF YEAST USB1 3.1.4
5UQK CLOSTRIDIUM DIFFICILE TOXIN A (TCDA) GLUCOSYLTRANSFERASE DOMAIN IN COMPLEX WITH U2F 3.4.22
2.4.1
5UQL CLOSTRIDIUM DIFFICILE TOXIN A (TCDA) GLUCOSYLTRANSFERASE DOMAIN IN COMPLEX WITH U2F 3.4.22
2.4.1
5UQM CLOSTRIDIUM DIFFICILE TOXIN B (TCDB) GLUCOSYLTRANSFERASE DOMAIN IN COMPLEX WITH U2F 3.4.22
2.4.1
5UQN CLOSTRIDIUM DIFFICILE TOXIN B (TCDB) GLUCOSYLTRANSFERASE DOMAIN IN COMPLEX WITH U2F 3.4.22
2.4.1
5UQT CLOSTRIDIUM DIFFICILE TOXIN B (TCDB) GLUCOSYLTRANSFERASE DOMAIN CO-CRYSTALLIZED WITH APIGENIN 3.4.22
2.4.1
5UQW CRYSTAL STRUCTURE OF HUMAN KRAS G12V MUTANT IN COMPLEX WITH GDP 3.6.5
3.6.5.2
5UQX USP7 IN COMPLEX WITH GNE6776 (6'-AMINO-4'-ETHYL-5'-(4-HYDROXYPHENYL)-N-METHYL-[3,3'-BIPYRIDINE]-6-CARBOXAMIDE) 3.4.19.12
5UR3 KAPOSI'S SARCOMA HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR 3.4.21.97
5URJ CRYSTAL STRUCTURE OF HUMAN BRR2 IN COMPLEX WITH T-3905516 3.6.4.13
5URK CRYSTAL STRUCTURE OF HUMAN BRR2 IN COMPLEX WITH T-3935799 3.6.4.13
5URM CRYSTAL STRUCTURE OF HUMAN BRR2 IN COMPLEX WITH T-1206548 3.6.4.13
5US2 2-SE-T2-DNA AND NATIVE RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5US4 CRYSTAL STRUCTURE OF HUMAN KRAS G12D MUTANT IN COMPLEX WITH GDP 3.6.5.2
5USA 5-SE-T2-DNA AND NATIVE RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5USE 5-SE-T4-DNA AND NATIVE RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5USG 5-SE-T2/4-DNA AND NATIVE RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5USJ CRYSTAL STRUCTURE OF HUMAN KRAS G12D MUTANT IN COMPLEX WITH GDPNP 3.6.5.2
5UTE KAPOSI'S SARCOMA HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR 3.4.21.97
5UTN KAPOSI'S SARCOMA HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR 3.4.21.97
5UTP CRYSTAL STRUCTURE OF BURKHOLDERIA CENOCEPACIA FAMILY 3 GLYCOSIDE HYDROLASE (NAGZ) BOUND TO N-ETHYLBUTYRYL-PUGNAC 3.2.1.52
5UTQ CRYSTAL STRUCTURE OF BURKHOLDERIA CENOCEPACIA FAMILY 3 GLYCOSIDE HYDROLASE (NAGZ) BOUND TO PUGNAC 3.2.1.52
5UTR CRYSTAL STRUCTURE OF BURKHOLDERIA CENOCEPACIA FAMILY 3 GLYCOSIDE HYDROLASE (NAGZ) BOUND TO (3S,4R,5R,6S)-3-BUTYRYL-4,5,6-TRIHYDROXYAZEPANE 3.2.1.52
5UTV SARS-UNIQUE FOLD IN THE ROUSETTUS BAT CORONAVIRUS HKU9 3.4.19.12
3.4.22.69
3.4.22
2.7.7.48
3.6.4.12
3.6.4.13
2.1.1
3.1.13
3.1
5UU7 TETRAGONAL THERMOLYSIN (295 K) IN THE PRESENCE OF 50% MPD 3.4.24.27
5UU8 TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 30% XYLOSE AS CRYOPROTECTANT 3.4.24.27
5UU9 TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 40% XYLOSE AS CRYOPROTECTANT 3.4.24.27
5UUA TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 50% XYLOSE AS CRYOPROTECTANT 3.4.24.27
5UUB TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 25% XYLOSE/25% MPD AS CRYOPROTECTANT 3.4.24.27
5UUC TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 50% MPD AS CRYOPROTECTANT 3.4.24.27
5UUD TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 50% DMF AS CRYOPROTECTANT 3.4.24.27
5UUE TETRAGONAL THERMOLYSIN CRYOCOOLED TO 100 K WITH 50% METHANOL AS CRYOPROTECTANT 3.4.24.27
5UV3 KAPOSI'S SARCOMA HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR 3.4.21.97
5UVG CRYSTAL STRUCTURE OF THE HUMAN NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) CATALYTIC DOMAIN WITH INSERTION DELETED AND CALCIUM BOUND 3.1.4.12
5UVJ SERIAL MILLISECOND CRYSTALLOGRAPHY OF MEMBRANE AND SOLUBLE PROTEIN MICRO-CRYSTALS USING SYNCHROTRON RADIATION 3.2.1.17
5UVL SERIAL MILLISECOND CRYSTALLOGRAPHY OF MEMBRANE AND SOLUBLE PROTEIN MICRO-CRYSTALS USING SYNCHROTRON RADIATION 3.4.21.64
5UVP KAPOSI'S SARCOMA HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR 3.4.21.97
5UWF CRYSTAL STRUCTURE OF HUMAN PDE10A IN COMPLEX WITH INHIBITOR 16D 3.1.4.17
3.1.4.35
5UWK MATRIX METALLOPROTEINASE-13 COMPLEXED WITH SELECTIVE INHIBITOR COMPOUND (S)-10A 3.4.24
5UWL MATRIX METALLOPROTEINASE-13 COMPLEXED WITH SELECTIVE INHIBITOR COMPOUND (S)-17A 3.4.24
5UWM MATRIX METALLOPROTEINASE-13 COMPLEXED WITH SELECTIVE INHIBITOR COMPOUND (R)-17A 3.4.24
5UWN MATRIX METALLOPROTEINASE-13 COMPLEXED WITH SELECTIVE INHIBITOR COMPOUND 10D 3.4.24
5UX4 CRYSTAL STRUCTURE OF RAT CATHEPSIN D WITH (5S)-3-(5,6-DIHYDRO-2H-PYRAN-3-YL)-1-FLUORO- 7-(2-FLUOROPYRIDIN-3-YL)SPIRO[CHROMENO[2,3- C]PYRIDINE-5,4'-[1,3]OXAZOL]-2'-AMINE 3.4.23.5
5UY7 CRYSTAL STRUCTURE OF A PEPTIDOGLYCAN GLYCOSYLTRANSFERASE FROM BURKHOLDERIA AMBIFARIA 2.4.1.129
3.4.16.4
5UYU CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3-AZAXANTHENE COMPOUND 12 3.4.23.46
5UZ0 CRYSTAL STRUCTURE OF AICARFT BOUND TO AN ANTIFOLATE 2.1.2.3
3.5.4.10
5V0N BACE1 IN COMPLEX WITH INHIBITOR 5G 3.4.23.46
5V0U CRYSTAL STRUCTURE OF POLYMERASE ACID PROTEIN (PA) FROM INFLUENZA A VIRUS, WILSON-SMITH/1933 (H1N1) BOUND TO FOLLOW ON FRAGMENT EBSI-4723 4-(5-CHLOROTHIOPHEN-2-YL)-1H-PYRAZOLE 3.1
5V1M STRUCTURE OF HUMAN USB1 WITH URIDINE 5'-MONOPHOSPHATE 3.1.4
5V1W CRYSTAL STRUCTURE OF BHGH81 IN COMPLEX WITH LAMINARO-BIOSE 3.2.1.6
5V2I CRYSTAL STRUCTURE OF A MUTANT GLYCOSYLASPARAGINASE (G172D) THAT CAUSES THE GENETIC DISEASE ASPARTYLGLUCOSAMINURIA 3.5.1.26
5V36 1.88 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF GLUTATHIONE REDUCTASE FROM STREPTOCOCCUS MUTANS UA159 IN COMPLEX WITH FAD 3.3.1.1
1.8.1.7
5V3A NOVEL STRUCTURAL INSIGHTS INTO GDP-MEDIATED REGULATION OF ACYL-COA THIOESTERASES 3.1.2
5V3B HUMAN A20 OTU DOMAIN (WT) WITH ACETAMIDYLATED C103 3.4.19.12
6.3.2
2.3.2
5V3P HUMAN A20 OTU DOMAIN (I325N) WITH ACETAMIDYLATED C103 3.4.19.12
6.3.2
2.3.2
5V48 SOLUBLE RABBIT NEPRILYSIN IN COMPLEX WITH THIORPHAN 3.4.24.11
5V4G RUTHENIUM(II)(CYMENE)(CHLORIDO)2-LYSOZYME ADDUCT WITH TWO BINDING SITES 3.2.1.17
5V4H RUTHENIUM(II)(CYMENE)(CHLORIDO)2-LYSOZYME ADDUCT FORMED WHEN RUTHENIUM(II)(CYMENE)(BROMIDO)2 UNDERWENT LIGAND EXCHANGE, RESULTING IN ONE BINDING SITE 3.2.1.17
5V4I OSMIUM(II)(CYMENE)(CHLORIDO)2-LYSOZYME ADDUCT WITH ONE BINDING SITE 3.2.1.17
5V4Q CRYSTAL STRUCTURE OF HUMAN GGT1 IN COMPLEX WITH DON 2.3.2.2
3.4.19.13
3.4.19.14
5V5D ROOM TEMPERATURE (280K) CRYSTAL STRUCTURE OF KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR (COMPOUND 250) 3.4.21.97
5V5E ROOM TEMPERATURE (280K) CRYSTAL STRUCTURE OF KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS PROTEASE IN COMPLEX WITH ALLOSTERIC INHIBITOR (COMPOUND 733) 3.4.21.97
5V5F CRYSTAL STRUCTURE OF RICE1 (PNT2) 3.1.13.1
5V5G OTU PROTEASE OF CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS BOUND TO UBIQUITIN VARIANT CC.4 3.4.19.12
2.7.7.48
5V5H OTU PROTEASE OF CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS BOUND TO UBIQUITIN VARIANT CC.2 3.4.19.12
2.7.7.48
5V5I OTU PROTEASE OF CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS BOUND TO UBIQUITIN VARIANT CC.1 3.4.19.12
2.7.7.48
5V69 CRYSTAL STRUCTURE OF THE MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS PAPAIN-LIKE PROTEASE BOUND TO UBIQUITIN VARIANT ME.4 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5V6A CRYSTAL STRUCTURE OF THE MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS PAPAIN-LIKE PROTEASE BOUND TO UBIQUITIN VARIANT ME.2 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5V6S CRYSTAL STRUCTURE OF SMALL MOLECULE ACRYLAMIDE 1 COVALENTLY BOUND TO K-RAS G12C 3.6.5.2
5V6U CRYSTAL STRUCTURE OF HUMAN CASPASE-7 SOAKED WITH ALLOSTERIC INHIBITOR 2-[(2-ACETYLPHENYL)SULFANYL]BENZOIC ACID 3.4.22.60
5V6V CRYSTAL STRUCTURE OF SMALL MOLECULE AZIRIDINE 3 COVALENTLY BOUND TO K-RAS G12C 3.6.5.2
5V6Z CRYSTAL STRUCTURE OF HUMAN CASPASE-7 SOAKED WITH ALLOSTERIC INHIBITOR 2-{[2-(4-CHLOROPHENYL)-2-OXOETHYL]SULFANYL}BENZOIC ACID 3.4.22.60
5V7D T4 LYSOZYME Y18YMBR 3.2.1.17
5V7E T4 LYSOZYME Y18YMCL 3.2.1.17
5V7F T4 LYSOZYME Y18YMI 3.2.1.17
5V83 STRUCTURE OF DCN1 BOUND TO NACM-HIT 3.2.1.17
5V86 STRUCTURE OF DCN1 BOUND TO NACM-OPT 3.2.1.17
5V88 STRUCTURE OF DCN1 BOUND TO NACM-COV 3.2.1.17
5V8F STRUCTURAL BASIS OF MCM2-7 REPLICATIVE HELICASE LOADING BY ORC-CDC6 AND CDT1 3.6.4.12
5V8G PEKIN DUCK LYSOZYME ISOFORM I (DEL-I) 3.2.1.17
5V8P SMALL MOLECULE INHIBITOR ABS-143 BOUND TO THE BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN 3.4.24.69
5V8R SMALL MOLECULE INHIBITOR ABS-143 BOUND TO THE BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN 3.4.24.69
5V8U SMALL MOLECULE INHIBITOR ABS-143 BOUND TO THE BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN 3.4.24.69
5V8V CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL 3.4.23.15
5V92 PEKIN DUCK EGG LYSOZYME ISOFORM III (DEL-III), ORTHORHOMBIC FORM 3.2.1.17
5V94 PEKIN DUCK EGG LYSOZYME ISOFORM III (DEL-III), CUBIC FORM 3.2.1.18
3.2.1.17
5V96 CRYSTAL STRUCTURE OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FROM NAEGLERIA FOWLERI WITH BOUND NAD AND ADENOSINE 3.3.1.1
5V9L KRAS G12C IN BOUND TO QUINAZOLINE BASED SWITCH II POCKET (SWIIP) BINDER 3.6.5.2
5V9O KRAS G12C INHIBITOR 3.6.5.2
5V9U CRYSTAL STRUCTURE OF SMALL MOLECULE ARS-1620 COVALENTLY BOUND TO K-RAS G12C 3.6.5.2
5V9X STRUCTURE OF MYCOBACTERIUM SMEGMATIS HELICASE LHR BOUND TO SSDNA AND AMP-PNP 3.6.4.13
5VA9 HUMAN PANCREATIC ALPHA AMYLASE IN COMPLEX WITH PEPTIDE INHIBITOR PIHA-L5(D10Y) 3.2.1.1
5VAJ BHRNASE H - AMIDE-RNA/DNA COMPLEX 3.1.26.4
5VAS PEKIN DUCK EGG LYSOZYME ISOFORM III (DEL-III), ORTHORHOMBIC FORM 3.2.1.17
5VBA STRUCTURE OF ESPG1 CHAPERONE FROM THE TYPE VII (ESX-1) SECRETION SYSTEM DETERMINED WITH THE ASSISTANCE OF N-TERMINAL T4 LYSOZYME FUSION 3.2.1.17
5VBD CRYSTAL STRUCTURE OF A PUTATIVE UBL DOMAIN OF USP9X 3.4.19.12
5VBE CRYSTAL STRUCTURE OF SMALL MOLECULE DISULFIDE 2C07 BOUND TO H-RAS M72C GDP 3.6.5.2
5VBM CRYSTAL STRUCTURE OF SMALL MOLECULE DISULFIDE 2C07 BOUND TO K-RAS CYS LIGHT M72C GDP 3.6.5.2
5VBS STRUCTURAL BASIS FOR A SIX LETTER ALPHABET INCLUDING GATCKX 2.7.7.49
2.7.7.7
3.4.23
3.1.26.4
2.7.7
3.1
5VBZ CRYSTAL STRUCTURE OF SMALL MOLECULE DISULFIDE 2C07 BOUND TO H-RAS M72C GPPNHP 3.6.5.2
5VCK HIV PROTEASE (PR) WITH TL-3 IN THE ACTIVE SITE AND (Z)-N-(THIAZOL-2-YL)-N'-TOSYLCARBAMIMIDATE IN THE EXOSITE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5VCN THE CRYSTAL STRUCTURE OF DER P 1 ALLERGEN COMPLEXED WITH FAB FRAGMENT OF MAB 5H8 3.4.22.65
5VCP CRYSTAL STRUCTURE OF A PEPTIDE DEFORMYLASE FROM BURKHOLDERIA XENOVORANS IN COMPLEX WITH ACTINONIN 3.5.1.88
5VEA HIV PROTEASE (PR) WITH TL-3 IN ACTIVE SITE AND 4-METHYLBENZENE-1,2-DIAMINE IN EXOSITE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5VEM HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE 5 (ENPP5, NPP5) 3.1
5VEN MURINE ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE 5 (ENPP5, NPP5) 3.1
5VEO MURINE ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE 5 (ENPP5, NPP5), INACTIVE (T72A), IN COMPLEX WITH AMP 3.1
5VET PHOSPHOLIPASE A2, RE-REFINEMENT OF THE PDB STRUCTURE 1JQ8 WITHOUT THE PUTATIVE COMPLEXED OLIGOPEPTIDE 3.1.1.4
5VEW STRUCTURE OF THE HUMAN GLP-1 RECEPTOR COMPLEX WITH PF-06372222 3.2.1.17
5VEX STRUCTURE OF THE HUMAN GLP-1 RECEPTOR COMPLEX WITH NNC0640 3.2.1.17
5VFD DIAZABICYCLOOCTENONE ETX2514 BOUND TO CLASS D BETA LACTAMASE OXA-24 FROM A. BAUMANNII 3.5.2.6
5VFO NUCLEOTIDE-DRIVEN TRIPLE-STATE REMODELING OF THE AAA-ATPASE CHANNEL IN THE ACTIVATED HUMAN 26S PROTEASOME 3.4.25.1
5VG0 ROOM TEMPERATURE X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A JONESIA DENITRIFICANS LYTIC POLYSACCHARIDE MONOOXYGENASE AT 1.1 ANGSTROM RESOLUTION. 3.2.1.14
5VGB CRYSTAL STRUCTURE OF NMECAS9 HNH DOMAIN BOUND TO ANTI-CRISPR ACRIIC1 3.1
5VGM CRYSTAL STRUCTURE OF DIHYDROOROTASE PYRC FROM VIBRIO CHOLERAE IN COMPLEX WITH ZINC AT 1.95 A RESOLUTION. 3.5.2.3
5VGR HUMAN ATLASTIN-3, GDP-BOUND 3.6.5
5VGV STRUCTURE OF THE C. BOTULINUM NEUROTOXIN SEROTYPE A WITH CU BOUND 3.4.24.69
5VGX STRUCTURE OF THE C. BOTULINUM NEUROTOXIN SEROTYPE A WITH HG BOUND 3.4.24.69
5VHA DHX36 WITH AN N-TERMINAL TRUNCATION 3.6.4.12
3.6.4.13
5VHC DHX36 WITH AN N-TERMINAL TRUNCATION BOUND TO ADP-BEF3 3.6.4.12
3.6.4.13
5VHD DHX36 WITH AN N-TERMINAL TRUNCATION BOUND TO ADP-ALF4 3.6.4.12
3.6.4.13
5VHE DHX36 IN COMPLEX WITH THE C-MYC G-QUADRUPLEX 3.6.4.12
3.6.4.13
5VI6 CRYSTAL STRUCTURE OF HISTONE DEACETYLASE 8 IN COMPLEX WITH TRAPOXIN A 3.5.1.98
5VI7 CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE 3.6.4.13
3.4.21.91
3.6.1.15
2.1.1.56
2.1.1.57
2.7.7.48
5VID RECEPTOR BINDING DOMAIN OF BONT/B IN COMPLEX WITH MINI-PROTEIN BINDER BOT.0671.2 3.4.24.69
5VIM CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS5 METHYLTRANSFERASE. 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5VJ3 HIV PROTEASE (PR) IN OPEN FORM WITH MG2+ IN ACTIVE SITE AND HIVE-9 IN EYE SITE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5VJO COMPLEX BETWEEN HYHEL10 FAB FRAGMENT HEAVY CHAIN MUTANT I29F AND PEKIN DUCK EGG LYSOZYME ISOFORM I (DEL-I) 3.2.1.18
5VJQ COMPLEX BETWEEN HYHEL10 FAB FRAGMENT HEAVY CHAIN MUTANT (I29F, S52T, Y53F) AND PEKIN DUCK EGG LYSOZYME ISOFORM I (DEL-I) 3.2.1.18
5VJV RHIZOBIALES-LIKE PHOSPHATASE 2 3.1.3.48
5VJW ARABIDOPSIS THALIANA RHIZOBIALES-LIKE PHOSPHATASE 2 COMPLEXED WITH TUNGSTATE 3.1.3.48
5VJY CRYSTAL STRUCTURE OF DUTP PYROPHOSPHATASE PROTEIN, FROM NAEGLERIA FOWLERI 3.6.1.23
5VL7 PCSK9 COMPLEX WITH FAB33 3.4.21
5VLA SHORT PCSK9 DELTA-P' COMPLEX WITH FUSION2 PEPTIDE 3.4.21
5VLE ULTRAHIGH RESOLUTION X-RAY CRYSTAL STRUCTURE OF RUTHENOCENE CONJUGATED PENICILLOATE AND PENILLOATE PRODUCTS IN COMPLEX WITH CTX-M-14 E166A BETA-LACTAMASE 3.5.2.6
5VLH SHORT PCSK9 DELTA-P' COMPLEX WITH PEPTIDE PEP1 3.4.21
5VLK SHORT PCSK9 DELTA-P' COMPLEX WITH SHRUNKEN PEPTIDE BEARING HOMO-ARGININE 3.4.21
5VLL SHORT PCSK9 DELTA-P' COMPLEX WITH PEPTIDE PEP3 3.4.21
5VM9 HUMAN ARGONAUTE3 BOUND TO GUIDE RNA 3.1.26
5VMR RECEPTOR BINDING DOMAIN OF BONT/B IN COMPLEX WITH MINI-PROTEIN BINDER BOT.2110.4 3.4.24.69
5VNP X-RAY CRYSTAL STRUCTURE OF HALOTAG BOUND TO THE P1 BENZOXADIAZOLE FLUOROGENIC LIGAND 3.8.1.5
5VNR X-RAY STRUCTURE OF PERDEUTERATED T4 LYSOZYME CYSTEINE-FREE PSEUDO-WILD TYPE AT CRYOGENIC TEMPERATURE 3.2.1.17
5VO3 CRYSTAL STRUCTURE OF DAPE IN COMPLEX WITH THE PRODUCTS (SUCCINIC ACID AND DIAMINOPIMELIC ACID) 3.5.1.18
5VOJ CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH JZ01-15, AN ANALOGUE OF 5172-MCP1P3 3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5VP0 DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4-(TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-2,3-DIHYDROPYRIDO[2,3-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915), A HIGHLY POTENT, SELECTIVE, AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS 3.1.4.17
5VP1 DISCOVERY OF CLINICAL CANDIDATE N-{(1S)-1-[3-FLUORO-4-(TRIFLUOROMETHOXY)PHENYL]-2-METHOXYETHYL}-7-METHOXY-2-OXO-2,3-DIHYDROPYRIDO[2,3-B]PYRAZINE-4(1H)-CARBOXAMIDE (TAK-915), A HIGHLY POTENT, SELECTIVE, AND BRAIN-PENETRATING PHOSPHODIESTERASE 2A INHIBITOR FOR THE TREATMENT OF COGNITIVE DISORDERS 3.1.4.17
5VP7 CRYSTAL STRUCTURE OF HUMAN KRAS G12A MUTANT IN COMPLEX WITH GDP 3.6.5.2
5VP8 I38T MUTANT OF 2009 H1N1 PA ENDONUCLEASE 3.1
5VP9 CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH AM-07, AN ANALOGUE OF 5172-MCP1P3 3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5VPH CRYSTAL STRUCTURE OF DER P 1 COMPLEXED WITH FAB 4C1 3.4.22.65
5VPI CRYSTAL STRUCTURE OF HUMAN KRAS G12A MUTANT IN COMPLEX WITH GTP 3.6.5.2
5VPK CRYSTAL STRUCTURE OF MITE ALLERGEN DER F 1 3.4.22.65
5VPL CRYSTAL STRUCTURE OF DER F 1 COMPLEXED WITH FAB 4C1 3.4.22.65
5VPM CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL 3.4.23.15
5VPQ CRYSTAL STRUCTURE OF BETA-LACTAMASE FROM BURKHOLDERIA PHYMATUM 3.5.2.6
5VPT 2009 H1N1 PA ENDONUCLEASE IN COMPLEX WITH RO-7 3.1
5VPX I38T MUTANT OF 2009 H1N1 PA ENDONUCLEASE IN COMPLEX WITH RO-7 3.1
5VPY CRYSTAL STRUCTURE OF HUMAN KRAS G12A MUTANT IN COMPLEX WITH GPPNHP 3.6.5.2
5VPZ CRYSTAL STRUCTURE OF HUMAN KRAS G12A MUTANT IN COMPLEX WITH GTP-GAMMA-S 3.6.5.2
5VQ0 CRYSTAL STRUCTURE OF HUMAN KRAS G12A MUTANT IN COMPLEX WITH GDP (EDTA SOAKED) 3.6.5.2
5VQ1 CRYSTAL STRUCTURE OF HUMAN KRAS Q61A MUTANT IN COMPLEX WITH GDP 3.6.5.2
5VQ2 CRYSTAL STRUCTURE OF HUMAN WT-KRAS IN COMPLEX WITH GTP 3.6.5.2
5VQ6 CRYSTAL STRUCTURE OF HUMAN WT-KRAS IN COMPLEX WITH GTP-GAMMA-S 3.6.5.2
5VQ8 CRYSTAL STRUCTURE OF HUMAN WT-KRAS IN COMPLEX WITH GDP (EDTA SOAKED) 3.6.5.2
5VQN E119D MUTANT OF 2009 H1N1 PA ENDONUCLEASE IN COMPLEX WITH RO-7 3.1
5VQQ CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-2-FLUORO-N-METHYLACETAMIDE (JLJ683), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQR CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-N-METHYLACRYLAMIDE (JLJ684), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQS CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)ACRYLAMIDE (JLJ685), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQT CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 2-CHLORO-N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-N-METHYLACETAMIDE (JLJ686), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQU CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-2-FLUORO-N-METHYLACETAMIDE (JLJ683), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQV CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-N-METHYLACRYLAMIDE (JLJ684), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQW CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)ACRYLAMIDE (JLJ685), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQX CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH 2-CHLORO-N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-N-METHYLACETAMIDE (JLJ686), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQY CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (K103N, Y181C) VARIANT IN COMPLEX WITH N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-N-METHYLACRYLAMIDE (JLJ684), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VQZ CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (K103N, Y181C) VARIANT IN COMPLEX WITH 2-CHLORO-N-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)-N-METHYLACETAMIDE (JLJ686), A NON-NUCLEOSIDE INHIBITOR 2.7.7.49
2.7.7.7
3.1.26.13
3.4.23.16
3.1.13.2
2.7.7
3.1
5VR6 STRUCTURE OF HUMAN STS-1 HISTIDINE PHOSPHATASE DOMAIN WITH SULFATE BOUND 3.1.3.48
5VRI CRYSTAL STRUCTURE OF SSOPOX ASA6 MUTANT (F46L-C258A-W263M-I280T) - CLOSED FORM 3.1.8.1
5VRJ 2009 H1N1 PA ENDONUCLEASE IN COMPLEX WITH RO-7 AND MAGNESIUM 3.1
5VRK CRYSTAL STRUCTURE OF SSOPOX ASA6 MUTANT (F46L-C258A-W263M-I280T) - OPEN FORM 3.1.8.1
5VRP CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL 3.4.23.15
5VS6 STRUCTURE OF DUB COMPLEX 3.4.19.12
5VSA CRYSTAL STRUCTURE OF SSOPOX ASA1 MUTANT (C258L-I261F-W263A) 3.1.8.1
5VSB STRUCTURE OF DUB COMPLEX 3.4.19.12
5VSK STRUCTURE OF DUB COMPLEX 3.4.19.12
5VTH CTX-M-14 P167S:E166A MUTANT 3.5.2.6
5VU2 ELECTRON CRYO-MICROSCOPY OF IMMATURE" CHIKUNGUNYA VLP" 3.4.21.90
5VVK CAS1-CAS2 BOUND TO FULL-SITE MIMIC 3.1
5VVL CAS1-CAS2 BOUND TO FULL-SITE MIMIC WITH NI 3.1
5VVO STRUCTURAL INVESTIGATIONS OF THE SUBSTRATE SPECIFICITY OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5VVT STRUCTURAL INVESTIGATIONS OF THE SUBSTRATE SPECIFICITY OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5VVU STRUCTURAL INVESTIGATIONS OF THE SUBSTRATE SPECIFICITY OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5VVV STRUCTURAL INVESTIGATIONS OF THE SUBSTRATE SPECIFICITY OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5VVX STRUCTURAL INVESTIGATIONS OF THE SUBSTRATE SPECIFICITY OF HUMAN O-GLCNACASE 3.2.1.169
3.2.1
5VW1 CRYSTAL STRUCTURE OF SPYCAS9-SGRNA-ACRIIA4 TERNARY COMPLEX 3.1
5VWM CRYSTAL STRUCTURE OF UDP-3-O-[3-HYDROXYMYRISTOYL] N-ACETYLGLUCOSAMINE DEACETYLASE (LPXC) FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH CHIR-090 INHIBITOR 3.5.1.108
5VXA STRUCTURE OF THE HUMAN MESH1-NADPH COMPLEX 3.1.7.2
5VXC CRYSTAL STRUCTURE ANALYSIS OF HUMAN CLYBL IN COMPLEX WITH FREE COASH 4.1.3.25
3.1.2.30
2.3.3
2.3.3.9
5VXO CRYSTAL STRUCTURE ANALYSIS OF HUMAN CLYBL IN COMPLEX WITH PROPIONYL-COA 4.1.3.25
3.1.2.30
2.3.3
2.3.3.9
5VXS CRYSTAL STRUCTURE ANALYSIS OF HUMAN CLYBL IN APO FORM 4.1.3.25
3.1.2.30
2.3.3
2.3.3.9
5VY2 CRYSTAL STRUCTURE OF THE F36A MUTANT OF HSNUDT16 3.6.1.62
3.6.1.64
5VY3 THERMOPLASMA ACIDOPHILUM 20S PROTEASOME USING 200KEV WITH STAGE POSITION 3.4.25.1
5VY4 THERMOPLASMA ACIDOPHILUM 20S PROTEASOME USING 200KEV WITH IMAGE SHIFT 3.4.25.1
5VYD CRYSTAL STRUCTURE OF PHOSPHODIESTERASE DOMAIN OF RHOPDE FUSION PROTEIN FROM THE CHOANOFLAGELLATE SALPINGOECA ROSETTA 3.1.4
5VYG CRYSTAL STRUCTURE OF HFA9 EGF REPEAT WITH O-GLUCOSE TRISACCHARIDE 3.4.21.22
5VYL CRYSTAL STRUCTURE OF N-TERMINAL HALF OF HERPES SIMPLEX VIRUS TYPE 1 UL37 PROTEIN 3.5.1
3.5.1.44
5VYM CRYSTAL STRUCTURE OF BETA-GALACTOSIDASE FROM BIFIDOBACTERIUM ADOLESCENTIS 3.2.1.23
5VZ2 STRUCTURE OF CLPP FROM STAPHYLOCOCCUS AUREUS IN COMPLEX WITH ACYLDEPSIPEPTIDE 3.4.21.92
5VZ6 HIV REVERSE TRANSCRIPTASE COMPLEXED WITH (E)-3-(PYRIMIDIN-2-YL)-N-(5-(5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)-1H-PYRAZOL-3-YL)ACRYLAMIDE 2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
5VZL CRYO-EM STRUCTURE OF THE CAS9-SGRNA-ACRIIA4 ANTI-CRISPR COMPLEX 3.1
5W0A CRYSTAL STRUCTURE OF TRICHODERMA HARZIANUM ENDOGLUCANASE I 3.2.1
5W0R CRYSTAL STRUCTURE OF MBP FUSED ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID) IN COMPLEX WITH CACODYLIC ACID 3.5.4.38
5W0U CRYSTAL STRUCTURE OF MBP FUSED ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID) IN COMPLEX WITH DCMP 3.5.4.38
5W0Z CRYSTAL STRUCTURE OF MBP FUSED ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID) 3.5.4.38
5W11 BIOCHEMICAL AND STRUCTURAL INSIGHTS INTO THE CATALYTIC MECHANISM OF THERMOSTABLE CELLOBIOHYDROLASE CEL7A FROM INDUSTRIALLY RELEVANT FUNGUS MYCELIOPHTHORA THERMOPHILA 3.2.1.176
3.2.1
5W12 ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR EC04 3.5.2.6
5W13 ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR SM23 3.5.2.6
5W14 ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR S03043 3.5.2.6
5W18 STAPHYLOCOCCUS AUREUS CLPP IN COMPLEX WITH (S)-N-((2R,6S,8AS,14AS,20S,23AS)-2,6-DIMETHYL-5,8,14,19,23-PENTAOXOOCTADECAHYDRO-1H,5H,14H,19H-PYRIDO[2,1-I]DIPYRROLO[2,1-C:2',1'-L][1]OXA[4,7,10,13]TETRAAZACYCLOHEXADECIN-20-YL)-3-PHENYL-2-(3-PHENYLUREIDO)PROPANAMIDE 3.4.21.92
5W1C CRYSTAL STRUCTURE OF MBP FUSED ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID) IN COMPLEX WITH CYTIDINE 3.5.4.38
5W1U CULEX QUINQUEFASCIATUS CARBOXYLESTERASE B2 3.1.1
5W21 CRYSTAL STRUCTURE OF A 1:1:1 FGF23-FGFR1C-AKLOTHO TERNARY COMPLEX 3.2.1.31
5W22 CRYSTAL STRUCTURE OF HUMAN WT-KRAS IN COMPLEX WITH GDP 3.6.5.2
5W26 INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 4-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID 3.2.1.18
5W2E HCV NS5B RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH NON-NUCLEOSIDE INHIBITOR MK-8876 3.4.22
3.4.21.98
3.6.1.15
3.6.4.13
2.7.7.48
5W2J CRYSTAL STRUCTURE OF DIMERIC FORM OF MOUSE GLUTAMINASE C 3.5.1.2
5W2U INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 7-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID 3.2.1.18
5W2W INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 8-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID 3.2.1.18
5W2Y INFLUENZA VIRUS NEURAMINIDASE N9 IN COMPLEX WITH 9-DEOXYGENATED 2,3-DIFLUORO-N-ACETYLNEURAMINIC ACID 3.2.1.18
5W3E CRYOEM STRUCTURE OF RHINOVIRUS B14 IN COMPLEX WITH C5 FAB (33 DEGREES CELSIUS, MOLAR RATIO 1:3, FULL PARTICLE) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5W3I CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 6E (SRI-29685) 3.1
5W3L CRYOEM STRUCTURE OF RHINOVIRUS B14 IN COMPLEX WITH C5 FAB (4 DEGREES CELSIUS, MOLAR RATIO 1:3, FULL PARTICLE) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5W3M CRYOEM STRUCTURE OF RHINOVIRUS B14 IN COMPLEX WITH C5 FAB (33 DEGREES CELSIUS, MOLAR RATIO 1:1, FULL PARTICLE) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5W3O CRYOEM STRUCTURE OF RHINOVIRUS B14 IN COMPLEX WITH C5 FAB (33 DEGREES CELSIUS, MOLAR RATIO 1:3, EMPTY PARTICLE) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5W3U CRYSTAL STRUCTURE OF SSOPOX ASB5 MUTANT (V27A-I76T-Y97W-Y99F-L130P-L226V) 3.1.8.1
5W3W CRYSTAL STRUCTURE OF SSOPOX ASD6 MUTANT (V27A-Y97W-L228M-W263M) - OPEN FORM 3.1.8.1
5W3Z CRYSTAL STRUCTURE OF SSOPOX ASC6 MUTANT (L72I-Y99F-I122L-L228M-F229S-W263L) 3.1.8.1
5W44 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 7A (SRI-29770) 3.1
5W49 THE CRYSTAL STRUCTURE OF HUMAN S-ADENOSYLHOMOCYSTEINE HYDROLASE (AHCY) BOUND TO OXADIAZOLE INHIBITOR 3.3.1.1
5W5G STRUCTURE OF HUMAN STS-1 HISTIDINE PHOSPHATASE DOMAIN 3.1.3.48
5W5W HIV PROTEASE (PR) IN OPEN FORM WITH MG2+ IN ACTIVE SITE AND HIVE-9 IN EYE SITE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5W6B PHOSPHOTRIESTERASE VARIANT S1 3.1.8.1
5W6E PDE1B COMPLEXED WITH COMPOUND 3S 3.1.4.17
5W6X CRYSTAL STRUCTURE OF THE HSNUDT16 IN COMPLEX WITH MG+2 AND ADP-RIBOSE 3.6.1.62
3.6.1.64
5W6Z CRYSTAL STRUCTURE OF THE H24W MUTANT OF HSNUDT16 3.6.1.62
3.6.1.64
5W73 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 9F (SRI-29835) 3.1
5W78 HUMAN ACYLOXYACYL HYDROLASE (AOAH), PROTEOLYTICALLY PROCESSED 3.1.1.77
5W7A RABBIT ACYLOXYACYL HYDROLASE (AOAH), PROTEOLYTICALLY PROCESSED, S262A MUTANT, WITH LPS (LOW QUALITY SAPOSIN DOMAIN) 3.1.1.77
5W7B RABBIT ACYLOXYACYL HYDROLASE (AOAH), PROTEOLYTICALLY PROCESSED, S262A MUTANT, WITH LPS 3.1.1.77
5W7C HUMAN ACYLOXYACYL HYDROLASE (AOAH), PROTEOLYTICALLY PROCESSED, S263A MUTANT, WITH LPS 3.1.1.77
5W7D MURINE ACYLOXYACYL HYDROLASE (AOAH), S262A MUTANT 3.1.1.77
5W7E MURINE ACYLOXYACYL HYDROLASE (AOAH), S262A MUTANT, WITH DIMYRISTOYL PHOSPHATIDYLCHOLINE 3.1.1.77
5W7F MURINE ACYLOXYACYL HYDROLASE (AOAH), S262A MUTANT, WITH LIPID A 3.1.1.77
5W7M CRYSTAL STRUCTURE OF ROQN 3.1.1
5W7N 2-SE-T2/4-DNA AND NATIVE RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5W7O 2-SE-T4-DNA AND NATIVE RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5W7U CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 8F (SRI-29928) 3.1
5W7W CRYSTAL STRUCTURE OF FHA DOMAIN OF HUMAN APLF 4.2.99.18
3.1
5W7X CRYSTAL STRUCTURE OF FHA DOMAIN OF HUMAN APLF IN COMPLEX WITH XRCC1 BISPHOSPHO PEPTIDE 4.2.99.18
3.1
5W7Y CRYSTAL STRUCTURE OF FHA DOMAIN OF HUMAN APLF IN COMPLEX WITH XRCC1 MONOPHOSPHORYLATED MUTATED PEPTIDE 4.2.99.18
3.1
5W81 PHOSPHORYLATED, ATP-BOUND STRUCTURE OF ZEBRAFISH CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) 3.6.3.49
5.6.1.6
5W8T CRYSTAL STRUCTURE OF MERS-COV PAPAIN-LIKE PROTEASE IN COMPLEX WITH THE C-TERMINAL DOMAIN OF HUMAN ISG15 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5W8U CRYSTAL STRUCTURE OF MERS-COV PAPAIN-LIKE PROTEASE IN COMPLEX WITH THE C-TERMINAL DOMAIN OF HUMAN ISG15 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5W8W BACILLUS CEREUS ZN-DEPENDENT METALLO-BETA-LACTAMASE AT PH 7 - NEW REFINEMENT 3.5.2.6
5W90 FEZ-1 METALLO-BETA-LACTAMASE FROM LEGIONELLA GORMANII MODELLED WITH UNKNOWN LIGAND 3.5.2.6
5W92 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH AN INHIBITOR - SRI-30049 3.1
5W95 MTB RV3802C WITH PEG BOUND 3.1.1
5W9G CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 9K (SRI-30023) 3.1
5WA6 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH AN INHIBITOR - SRI-30007 3.1
5WA7 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 9B (SRI-30101) 3.1
5WA8 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT NUCLEOSIDE L-ALA PHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5WA9 HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N MUTANT NUCLEOSIDE D-ALA PHOSPHORAMIDATE SUBSTRATE COMPLEX 3
5WAA HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) C84R MUTANT 3
5WAC ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR CR157 3.5.2.6
5WAD ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR CR161 3.5.2.6
5WAE ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR CR167 3.5.2.6
5WAF ADC-7 IN COMPLEX WITH BORONIC ACID TRANSITION STATE INHIBITOR CR192 3.5.2.6
5WAP CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 10I (SRI-30025) 3.1
5WB3 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 10J (SRI-30026) 3.1
5WB6 FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(11S)-11-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-6-FLUORO-2-OXO-1,3,4,10,11,13-HEXAHYDRO-2H-5,9:15,12-DI(AZENO)-1,13-BENZODIAZACYCLOHEPTADECIN-18-YL]CARBAMATE 3.4.21.27
5WBN CRYSTAL STRUCTURE OF FRAGMENT 3-(3-BENZYL-2-OXO-2H-[1,2,4]TRIAZINO[2,3-C]QUINAZOLIN-6-YL)PROPANOIC ACID BOUND IN THE UBIQUITIN BINDING POCKET OF THE HDAC6 ZINC-FINGER DOMAIN 3.5.1.98
3.5.1
5WC0 KATANIN HEXAMER IN SPIRAL CONFORMATION 3.6.4.3
5.6.1.1
5WC1 KATANIN AAA ATPASE DOMAIN 3.6.4.3
5.6.1.1
5WCB KATANIN HEXAMER IN THE RING CONFORMATION 3.6.4.3
5.6.1.1
5WCH CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN USP9X 3.4.19.12
5WCK NATIVE FEZ-1 METALLO-BETA-LACTAMASE FROM LEGIONELLA GORMANII 3.5.2.6
5WCQ PHOSPHOTRIESTERASE VARIANT S2 3.1.8.1
5WCS CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 6B (SRI-29789) 3.1
5WCT CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 6C (SRI-29775) 3.1
5WCZ CRYSTAL STRUCTURE OF WILD-TYPE MALL FROM BACILLUS SUBTILIS WITH TS ANALOGUE 1-DEOXYNOJIRIMYCIN 3.2.1.10
5WDC CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 9E (SRI-29843) 3.1
5WDN CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 6D (SRI-29680) 3.1
5WDO H-RAS BOUND TO GMP-PNP AT 277K 3.6.5.2
5WDP H-RAS MUTANT L120A BOUND TO GMP-PNP AT 277K 3.6.5.2
5WDQ H-RAS MUTANT L120A BOUND TO GMP-PNP AT 100K 3.6.5.2
5WDR CHOANOFLAGELLATE SALPINGOECA ROSETTA RAS WITH GMP-PNP 3.6.5.2
5WDS CHOANOFLAGELLATE SALPINGOECA ROSETTA RAS WITH GDP BOUND 3.6.5.2
5WDW CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 10K (SRI-30027) 3.1
5WDX STRUCTURE OF NS3 FROM HCV STRAIN JFH-1 THAT IS AN UNUSUALLY ROBUST HELICASE THAT IS PRIMED TO BIND AND UNWIND VIRAL RNA 2.7.7.48
3.4.21.98
3.6.1.15
3.6.4.13
5WE7 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH AN INHIBITOR - SRI-29782 3.1
5WE9 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE IN COMPLEX WITH INHIBITOR 7B (SRI-29731) 3.1
5WEA HUMAN ARGONAUTE2 HELIX-7 MUTANT 3.1.26
5WEF CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE (F105S MUTANT) IN COMPLEX WITH INHIBITOR 7A (SRI-29770) 3.1
5WEI CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE (E119D MUTANT) IN COMPLEX WITH INHIBITOR 7A (SRI-29770) 3.1
5WEJ 1.95 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A DIPEPTIDYL OXAZOLIDINONE-BASED INHIBITOR 3.6.1.15
3.4.22.66
2.7.7.48
5WF3 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE (E119D MUTANT) IN COMPLEX WITH INHIBITOR 9K (SRI-30023) 3.1
5WF5 AGONIST BOUND HUMAN A2A ADENOSINE RECEPTOR WITH D52N MUTATION AT 2.60 A RESOLUTION 3.2.1.17
5WF6 AGONIST BOUND HUMAN A2A ADENOSINE RECEPTOR WITH S91A MUTATION AT 2.90 A RESOLUTION 3.2.1.17
5WFE CAS1-CAS2-IHF-DNA HOLO-COMPLEX 3.1
5WFI X-RAY STRUCTURE OF MHV PLP2 (CYS1716SER) CATALYTIC MUTANT IN COMPLEX WITH FREE UBIQUITIN 3.4.22
3.4.19.12
3.4.22.69
2.7.7.48
3.6.4.12
3.6.4.13
2.1.1
3.1.13
3.1
5WFW CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE (E119D MUTANT) IN COMPLEX WITH INHIBITOR 10J (SRI-30026) 3.1
5WFZ CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE (E119D MUTANT) IN COMPLEX WITH INHIBITOR 8E (SRI-30049) 3.1
5WG8 STRUCTURE OF PP5C WITH LB-100; 7-OXABICYCLO[2.2.1]HEPTANE-2,3-DICARBONYL MOIETY MODELED IN THE DENSITY 3.1.3.16
5WG9 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS PA ENDONUCLEASE (E119D MUTANT) IN COMPLEX WITH INHIBITOR 9B (SRI-30101) 3.1
5WH5 CRYSTAL STRUCTURE OF THE PDE4D2 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR (R)-ZL-N-91 3.1.4.53
5WH6 CRYSTAL STRUCTURE OF PDE4D2 IN COMPLEX WITH INHIBITOR (S_ZL-N-91) 3.1.4.53
5WHB KRAS G12V, BOUND TO GDP AND MINIPROTEIN 225-11(A30R) 3.6.5.2
5WHC USP7 IN COMPLEX WITH CPD2 (4-(3-(1-METHYLPIPERIDIN-4-YL)-1,2,4-OXADIAZOL-5-YL)PHENOL) 3.4.19.12
5WHD CRYSTAL STRUCTURE OF KRAS G12V/D38P, BOUND TO GDP 3.6.5.2
5WHE KRAS G12V/D38P, BOUND TO GPPNHP AND MINIPROTEIN 225-11 3.6.5.2
5WHW USING SOUND PULSES TO SOLVE THE CRYSTAL HARVESTING BOTTLENECK 3.4.21.64
5WI3 STRUCTURE OF ACINETOBACTER BAUMANNII CARBAPENEMASE OXA-239 K82D BOUND TO CEFOTAXIME 3.5.2.6
5WI6 HUMAN BETA-1 TRYPTASE MUTANT ILE99CYS 3.4.21.59
5WI7 STRUCTURE OF ACINETOBACTER BAUMANNII CARBAPENEMASE OXA-239 K82D BOUND TO DORIPENEM 3.5.2.6
5WIB STRUCTURE OF ACINETOBACTER BAUMANNII CARBAPENEMASE OXA-239 K82D BOUND TO IMIPENEM 3.5.2.1
5WIG STRUCTURE OF NEW DELHI METALLO-BETA-LACTAMASE 4 (NDM-4) 3.5.2.6
5WJ6 CRYSTAL STRUCTURE OF GLUTAMINASE C IN COMPLEX WITH INHIBITOR 2-PHENYL-N-{5-[4-({5-[(PHENYLACETYL)AMINO]-1,3,4-THIADIAZOL-2-YL}AMINO)PIPERIDIN-1-YL]-1,3,4-THIADIAZOL-2-YL}ACETAMIDE (UPGL-00004) 3.5.1.2
5WJG USING SOUND PULSES TO SOLVE THE CRYSTAL HARVESTING BOTTLENECK 3.4.21.64
5WJH USING SOUND PULSES TO SOLVE THE CRYSTAL HARVESTING BOTTLENECK 3.4.21.64
5WJI CRYSTAL STRUCTURE OF THE F61S MUTANT OF HSNUDT16 3.6.1.62
3.6.1.64
5WJR HIGH RESOLUTION NATIVE HEXAMER DNA AND RNA HYBRID IN COMPLEX WITH RNASE H CATALYTIC DOMAIN D132N MUTANT 3.1.26.4
5WKJ 2.05 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR GC376 3.4.19.12
3.4.22.69
3.4.22
5WKK 1.55 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR GC813 3.4.19.12
3.4.22.69
3.4.22
5WKL 1.85 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH PIPERIDINE-BASED PEPTIDOMIMETIC INHIBITOR 17 3.4.19.12
3.4.22.69
3.4.22
5WKM 2.25 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH PIPERIDINE-BASED PEPTIDOMIMETIC INHIBITOR 21 3.4.19.12
3.4.22.69
3.4.22
5WLB KRAS G12V, BOUND TO GPPNHP AND MINIPROTEIN 225-15A/B 3.6.5.2
5WLE CRYSTAL STRUCTURE OF THE PPS PHD FINGER IN COMPLEX WITH H3K4ME3 3.6
5WLF CRYSTAL STRUCTURE OF THE APO PPS PHD FINGER 3.6
5WLO A NOVEL 13-RING MACROCYCLIC HIV-1 PROTEASE INHIBITORS INVOLVING THE P1'-P2' LIGANDS 2.7.7.49
3.1.13.2
3.1.26.13
5WLY E. COLI LPXH- 8 MUTATIONS 3.6.1.54
5WN0 APE1 EXONUCLEASE SUBSTRATE COMPLEX WITH A C/G MATCH 3.1
4.2.99.18
5WN1 APE1 EXONUCLEASE PRODUCT COMPLEX 3.1
4.2.99.18
5WN2 APE1 EXONUCLEASE SUBSTRATE COMPLEX WITH PHOSPHOGLYCOLATE 3.1
4.2.99.18
5WN3 APE1 F266A EXONUCLEASE SUBSTRATE COMPLEX WITH A C/T MISMATCH 3.1
4.2.99.18
5WN4 APE1 EXONUCLEASE SUBSTRATE COMPLEX WITH A C/T MISMATCH 3.1
4.2.99.18
5WN5 APE1 EXONUCLEASE SUBSTRATE COMPLEX WITH A C/T MISMATCH AND MN2+ 3.1
4.2.99.18
5WOT NMR SOLUTION STRUCTURE OF A-LYTIC PROTEASE USING TWO 4D-SPECTRA 3.4.21.12
5WPB CRYSTAL STRUCTURE OF FRAGMENT 3-(3-(PYRIDIN-2-YLMETHOXY)QUINOXALIN-2-YL)PROPANOIC ACID BOUND IN THE UBIQUITIN BINDING POCKET OF THE HDAC6 ZINC-FINGER DOMAIN 3.5.1.98
3.5.1
5WPL KRAS G12V, BOUND TO GPPNHP AND MINIPROTEIN 225-11 3.6.5.2
5WPM KRAS G12V, BOUND TO GPPNHP AND MINIPROTEIN 225-11(A30R) 3.6.5.2
5WQ3 CRYSTAL STRUCTURE OF TYPE-II LOG FROM CORYNEBACTERIUM GLUTAMICUM 3.2.2
5WQA CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN COMPLEXED WITH SELAGINPULVILINS K 3.1.4.53
5WQE CRYSTAL STRUCTURE OF ALICYCLOBACILLUS ACIDOTERRESTRIS C2C1 IN COMPLEX WITH SINGLE-GUIDE RNA AT 3.1 ANGSTROM RESOLUTION 3.1
5WQS CRYSTAL STRUCTURE OF APO BETA-AMYLASE FROM SWEET POTATO 3.2.1.2
5WQU CRYSTAL STRUCTURE OF SWEET POTATO BETA-AMYLASE COMPLEXED WITH MALTOTETRAOSE 3.2.1.2
5WR2 THERMOLYSIN, SFX LIGANDED FORM WITH OIL-BASED CARRIER 3.4.24.27
5WR3 THERMOLYSIN, SFX LIGANDED FORM WITH WATER-BASED CARRIER 3.4.24.27
5WR4 THERMOLYSIN, SFX UNLIGANDED FORM WITH OIL-BASED CARRIER 3.4.24.27
5WR5 THERMOLYSIN, LIGANDED FORM WITH CRYO CONDITION 1 3.4.24.27
5WR6 THERMOLYSIN, LIGANDED FORM WITH CRYO CONDITION 2 3.4.24.27
5WR9 CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME 3.2.1.17
5WRA CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME 3.2.1.17
5WRB CRYSTAL STRUCTURE OF HEN EGG-WHITE LYSOZYME 3.2.1.17
5WRC CRYSTAL STRUCTURE OF PROTEINASE K FROM ENGYODONTIUM ALBUM 3.4.21.64
5WRT CRYSTAL STRUCTURE OF TYPE I INORGANIC PYROPHOSPHATASE FROM TOXOPLASMA GONDII. 3.6.1.1
5WRU CRYSTAL STRUCTURE OF TYPE I INORGANIC PYROPHOSPHATASE FROM P FALCIPARUM 3.6.1.1
5WS2 CRYSTAL STRUCTURE OF MPY-RNASE J (MUTANT S247A), AN ARCHAEAL RNASE J FROM METHANOLOBUS PSYCHROPHILUS R15, COMPLEX WITH RNA 3.1
5WS4 CRYSTAL STRUCTURE OF TRIPARTITE-TYPE ABC TRANSPORTER MACB FROM ACINETOBACTER BAUMANNII 3.6.3
7.6.2
5WS7 CRYSTAL STRUCTURE OF HUMAN MTH1(G2K/C87A/C104S MUTANT) IN COMPLEX WITH 2-OXO-DATP 3.6.1.55
3.6.1.56
5WSN STRUCTURE OF JAPANESE ENCEPHALITIS VIRUS 3.4.21.91
3.6.1.15
3.6.4.13
5WTE CRYO-EM STRUCTURE FOR HEPATITIS A VIRUS FULL PARTICLE 3.6.1.15
3.4.22.28
2.7.7.48
5WTF CRYO-EM STRUCTURE FOR HEPATITIS A VIRUS EMPTY PARTICLE 3.6.1.15
3.4.22.28
2.7.7.48
5WTH CRYO-EM STRUCTURE FOR HEPATITIS A VIRUS COMPLEXED WITH FAB 3.6.1.15
3.4.22.28
2.7.7.48
5WTJ CRYSTAL STRUCTURE OF AN ENDONUCLEASE 3.1
5WTK CRYSTAL STRUCTURE OF RNP COMPLEX 3.1
5WUG EXPRESSION, CHARACTERIZATION AND CRYSTAL STRUCTURE OF A NOVEL BETA-GLUCOSIDASE FROM PAENIBACILLUS BARENGOLTZII 3.2.1.21
5WUP CRYSTAL STRUCTURE OF A INSECT GROUP III CHITINASE (CAD1) FROM OSTRINIA FURNACALIS 3.2.1.14
5WUS CRYSTAL STRUCTURE OF A INSECT GROUP III CHITINASE (CAD2) FROM OSTRINIA FURNACALIS 3.2.1.14
5WV1 CRYSTAL STRUCTURE OF THE COMPLEX OF RIBOSOME INACTIVATING PROTEIN FROM MOMORDICA BALSAMINA WITH RIBOSE SUGAR AT 1.90 A RESOLUTION. 3.2.2.22
5WV8 CRYSTAL STRUCTURE OF A MUTANT INSECT GROUP III CHITINASE (CAD1-E217L) FROM OSTRINIA FURNACALIS 3.2.1.14
5WV9 CRYSTAL STRUCTURE OF A INSECT GROUP III CHITINASE COMPLEX WITH (GLCNAC)6 (CAD1-(GLCNAC)6 ) FROM OSTRINIA FURNACALIS 3.2.1.14
5WVB CRYSTAL STRUCTURE OF A MUTANT INSECT GROUP III CHITINASE COMPLEX WITH (GLCNAC)6 (CAD1-E217L-(GLCNAC)6 ) FROM OSTRINIA FURNACALIS 3.2.1.14
5WVF CRYSTAL STRUCTURE OF A MUTANT INSECT GROUP III CHITINASE (CAD2-E647L) FROM OSTRINIA FURNACALIS 3.2.1.14
5WVG CRYSTAL STRUCTURE OF A MUTANT INSECT GROUP III CHITINASE COMPLEX WITH (GLCNAC)5 (CAD1-E647L-(GLCNAC)5 ) FROM OSTRINIA FURNACALIS 3.2.1.14
5WVH CRYSTAL STRUCTURE OF AN INSECT GROUP III CHITINASE COMPLEX WITH (GLCNAC)6 (CAD2-(GLCNAC)6 ) FROM OSTRINIA FURNACALIS 3.2.1.14
5WVP EXPRESSION, CHARACTERIZATION AND CRYSTAL STRUCTURE OF A NOVEL BETA-GLUCOSIDASE FROM PAENIBACILLUS BARENGOLTZII 3.2.1.21
5WVU CRYSTAL STRUCTURE OF CARBOXYPEPTIDASE FROM THERMUS THERMOPHILUS 3.4.17.19
5WWD CRYSTAL STRUCTURE OF ATNUDX1 3.6.1.55
3.6.1.67
3.6.1.22
5WX1 THE CLOSED-CONFORMATION CRYSTAL STRUCTURE OF THE FULL-LENGTH PESTIVIRUS NS3 WITH ITS NS4A PROTEASE COFACTOR SEGMENT 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
5WXB CRYSTAL STRUCTURE OF ZIKV MTASE IN COMPLEX WITH SAH 3.4.21.91
3.6.1.15
3.6.4.13
5WXS CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH S2444 3.4.21.73
5WXT CRYSTAL STRUCTURE OF UPA-S195A IN COMPLEX WITH S2444 3.4.21.73
5WXV THE CRYSTAL STRUCTURE OF VABB-ICL DOMAIN FROM VIBRIO ANGUILLARUM 775 3.3.2.1
5WY6 CRYSTAL STRUCTURE OF ATNUDX1 (E56A) 3.6.1.55
3.6.1.67
3.6.1.22
5WY8 CRYSTAL STRUCTURE OF PTP DELTA IG1-IG3 IN COMPLEX WITH IL1RAPL1 IG1-IG3 3.1.3.48
5WYG THE CRYSTAL STRUCTURE OF THE APO FORM OF MTB MAZF 3.1
5WYN HTRA2 PATHOGENIC MUTANT 3.4.21.108
5WZ1 CRYSTAL STRUCTURE OF ZIKA VIRUS NS5 METHYLTRANSFERASE BOUND TO S-ADENOSYL-L-METHIONINE 3.4.21.91
3.6.1.15
3.6.4.13
5WZ2 CRYSTAL STRUCTURE OF ZIKA VIRUS NS5 METHYLTRANSFERASE BOUND TO SAM AND RNA ANALOGUE (M7GPPPA) 3.4.21.91
3.6.1.15
3.6.4.13
5WZ3 CRYSTAL STRUCTURE OF ZIKA VIRUS NS5 RNA-DEPENDENT RNA POLYMERASE(RDRP) 3.4.21.91
3.6.1.15
3.6.4.13
5WZ4 CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS VAPC20 (RV2549C), SARCIN-RICIN LOOP CLEAVING TOXIN 3.1
5WZF CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS VAPC20 (RV2549C), SARCIN-RICIN LOOP CLEAVING TOXIN 3.1
5WZM CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE 3.1.1.4
5WZN ALPHA-N-ACETYLGALACTOSAMINIDASE NAGBB FROM BIFIDOBACTERIUM BIFIDUM - GALNAC COMPLEX 3.2.1.49
3.2.1
5WZO CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE, CRYSTALLIZED WITH CALCIUM 3.1.1.4
5WZP ALPHA-N-ACETYLGALACTOSAMINIDASE NAGBB FROM BIFIDOBACTERIUM BIFIDUM - LIGAND FREE 3.2.1.49
3.2.1
5WZQ ALPHA-N-ACETYLGALACTOSAMINIDASE NAGBB FROM BIFIDOBACTERIUM BIFIDUM - QUADRUPLE MUTANT 3.2.1.49
3.2.1
5WZR ALPHA-N-ACETYLGALACTOSAMINIDASE NAGBB FROM BIFIDOBACTERIUM BIFIDUM - GAL-NHAC-DNJ COMPLEX 3.2.1.49
3.2.1
5WZS CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE WITH COMPOUND 8 3.1.1.4
5WZT CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE WITH COMPOUND 14 3.1.1.4
5WZU CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE WITH COMPOUND 24 3.1.1.4
5WZV CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE WITH ME-INDOXAM 3.1.1.4
5WZW CRYSTAL STRUCTURE OF HUMAN SECRETED PHOSPHOLIPASE A2 GROUP IIE WITH LY311727 3.1.1.4
5X04 12:0-ACP THIOESTERASE FROM UMBELLULARIA CALIFORNICA 3.1.2.21
5X09 CRYSTAL STRUCTURE OF SUBUNIT A MUTANT P235A/S238C OF THE A-ATP SYNTHASE FROM PYROCOCCUS HORIKOSHII OT3 3.6.3.14
7.1.2.2
3.1
5X16 SIRT6 APO STRUCTURE 3.5.1
2.3.1.286
5X1X SOLUTION NMR STRUCTURE OF DNA MISMATCH REPAIR PROTEIN MUTT (FAMILY NUDIX HYDROLASE) FROM METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 252 3.6.1.55
3.6.1
5X33 LEUKOTRIENE B4 RECEPTOR BLT1 IN COMPLEX WITH BIIL260 3.2.1.17
5X34 SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE, UNGLYCOSYLATED FORM 3.2.1.91
5X35 SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE WITH MANNOSYLATED THR1 3.2.1.91
5X36 SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE WITH MANNOSYLATED SER3 3.2.1.91
5X37 SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE WITH MANNOSYLATED SER14 3.2.1.91
5X38 SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE WITH GLUCOSYLATED SER3 3.2.1.91
5X39 SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE Q2A MUTANT WITH MANNOSYLATED SER3 3.2.1.91
5X3C SOLUTION STRUCTURE OF THE FAMILY 1 CARBOHYDRATE-BINDING MODULE Y5A MUTANT WITH MANNOSYLATED SER3 3.2.1.91
5X3I KFLA1895 D451A MUTANT 3.2.1.204
5X3J KFLA1895 D451A MUTANT IN COMPLEX WITH CYCLOBIS-(1->6)-ALPHA-NIGEROSYL 3.2.1.204
5X3K KFLA1895 D451A MUTANT IN COMPLEX WITH ISOMALTOSE 3.2.1.204
5X45 CRYSTAL STRUCTURE OF 2A PROTEASE FROM HUMAN RHINOVIRUS C15 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5X49 CRYSTAL STRUCTURE OF HUMAN MITOCHONDRIAL X-PROLYL AMINOPEPTIDASE (XPNPEP3) 3.4.11.9
5X4L CRYSTAL STRUCTURE OF THE UBX DOMAIN OF HUMAN UBXD7 IN COMPLEX WITH P97 N DOMAIN 3.6.4.6
5X55 CRYSTAL STRUCTURE OF MIMIVIRUS URACIL-DNA GLYCOSYLASE 3.2.2
5X5G CRYSTAL STRUCTURE OF TLA-3 EXTENDED-SPECTRUM BETA-LACTAMASE IN A COMPLEX WITH OP0595 3.5.2.6
5X61 CRYSTAL STRUCTURE OF ACETYLCHOLINESTERASE CATALYTIC SUBUNIT OF THE MALARIA VECTOR ANOPHELES GAMBIAE, 3.4 A 3.1.1.7
5X6A CRYSTAL STRUCTURE OF AN ENDOGLUCANASE PMO-5 3.2.1
5X6S ACETYL XYLAN ESTERASE FROM ASPERGILLUS AWAMORI 3.1.1.72
5X7B CRYSTAL STRUCTURE OF SHP2_SH2-CAGA EPIYA_C PEPTIDE COMPLEX 3.1.3.48
5X7D STRUCTURE OF BETA2 ADRENOCEPTOR BOUND TO CARAZOLOL AND AN INTRACELLULAR ALLOSTERIC ANTAGONIST 3.2.1.17
5X7O CRYSTAL STRUCTURE OF PAENIBACILLUS SP. 598K ALPHA-1,6-GLUCOSYLTRANSFERASE 2.4.1
3.2.1.20
5X88 A CRYSTAL STRUCTURE OF CUTINASES FROM MALBRANCHEA CINNAMOMEA 3.1.1.74
5X8Y A MUTATION IDENTIFIED IN NEONATAL MICROCEPHALY DESTABILIZES ZIKA VIRUS NS1 ASSEMBLY IN VITRO 3.4.21.91
3.6.1.15
3.6.4.13
5X93 HUMAN ENDOTHELIN RECEPTOR TYPE-B IN COMPLEX WITH ANTAGONIST K-8794 3.2.1.17
5X94 CRYSTAL STRUCTURE OF SHP2_SH2-CAGA EPIYA_D PEPTIDE COMPLEX 3.1.3.48
5X9I UNIQUE CHOLOYLGLYCINE HYDROLASE(CGH) MEMBER MUTANT (C1S) FROM SHEWANELLA LOIHICA PV-4 3.5.1.24
5X9S CRYSTAL STRUCTURE OF FULLY MODIFIED H-RAS-GPPNHP 3.6.5.2
5XA7 COMPLETE STRUCTURE FACTORS AND AN ATOMIC MODEL OF THE CALCIUM PUMP (SERCA1A) AND ASSOCIATED PHOSPHOLIPIDS IN THE E1-2CA2+ CRYSTALS 3.6.3.8
7.2.2.10
5XA8 COMPLETE STRUCTURE FACTORS AND AN ATOMIC MODEL OF THE CALCIUM PUMP (SERCA1A) AND ASSOCIATED PHOSPHOLIPIDS IN THE E1-ALF4-ADP-2CA2+ CRYSTALS 3.6.3.8
7.2.2.10
5XA9 COMPLETE STRUCTURE FACTORS AND AN ATOMIC MODEL OF THE CALCIUM PUMP (SERCA1A) AND ASSOCIATED PHOSPHOLIPIDS IN THE E2-ALF-(TG) CRYSTALS OF C2 SYMMETRY 3.6.3.8
7.2.2.10
5XAA COMPLETE STRUCTURE FACTORS AND AN ATOMIC MODEL OF THE CALCIUM PUMP (SERCA1A) AND ASSOCIATED PHOSPHOLIPIDS IN THE E2-ALF-(TG) CRYSTALS OF P21212 SYMMETRY 3.6.3.8
7.2.2.10
5XAB COMPLETE STRUCTURE FACTORS AND AN ATOMIC MODEL OF THE CALCIUM PUMP (SERCA1A) AND ASSOCIATED PHOSPHOLIPIDS IN THE E2(TG) CRYSTALS 3.6.3.8
7.2.2.10
5XAQ CRYSTAL STRUCTURE OF ANIMALIA-SPECIFIC TRNA DEACYLASE FROM MUS MUSCULUS 3.1
3.1.1.96
5XBC CRYSTAL STRUCTURE BASIS FOR PEDV NSP1 2.7.7.48
3.4.19.12
3.6.4.12
3.6.4.13
5XBL STRUCTURE OF NUCLEASE IN COMPLEX WITH ASSOCIATED PROTEIN 3.1
5XBU CRYSTAL STRUCTURE OF GH45 ENDOGLUCANASE EG27II IN APO-FORM 3.2.1.4
5XBX CRYSTAL STRUCTURE OF GH45 ENDOGLUCANASE EG27II IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5XBZ CRYSTAL STRUCTURE OF GH FAMILY 81 BETA-1,3-GLUCANASE FROM RHIZOMUCR MIEHEI COMPLEXED WITH LAMINARIPENTAOSE 3.2.1.39
3.2.1.6
5XC0 CRYSTAL STRUCTURE OF AN AROMATIC MUTANT (W6A) OF AN ALKALI THERMOSTABLE GH10 XYLANASE FROM BACILLUS SP. NG-27 3.2.1.8
5XC1 CRYSTAL STRUCTURE OF THE COMPLEX OF AN AROMATIC MUTANT (W6A) OF AN ALKALI THERMOSTABLE GH10 XYLANASE FROM BACILLUS SP. NG-27 WITH S-1,2-PROPANEDIOL 3.2.1.8
5XC4 CRYSTAL STRUCTURE OF GH45 ENDOGLUCANASE EG27II AT PH4.0, IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5XC6 DENGUE VIRUS 4 NS3 HELICASE IN COMPLEX WITH SSRNA SLA12 3.4.21.91
3.6.1.15
3.6.4.13
5XC7 DENGUE VIRUS 4 NS3 HELICASE D290A MUTANT 3.4.21.91
3.6.1.15
3.6.4.13
5XC8 CRYSTAL STRUCTURE OF GH45 ENDOGLUCANASE EG27II AT PH5.5, IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5XC9 CRYSTAL STRUCTURE OF GH45 ENDOGLUCANASE EG27II AT PH8.0, IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5XCA CRYSTAL STRUCTURE OF GH45 ENDOGLUCANASE EG27II D137A MUTANT IN COMPLEX WITH CELLOBIOSE 3.2.1.4
5XCO CRYSTAL STRUCTURE OF HUMAN K-RAS G12D MUTANT IN COMPLEX WITH GDP AND CYCLIC INHIBITORY PEPTIDE 3.6.5.2
5XCY STRUCTURE OF THE CELLOBIOHYDROLASE CEL6A FROM PHANEROCHAETE CHRYSOSPORIUM AT 1.2 ANGSTROM 3.2.1
5XCZ STRUCTURE OF THE CELLOBIOHYDROLASE CEL6A FROM PHANEROCHAETE CHRYSOSPORIUM IN COMPLEX WITH CELLOBIOSE AT 2.1 ANGSTROM 3.2.1
5XD0 APO STRUCTURE OF BETA-1,3-1,4-GLUCANASE FROM PAENIBACILLUS SP.X4 3.2.1.73
3.2.1
5XD1 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH AP5A, ATP AND MAGNESIUM 3.6.1.69
3.6.1.58
3.6.1.61
5XD2 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH AP5A, ATP AND MANGANESE 3.6.1.69
3.6.1.58
3.6.1.61
5XD3 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH ATP (I) 3.6.1.69
3.6.1.58
3.6.1.61
5XD4 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH ATP (II) 3.6.1.69
3.6.1.58
3.6.1.61
5XD5 CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MUTT1 IN COMPLEX WITH ATP, MAGNESIUM FLUORIDE AND PHOSPHATE 3.6.1.69
3.6.1.58
3.6.1.61
5XDR CRYSTAL STRUCTURE OF HUMAN DEAH-BOX RNA HELICASE DHX15 IN COMPLEX WITH ADP 3.6.4.13
5XE0 CRYSTAL STRUCTURE OF EV-D68-3DPOL IN COMPLEX WITH GTP 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5XE2 ENDORIBONUCLEASE FROM MYCOBACTERIAL SPECIES 3.1
5XE3 ENDORIBONUCLEASE IN COMPLEX WITH ITS COGNATE ANTITOXIN FROM MYCOBACTERIAL SPECIES 3.1
5XE5 DISCOVERY AND STRUCTURAL ANALYSIS OF A PHLORETIN HYDROLASE FROM THE OPPORTUNISTIC PATHOGEN MYCOBACTERIUM ABSCESSUS 3.7.1.4
5XEV CRYSTAL STRUCTURE OF A NOVEL XAA-PRO DIPEPTIDASE FROM DEINOCOCCUS RADIODURANS 3.4.13.9
5XEY DISCOVERY AND STRUCTURAL ANALYSIS OF A PHLORETIN HYDROLASE FROM THE OPPORTUNISTIC PATHOGEN MYCOBACTERIUM ABSCESSUS 3.7.1.4
5XF1 STRUCTURE OF THE FULL-LENGTH GLUCAGON CLASS B G PROTEIN-COUPLED RECEPTOR 3.2.1.17
5XF8 CRYO-EM STRUCTURE OF THE CDT1-MCM2-7 COMPLEX IN AMPPNP STATE 3.6.4.12
5XFY CRYSTAL STRUCTURE OF A NOVEL PET HYDROLASE S131A MUTANT FROM IDEONELLA SAKAIENSIS 201-F6 3.1.1.101
5XFZ CRYSTAL STRUCTURE OF A NOVEL PET HYDROLASE R103G/S131A MUTANT FROM IDEONELLA SAKAIENSIS 201-F6 3.1.1.101
5XG0 CRYSTAL STRUCTURE OF A NOVEL PET HYDROLASE FROM IDEONELLA SAKAIENSIS 201-F6 3.1.1.101
5XG4 CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH QUERCETIN 3.4.21.73
5XGW ISOASPARTYL DIPEPTIDASE FROM COLWELLIA PSYCHRERYTHRAEA STRAIN 34H 3.4.19
5XGX CRYSTAL STRUCTURE OF COLWELLIA PSYCHRERYTHRAEA STRAIN 34H ISOASPARTYL DIPEPTIDASE E80Q MUTANT COMPLEXED WITH BETA-ISOASPARTYL LYSINE 3.4.19
5XH2 CRYSTAL STRUCTURE OF A NOVEL PET HYDROLASE R103G/S131A MUTANT IN COMPLEX WITH PNP FROM IDEONELLA SAKAIENSIS 201-F6 3.1.1.101
5XH3 CRYSTAL STRUCTURE OF A NOVEL PET HYDROLASE R103G/S131A MUTANT IN COMPLEX WITH HEMT FROM IDEONELLA SAKAIENSIS 201-F6 3.1.1.101
5XH6 CRYSTAL STRUCTURE OF THE ACIDAMINOCOCCUS SP. BV3L6 CPF1 RVR VARIANT IN COMPLEX WITH CRRNA AND TARGET DNA (TATA PAM) 3.1
3.1.21.1
4.6.1.22
5XH7 CRYSTAL STRUCTURE OF THE ACIDAMINOCOCCUS SP. BV3L6 CPF1 RR VARIANT IN COMPLEX WITH CRRNA AND TARGET DNA (TCCA PAM) 3.1
3.1.21.1
4.6.1.22
5XHR CRYSTAL STRUCTURE OF P99 BETA-LACTAMASE IN COMPLEX WITH A PENICILLIN DERIVATIVE MPC-1 3.5.2.6
5XHS CRYSTAL STRUCTURE OF SIRT5 COMPLEXED WITH A FLUOROGENIC SMALL-MOLECULE SUBSTRATE SUBKA 3.5.1
2.3.1
5XI8 STRUCTURE AND FUNCTION OF THE TPR DOMAIN 3.4
5XJH CRYSTAL STRUCTURE OF PETASE FROM IDEONELLA SAKAIENSIS 3.1.1.101
5XJV TWO INTERMEDIATE STATES OF CONFORMATION SWITCH IN DUAL SPECIFICITY PHOSPHATASE 13A 3.1.3.16
3.1.3.48
5XKM CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 6-METHYL-N-(1-(4-(TRIFLUOROMETHOXY)PHENYL)PROPYL)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE 3.1.4.17
5XKS CRYSTAL STRUCTURE OF MONOACYLGLYCEROL LIPASE FROM THERMOPHILIC GEOBACILLUS SP. 12AMOR 3.1.1.23
5XM6 THE OVERALL STRUCTURE OF VREH2 3.3.2
5XM7 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-((2S,3R)-3-AMINO-2-HYDROXY-4-PHENYLBUTANAMIDO)-N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5XNX CRYSTALLOGRAPHIC STRUCTURE OF THE ENZYMATICALLY ACTIVE N-TERMINAL DOMAIN OF THE REL PROTEIN FROM MYCOBACTERIUM TUBERCULOSIS 2.7.6.5
3.1.7.2
5XO0 CRYSTAL STRUCTURE OF THE ISOCHORISMATASE DOMAIN OF ANGB FROM VIBRIO ANGUILLARUM 775 3.3.2.1
5XO1 CRYSTAL STRUCTURE OF THE ISOCHORISMATASE DOMAIN OF VABB FROM VIBRIO ANGUILLARUM 775 3.3.2.1
5XOY CRYSTAL STRUCTURE OF LYSK FROM THERMUS THERMOPHILUS IN COMPLEX WITH LYSINE 3.5.1
3.5.1.130
5XP6 NATIVE STRUCTURE OF NDM-1 CRYSTALLIZED AT PH5.5 3.5.2.6
5XP9 CRYSTAL STRUCTURE OF BISMUTH BOUND NDM-1 3.5.2.6
5XPE NEUTRON STRUCTURE OF THE T26H MUTANT OF T4 LYSOZYME 3.2.1.17
5XPF HIGH-RESOLUTION X-RAY STRUCTURE OF THE T26H MUTANT OF T4 LYSOZYME 3.2.1.17
5XPR HUMAN ENDOTHELIN RECEPTOR TYPE-B IN COMPLEX WITH ANTAGONIST BOSENTAN 3.2.1.17
5XPX STRUCTURE ELUCIDATION OF TRUNCATED AMS3 LIPASE FROM AN ANTARCTIC PSEUDOMONAS 3.1.1.3
5XR2 SAV0551 3.1.2
3.5.1.124
3.5.1
5XR3 SAV0551 WITH GLYOXYLATE 3.1.2
3.5.1.124
3.5.1
5XRC A TRIMODULAR GH5_4 SUBFAMILY ENDOGLUCANASE STRUCTURE WITH LARGE UNIT CELL 3.2.1.4
5XS4 STRUCTURE OF COXSACKIEVIRUS A6 (CVA6) VIRUS A-PARTICLE 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5XS5 STRUCTURE OF COXSACKIEVIRUS A6 (CVA6) VIRUS PROCAPSID PARTICLE 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5XS7 STRUCTURE OF COXSACKIEVIRUS A6 (CVA6) VIRUS A-PARTICLE IN COMPLEX WITH THE NEUTRALIZING ANTIBODY FRAGMENT 1D5 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5XSI THE CATALYTIC DOMAIN OF GDPP 3.1.4
5XSN THE CATALYTIC DOMAIN OF GDPP WITH C-DI-AMP 3.1.4
5XSP THE CATALYTIC DOMAIN OF GDPP WITH 5'-PAPA 3.1.4
5XSV CRYSTAL STRUCTURE OF AN ARCHAEAL CHITINASE IN THE LIGAND-FREE FORM 3.2.1.14
5XSW CRYSTAL STRUCTURE OF AN ARCHAEAL CHITINASE IN THE SUBSTRATE-COMPLEX FORM (P63) 3.2.1.14
5XSX CRYSTAL STRUCTURE OF AN ARCHAEAL CHITINASE IN THE SUBSTRATE-COMPLEX FORM (P212121) 3.2.1.14
5XSZ CRYSTAL STRUCTURE OF ZEBRAFISH LYSOPHOSPHATIDIC ACID RECEPTOR LPA6 3.2.1.17
5XT3 THE CATALYTIC DOMAIN OF GDPP WITH C-DI-GMP 3.1.4
5XTJ MANNANASE(RMMAN134A) 3.2.1.78
5XTT CRYSTAL STRUCTURE OF RMMAN134A-M3 COMPLEX 3.2.1.78
5XU5 COMPLEX STRUCTURE OF RMMAN134A-M4 3.2.1.78
5XU8 CRYSTAL STRUCTURE OF HUMAN USP2 IN COMPLEX WITH UBIQUITIN AND 6-THIOGUANINE 3.4.19.12
5XUG COMPLEX STRUCTURE(RMMAN134A-M5). 3.2.1.78
5XUI CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 2-METHYL-5-[2-([1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)ET HYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-OL 3.1.4.17
3.1.4.35
5XUJ CRYSTAL STRUCTURE OF PDE10A IN COMPLEX WITH 7-(4-CHLOROPHENYL)-2-METHYLPYRAZOLO[1,5-A]PYRIMIDINE 3.1.4.17
3.1.4.35
5XUL COMPLEX STRUCTURE (RMMAN134A-M6). 3.2.1.78
5XUW CRYSTAL STRUCTURE OF LYSOZYME FROM EQUUS ASINUS 3.2.1.17
5XVE CRYSTAL STRUCTURE OF HUMAN USP2 C276S MUTANT IN COMPLEX WITH UBIQUITIN 3.4.19.12
5XVN E. FAR CAS1-CAS2/PRESPACER BINARY COMPLEX 3.1
5XVO E. FAE CAS1-CAS2/PRESPACER/TARGET TERNARY COMPLEX REVEALING DNA SAMPLING AND HALF-INTEGRATION STATES 3.1
5XVP E. FAE CAS1-CAS2/PRESPACER/TARGET TERNARY COMPLEX REVEALING THE FULLY INTEGRATED STATES 3.1
5XVS CRYSTAL STRUCTURE OF UDP-GLCNAC 2-EPIMERASE NEUC COMPLEXED WITH UDP 3.2.1.184
3.2.1.183
5XW1 CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR, PRN, AT PH10 3.4.21.4
5XW4 CRYSTAL STRUCTURE OF BUDDING YEAST CDC14P (WILD TYPE) IN THE APO STATE 3.1.3.48
5XW5 CRYSTAL STRUCTURE OF BUDDING YEAST CDC14P (C283S) BOUND TO A SWI6P PHOSPHOPEPTIDE 3.1.3.48
5XW8 CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR, PRN, AT PH 7 3.4.21.4
5XW9 CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR, PRY, AT PH 7 3.4.21.4
5XWA CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR, PRY, AT PH 10 3.4.21.4
5XWF CRYSTAL STRUCTURE OF CHITINASE (RMCHI1) FROM RHIZOMUCOR MIEHEI (SP3221/SAD) 3.2.1.14
5XWI CRYSTAL STRUCTURE OF SPAP, AN ALKALINE PHOSPHATASE FROM SPHINGOMONAS SHOWING COVALENT INTERMEDIATE 3.1.3.1
5XWJ CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR, TRE, AT PH 7 3.4.21.4
5XWK CRYSTAL STRUCTURE OF SPAP, AN ALKALINE PHOSPHATASE FROM SPHINGOMONAS IN COMPLEX WITH INORGANIC PHOSPHATE 3.1.3.1
5XWL CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR, TRE, AT PH 10 3.4.21.4
5XWP CRYSTAL STRUCTURE OF LBUCAS13A-CRRNA-TARGET RNA TERNARY COMPLEX 3.1
5XWQ CRYSTAL STRUCTURE OF CHITINASE (RMCHI1) FROM RHIZOMUCOR MIEHEI (SP P32 2 1, MR) 3.2.1.14
5XWT CRYSTAL STRUCTURE OF PTPDELTA IG1-FN1 IN COMPLEX WITH SALM5 LRR-IG 3.1.3.48
5XWU CRYSTAL STRUCTURE OF PTPDELTA IG1-IG3 IN COMPLEX WITH SALM2 LRR-IG 3.1.3.48
5XWY ELECTRON CRYO-MICROSCOPY STRUCTURE OF LBUCAS13A-CRRNA BINARY COMPLEX 3.1
5XYA CRYSTAL STRUCTURE OF A SERINE PROTEASE FROM STREPTOCOCCUS SPECIES 3.4.21.110
5XYH CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF 1,4-BETA-CELLOBIOSIDASE (CBSA) FROM XANTHOMONAS ORYZAE PV. ORYZAE 3.2.1.91
3.2.1
5XYR CRYSTAL STRUCTURE OF A SERINE PROTEASE FROM STREPTOCOCCUS SPECIES 3.4.21.110
5XZO CRYSTAL STRUCTURE OF GH10 XYLANASE XYL10C FROM BISPORA. SP MEY-1 3.2.1.8
5XZR THE ATOMIC STRUCTURE OF SHP2 E76A MUTANT IN COMPLEX WITH ALLOSTERIC INHIBITOR 9B 3.1.3.48
5XZU CRYSTAL STRUCTURE OF GH10 XYLANASE FROM BISPORA. SP MEY-1 WITH XYLOBIOSE 3.2.1.8
5Y09 CRYSTAL STRUCTURE OF DEG9 AT 295 K 3.4.21
5Y0V CRYSTAL STRUCTURE OF INSECT BETA-N-ACETYL-D-HEXOSAMINIDASE OFHEX1 COMPLEXED WITH BERBERINE 3.2.1.52
5Y0Z HUMAN SIRT2 IN COMPLEX WITH A SPECIFIC INHIBITOR, NPD11033 3.5.1
2.3.1.286
5Y15 CRYSTAL STRUCTURE OF HUMAN DUSP28 3.1.3.16
3.1.3.48
5Y16 CRYSTAL STRUCTURE OF HUMAN DUSP28(Y102H) 3.1.3.16
3.1.3.48
5Y19 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-((2S,3R)-3-AMINO-2-HYDROXY-4-PHENYLBUTANAMIDO)- N-HYDROXY-4-METHYLPENTANAMIDE. 3.4.11
5Y1B CRYSTAL STRUCTURE OF INSECT BETA-N-ACETYL-D-HEXOSAMINIDASE OFHEX1 COMPLEXED WITH A BERBERINE DERIVATIVE (SYSU-00679) 3.2.1.52
5Y1H CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-(3-(2,4-DIFLUOROBENZYL)UREIDO)-N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5Y1K CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-(3-(2-CHLOROBENZYL)UREIDO)-N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5Y1Q CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-(3-(3-CHLOROBENZYL)UREIDO)-N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5Y1R CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-N-HYDROXY-4-METHYL-2-(3-( O-TOLYL)UREIDO)PENTANAMIDE 3.4.11
5Y1S CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-(3-(3,4-DIMETHYLBENZYL)UREIDO)-N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5Y1T CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-(3-(2,3-DIMETHYLBENZYL)UREIDO)-N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5Y1V CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-2-(3-(2,6-DIETHYLPHENYL)UREIDO)- N-HYDROXY-4-METHYLPENTANAMIDE 3.4.11
5Y1W CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N WITH MAGNESIUM BOUND TO ACTIVE SITE ZINC 3.4.11
5Y1X CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH ACTINONIN 3.4.11
5Y28 CRYSTAL STRUCTURE OF H. PYLORI HTRA WITH PDZ2 DELETION 3.4.21.107
5Y29 CRYSTAL STRUCTURE OF OSTRINIA FURNACALIS GROUP II CHITINASE CATALYTIC DOMAIN 1 3.2.1.14
5Y2A CRYSTAL STRUCTURE OF OSTRINIA FURNACALIS GROUP II CHITINASE CATALYTIC DOMAIN 2 3.2.1.14
5Y2B CRYSTAL STRUCTURE OF OSTRINIA FURNACALIS GROUP II CHITINASE CATALYTIC DOMAIN 1 IN COMPLEX WITH HEPTA-N-ACETYLCHITOOCTAOSE (NAG)7 3.2.1.14
5Y2C CRYSTAL STRUCTURE OF OSTRINIA FURNACALIS GROUP II CHITINASE CATALYTIC DOMAIN 2 E2180L MUTANT IN COMPLEX WITH PENTA-N-ACETYLCHITOOCTAOSE (NAG)5 3.2.1.14
5Y2D CRYSTAL STRUCTURE OF H. PYLORI HTRA 3.4.21.107
5Y2F HUMAN SIRT6 IN COMPLEX WITH ALLOSTERIC ACTIVATOR MDL-801 3.5.1
2.3.1.286
5Y2X CRYSTAL STRUCTURE OF APO-HALOTAG (M175C) 3.8.1.5
5Y2Y CRYSTAL STRUCTURE OF HALOTAG (M175C) COMPLEXED WITH DANSYL-PEG2-HALOTAG LIGAND 3.8.1.5
5Y32 CRYSTAL STRUCTURE OF PTP DELTA IG1-IG2 IN COMPLEX WITH IL1RAPL1 3.1.3.48
5Y36 CRYO-EM STRUCTURE OF SPCAS9-SGRNA-DNA TERNARY COMPLEX 3.1
5Y3E CRYSTAL STRUCTURE OF SARS CORONAVIRUS PAPAIN-LIKE PROTEASE IN COMPLEX WITH GLYCEROL 3.4.19.12
3.4.22.69
3.4.22
5Y3I CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM AMINOPEPTIDASE N IN COMPLEX WITH (S)-N-HYDROXY-4-METHYL-2-(3-(3-METHYLBENZYL)UREIDO)PENTANAMIDE 3.4.11
5Y3Q CRYSTAL STRUCTURE OF SARS CORONAVIRUS PAPAIN-LIKE PROTEASE CONJUGATED WITH BETA-MERCAPTOETHANOL 3.4.19.12
3.4.22.69
3.4.22
5Y3R CRYO-EM STRUCTURE OF HUMAN DNA-PK HOLOENZYME 3.6.4
4.2.99
5Y48 CRYSTAL STRUCTURE OF THE COMPLEX OF RIBOSOME INACTIVATING PROTEIN FROM MOMORDICA BALSAMINA WITH PYRIMIDINE-2,4-DIONE AT 1.70 ANGSTROM RESOLUTION 3.2.2.22
5Y4H HUMAN SIRT3 IN COMPLEX WITH HALISTANOL SULFATE 3.5.1
2.3.1.286
5Y4Z CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE COMPLEX WITH AMPPNP 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5Y59 CRYSTAL STRUCTURE OF KU80 AND SIR4 3.6.4.12
5Y5B CRYSTAL STRUCTURE OF IMP-1 METALLO-BETA-LACTAMASE 3.5.2.6
5Y5E CRYSTAL STRUCTURE OF PHOSPHOLIPASE A2 WITH INHIBITOR 3.1.1.4
5Y5N CRYSTAL STRUCTURE OF HUMAN SIRTUIN 2 IN COMPLEX WITH A SELECTIVE INHIBITOR 3.5.1
2.3.1.286
5Y5O CRYSTAL STRUCTURE OF THE DUTPASE OF WHITE SPOT SYNDROME VIRUS IN THE APO STATE 3.6.1.23
5Y5P CRYSTAL STRUCTURE OF THE DUTPASE OF WHITE SPOT SYNDROME VIRUS IN COMPLEX WITH DU,PPI AND MG2+ 3.6.1.23
5Y5Q CRYSTAL STRUCTURE OF THE WSSV DUTPASE D88N/R158E MUTANT IN COMPLEX WITH DUTP 3.6.1.23
5Y5Y V/A-TYPE ATPASE/SYNTHASE FROM THERMUS THERMOPHILUS, PERIPHERAL DOMAIN, ROTATIONAL STATE 1 3.6.3.14
7.1.2.2
5Y6M ZIKA VIRUS HELICASE IN COMPLEX WITH ADP-ALF3 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5Y6N ZIKA VIRUS HELICASE IN COMPLEX WITH ADP 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5Y6O CRYSTAL STRUCTURE OF DAXX N-TERMINAL FOUR-HELIX BUNDLE DOMAIN (4HB) IN COMPLEX WITH ATRX 3.6.4.12
5Y6R CRYSTAL STRUCTURE OF CSFV NS5B 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
5Y6Z CRYSTAL STRUCTURE OF THE COXSACKIEVIRUS A16 POLYMERASE ELONGATION COMPLEX 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5Y7G CRYSTAL STRUCTURE OF PAFAN1 BOUND TO 1NT 5'FLAP DNA WITH GAP 3.1.4.1
5Y7H CRYSTAL STRUCTURE OF HUMAN DPP4 IN COMPLEX WITH INHIBITOR3 3.4.14.5
5Y7J CRYSTAL STRUCTURE OF HUMAN DPP4 IN COMPLEX WITH INHIBITOR2 3.4.14.5
5Y7K CRYSTAL STRUCTURE OF HUMAN DPP4 IN COMPLEX WITH INHIBITOR1 3.4.14.5
5Y7Q CRYSTAL STRUCTURE OF PAFAN1 BOUND TO 2NT 5'FLAP DNA WITH GAP 3.1.4.1
5Y98 CRYSTAL STRUCTURE OF NATIVE UNBOUND PEPTIDYL TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII AT 1.36 A RESOLUTION 3.1.1.29
5Y9A CRYSTAL STRUCTURE OF THE COMPLEX OF PEPTIDYL TRNA HYDROLASE WITH A PHOSPHATE ION AT THE SUBSTRATE BINDING SITE AND CYTARABINE AT A NEW LIGAND BINDING SITE AT 1.1 A RESOLUTION 3.1.1.29
5Y9L HUMAN KALLIKREIN 7 IN COMPLEX WITH 1,3,6-TRISUBSTITUTED 1,4-DIAZEPANE-7-ONE 3.4.21.117
5Y9P STAPHYLOCOCCUS AUREUS RNASE HII 3.1.26.4
5YAE FERULIC ACID ESTERASE FROM STREPTOMYCES CINNAMONEUS AT 2.4 A RESOLUTION 3.1.1.73
5YAL FERULIC ACID ESTERASE FROM STREPTOMYCES CINNAMONEUS AT 1.5 A RESOLUTION 3.1.1.73
5YAO THE COMPLEX STRUCTURE OF SZ529 AND EXPOXID 3.3.2.8
5YBH STRUCTURAL OF THE HIGHLY CONSERVED ATPASE FROM TYPE III SECRETION SYSTEM OF BACTERIAL PATHOGENS 3.6.3.14
7.1.2.2
5YBI STRUCTURE OF THE BACTERIAL PATHOGENS ATPASE WITH SUBSTRATE AMPPNP 3.6.3.14
7.1.2.2
5YC6 THE CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH 4-BROMOBENZYLAMIRNE AT PH4.6 3.4.21.73
5YC7 THE CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH 4-BROMOBENZYLAMIRNE AT PH7.4 3.4.21.73
5YD0 CRYSTAL STRUCTURE OF SCHLAFEN 13 (SLFN13) N'-DOMAIN 3.1
5YD7 CRYSTAL STRUCTURE OF VIM-2 METALLO-BETA-LACTAMASE 3.5.2.6
5YD8 CRYSTAL STRUCTURE OF HUMAN PCNA IN COMPLEX WITH APIM OF HUMAN ZRANB3 3.6.4
3.1
5YDJ CRYSTAL STRUCTURE OF ANOPHELES GAMBIAE ACETYLCHOLINESTERASE IN COMPLEX WITH PMSF 3.1.1.7
5YE7 THE CRYSTAL STRUCTURE OF LP-PLA2 IN COMPLEX WITH A NOVEL INHIBITOR 3.1.1.47
5YE8 THE CRYSTAL STRUCTURE OF LP-PLA2 IN COMPLEX WITH A NOVEL INHIBITOR 3.1.1.47
5YE9 THE CRYSTAL STRUCTURE OF LP-PLA2 IN COMPLEX WITH A NOVEL INHIBITOR 3.1.1.47
5YEA THE CRYSTAL STRUCTURE OF LP-PLA2 IN COMPLEX WITH A NOVEL INHIBITOR 3.1.1.47
5YEW STRUCTURAL BASIS FOR GTP HYDROLYSIS AND CONFORMATIONAL CHANGE OF MITOFUSIN 1 IN MEDIATING MITOCHONDRIAL FUSION 3.6.5
5YF5 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-694) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
5YF6 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-682) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
5YF7 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-672) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
5YF8 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-672, Y471A-E472A MUTANT) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
5YFB CRYSTAL STRUCTURE OF A NEW DPP III FAMILY MEMBER 3.4.14.4
5YFC CRYSTAL STRUCTURE OF A NEW DPP III FAMILY MEMBER 3.4.14.4
5YFD CRYSTAL STRUCTURE OF A NEW DPP III FAMILY MEMBER 3.4.14.4
5YFE ENZYMATIC AND STRUCTURAL CHARACTERIZATION OF THE POLY (ETHYLENE TEREPHTHALATE) HYDROLASE PETASE FROM I. SAKAIENSIS 3.1.1.101
5YGX STRUCTURE OF BACE1 IN COMPLEX WITH N-(3-((4R,5R,6S)-2-AMINO-6-(1,1-DIFLUOROETHYL)-5-FLUORO-4-METHYL-5,6-DIHYDRO-4H-1,3-OXAZIN-4-YL)-4-FLUOROPHENYL)-5-(FLUOROMETHOXY)PYRAZINE-2-CARBOXAMIDE 3.4.23.46
5YGY CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH (S)-N-(3-(2-AMINO-6-(FLUOROMETHYL)-4 -METHYL-4H-1,3-OXAZIN-4-YL)-4-FLUOROPHENYL)-5-CYANOPICOLINAMIDE 3.4.23.46
5YHP PROLINE IMINOPEPTIDASE FROM PSYCHROPHILIC YEAST GLACIOZYMA ANTARCTICA 3.4.11.5
5YHT CRYSTAL STRUCTURE OF A PHOSPHATASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH ITS SUBSTRATE 3.1.3.15
5YHU CRYSTAL STRUCTURE OF THE DNA-BINDING DOMAIN OF HUMAN MYELIN-GENE REGULATORY FACTOR 3.4
5YI6 CRISPR ASSOCIATED PROTEIN CAS6 3.1
5YIA CRYSTAL STRUCTURE OF KNI-10343 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 3.4.23.39
5YIB CRYSTAL STRUCTURE OF KNI-10743 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 3.4.23.39
5YIC CRYSTAL STRUCTURE OF KNI-10333 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 3.4.23.39
5YID CRYSTAL STRUCTURE OF KNI-10395 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 3.4.23.39
5YIE CRYSTAL STRUCTURE OF KNI-10742 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 3.4.23.39
5YIN HEN EGG-WHITE LYSOZYME PRECIPITANT-FREE ORTHORHOMBIC FORM 3.2.1.17
5YJ7 STRUCTURAL INSIGHT INTO THE BETA-GH1 GLUCOSIDASE BGLN1 FROM OLEAGINOUS MICROALGAE NANNOCHLOROPSIS 3.2.1.21
5YJK HUMAN KALLIKREIN 7 IN COMPLEX WITH 1,4-DIAZEPANE-7-ONE 1-ACETAMIDE DERIVATIVE 3.4.21.117
5YJM HUMAN CHYMASE IN COMPLEX WITH 7-OXO-3-(PHENOXYIMINO)-1,4-DIAZEPANE DERIVATIVE 3.4.21.39
5YJP HUMAN CHYMASE IN COMPLEX WITH 3-(ETHOXYIMINO)-7-OXO-1,4-DIAZEPANE DERIVATIVE 3.4.21.39
5YKD CRYSTAL STRUCTURE OF DIHYDROPYRIMIDINASE FROM PSEUDOMONAS AERUGINOSA PAO1 AT 2.17 ANGSTROM RESOLUTION 3.5.2.2
5YKP HUMAN METHIONINE AMINOPEPTIDASE TYPE 1B (F309M MUTANT) IN COMPLEX WITH OVALICIN 3.4.11.18
5YKY CRYSTAL STRUCTURE OF CROSS-LINKED TETRAGONAL HEN EGG WHITE LYSOZYME SOAKED WITH 10 MM ROSE BENGAL AND 10MM H2PTCL6 3.2.1.17
5YL8 THE CRYSTAL STRUCTURE OF INACTIVE DIMERIC PEPTIDYL-TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII AT 1.79 A RESOLUTION 3.1.1.29
5YLA CRYSTAL STRUCTURE OF A DIMERIC PEPTIDYL-TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII AT 1.67 A RESOLUTION 3.1.1.29
5YLU CRYSTAL STRUCTURE OF THE GASTRIC PROTON PUMP COMPLEXED WITH VONOPRAZAN 3.6.3.10
7.2.2.19
5YLV CRYSTAL STRUCTURE OF THE GASTRIC PROTON PUMP COMPLEXED WITH SCH28080 3.6.3.10
7.2.2.19
5YM6 CRYSTAL STRUCTURE OF PORCINE DELTA CORONAVIRUS NSP9 2.7.7.48
3.6.4.12
3.6.4.13
5YM8 CRYSTAL STRUCTURE OF PORCINE DELTA CORONAVIRUS NSP9-N7 2.7.7.48
3.6.4.12
3.6.4.13
5YMX MYXOCOCCUS XANTHUS MGLA IN GDP BOUND CONFORMATION 3.6.5.2
5YN2 CRYSTAL STRUCTURE OF APO PULLULANASE FROM KLEBSIELLA PNEUMONIAE IN SPACE GROUP P43212 3.2.1.41
5YN4 CRYSTAL STRUCTURE OF DIMERIC PEPTIDYL TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII WITH OCCLUDED SUBSTRATE BINDING SITE AT 1.47 A RESOLUTION 3.1.1.29
5YN5 CRYSTAL STRUCTURE OF MERS-COV NSP10/NSP16 COMPLEX 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YN6 CRYSTAL STRUCTURE OF MERS-COV NSP10/NSP16 COMPLEX BOUND TO SAM 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YN7 CRYSTAL STRUCTURE OF PULLULANASE FROM KLEBSIELLA PNEUMONIAE COMPLEX AT 0.1 MM BETA-CYCLODEXTRIN 3.2.1.41
5YN8 CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SAH 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNA CRYSTAL STRUCTURE OF PULLULANASE FROM KLEBSIELLA PNEUMONIAE COMPLEX AT 1 MM ALPHA-CYCLODEXTRIN 3.2.1.41
5YNB CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SINEFUNGIN 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNC CRYSTAL STRUCTURE OF PULLULANASE FROM KLEBSIELLA PNEUMONIAE COMPLEX AT 1 MM BETA-CYCLODEXTRIN 3.2.1.41
5YND CRYSTAL STRUCTURE OF PULLULANASE FROM KLEBSIELLA PNEUMONIAE COMPLEX AT 1 MM GAMMA-CYCLODEXTRIN 3.2.1.41
5YNE CRYSTAL STRUCTURE OF PULLULANASE FROM KLEBSIELLA PNEUMONIAE COMPLEX AT 10 MM ALPHA-CYCLODEXTRIN 3.2.1.41
5YNF CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO M7GPPPA 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNG CRYSTAL STRUCTURE OF SZ348 IN COMPLEX WITH CYCLOPENTENE OXIDE 3.3.2.8
5YNH CRYSTAL STRUCTURE OF PULLULANASE FROM KLEBSIELLA PNEUMONIAE COMPLEX AT 10 MM GAMMA-CYCLODEXTRIN 3.2.1.41
5YNI CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SAM AND M7GPPPG 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNJ CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO M7GPPPG 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNL CRYSTAL STRUCTURE OF A COLD-ADAPTED ARGINASE FROM PSYCHROPHILIC YEAST, GLACIOZYMA ANTARCTICA 3.5.3.1
5YNM CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SAM AND M7GPPPA 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNN CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10COMPLEX BOUND TO SINEFUNGIN AND M7GPPPG 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNO CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SAH AND M7GPPPA 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNP CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SINEFUNGIN AND M7GPPPA 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNQ CRYSTAL STRUCTURE OF MERS-COV NSP16/NSP10 COMPLEX BOUND TO SAH AND M7GPPPG 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YNS CRYSTAL STRUCTURE OF PETASE R280A MUTANT FROM IDEONELLA SAKAIENSIS 3.1.1.101
5YNZ CRYSTAL STRUCTURE OF THE DIHYDROOROTASE DOMAIN (K1556A) OF HUMAN CAD 6.3.5.5
2.1.3.2
3.5.2.3
5YO1 STRUCTURE OF EPEPN E298A MUTANT IN COMPLEX WITH PUROMYCIN 3.4.11.2
5YOD CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 PROTEASE IN COMPLEX WITH A SMALL MOLECULE INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YOF CRYSTAL STRUCTURE OF ZIKA VIRUS NS3 PROTEASE IN COMPLEX WITH A DIPEPTIDE INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YOH MYCOBACTERIUM TUBERCULOSIS METHIONINE AMINOPEPTIDASE TYPE 1C (C105M MUTANT) IN COMPLEX WITH METHIONINE 3.4.11.18
5YOI MYCOBACTERIUM TUBERCULOSIS METHIONINE AMINOPEPTIDASE TYPE 1C (C105T MUTANT) IN COMPLEX WITH METHIONINE 3.4.11.18
5YOJ STRUCTURE OF A17 HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR KNI-1657 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5YOK STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR KNI-1657 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5YOX HD DOMAIN-CONTAINING PROTEIN YGK1(YGL101W) 3.1.3.89
5YP1 CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE IV (DPP IV) FROM PSEUDOXANTHOMONAS MEXICANA WO24 3.4.14.5
5YP2 CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE IV (DPP IV) WITH DPP4 INHIBITOR FROM PSEUDOXANTHOMONAS MEXICANA WO24 3.4.14.5
5YP4 CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE IV (DPP IV) WITH LYS-PRO FROM PSEUDOXANTHOMONAS MEXICANA WO24 3.4.14.5
5YP8 P62/SQSTM1 ZZ DOMAIN WITH ARG-PEPTIDE 3.6.4.10
5YPA P62/SQSTM1 ZZ DOMAIN WITH LYS-PEPTIDE 3.6.4.10
5YPB P62/SQSTM1 ZZ DOMAIN WITH HIS-PEPTIDE 3.6.4.10
5YPC P62/SQSTM1 ZZ DOMAIN WITH PHE-PEPTIDE 3.6.4.10
5YPD MYCOBACTERIUM TUBERCULOSIS METHIONINE AMINOPEPTIDASE TYPE 1C (C105N MUTANT) IN COMPLEX WITH METHIONINE 3.4.11.18
5YPE P62/SQSTM1 ZZ DOMAIN WITH TYR-PEPTIDE 3.6.4.10
5YPF P62/SQSTM1 ZZ DOMAIN WITH TRP-PEPTIDE 3.6.4.10
5YPG P62/SQSTM1 ZZ DOMAIN WITH LEU-PEPTIDE 3.6.4.10
5YPH P62/SQSTM1 ZZ DOMAIN WITH ILE-PEPTIDE 3.6.4.10
5YPJ MYCOBACTERIUM TUBERCULOSIS METHIONINE AMINOPEPTIDASE TYPE 1C (C105N MUTANT). 3.4.11.18
5YQ1 CRYSTAL STRUCTURE OF E.COLI AMINOPEPTIDASE N IN COMPLEX WITH O-METHYL-L-TYROSINE 3.4.11.2
5YQ2 CRYSTAL STRUCTURE OF E.COLI AMINOPEPTIDASE N IN COMPLEX WITH PUROMYCIN AMINONUCLEOSIDE 3.4.11.2
5YQ8 CRYSTAL STRUCTURE OF RETROVIRAL PROTEASE-LIKE DOMAIN OF DDI1 FROM LEISHMANIA MAJOR 3.4.23
5YQB CRYSTAL STRUCTURE OF E.COLI AMINOPEPTIDASE N IN COMPLEX WITH PUROMYCIN 3.4.11.2
5YQL CRYSTAL STRUCTURE OF SIRT2 IN COMPLEX WITH SELECTIVE INHIBITOR A2I 3.5.1
2.3.1.286
5YQM CRYSTAL STRUCTURE OF SIRT2 IN COMPLEX WITH SELECTIVE INHIBITOR A29 3.5.1
2.3.1.286
5YQN CRYSTAL STRUCTURE OF SIRT2 IN COMPLEX WITH SELECTIVE INHIBITOR L55 3.5.1
2.3.1.286
5YQO CRYSTAL STRUCTURE OF SIRT2 IN COMPLEX WITH SELECTIVE INHIBITOR L5C 3.5.1
2.3.1.286
5YQR CRYSTAL STRUCTURE OF THE PH-LIKE DOMAIN OF LAM6 3.2.1.17
5YQT CRYSTAL STRUCTURE OF THE L74F/M78V/I80V/L114F MUTANT OF LEH COMPLEXED WITH CYCLOPENTENE OXIDE 3.3.2.8
5YR4 HUMAN METHIONINE AMINOPEPTIDASE TYPE 1B (F309M MUTANT) IN COMPLEX WITH TNP470 3.4.11.18
5YR5 HUMAN METHIONINE AMINOPEPTIDASE TYPE 1B (F309L MUTANT) IN COMPLEX WITH OVALICIN 3.4.11.18
5YR6 HUMAN METHIONINE AMINOPEPTIDASE TYPE 1B (F309L MUTANT) IN COMPLEX WITH TNP470 3.4.11.18
5YR7 HUMAN METHIONINE AMINOPEPTIDASE TYPE 1B (F309L MUTANT) 3.4.11.18
5YRQ CRYSTAL STRUCTURE OF RAD5 AND REV1 3.6.4
2.7.7
5YRS X-RAY SNAPSHOT OF HIV-1 PROTEASE IN ACTION: OBSERVATION OF TETRAHEDRAL INTERMEDIATE AND ITS SIHB WITH CATALYTIC ASPARTATE 3.4.23.16
2.7.7.49
2.7.7.7
3.1.26.13
3.1.13.2
2.7.7
3.1
5YS4 CRYSTAL STRUCTURE OF RETROVIRAL PROTEASE-LIKE DOMAIN OF DDI1 FROM LEISHMANIA MAJOR 3.4.23
5YSI SDEA MART-C DOMAIN EE/AA NCA COMPLEX 3.4.22
2.3.2
2.4.2.31
5YSJ SDEA MART-C DOMAIN WT APO 3.4.22
2.3.2
2.4.2.31
5YSK SDEA MART-C DOMAIN EE/AA APO 3.4.22
2.3.2
2.4.2.31
5YTK CRYSTAL STRUCTURE OF SIRT3 BOUND TO A LEUCYLATED ACECS2 3.5.1
2.3.1.286
5YUQ THE HIGH RESOLUTION STRUCTURE OF CHITINASE (RMCHI1) FROM THE THERMOPHILIC FUNGUS RHIZOMUCOR MIEHEI (SP P1) 3.2.1.14
5YVD STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF ENDORIBONUCLEASE NSP15 ENCODED BY MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS 2.7.7.48
3.4.19.12
3.4.22.69
3.6.4.12
3.6.4.13
5YVJ CRYSTAL STRUCTURE OF FULL LENGTH NS2B47-NS3 (GD4NS2BNS3) FROM DENGUE VIRUS 4 IN OPEN CONFORMATION 3.4.21.91
3.6.1.15
3.6.4.13
5YVU CRYSTAL STRUCTURES OF UNLINKED FULL LENGTH NS3 FROM DENGUE VIRUS PROVIDE INSIGHTS INTO DYNAMICS OF PROTEASE DOMAIN 3.4.21.91
3.6.1.15
3.6.4.13
5YVV CRYSTAL STRUCTURE OF FULL LENGTH NS3 PROTEIN (GD4NS2BNS3) FROM DENV4 IN CLOSED CONFORMATION 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YVW CRYSTAL STRUCTURE OF FULL LENGTH NS3 PROTEIN (ED4NS2BNS3) FROM DENV4 IN CLOSED CONFORMATION 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YVY CRYSTAL STRUCTURE OF UNLINKED FULL LENGTH NS3 PROTEIN (ED4NS2BNS3) FROM DENV4 IN CLOSED CONFORMATION 3.4.21.91
3.6.1.15
3.6.4.13
5YW1 CRYSTAL STRUCTURE OF FULL LENGTH NS3 PROTEIN (ED4NS2BNS3) IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
5YWO STRUCTURE OF JEV-2F2 FAB COMPLEX 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YWP JEV-2H4 FAB COMPLEX 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YWS CRYSTAL STRUCTURE OF TREX1 IN COMPLEX WITH A Y STRUCTURED DNA 3.1.11.2
5YWT CRYSTAL STRUCTURE OF TREX1 IN COMPLEX WITH A DUPLEX DNA WITH 3' OVERHANG 3.1.11.2
5YWU CRYSTAL STRUCTURE OF TREX1 IN COMPLEX WITH A INOSINE CONTAINED DSDNA 3.1.11.2
5YWV CRYSTAL STRUCTURE OF TREX1 IN COMPLEX WITH A INOSINE CONTAINED SSDNA 3.1.11.2
5YXA CRYSTAL STRUCTURE OF THE C-TERMINAL FRAGMENT OF NS1 PROTEIN FROM YELLOW FEVER VIRUS 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5YXF MYCOBACTERIUM TUBERCULOSIS METHIONINE AMINOPEPTIDASE TYPE 1C (C105L MUTANT) IN COMPLEX WITH METHIONINE 3.4.11.18
5YXZ CO-CRYSTAL STRUCTURE OF KRAS (G12C) COVALENTLY BOUND WITH QUINAZOLINE BASED INHIBITOR JBI484 3.6.5.2
5YY1 CO-CRYSTAL STRUCTURE OF KRAS (G12C) COVALENTLY BOUND WITH QUINAZOLINE BASED INHIBITOR JBI739 3.6.5.2
5YZ7 CRYSTAL STRUCTURE OF OSD14 IN COMPLEX WITH D-RING-OPENED 7'-CARBA-4BD 3.1
5Z01 NATIVE ESCHERICHIA COLI L,D-CARBOXYPEPTIDASE A (LDCA) 3.4.17.13
5Z03 MUTANT (S106A) ESCHERICHIA COLI L,D-CARBOXYPEPTIDASE A (LDCA) 3.4.17.13
5Z0R STRUCTURAL INSIGHT INTO THE ZIKA VIRUS CAPSID ENCAPSULATING THE VIRAL GENOME 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5Z0T THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE I (TVA I) MUTANT A357V/Q359N/Y360E (AQY/VNE) 3.2.1.135
5Z0U THERMOACTINOMYCES VULGARIS R-47 ALPHA-AMYLASE I (TVA I) 11 RESIDUES (FROM A363 TO N373) DELETION MUTANT (DEL11) 3.2.1.135
5Z0V STRUCTURAL INSIGHT INTO THE ZIKA VIRUS CAPSID ENCAPSULATING THE VIRAL GENOME 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5Z1C THE CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH 4-IODOBENZYLAMINE AT PH7.4 3.4.21.73
5Z34 THE STRUCTURE OF A CHITIN DEACETYLASE FROM BOMBYX MORI PROVIDE THE FIRST INSIGHT INTO INSECT CHITIN DEACETYLATION MECHANISM 3.5.1.41
5Z37 CRYSTAL STRUCTURE OF ABRIN A CHAIN (RECOMBINANT) AT 1.3 ANGSTROMS 3.2.2.22
5Z3A GLYCOSIDASE WILD TYPE 3.2.1.205
5Z3C GLYCOSIDASE E178A 3.2.1.205
5Z3E GLYCOSIDASE E335A 3.2.1.205
5Z3F GLYCOSIDASE E335A IN COMPLEX WITH GLUCOSE 3.2.1.205
5Z3I CRYSTAL STRUCTURE OF ABRIN A CHAIN (RECOMBINANT) IN COMPLEX WITH ADENINE AT 1.65 ANGSTROMS 3.2.2.22
5Z3J CRYSTAL STRUCTURE OF ABRIN A CHAIN (RECOMBINANT) IN COMPLEX WITH NICOTINAMIDE AT 1.7 ANGSTROMS 3.2.2.22
5Z3M CRYSTAL STRUCTURE OF LOW MOLECULAR WEIGHT PHOSPHOTYROSINE PHOSPHATASE (VCLMWPTP-2) FROM VIBRIO CHOLERAEO395 3.1.3.48
5Z3Q CRYSTAL STRUCTURE OF A SOLUBLE FRAGMENT OF POLIOVIRUS 2C ATPASE (2.55 ANGSTROM) 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5Z40 CRYSTAL STRUCTURE OF PYRROLIDONE CARBOXYLATE PEPTIDASE I FROM DEIONOCOCCUS RADIODURANS R1 3.4.19.3
5Z47 CRYSTAL STRUCTURE OF PYRROLIDONE CARBOXYLATE PEPTIDASE I WITH DISORDERED LOOP A FROM DEINOCOCCUS RADIODURANS R1 3.4.19.3
5Z48 CRYSTAL STRUCTURE OF PYRROLIDONE CARBOXYLATE PEPTIDASE I FROM DEINOCOCCUS RADIODURANS R1 BOUND TO PYROGLUTAMATE 3.4.19.3
5Z5D CRYSTAL STRUCTURE OF A THERMOSTABLE GLYCOSIDE HYDROLASE FAMILY 43 {BETA}-1,4-XYLOSIDASE FROM GEOBACILLUS THERMOLEOVORANS IT-08 3.2.1.37
5Z5F CRYSTAL STRUCTURE OF A THERMOSTABLE GLYCOSIDE HYDROLASE FAMILY 43 {BETA}-1,4-XYLOSIDASE FROM GEOBACILLUS THERMOLEOVORANS IT-08 IN COMPLEX WITH L-ARABINOSE 3.2.1.37
5Z5H CRYSTAL STRUCTURE OF A THERMOSTABLE GLYCOSIDE HYDROLASE FAMILY 43 {BETA}-1,4-XYLOSIDASE FROM GEOBACILLUS THERMOLEOVORANS IT-08 IN COMPLEX WITH D-XYLOSE 3.2.1.37
5Z5I CRYSTAL STRUCTURE OF A THERMOSTABLE GLYCOSIDE HYDROLASE FAMILY 43 {BETA}-1,4-XYLOSIDASE FROM GEOBACILLUS THERMOLEOVORANS IT-08 IN COMPLEX WITH L-ARABINOSE AND D-XYLOSE 3.2.1.37
5Z5M CRYSTAL STRUCTURE OF (S)-ALLANTOIN SYNTHASE 3.5.2.17
4.1.1.97
5Z5O STRUCTURE OF PYCNONODYSOSTOSIS DISEASE RELATED I249T MUTANT OF HUMAN CATHEPSIN K 3.4.22.38
5Z5X HVF18 IN COMPLEX WITH LPS MICELLES 3.4.21.5
5Z65 CRYSTAL STRUCTURE OF PORCINE AMINOPEPTIDASE N ECTODOMAIN IN FUNCTIONAL FORM 3.4.11
3.4.11.2
5Z66 STRUCTURE OF PERIPLASMIC TREHALASE FROM DIAMONDBACK MOTH GUT BACTERIA COMPLEXED WITH VALIDOXYLAMINE 3.2.1.28
5Z6H STRUCTURE OF PERIPLASMIC TREHALASE FROM DIAMONDBACK MOTH GUT BACTERIA IN THE APO FORM 3.2.1.28
5Z6O CRYSTAL STRUCTURE OF PENICILLIUM CYCLOPIUM PROTEASE 3.4.21.64
5Z6Q CRYSTAL STRUCTURE OF AAA OF SPASTIN 3.6.4.3
5.6.1.1
5Z6R SPASTIN AAA WITH ATP 3.6.4.3
5.6.1.1
5Z6W CRYSTAL STRUCTURE OF PAFAN1 BOUND TO 2NT 5'FLAP DNA WITH GAP WITH MANGANESE 3.1.4.1
5Z73 CRYSTAL STRUCTURE OF ALKALINE/NEUTRAL INVERTASE INVB FROM ANABAENA SP. PCC 7120 3.2.1.26
5Z74 CRYSTAL STRUCTURE OF ALKALINE/NEUTRAL INVERTASE INVB FROM ANABAENA SP. PCC 7120 COMPLEXED WITH SUCROSE 3.2.1.26
5Z7C CRYSTAL STRUCTURE OF CYCLIC GMP-AMP SPECIFC PHOSPHODIESTERASES IN V.CHOLERAE (V-CGAP3) 3.1.4
5Z7M SMCHIA SLIDING-INTERMEDIATE WITH CHITOHEXAOSE 3.2.1.14
5Z7N SMCHIA SLIDING-INTERMEDIATE WITH CHITOPENTAOSE 3.2.1.14
5Z7O SMCHIA SLIDING-INTERMEDIATE WITH CHITOTETRAOSE 3.2.1.14
5Z7P SMCHIA SLIDING-INTERMEDIATE WITH CHITOTRIOSE 3.2.1.14
5Z93 CRYSTAL STRUCTURE OF SIRT3 IN COMPLEX WITH H3K9BHB PEPTIDE 3.5.1
2.3.1.286
5Z94 CRYSTAL STRUCTURE OF SIRT3 IN COMPLEX WITH H3K4BHB PEPTIDE 3.5.1
2.3.1.286
5Z9X ARABIDOPSIS SMALL RNA DEGRADING NUCLEASE 1 IN COMPLEX WITH AN RNA SUBSTRATE 3.1
5Z9Z THE C-TERMINAL RRM DOMAIN OF ARABIDOPSIS SMALL RNA DEGRADING NUCLEASE 1 (E329A/E330A/E332A) 3.1
5ZA2 FOX-4 BETA-LACTAMASE COMPLEXED WITH AVIBACTAM 3.5.2.6
5ZA7 UPA-HMA 3.4.21.73
5ZA8 UPA-BB2-27F 3.4.21.73
5ZA9 UPA-BB2-50F 3.4.21.73
5ZAE UPA-6F-HMA 3.4.21.73
5ZAF UPA-BB2-28F 3.4.21.73
5ZAG UPA-BB2-94F 3.4.21.73
5ZAH UPA-BB2-30F 3.4.21.73
5ZAJ UPA-31F 3.4.21.73
5ZAK CRYO-EM STRUCTURE OF HUMAN DICER AND ITS COMPLEXES WITH A PRE-MIRNA SUBSTRATE 3.1.26.3
5ZAL CRYO-EM STRUCTURE OF HUMAN DICER AND ITS COMPLEXES WITH A PRE-MIRNA SUBSTRATE 3.1.26.3
5ZAM CRYO-EM STRUCTURE OF HUMAN DICER AND ITS COMPLEXES WITH A PRE-MIRNA SUBSTRATE 3.1.26.3
5ZB7 CTX-M-64 APOENZYME 3.5.2.6
5ZBH THE CRYSTAL STRUCTURE OF HUMAN NEUROPEPTIDE Y Y1 RECEPTOR WITH BMS-193885 3.2.1.17
5ZBJ CRYSTAL STRUCTURE OF TYPE-I LOG FROM PSEUDOMONAS AERUGINOSA PAO1 3.2.2
3.2.2.4
5ZBK CRYSTAL STRUCTURE OF TYPE-I LOG FROM PSEUDOMONAS AERUGINOSA PAO1 IN COMPLEX WITH AMP 3.2.2
3.2.2.4
5ZBL CRYSTAL STRUCTURE OF TYPE-I LOG FROM CORYNEBACTERIUM GLUTAMICUM IN COMPLEX WITH AMP 3.2.2
5ZBQ THE CRYSTAL STRUCTURE OF HUMAN NEUROPEPTIDE Y Y1 RECEPTOR WITH UR-MK299 3.2.1.17
5ZBZ CRYSTAL STRUCTURE OF THE DEAD DOMAIN OF HUMAN EIF4A WITH SANGUINARINE 3.6.4.13
5ZC5 UPA-NU-09F 3.4.21.73
5ZC6 SOLUTION STRUCTURE OF H-RAST35S MUTANT PROTEIN IN COMPLEX WITH KBFM123 3.6.5.2
5ZC9 CRYSTAL STRUCTURE OF THE HUMAN EIF4A1-ATP ANALOG-ROCA-POLYPURINE RNA COMPLEX 3.6.4.13
5ZCG CRYSTAL STRUCTURE OF OSPP2C50 S265L/I267V:OSPYL/RCAR3 WITH (+)-ABA 3.1.3.16
5ZCH CRYSTAL STRUCTURE OF OSPP2C50 I267W:OSPYL/RCAR3 WITH (+)-ABA 3.1.3.16
5ZCL CRYSTAL STRUCTURE OF OSPP2C50 I267L:OSPYL/RCAR3 WITH (+)-ABA 3.1.3.16
5ZCU CRYSTAL STRUCTURE OF RCAR3:PP2C WILD-TYPE WITH PYRABACTIN 3.1.3.16
5ZDZ HAIRPIN FORMING COMPLEX, RAG1/2-NICKED 12RSS/23RSS COMPLEX IN CA2+ 3.1
2.3.2.27
5ZE0 HAIRPIN FORMING COMPLEX, RAG1/2-NICKED(WITH DIDEOXY) 12RSS/23RSS COMPLEX IN MG2+ 3.1
2.3.2.27
5ZE1 HAIRPIN FORMING COMPLEX, RAG1/2-NICKED 12RSS/23RSS COMPLEX IN 2MM MN2+ FOR 10 MIN AT 4'C 3.1
2.3.2.27
5ZE2 HAIRPIN COMPLEX, RAG1/2-HAIRPIN 12RSS/23RSS COMPLEX IN 5MM MN2+ FOR 2 MIN AT 4'C 3.1
2.3.2.27
5ZE9 CRYSTAL STRUCTURE OF AMP-PNP BOUND MUTANT A3B3 COMPLEX FROM ENTEROCOCCUS HIRAE V-ATPASE 3.6.3.15
7.2.2.1
5ZEE CRYSTAL STRUCTURE OF ENTAMOEBA HISTOLYTICA ARGINASE IN COMPLEX WITH N(OMEGA)-HYDROXY-L-ARGININE (NOHA) AT 1.74 A 3.5.3.1
5ZEF CRYSTAL STRUCTURE OF ENTAMOEBA HISTOLYTICA ARGINASE IN COMPLEX WITH L- NORVALINE AT 2.01 A 3.5.3.1
5ZEH CRYSTAL STRUCTURE OF ENTAMOEBA HISTOLYTICA ARGINASE IN COMPLEX WITH L- ORNITHINE AT 2.35 A 3.5.3.1
5ZEQ CARBOXYPEPTIDASE B IN COMPLEX WITH DD28 3.4.17.2
5ZF3 CRYSTAL STRUCTURES OF ENDO-BETA-1,4-XYLANASE II COMPLEXED WITH XYLOTRIOSE 3.2.1.8
5ZFH MOUSE KALLIKREIN 7 3.4.21.117
5ZFI MOUSE KALLIKREIN 7 IN COMPLEX WITH 6-BENZYL-1,4-DIAZEPAN-7-ONE DERIVATIVE 3.4.21.117
5ZFL CRYSTAL STRUCTURE OF BETA-LACTAMASE PENP MUTANT E166Y 3.5.2.6
5ZFT CRYSTAL STRUCTURE OF BETA-LACTAMASE PENP MUTANT-E166Y IN COMPLEX WITH CEPHALORIDINE AS PRE-DEACYLATION" INTERMEDIATE" 3.5.2.6
5ZG6 CRYSTAL STRUCTURE OF BETA-LACTAMASE PENP MUTANT-E166Y IN COMPLEX WITH CEPHALORIDINE AS POST-ACYLATION" INTERMEDIATE" 3.5.2.6
5ZGC CRYSTAL STRUCTURE OF SIRT3 IN COMPLEX WITH H4K16BHB PEPTIDE 3.5.1
2.3.1.286
5ZGE CRYSTAL STRUCTURE OF NDM-1 AT PH5.5 (BIS-TRIS) IN COMPLEX WITH HYDROLYZED AMPICILLIN 3.5.2.6
5ZGF CRYSTAL STRUCTURE OF NDM-1 Q123G MUTANT 3.5.2.6
5ZGI CRYSTAL STRUCTURE OF NDM-1 AT PH6.5 (SUCCINATE) WITH 1 MOLECULE PER ASYMMETRIC UNIT 3.5.2.6
5ZGP CRYSTAL STRUCTURE OF NDM-1 AT PH6.2 (BIS-TRIS) IN COMPLEX WITH HYDROLYZED AMPICILLIN 3.5.2.6
5ZGQ CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 (TRIS-HCL, (NH4)2SO4) IN COMPLEX WITH HYDROLYZED AMPICILLIN 3.5.2.6
5ZGR CRYSTAL STRUCTURE OF NDM-1 AT PH7.3 (HEPES) IN COMPLEX WITH HYDROLYZED AMPICILLIN 3.5.2.6
5ZGT CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 (HEPES) WITH 2 MOLECULES PER ASYMMETRIC UNIT 3.5.2.6
5ZGU CRYSTAL STRUCTURE OF NDM-1 AT PH7.0 (HEPES) WITH 2 MOLECULES PER ASYMMETRIC UNIT 3.5.2.6
5ZGV CRYSTAL STRUCTURE OF NDM-1 AT PH8.0 (TRIS) WITH 2 MOLECULES PER ASYMMETRIC UNIT 3.5.2.6
5ZGW CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 WITH 1 MOLECULE PER ASYMMETRIC UNIT (CRYSTALLIZED AT SUCCINATE PH5.5 AND SOAKED AT SUCCINATE PH7.5) 3.5.2.6
5ZGX CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 (SUCCINATE) WITH 1 MOLECULE PER ASYMMETRIC UNIT 3.5.2.6
5ZGY CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 (BIS-TRIS) WITH 1 MOLECULE PER ASYMMETRIC UNIT 3.5.2.6
5ZGZ CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 (IMIDAZOLE) WITH 1 MOLECULE PER ASYMMETRIC UNIT 3.5.2.6
5ZH0 CRYSTAL STRUCTURES OF ENDO-BETA-1,4-XYLANASE II 3.2.1.8
5ZH1 CRYSTAL STRUCTURE OF NDM-1 AT PH7.5 (IMIDAZOLE) WITH 2 MOLECULES PER ASYMMETRIC UNIT 3.5.2.6
5ZH8 CRYSTAL STRUCTURE OF FMTA FROM STAPHYLOCOCCUS AUREUS AT 2.58 A 3.1.1.103
5ZH9 CRYSTAL STRUCTURES OF MUTANT ENDO-BETA-1,4-XYLANASE II (Y88F) 3.2.1.8
5ZHF STRUCTURE OF VANYB UNBOUND 3.4.16.4
3.4.17
5ZHH STRUCTURE OF INOSITOL MONOPHOSPHATASE FROM ANABAENA (NOSTOC) SP. PCC 7120 3.1.3.25
5ZHP M3 MUSCARINIC ACETYLCHOLINE RECEPTOR IN COMPLEX WITH A SELECTIVE ANTAGONIST 3.2.1.17
5ZHR CRYSTAL STRUCTURE OF OSD14 IN COMPLEX WITH COVALENTLY BOUND KK094 3.1
5ZHS CRYSTAL STRUCTURE OF OSD14 IN COMPLEX WITH COVALENTLY BOUND KK052 3.1
5ZHT CRYSTAL STRUCTURE OF OSD14 IN COMPLEX WITH COVALENTLY BOUND KK073 3.1
5ZHU CRYSTAL STRUCTURE OF THE DNA-BINDING DOMAIN OF HUMAN MYELIN-GENE REGULATORY FACTOR 3.4
5ZHW VANYB IN COMPLEX WITH D-ALANINE-D-ALANINE 3.4.16.4
3.4.17
5ZHZ CRYSTAL STRUCTURE OF THE APURINIC/APYRIMIDINIC ENDONUCLEASE IV FROM MYCOBACTERIUM TUBERCULOSIS 3.1.21.2
5ZI5 CRYSTAL STRUCTURE OF LEGIONELLA PNEUMOPHILA AMINOPEPTIDASE A 3.4.11.2
5ZI7 CRYSTAL STRUCTURE OF LEGIONELLA PNEUMOPHILA AMINOPEPTIDASE A IN COMPLEX WITH GLUTAMIC ACID 3.4.11.2
5ZI9 CRYSTAL STRUCTURE OF TYPE-II LOG FROM STREPTOMYCES COELICOLOR A3 3.2.2
5ZID CRYSTAL STRUCTURE OF HUMAN DPP-IV IN COMPLEX WITH HL2 3.4.14.5
5ZIE CRYSTAL STRUCTURE OF LEGIONELLA PNEUMOPHILA AMINOPEPTIDASE A IN COMPLEX WITH ASPARTIC ACID 3.4.11.2
5ZII CRYSTAL STRUCTURES OF MUTANT ENDO-BETA-1,4-XYLANASE II (Y88F)COMPLEXED WITH XYLOTRIOSE 3.2.1.8
5ZIO CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH L-CAPTOPRIL 3.5.2.6
5ZIT CRYSTAL STRUCTURE OF HUMAN ENTEROVIRUS D68 RDRP IN COMPLEX WITH NADPH 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5ZIU CRYSTAL STRUCTURE OF HUMAN ENTERVIRUS D68 RDRP 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
5ZIW CRYSTAL STRUCTURES OF MUTANT ENDO-BETA-1,4-XYLANASE(Y77F) 3.2.1.8
5ZJ1 CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH D-CAPTOPRIL DERIVATIVE CYT-14 3.5.2.6
5ZJ2 CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH D-CAPTOPRIL 3.5.2.6
5ZJ7 CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH D-CAPTOPRIL DERIVATIVE CY22 3.5.2.6
5ZJ8 CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH D-CAPTOPRIL DERIVATIVE CY32 3.5.2.6
5ZJC CRYSTAL STRUCTURE OF NDM-1 IN COMPLEX WITH D-CAPTOPRIL DERIVATIVE CY41 3.5.2.6
5ZK0 CRYSTAL STRUCTURE OF PEPTIDYL-TRNA HYDROLASE MUTANT -M71A FROM VIBRIO CHOLERAE 3.1.1.29
5ZKI HUMAN EXOG-H140A IN COMPLEX WITH DUPLEX DNA 3.1.30
5ZKJ HUMAN EXOG-H140A IN COMPLEX WITH RNA/DNA HYBRID DUPLEX 3.1.30
5ZKQ CRYSTAL STRUCTURE OF THE HUMAN PLATELET-ACTIVATING FACTOR RECEPTOR IN COMPLEX WITH ABT-491 3.2.1.17
5ZKS CRYSTAL STRUCTURE OF DFA-IIIASE FROM ARTHROBACTER CHLOROPHENOLICUS A6 3.2.1
4.2.2.17
5ZKU CRYSTAL STRUCTURE OF DFA-IIIASE FROM ARTHROBACTER CHLOROPHENOLICUS A6 IN COMPLEX WITH DFA-III 3.2.1
4.2.2.17
5ZKW CRYSTAL STRUCTURE OF DFA-IIIASE FROM ARTHROBACTER CHLOROPHENOLICUS A6 IN COMPLEX WITH GF2 3.2.1
4.2.2.17
5ZKZ CRYSTAL STRUCTURES OF MUTANT ENDO-BETA-1,4-XYLANASE II(Y77F) COMPLEXED WITH XYLOTRIOSE 3.2.1.8
5ZL5 CRYSTAL STRUCTURE OF DFA-IIIASE MUTANT C387A FROM ARTHROBACTER CHLOROPHENOLICUS A6 3.2.1
4.2.2.17
5ZLA CRYSTAL STRUCTURE OF MUTANT C387A OF DFA-IIIASE FROM ARTHROBACTER CHLOROPHENOLICUS A6 IN COMPLEX WITH DFA-III 3.2.1
4.2.2.17
5ZLR STRUCTURE OF NEUC 3.2.1.184
3.2.1.183
5ZLT CRYSTAL STRUCTURE OF UDP-GLCNAC 2-EPIMERASE NEUC COMPLEXED WITH UDP 3.2.1.184
3.2.1.183
5ZLZ STRUCTURE OF TPA AND PAI-1 3.4.21.68
5ZMA STRUCTURAL BASIS FOR AN ALLOSTERIC EYA2 PHOSPHATASE INHIBITOR 3.1.3.48
5ZMF AMPPNP COMPLEX OF C. REINHARDTII ARSA1 3.6
5ZMQ CRYSTAL STRUCTURE OF ZIKA NS3 PROTEASE WITH PHENYLACETYL-LYS-LYS-ARG-COOH INHIBITOR 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5ZMS CRYSTAL STRUCTURE OF ZIKA NS3 PROTEASE IN COMPLEX WITH 4-GUANIDINOMETHYL-PHENYLACETYL-LYS-LYS-ARG-H 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5ZMV CRYSTAL STRUCTURE OF THE E309A MUTANT OF SR CA2+-ATPASE IN E2(TG) 3.6.3.8
7.2.2.10
5ZMW CRYSTAL STRUCTURE OF THE E309Q MUTANT OF SR CA2+-ATPASE IN E2(TG) 3.6.3.8
7.2.2.10
5ZN8 CRYSTAL STRUCTURE OF NICOTINAMIDASE PNCA FROM BACILLUS SUBTILIS 3
5ZNL CRYSTAL STRUCTURE OF PDE10A CATALYTIC DOMAIN COMPLEXED WITH LHB-6 3.1.4.17
3.1.4.35
5ZNO CRYSTAL STRUCTURE OF PET-DEGRADING CUTINASE CUT190 S176A/S226P/R228S/ MUTANT IN CA(2+)-BOUND STATE 3.1.1.74
5ZNS INSECT CHITIN DEACETYLASE 3.5.1.41
5ZNT INSECT CHITIN DEACETYLASE 3.5.1.41
5ZO3 APO FORM OF THE NUCLEASE 3.1.13
5ZO4 INACTIVE STATE OF THE NUCLEASE 3.1.13
5ZO5 ACTIVE STATE OF THE NUCLEASE 3.1.13
5ZOA THE CRYSTAL STRUCTURE OF A THERMOBIFIDA FUSCA CUTINASE 3.1.1.74
5ZOB CRYSTAL STRUCTURE OF ZIKA NS3 PROTEASE WITH 4-GUANIDINOMETHYL-PHENYLACETYL-ARG-ARG-ARG-4-AMIDINOBENZYLAMIDE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
5ZOD CRYSTAL STRUCTURE OF HFEN1 IN APO FORM 3.1
5ZOE CRYSTAL STRUCTURE OF D181A HFEN1 IN COMPLEX WITH DNA 3.1
5ZOF CRYSTAL STRUCTURE OF D181A/R192F HFEN1 IN COMPLEX WITH DNA 3.1
5ZOG CRYSTAL STRUCTURE OF R192F HFEN1 IN COMPLEX WITH DNA 3.1
5ZON HISTIDINOL PHOSPHATE PHOSPHATASE FROM MYCOBACTERIUM TUBERCULOSIS 3.1.3.15
5ZQG COMPLEX STRUCTURE OF PEDV 3CLPRO MUTANT (C144A) WITH NEMO-231 PEPTITE SUBSTRATE 2.7.7.48
3.4.19.12
3.6.4.12
3.6.4.13
5ZQK DENGUE VIRUS NON STRUCTURAL PROTEIN 5 3.4.21.91
3.6.1.15
3.6.4.13
5ZQL CRYSTAL STRUCTURE OF HUMAN KATANIN AAA ATPASE DOMAIN 3.6.4.3
5.6.1.1
5ZQM CRYSTAL STRUCTURE OF HUMAN KATANIN AAA ATPASE DOMAIN COMPLEX WITH ATPGAMMAS 3.6.4.3
5.6.1.1
5ZQV CRYSTAL STRUCTURE OF PROTEIN PHOSPHATE 1 COMPLEXED WITH PP1 BINDING DOMAIN OF GM 3.1.3.16
5ZQX CRYSTAL STRUCTURE OF BETA-XYLOSIDASE MUTANT (E186Q) FROM BACILLUS PUMILUS 3.2.1.37
5ZQY CRYSTAL STRUCTURE OF A POLY(ADP-RIBOSE) GLYCOHYDROLASE 3.2.1.143
3.5.1
3.2.2
5ZRC STRUCTURAL INSIGHTS INTO THE CATALYSIS MECHANISM OF M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 3.6.1
5ZRG M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 IN COMPLEX WITH DCMP 3.6.1
5ZRH M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 IN COMPLEX WITH CMP 3.6.1
5ZRI M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 IN COMPLEX WITH 5M-DCMP 3.6.1
5ZRK M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 IN COMPLEX WITH DCTP 3.6.1
5ZRL M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 IN COMPLEX WITH CDP 3.6.1
5ZRO M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 IN COMPLEX WITH 5MDCTP 3.6.1
5ZRP M. SMEGMATIS ANTIMUTATOR PROTEIN MUTT2 FORM 3 3.6.1
5ZRX CRYSTAL STRUCTURE OF EPHA2/SHIP2 COMPLEX 3.1.3.86
2.7.10.1
5ZT0 CRYSTAL STRUCTURE OF PROTEIN PHOSPHATE 1 COMPLEXED WITH PP1 BINDING DOMAIN OF GL 3.1.3.16
5ZT1 STRUCTURE OF THE BACTERIAL PATHOGENS ATPASE WITH SUBSTRATE ATP GAMMA S 3.6.3.14
7.1.2.2
5ZTF STRUCTURE OF CA2+ ATPASE 3.6.3.8
7.2.2.10
5ZTM CRYSTAL STRUCTURE OF MLE DSRBDS IN COMPLEX WITH ROX2 (R2H1) 3.6.4.13
5ZTY CRYSTAL STRUCTURE OF HUMAN G PROTEIN COUPLED RECEPTOR 3.2.1.17
5ZU1 CRYSTAL STRUCTURE OF BZ JUNCTION IN DIVERSE SEQUENCE 3.5.4.37
5ZU7 CRYSTAL STRUCTURE OF MERS-COV MACRO DOMAIN IN COMPLEX WITH AMP 3.4.19.12
3.4.22.69
5ZU9 CRYSTAL STRUCTURE OF MERS-COV MACRO DOMAIN IN COMPLEX WITH ADP 3.4.19.12
3.4.22.69
5ZUA CRYSTAL STRUCTURE OF MERS-COV MACRO DOMAIN IN COMPLEX WITH ATP 3.4.19.12
3.4.22.69
5ZUB CRYSTAL STRUCTURE OF MERS-COV MACRO DOMAIN IN COMPLEX WITH NAD 3.4.19.12
3.4.22.69
5ZUN CRYSTAL STRUCTURE OF HUMAN MONOACYLGLYCEROL LIPASE IN COMPLEX WITH COMPOUND 3L 3.1.1.23
5ZUO CRYSTAL STRUCTURE OF BZ JUNCTION IN DIVERSE SEQUENCE 3.5.4.37
5ZUP CRYSTAL STRUCTURE OF BZ JUNCTION IN DIVERSE SEQUENCE 3.5.4.37
5ZUU CRYSTAL STRUCTURE OF ATCPSF30 YTH DOMAIN IN COMPLEX WITH 10MER M6A-MODIFIED RNA 3.1.21
5ZVA APOBEC3F CHIMERIC CATALYTIC DOMAIN IN COMPLEX WITH DNA(DC9) 3.5.4
3.5.4.38
5ZVB APOBEC3F CHIMERIC CATALYTIC DOMAIN IN COMPLEX WITH DNA(DT9) 3.5.4
3.5.4.38
5ZVJ CRYSTAL STRUCTURE OF HTRA1 FROM MYCOBACTERIUM TUBERCULOSIS 3.4.21
3.4.21.107
5ZWK CRYSTAL STRUCTURE OF HUMAN LIVER FRUCTOSE-1,6-BISPHOAPHATASE COMPLEX WITH FRUCTOSE-1,6-BISPHOPHATE AND AMP 3.1.3.11
5ZX8 CRYSTAL STRUCTURE OF PEPTIDYL-TRNA HYDROLASE FROM THERMUS THERMOPHILUS 3.1.1.29
5ZYB CRYSTAL STRUCTURE OF MOX-1 COMPLEXED WITH A BORONIC ACID TRANSITION STATE INHIBITOR S02030 3.5.2.6
5ZYF CRYSTAL STRUCTURE OF STREPTOCOCCUS PYOGENES TYPE II-A CAS2 3.1
5ZYT CRYSTAL STRUCTURE OF HUMAN MGME1 WITH 3' OVERHANG DOUBLE STRAND DNA3 3.1
5ZYV CRYSTAL STRUCTURE OF HUMAN MGME1 WITH SINGLE STRAND DNA2 AND CA2+ 3.1
5ZYW THE CRYSTAL STRUCTURE OF APO-HSMGME1 WITH MN2+ 3.1
5ZZ2 CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR LW1634 3.1.4.35
5ZZV CRYSTAL STRUCTURE OF PEG-1500 CRYSTALLIZED PEPTIDYL-TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII AT 1.5 A RESOLUTION 3.1.1.29
621P THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES 3.6.5.2
6A0E CRYSTAL STRUCTURE OF HUMAN PROTEIN N-TERMINAL ASPARAGINE AMIDOHYDROLASE (NTAN1) 3.5.1
3.5.1.121
6A0F CRYSTAL STRUCTURE OF HUMAN PROTEIN N-TERMINAL ASPARAGINE AMIDOHYDROLASE (NTAN1) C75S MUTANT WITH ASN-PHE-ALA-ALA-ARG PEPTIDE 3.5.1
3.5.1.121
6A0H CRYSTAL STRUCTURE OF HUMAN PROTEIN N-TERMINAL ASPARAGINE AMIDOHYDROLASE (NTAN1) C75S MUTANT WITH ASN-LEU-ALA-ALA-ARG PEPTIDE 3.5.1
3.5.1.121
6A0I CRYSTAL STRUCTURE OF HUMAN PROTEIN N-TERMINAL ASPARAGINE AMIDOHYDROLASE (NTAN1) C75S MUTANT 3.5.1
3.5.1.121
6A0P CRYSTAL STRUCTURE OF USUTU VIRUS ENVELOPE PROTEIN IN THE PRE-FUSION STATE 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
6A10 CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME CRYSTALLIZED BY AMMONIUM SULFATE 3.2.1.17
6A12 X-RAY STRUCTURE OF LIPASE FROM GEOBACILLUS THERMOLEOVORANS 3.1.1.3
6A2Q MYCOBACTERIUM TUBERCULOSIS LEXA C-DOMAIN I 3.4.21.88
6A2R MYCOBACTERIUM TUBERCULOSIS LEXA C-DOMAIN II 3.4.21.88
6A2S MYCOBACTERIUM TUBERCULOSIS LEXA C-DOMAIN S160A 3.4.21.88
6A2T MYCOBACTERIUM TUBERCULOSIS LEXA C-DOMAIN K197A 3.4.21.88
6A31 CRYSTAL STRUCTURE OF NA+ BOUND PEPTIDYL-TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII AT 2.19 A RESOLUTION 3.1.1.29
6A3H 2-DEOXY-2-FLURO-B-D-CELLOTRIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.6 ANGSTROM RESOLUTION 3.2.1.4
6A3N CRYSTAL STRUCTURE OF THE PDE9 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 2 3.1.4.35
6A45 STRUCTURE OF MOUSE TREX2 3.1.11.2
6A46 STRUCTURE OF TREX2 IN COMPLEX WITH A NUCLEOTIDE (DCMP) 3.1.11.2
6A47 STRUCTURE OF TREX2 IN COMPLEX WITH A Y STRUCTURED DSDNA 3.1.11.2
6A48 CRYSTAL STRUCTURE OF REELIN N-TERMINAL REGION 3.4.21
6A4A OLIGORIBONUCLEASE (ORN) FROM COLWELLIA PSYCHRERYTHRAEA STRAIN 34H 3.1
6A4D PNP-TMP BOUND OLIGORIBONUCLEASE (ORN) FROM COLWELLIA PSYCHRERYTHRAEA STRAIN 34H 3.1
6A4E TWO LINKED URIDINE BOUND OLIGORIBONUCLEASE (ORN) FROM COLWELLIA PSYCHRERYTHRAEA STRAIN 34H 3.1
6A4F SEPARATED URIDINE BOUND OLIGORIBONUCLEASE (ORN) FROM COLWELLIA PSYCHRERYTHRAEA STRAIN 34H 3.1
6A4N HEWL CRYSTALS SOAKED IN 2.5M GUHCL FOR 8 MINUTES 3.2.1.17
6A4O HEWL CRYSTALS SOAKED IN 2.5M GUHCL FOR 20 MINUTES 3.2.1.17
6A4P HEWL CRYSTALS SOAKED IN 2.5M GUHCL FOR 40 MINUTES 3.2.1.17
6A4Q HEWL CRYSTALS SOAKED IN 2.5M GUHCL FOR 110 MINUTES 3.2.1.17
6A4R CRYSTAL STRUCTURE OF ASPARTATE BOUND PEPTIDASE E FROM SALMONELLA ENTERICA 3.4.13.21
6A4S CRYSTAL STRUCTURE OF PEPTIDASE E WITH ORDERED ACTIVE SITE LOOP FROM SALMONELLA ENTERICA 3.4.13.21
6A4T CRYSTAL STRUCTURE OF PEPTIDASE E FROM DEINOCOCCUS RADIODURANS R1 3.4.21
6A69 CRYO-EM STRUCTURE OF A P-TYPE ATPASE 3.6.3.8
7.2.2.10
6A6A VANYB IN COMPLEX WITH D-ALANINE 3.4.16.4
3.4.17
6A6C CRYSTAL STRUCTURE OF CARBOHYDRATE-BINDING MODULE FAMILY 56 BETA-1,3-GLUCAN BINDING DOMAIN 3.2.1.39
6A6X THE CRYSTAL STRUCTURE OF THE MTB MAZE-MAZF-MT9 COMPLEX 3.1
6A7V CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS VAPBC11 TOXIN-ANTITOXIN COMPLEX 3.1
6A8G THE CRYSTAL STRUCTURE OF MUPAIN-1-IG IN COMPLEX WITH MUPA-SPD AT PH8.5 3.4.21.73
6A8H CRYSTAL STRUCTURE OF ENDO-ARABINANASE ABN-TS D27A MUTANT IN COMPLEX WITH ARABINOTRIOSE 3.2.1.99
6A8I CRYSTAL STRUCTURE OF ENDO-ARABINANASE ABN-TS D147N MUTANT IN COMPLEX WITH ARABINOHEXAOSE 3.2.1.99
6A8L CRYSTAL STRUCTURE OF NICOTINAMIDASE/ PYRAZINAMIDASE PNCA FROM BACILLUS SUBTILIS 3
6A8N THE CRYSTAL STRUCTURE OF MUPAIN-1-IG-2 IN COMPLEX WITH MUPA-SPD AT PH8.5 3.4.21.73
6A8O CRYSTAL STRUCTURES OF THE SERINE PROTEASE DOMAIN OF MURINE PLASMA KALLIKREIN WITH PEPTIDE INHIBITOR MUPAIN-1-16 3.4.21.34
6A8U PHOQ SENSOR DOMAIN (WILD TYPE): ANALYSIS OF INTERNAL CAVITY 2.7.13.3
3.1.3
6A8V PHOQ SENSOR DOMAIN (D179R MUTANT): ANALYSIS OF INTERNAL CAVITY 2.7.13.3
3.1.3
6A8Y YR26_SDS 3.4.21.75
6A8Z CRYSTAL STRUCTURE OF M1 ZINC METALLOPEPTIDASE FROM DEINOCOCCUS RADIODURANS 3.4.11.2
6A9E CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF ATG2 3.2.1.17
6A9J CRYSTAL STRUCTURE OF THE PE-BOUND N-TERMINAL DOMAIN OF ATG2 3.2.1.17
6A9T CRYSTAL STRUCTURE OF ICP55 FROM SACCHAROMYCES CEREVISIAE (N-TERMINAL 58 RESIDUES DELETION) 3.4.11.26
6A9U CRYSTAL STRCTURE OF ICP55 FROM SACCHAROMYCES CEREVISIAE BOUND TO APSTATIN INHIBITOR 3.4.11.26
6A9V CRYSTAL STRUCTURE OF ICP55 FROM SACCHAROMYCES CEREVISIAE (N-TERMINAL 42 RESIDUES DELETION) 3.4.11.26
6AA3 CRYSTAL STRUCTURE OF MTH1 IN APO FORM (COCKTAIL NO. 1) 3.6.1.55
3.6.1.56
6AA4 CRYSTAL STRUCTURE OF MTH1 IN COMPLEX WITH ALPHA-MANGOSTIN (COCKTAIL NO. 9) 3.6.1.55
3.6.1.56
6AA5 CRYSTAL STRUCTURE OF MTH1 IN COMPLEX WITH 3-ISOMANGOSTIN 3.6.1.55
3.6.1.56
6AAE CRYSTAL STRUCTURE OF CHLORAMPHENICOL-METABOLIZAING ENZYME ESTDL136 3.1.1.1
6ABN CRYSTAL STRUCTURE OF HEWL AT PH 8.6 3.2.1.17
6ABZ CRYSTAL STRUCTURE OF HEWL IN DEIONIZED WATER 3.2.1.17
6AC2 CRYSTAL STRUCTURE OF HEWL AT PH 2.2 3.2.1.17
6AC6 AB INITIO CRYSTAL STRUCTURE OF SELENOMETHIONINE LABELLED MYCOBACTERIUM SMEGMATIS MFD 3.6.4
6ACA CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS MFD AT 3.6 A RESOLUTION 3.6.4
6ACB CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR LW1805 3.1.4.35
6ACE HISTONE LYSINE DESUCCINYLASE SIRT5 IN COMPLEX WITH SUCCINYL PEPTIDE H3K122 3.5.1
2.3.1
6ACL HISTONE LYSINE DESUCCINYLASE SIRT5 IN COMPLEX WITH SUCCINYL PEPTIDE H2AK95 3.5.1
2.3.1
6ACO HISTONE LYSINE DESUCCINYLASE SIRT5 IN COMPLEX WITH SUCCINYL PEPTIDE H2BK120 3.5.1
2.3.1
6ACP HISTONE LYSINE DESUCCINYLASE SIRT5 IN COMPLEX WITH SUCCINYL PEPTIDE H4K91 3.5.1
2.3.1
6ACU THE STRUCTURE OF CVA10 VIRUS MATURE VIRION 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6ACW THE STRUCTURE OF CVA10 VIRUS PROCAPSID PARTICLE 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6ACX CRYSTAL STRUCTURE OF MYCOBACTERIUM SMEGMATIS MFD IN COMPLEX WITH ADP + PI AT 3.5 A RESOLUTION. 3.6.4
6ACY THE STRUCTURE OF CVA10 VIRUS A-PARTICLE 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6ACZ THE STRUCTURE OF CVA10 VIRUS A-PARTICLE FROM ITS COMPLEX WITH FAB 2G8 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AD0 THE STRUCTURE OF CVA10 MATURE VIRION IN COMPLEX WITH FAB 2G8 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AD1 THE STRUCTURE OF CVA10 PROCAPSID FROM ITS COMPLEX WITH FAB 2G8 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AD5 CRYSTAL STRUCTURE OF HEWL IN COMPLEX WITH TEMED (IN THE AROMA FORM) AFTER 24 HOURS UNDER FIBRILLATION CONDITIONS 3.2.1.17
6ADF STRUCTURE OF HEWL CO-CRYSTALLISED WITH TEMED 3.2.1.17
6ADW CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE (APO FORM) 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
6ADX CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE (ADP-MN2+ COMPLEX, FORM 1) 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
6ADY CRYSTAL STRUCTURE OF THE ZIKA VIRUS NS3 HELICASE (ADP-MN2+ COMPLEX, FORM 2) 3.4.21.91
3.6.1.15
3.6.4.13
2.1.1.56
2.1.1.57
2.7.7.48
6AE4 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-694, Y471A MUTANT) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
6AE5 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-672, Y471A MUTANT, FORM 1) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
6AE6 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-672, Y471A MUTANT, FORM 2) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
6AE7 CRYSTALS STRUCTURE OF CLASSICAL SWINE FEVER VIRUS NS5B (RESIDUES 1-672, E472A MUTANT) 2.7.7.48
3.4.21.113
3.6.1.15
3.6.4.13
6AE9 X-RAY STRUCTURE OF THE PHOTOSYSTEM II PHOSPHATASE PBCP 3.1.3.16
6AEA CRYSTAL STRUCTURE OF HEWL IN COMPLEX WITH TEMED (IN THE AROMA FORM) AFTER 5 HOURS UNDER FIBRILLATION CONDITIONS 3.2.1.17
6AEK CRYSTAL STRUCTURE OF ENPP1 IN COMPLEX WITH PAPG 3.1.4.1
3.6.1.9
6AEL CRYSTAL STRUCTURE OF ENPP1 IN COMPLEX WITH 3'3'-CGAMP 3.1.4.1
3.6.1.9
6AF5 DJ-1 AFTER BACKSOAKING 3.1.2
3.5.1
3.5.1.124
6AF7 DJ-1 C106S UNBOUND 3.1.2
3.5.1
3.5.1.124
6AF9 DJ-1 WITH ISATIN BOUND (HIGH CONCENTRATION) 3.1.2
3.5.1
3.5.1.124
6AFA DJ-1 WITH ISATIN (LOW CONCENTRATION) 3.1.2
3.5.1
3.5.1.124
6AFB DJ-1 C106S INCUBATED WITH ISATIN 3.1.2
3.5.1
3.5.1.124
6AFC DJ-1 WITH COMPOUND 4 3.1.2
3.5.1
3.5.1.124
6AFD DJ-1 WITH COMPOUND 6 3.1.2
3.5.1
3.5.1.124
6AFE DJ-1 WITH COMPOUND 7 3.1.2
3.5.1
3.5.1.124
6AFF DJ-1 WITH COMPOUND 8 3.1.2
3.5.1
3.5.1.124
6AFG DJ-1 WITH COMPOUND 9 3.1.2
3.5.1
3.5.1.124
6AFH DJ-1 WITH COMPOUND 10 3.1.2
3.5.1
3.5.1.124
6AFI DJ-1 WITH COMPOUND 11 3.1.2
3.5.1
3.5.1.124
6AFJ DJ-1 WITH COMPOUND 13 3.1.2
3.5.1
3.5.1.124
6AFL DJ-1 WITH COMPOUND 15 3.1.2
3.5.1
3.5.1.124
6AFM CRYSTAL STRUCTURE OF CLASS A B-LACTAMASE, PENL, VARIANT CYS69TYR, FROM BURKHOLDERIA THAILANDENSIS 3.5.2.6
6AFN CRYSTAL STRUCTURE OF CLASS A B-LACTAMASE, PENL, VARIANT CYS69TYR, FROM BURKHOLDERIA THAILANDENSIS, IN COMPLEX WITH CEFTAZIDIME-LIKE BORONIC ACID 3.5.2.6
6AFO CRYSTAL STRUCTURE OF CLASS A B-LACTAMASE, PENL, VARIANT ASN136ASP, FROM BURKHOLDERIA THAILANDENSIS 3.5.2.6
6AFP CRYSTAL STRUCTURE OF CLASS A B-LACTAMASE, PENL, VARIANT ASN136ASP, FROM BURKHOLDERIA THAILANDENSIS, IN COMPLEX WITH CEFTAZIDIME-LIKE BORONIC ACID 3.5.2.6
6AFS PROTON PYROPHOSPHATASE - TWO PHOSPHATES-BOUND 3.6.1.1
7.1.3.1
6AFT PROTON PYROPHOSPHATASE - E301Q 3.6.1.1
7.1.3.1
6AFU PROTON PYROPHOSPHATASE-L555M MUTANT 3.6.1.1
7.1.3.1
6AFV PROTON PYROPHOSPHATASE-L555K MUTANT 3.6.1.1
7.1.3.1
6AFW PROTON PYROPHOSPHATASE-T228D MUTANT 3.6.1.1
7.1.3.1
6AFX PROTON PYROPHOSPHATASE - E225A 3.6.1.1
7.1.3.1
6AFY PROTON PYROPHOSPHATASE-E225S MUTANT 3.6.1.1
7.1.3.1
6AFZ PROTON PYROPHOSPHATASE-E225H MUTANT 3.6.1.1
7.1.3.1
6AG0 THE X-RAY CRYSTALLOGRAPHIC STRUCTURE OF MALTOOLIGOSACCHARIDE-FORMING AMYLASE FROM BACILLUS STEAROTHERMOPHILUS STB04 3.2.1.1
6AG2 UPA-HMA 3.4.21.73
6AG3 CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH 3,5-BIS(AZANYL)-N-CARBAMIMIDOYL-6-(2,4-DIMETHOXYPYRIMIDIN-5-YL)PYRAZINE-2-CARBOXAMIDE 3.4.21.73
6AG7 THE CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH HMA-55F 3.4.21.73
6AG9 CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH 3,5-BIS(AZANYL)-6-(1-BENZOFURAN-2-YL)-N-CARBAMIMIDOYL-PYRAZINE-2- CARBOXAMIDE 3.4.21.73
6AGN STRUCTURE OF HEWL CO-CRYSTALLISED WITH CINNAMALDEHYDE 3.2.1.17
6AGP STRUCTURE OF RAC1 IN THE LOW-AFFINITY STATE FOR MG2+ 3.6.5.2
6AGR STRUCTURE OF HEWL CO-CRYSTALLISED WITH PHENYLETHYL ALCOHOL 3.2.1.17
6AGW PRO-DOMAIN OF CASPASE-8 3.4.22.61
6AHH CRYSTAL STRUCTURE OF HEWL IN COMPLEX WITH PHENYLETHYL ALCOHOL (IN THE AROMA FORM) AFTER 5 HOURS UNDER FIBRILLATION CONDITIONS 3.2.1.17
6AHL CRYSTAL STRUCTURE OF HEWL IN COMPLEX WITH CINNAMALDEHYDE (IN THE AROMA FORM) AFTER 5 HOURS UNDER FIBRILLATION CONDITIONS 3.2.1.17
6AHS MOUSE KALLIKREIN 7 IN COMPLEX WITH IMIDAZOLINYLINDOLE DERIVATIVE 3.4.21.117
6AHV CRYSTAL STRUCTURE OF HUMAN RPP40 3.1.26.5
6AI6 CRYSTAL STRUCTURE OF SPCAS9-NG 3.1
6AIB CRYSTAL STRUCTURES OF THE N-TERMINAL RECA-LIKE DOMAIN 1 OF STAPHYLOCOCCUS AUREUS DEAD-BOX COLD SHOCK RNA HELICASE CSHA 3.6.4.13
6AIC CRYSTAL STRUCTURES OF THE N-TERMINAL DOMAIN OF STAPHYLOCOCCUS AUREUS DEAD-BOX COLD SHOCK RNA HELICASE CSHA IN COMPLEX WITH AMP 3.6.4.13
6AIL CRYSTAL STRUCTURE AT 1.3 ANGSTROMS RESOLUTION OF A NOVEL UDG, UDGX, FROM MYCOBACTERIUM SMEGMATIS 3.2.2.27
6AIT CRYSTAL STRUCTURE OF E. COLI BEPA 3.4
6AIX CRYSTAL STRUCTURE OF DXO IN COMPLEX WITH ADENOSINE 3', 5' BISPHOSPHATE AND TWO MAGNESIUM IONS 3.1.13
3.6.1
6AIY CRYSTAL STRUCTURE OF DXO (E234A MUTANT) IN COMPLEX WITH ADENOSINE 3', 5' BISPHOSPHATE AND TWO MAGNESIUM IONS 3.1.13
3.6.1
6AJ0 THE STRUCTURE OF ENTEROVIRUS D68 MATURE VIRION 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AJ2 THE STRUCTURE OF ICAM-5 TRIGGERED ENTEROVIRUS D68 VIRUS A-PARTICLE 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AJ3 THE STRUCTURE OF ENTEROVIRUS D68 PROCAPSID 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AJ7 THE STRUCTURE OF ENTEROVIRUS D68 MATURE VIRION IN COMPLEX WITH FAB 15C5 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AJ9 THE STRUCTURE OF ENTEROVIRUS D68 MATURE VIRION IN COMPLEX WITH FAB 15C5 AND 11G1 3.4.22.29
3.6.1.15
3.4.22.28
2.7.7.48
6AJD CRYSTAL STRUCTURE OF A MONOMETALLIC DIHYDROPYRIMIDINASE FROM PSEUDOMONAS AERUGINOSA PAO1 REVEALS NO LYSINE CARBAMYLATION WITHIN THE ACTIVE SITE 3.5.2.2
6AJF CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS 3.2.1.17
6AJG CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS COMPLEXED WITH SQ109 3.2.1.17
6AJH CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS COMPLEXED WITH AU1235 3.2.1.17
6AJI CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS COMPLEXED WITH RIMONABANT 3.2.1.17
6AJJ CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS COMPLEXED WITH ICA38 3.2.1.17
6AJO COMPLEX FORM OF URACIL DNA GLYCOSYLASE X AND URACIL-DNA. 3.2.2.27
6AJP COMPLEX FORM OF URACIL DNA GLYCOSYLASE X AND DEOXYURIDINE MONOPHOSPHATE. 3.2.2.27
6AJQ E52Q MUTANT FORM OF URACIL DNA GLYCOSYLASE X FROM MYCOBACTERIUM SMEGMATIS. 3.2.2.27
6AJR COMPLEX FORM OF URACIL DNA GLYCOSYLASE X AND URACIL 3.2.2.27
6AJS H109S MUTANT FORM OF URACIL DNA GLYCOSYLASE X. 3.2.2.27
6AKQ THE PDZ TANDEM FRAGMENT OF A. AEOLICUS S2P HOMOLOG WITH THE PA12 TAG INSERTED BETWEEN THE RESIDUES 263 AND 267 3.4.24
6AKR CRYSTAL STRUCTURE OF THE PDE4D CATALYTIC DOMAIN IN COMPLEX WITH OSTHOLE 3.1.4.53